INDEX TO VOLUME 61—1993

AUTHOR INDEX

Original articles are indicated by (O), editorial (E), correspondence (C), obituaries (Ob), abstracts (A), book reviews (B). Page numbers followed by A are abstracts of the 14th International Leprosy Congress.

Abalos, R., (A)9A
Abalos, R. M., (A)360, 75A, 97A, 101A, 125A, (O)192
Abbot, N. C., (A)129, 657, (C)474
Abbott, N., (A)126A
Abdullah, M., (A)341
Abe, C., (A)134
Abe, M., (A)346, 346
Abel, K., (A)76A, (O)398
Abou-Zeid, C., (A)368
Abraham, T., (A)59A, 130A, 156A, 165A
Abrams, J. S., (A)366, 655, 666
Abrikosova, T. N., (A)173
Abuirjeie, M. A., (A)338
Achong, L., (A)20A
Ackerson, L., (A)371
Adams, E., (A)135, 104A
Adams, L. B., (A)78A, 102A
Afanasyev, S. S., (A)181
Agarwal, B. M., (A)113A
Aggarwal, R., (A)654
Agnihotri, N., (A)128
Agrawal, B. M., (A)143, 116A
Aguas, A. P., (A)160, 652
Aguilar, D., (A)176
Agusni, I., (A)167A
Ahmed, S., (A)368
Ahouandogbo, F., (A)63A
Ahsan Ali, A. K., (A)71A
Aihara, Y., (A)491
Ajupova, A., (A)80A, 123A
Akai, P. S., (A)155A
Akaike, T., (A)503
Akbar, M. S., (A)368
Akinsanya, (A)51A
Akintunde, S. O., (A)51A
Akoglu, T., (A)95A, 100A
Al-Attouaj. R., (A)129
Al-Haddidi, H. F., (A)338
Al-Hajjaj, M. S., (A)365
Al Nabhani, M. G., (A)45A
Al-Orainey, I. O., (A)365
Al Qubati, Y., (A)45A
Alam, M., (A)109A
Alam, S. E., (A)656
Alatkar, I., (A)39A
Alban, Y., (A)153A
Alberto, F. L., (A)500
Albrecht, L., (A)659
Albuquerque, E. C. A., (A)12A
Alekseyev, L., (A)95A, 95A, 105A
Alencar, A. A. F., (A)30A, 122A
Alexandar, M., (A)39A
Alexander, M., (A)39A
Alexander, R., (A)127A, 135A
Alexander, S. A., (A)67A
Alexeyev, L. P., (A)353
Alfaro, F., (A)101A, 101A
Alfaro-Bustamante, F., (O)245
Alldred, N., (A)163A
Allen, B. W., (A)502
Almeida, J. G., (A)44A, 82A, (C)630
Almeida, S., (A)150A
Almeida, S. M., (A)12A
Almodovar, P. I., (A)342
Alugupalli, S., (A)152, 176, 658
Alvarenga, A., (A)14A, 305, 309, 341
Alvares, M., (A)34A
Alves, S. C., (A)135A
Alves, T. M., (A)35A
Alvim, M. F. S., (A)53A, 66A, 94A
Ameglio, F., (A)368
Amezcua, M. E., (A)488
Amimo, R. K., (A)36A
Amiruddin, M.D., (A)73A
Anagonou, S., (A)63A
Anand, B., (A)137A
Anandan, D., (A)353
Anandaraj, H., (A)131A, 164A
Ananth Reddy, S., (A)25A
Anantharaman, D. S., (A)103A, (O)563
Anantharaman, K., (A)15A
Andersen, A. B., (A)134, 492
Andersen, P., (A)152, 666
Anderson, P., (A)365
Anderson, R., (A)124, 378, 486
Ando, M., (A)503
Andrade, A. L. S. S., (A)127, (C)461
Andrade, H. F., Jr., (A)354
Andrade, V. L. G., (A)11A, 35A, 71A, 121A, 126A
Andre, J., (A)362
Andrew, E., (A)156
Andrews, R. E., (A)179
Anes, E., (A)140
Anides-Fonseca, A. E., (A)141A
Annie, Sister, (A)25A
Antia, N., (A)4A, 6A, 18A, 22A, 77A, 87A, 100A, 143A, 162A
Antia, N. H., (A)138, 344, 489
Antunes, S. L. G., (A)126A
Aparecida Grossi, M., (A)26A, 26A, 26A, 26A, 27A

Appelberg, R., (A)132
Arain, G. M., (A)656
Aramburu, J., (A)63A
Aranha, M. S. F., (A)129A, 134A
Araujo, A. J. G., (A)71A
Arbeit, R. F., (A)658
Arce, M., (A)101A
Arce, R., (C)468
Arevalo-Lopez, A., (A)152A
Arif, M. A., (A)60A
Armati, P. J., (A)488
Armoa, G. R. G., (A)664
Armstrong, D., (A)367
Arnelles, M., (A)12A
Arolkar, S., (A)143A, 162A
Aroni, K., (C)634
Arrigo, P., (A)107A
Arthur, M., (A)169
Arulprakasam, P., (A)148A
Arunthathi, S., (A)28A, 28A, 28A, 119A, 164A, 166A
Arzet, H., (A)21A
Asano, G., (A)356
Aschhoff, M., (A)12A, 650, 650
Ashtekar, D. R., (A)365
Asilian, A., (A)74A
Askgaard, D., (A)152, 161
Aspar, N., (A)167A
Aspinall, G. O., (A)366
Asri, M., (A)148, 16A, 67A
Atrio, N., (A)647
Auge, S., (A)669
Augier, J., (A)490
Ausina, V., (A)152
Avancini, E., (A)166A
Avelleira, J. C., (A)11A, 11A, 29A, 35A, 121A, 121A, 126A
Avelleira, J. C. R., (A)649
Awh, O. D., (A)167
Awofeso, N., (A)35A, 142A
Axouaou, N., (A)76A
Ayala, J. L., (A)88A
Ayala-Diaz, J. L., (A)46A
Ayub, Q., (A)667
Aznar, C., (A)178
Azouaou, N., (O)398
Azulay, D. R., (A)23A
Azulay, R. D., (A)23A

Babu, M., (A)142A
Baccarelli, R., (A)159A, 161A
Bach, M.-A., (A)350
Backstrom, B. T., (A)129, 652
Bacon, K., (A)375
Badrinath, S., (A)352
Baduksharova, N. M., (A)181
Baer, H. H., (A)492
Bagga, A. K., (A)351
Bahadur, R. R., (A)650
Bahceci, E., (A)364, 95A, 100A
Bai, G. H., (A)664
Bai, G. S., (C)462
Bajaksouzian, S., (A)662
Baker, D. M., (A)147
Bakhtiar, M., (A)165
Bakirtzief, Z., (A)132A
Bakker, A., (A)351
Balagon, M. V. F., (A)106A
Balamurugan, M., (A)149A
Balassiano, V., (A)135A
Balasubramanyam, S., (A)147A, 147A
Balina, L. M., (A)56A, 91A
Bally, R., (A)377
Balybin, E., (A)34A, 35A, 101A
Balz, M., (A)377
Bambery, P., (E)455
Bandkar, K. R., (A)30A
Bandyopadhyay, S. K., (A)50A
Banerjee, D. K., (A)357, 111A, (O)605
Banerjee, P., (A)80A
Banu, M. J., (A)109A, 114A
Baquillon, G., (A)362
Baracca, G., (A)156A
Baral, J. P., (A)40A
Baranda, L., (O)581
Baranov, Y. N., (A)353
Barba-Rubio, J., (A)101A
Barber, T. W., (A)658
Barcelo, M. G., (A)152
Barclay, R., (A)141
Bardapurker, J., (A)655
Barker, R. H., (A)662
Barletta, R. G., (A)507
Barnes, P. F., (A)366
Barocio, A., (A)48A, 134A, 168A
Barongo, L. R., (O)556
Barradell, L. B., (A)658
Barrau, P., (A)648
Barrera, L. F., (A)367
Barrios, C., (A)135
Barrow, W. W., (A)484, 667
Barrozo, M. S., (A)132A
Bartels, H., (A)7A
Barthelemy, J., (A)648
Basak, P., (A)652
Baskin, G. B., (A)75A, 79A
Basskaran, E., (A)153A
Basten, A., (A)135, 104A
Batalla, J., (A)12A
Batra, H. V., (A)133, 134
Battesti, J. P., (A)178
Baudino, R., (A)82A
Baumgart, K. W., (A)86A
Bawamkar, B. R., (A)134A
Baynes, R. D., (A)126
Beaman, B., (A)169
Bechelli, L. M., (A)44A
Beck, J. S., (A)129, 130, 657, 126A, (C)474
Becx-Bleumink, M., (E)82
Beena, K. R., (A)18A, 18A, 22A, 345, 349, 95A, 100A

Beimnet, K., (A)654
Beine, A.-O., (A)160A
Belda, F., (A)152
Beliard, N., (A)4A, 24A, 28A, 32A, 154A
Beligon, C., (A)648
Belisle, J. T., (A)492, 493
Bell-Krotoski, J., (A)146A, 146A, 159A
Bellance, R., (A)54A
Benani, Y., (A)48A
Bendiche, M., (A)363
Benet, L. Z., (A)122
Benheimer, H., (A)80A
Benis, P., (A)128A
Benmeir, P., (A)150
Bennedsen, J., (A)134, 152
Benz, R., (A)144, 498
Beradin, R., (A)154A
Berenhoff, J., (A)145A
Berg, P. A., (A)507
Bergh, S., (A)358
Berhan, T. Y., (A)654
Berhe, D., (A)61A
Berjeaud, J.-M., (A)669
Berman, T., (A)150A
Bermudez, L. E., (A)130, 367, 659
Bernard, E. M., (A)367
Bernardin, R., (A)29A, 150A
Beschin, A., (A)368
Besra, G. S., (A)152, 495, 499, 670
Betto, P., (C)471
Bharadwaj, V. P., (A)350, 67A, 81A, 98A, 113A, 114A
Bharambe, M. S., (A)651
Bharti, R., (A)9A
Bhat, L., (A)119A
Bhatia, A. S., (A)2A, 7A, 13A, 19A, 67A, 114A, 122A, 1233, (O)433
Bhatia, V. N., (A)655
Bhatki, W., (A)3A, 159A
Bhatki, W. S., (A)340
Bhatnagar, S., (A)92A
Bhatt, A. D., (A)365
Bhattacharjee, R., (A)134A
Bhoopat, L., (A)22A, 99A, 104A
Bhutani, L. K., (A)96A
Biehle, J., (A)153
Bien-Aime, G., (A)71A
Bierling, P., (A)660
Bijleveld, I., (A)40A
Birdi, T., (A)77A
Birke, J., (A)364, 145A, 146A
Birnbaum, G., (A)659
Bisen, P. S., (A)89A
Bisht, D., (A)91A
Biswas, A., (A)125
Biswas, S. K., (A)111A
Bjune, G., (A)137A
Blacklock, Z., (A)163
Blanc, G., (A)4A, 24A, 28A, 32A, 48A, 154A
Blanc, L., (A)6A, 7A, 43A, 48A
Blanchard, J. L., (A)75A, 79A
Bliss, L., (A)74A, 74A
Bloom, B. R., (A)161, 507, 655, 665, 87A, 88A
Blum, L., (O)214
Bobin, P., (A)2A, 6A, 7A, 21A, 647
Boddingius, J., (A)487
Bodmer, T., (A)377, 497
Bogaert, H., (A)28A, 46A, 46A, 133A, 134A
Bohm, R. P., Jr., (A)75A, 79A, (O)236
Bollen, A., (A)372
Bollet, C., (A)153
Bolton, R. C., (A)152
Bonoldi, E., (C)471
Boom, W. H., (A)153, 666
Booth, R. J., (A)493
Boratto, L., (A)26A, 26A, 126A
Borgdorff, M. W., (O)556
Borges, E., (A)12A
Bos, J. D., (A)25A
Bosne, S., (A)502
Bothamley, G., (A)130
Bothwell, T. H., (A)126
Bottasso, O. A., (A)94A, (C)468, (O)586
Bottger, E. C., (A)156, 372, 373, 377
Bouchonnet, F., (A)178
Boudghene-Stambouli, O., (A)70A
Boutin, J.-P., (A)147
Box, J. D., (A)174
Boyau, M. L., (A)58A
Bozeman, P. M., (A)121
Braak, L. H., (A)142A
Bramhne, H. G., (A)124A
Brandsma, J. W., (A)340, 143A, 145A, 146A, 155A
Brandt, F., (A)346
Brasil, M. T. L. R. F., (A)4A, 29A, 29A
Brasiliense, M. S. L., (A)57A
Brattegaard K., (A)505
Braun, H., (A)4A
Breckenridge, A. M., (A)121
Bremer, H. J., (A)372
Brenden, M., (A)487
Brennan, P. J., (A)134, 144, 152, 366, 375, 492, 493, 76A, 84A, 103A, 106A, 115A, 115A, 115A, (O)381
Brenner, M. B., (A)136
Brindle, R., (A)171
Brindle, R. J., (A)502
Britton, W., (A)130, 46A
Britton, W. J., (A)352, 488, 86A, 104A, (O)35
Brooks, L. A., (A)499, 84A
Brooks, P., (A)115A
Brown, B. A., (A)154, 374
Brown, M. E., (A)65A
Brown, S. T., (A)367
Brown, T. R., (A)148A
Brown, W. J., (A)497
Bruni, M., (A)14A
Buehre, Y., (A)161A
Bull, H. A., (A)132
Bulto, T., (A)163A
Burggraaf, J. D., (A)136, 143, 496, 86A

Butcher, P. D., (A)111A
Butler, W. R., (A)154, 505
Butlin, C. R., (A)45A, 46A, 126A, 145A, (O)51
Butt, K. I., (A)355, 356, 120A, 120A
Buzzar, M., (A)4A, 43A, 47A, 47A, 47A, 165A
Byass, P., (A)158A

Cabanos, G. C., (A)71A
Cadranel, J., (A)178
Cakiner, T., (A)26A, 26A, 364, 95A, 100A, 117A
Caldera, D., (A)343
Callera, F., (A)500
Calvo, R., (A)17A
Camarena, J. J., (A)33A
Camargo, L., (A)150A, 159A
Cambiaso, C. L., (A)660
Camp, R., (A)375
Campos, L. C., (A)143A
Campos, W., (A)26A, 26A, 26A, 26A, 27A, 123A
Canario, S., (A)46A, 46A, 501, 133A, 134A, 156A
Candida, (A)486
Cannon, L., (A)94A
Cano, A. S., (A)101A
Cantalice F., J. P., (A)136A
Cantillo, L., (A)148
Cao, Y., (A)73A
Cardines, R., (A)147
Cardo, P. P., (A)107A, (C)464
Cardoso Guillen, E., (A)340
Carlson, L. D. C., (A)156
Carlucci, S., (A)368
Carnochan, F. M. T., (A)129
Carolina, J. C., (A)54A, 168A
Carpenter, L., (A)171
Carpintero, P., (A)30A
Carrazana Hernandez, G. B., (A)148, 340
Cartaya Gonzalez, T., (A)109A
Cartel, J.-L., (A)2A, 147, 147, 347, 37A, 61A, 64A, 72A, (O)29, 199, 533
Casabianca, M. N., (A)28A, 52A, 58A
Casals, J. B., (A)506
Castellanos Garcia, F., (A)38A
Castellanos, F., (A)48A, 134A, 143A, 168A
Castellazzi, Z., (A)501
Castro, A. P., (A)160
Castro, E., (A)488, 88A
Castro Chavez, R., (A)148
Catanzaro, A., (A)174, 376
Caudron, B., (A)358
Cauthen, G. M., (A)370
Cavalieri, S. J., (A)153
Cave, M. D., (A)378
Cazares, J. V., (A)488
Cecere, L., (A)82A
Cellona, R. V., (A)6A, 131, 360, 73A, 75A, 97A, (O)192
Cerrano, A., (A)156A
Chabot, M., (A)63A
Chae, G.-T., (A)78A, 96A
Chai, W. G., (A)498
Chaicumpar, K., (A)85A
Chaipar, W., (A)40A
Chakrabarty, A. N., (A)158, 357, 74A, 80A, 80A, 112A, 112A, 117A
Chalise, Y., (A)73A
Chambers, H. F., (A)663
Champsi, J., (A)659
Chan, G., (A)17A, 17A, 18A, 73A, 109A
Chan, G. P., (A)141, 94A, (O)66
Chan, H., et al., (A)341
Chan, J., (A)507
Chandi, S., (A)122A
Chandrasekhar, S., (A)77A
Chandrashekhar, R., (A)125A
Chang, P., (A)98A
Chang, Y. T., (A)76A
Chanteau, S., (A)347, 358, 61A, 64A, 72A, (O)29, 199, 533
Chantraprachoom, C., (A)656
Chaparas, S. D., (A)134
Charlebois, R., (A)4A, 24A, 28A, 32A, 71A
Charles-Nicolas, C., (A)168A
Chatterjee, B. R., (A)131
Chatterjee, D., (A)366, 493, 115A
Chattopadhyay, S. P., (A)149, 648
Chaturvedi, R. M., (A)151
Chaturvedi, V., (A)88A, 91A
Chaudhary, S. D., (A)350
Chaudhuri, S. K., (A)80A, 112A
Chauhan, G., (A)14A, 149A, 160A
Chauhan, S. L., (A)649, 649
Chaurand, P., (A)669
Chauvin, J. P., (A)369
Chavez, V., (A)17A, 17A, 18A
Chawla, L. S., (A)123A
Chawla, P. K., (A)155
Chehl, S., (A)78A
Chellam, P., (A)148A
Chen, J., (A)31A, 42A, 61A, 651
Chen, S., (A)135
Chen, X., (A)64A, 67A, 70A
Chen, X.-S., et al., (A)151
Chen, Y., (A)62A
Chen, Z., (A)144A
Chen, Z.-L., (A)651
Cheng, N., (A)487
Cheng, S. H., (A)158
Cheng, Z.-Q., (A)10A, 52A
Cherian, J., (A)40A
Cheriyan, C. S., (A)48A, 127A, 130A, 165A
Chervenak, K. A., (A)153
Chevallard, A., (A)37A
Chiang, T., (A)125, 151, 656
Chiewchanvit, S., (A)99A
Childerstone, A., (A)667
Chin-A-Lien, R. A. M., (A)139, 25A, 36A, 90A
China, R. A., (A)123A
Chiplunkar, S., (A)85A, 96A
Chiplunkar, S. V., (O)51, 421
Chirawatkul, A., (A)39A, 40A

Chitale, S., (A)115A
Cho, S.-N., (A)155, 167, 360, 97A, (O)236
Chocair, P. R., (A)124A
Choi, H.-Y., (A)96A
Chomyc, S., (A)496
Chong, P. Y., (A)647
Chong, Y., (A)155
Chongate, P. N., (A)55A
Chopra, N. K., (A)6A, 25A, 49A, 49A, 50A, 69A
Choudhury, A. M., (A)500
Chryssou, S., (A)35A
Chu, C. Q., (A)156
Chuidian, F., (A)664
Chukwu, J. N., (A)58A
Chum, H., (A)41A, 167A
Chum, H. J., (A)65A, (O)556
Chum, J. H., (A)306
Chureau, C., (A)178
Cigarran, S., (A)486
Clark-Curtiss, J. E., (A)84A, 86A
Clarridge, J. E., (A)177
Clavel-Seres, S., (A)373, 502
Clement, F., (A)179
Clements, B. C., (A)342
Clinical Study Group, (A)305
Cocito, C., (A)141, 162, 368, 369
Coene, M., (A)141, 162, 369
Cogniaux, J., (A)662
Cohen, Y., (A)156, 172
Cohn, D. L., (A)157
Coimbra, T. M., (A)120A
Cole, S. T., (A)163, 317, 358, 359, 361, 497, 661, 108A, 165A, (O)600
Coleman, M. D., (A)121, 485
Coleman, W. C., (A)364
Coll, A., (O)214
Collins, D. M., (A)378, 502
Collins, J., (A)169
Colston, M. J., (A)142, 23A, 34A, 496, 497, 84A, 99A, 106A, 115A, 125A, (O)9
Columbie, Y., (A)647
Commons, P., (A)151A
Compostella, L., (A)156A
Constant-Desportes, M., (A)168A
Content, J., (A)161, 177, 108A
Converse, P. J., (A)76A
Convit, J., (A)88A, 89A, 99A, 103A, (O)185
Cooksey, R. C., (A)494
Coor, V., (A)146A
Cornelisse, Y. E., (A)489, 102A
Costa, A. P. V. F., (A)127
Costaperira, R., (A)365
Costello, A. M. D., (A)368
Cotte, L., (A)369
Coulibaly, I., (A)158
Courtright, P., (A)341, 118A, 118A
Cousins, D. V., (A)378
Coutinho, R., (A)29A
Coutinho, R. B., (A)649
Cox, R. A., (A)142
Coyle, M. B., (A)156
Craig, L., (A)76A
Crawford, C. L., (A)79A
Crawford, J. T., (A)378, 494, 494, 505
Cree, I., (A)126A
Cross, C., (A)104A
Crouzat, M., (A)2A
Crowle, A. J., (A)157, 176, 337
Cruaud, P., (O)44
Cruz, C., (A)55A
Cruz, R. C. S., (A)55A
Cunanan, A., Jr., (A)73A
Cunha, M. G. S., A)11A, 53A
Currie, H., (A)144A, 145A, 158A, 158A
Curtis, J., (A)79A, 150A, 150A
Cynamon, M. H., (A)166, 166
Cypreste, D. M., (A)133A, 133A, 167A

Daffe, M., (A)155, 162, 165, 168, 664
Dagnia, H. T., (A)378
Dai, X., (A)61A
Dai, Z.-C., (A)45A
Dale, J. W., (A)378
Dalla Fontana, A., (A)59A, 94A
Dalloz, C., (A)54A
Dalovisio, J. R., (A)157
Damasco, M. H. S., (A)12A
Dambreville, M., (A)4A, 24A, 28A, 32A, 154A
Damiani, G., (A)134, 107A
Dandekar, S., (A)72A, 97A
Daniel, E., (A)119A, 119A, 119A, 160A, 164A, 166A
Daniel, J., (A)43A
Danser-de Vries, C., (A)119A
Darisini, D., (A)129A
Das, B., (A)132A
Das, P. K., (A)136, 143, 174, 496, 86A, 105A
Das, S., (A)158
Dasi, M. A., (A)33A
Dastidar, S. G., (A)158, 357, 74A, 80A, 80A, 112A, 112A, 117A
Daugelat, S., (A)133
Daumerie, D., (A)48A
Dautzenberg, B., (A)369
Dave, P., (A)152A
Dave, P. V., (A)51A
Dave, S., (A)136A, 138A
Davenport, M. P., (A)352
David, H. L., (A)373, (O)44
Davies, J. K., (A)159
Davis, E. O., (A)496, 115A
Dawson, D. J., (A)173
Day, R., (A)148, 19A
Dayal, S., (A)59A
Dayunghirang, J., (A)10A
De, J., (A)70A
de Almeida, A. M., (A)30A, 31A, (E)102
de Blaquiere, G., (A)79A
De Bolle, X., (A)357
De Britto, L. J., (O)563

De Bruyn, J., (A)134, 177, 495, (O)29
De Cock, M., (O)29
De Glopper-Van Der Veer, E., (A)139
De Kesel, M., (A)141, 162, 369
de la Barrera, S., (A)91A
De Lange, W. E., (A)100A, 100A
De Lisle, G. W., (A)502
de Mallac, M. J., (A)62A
de Mendonca Lima, L., (A)108A
de Oliveira, E. B., (O)218
de Oliveira Cortes, J. L., (A)50A
de Rijk, A., (A)144A
de Rojas, V., (A)57A
De Smet, K. S. E., (A)84A
de Soldenhoff, R., (A)128, 12A, 20A
de Vries, R. R. P., (A)133, 139, 489, 102A, 105A
De Wit, M. Y. L., (A)362, 498, 67A, 75A, 108A
DeBrito, T., (A)354
Debueger, M., (A)351
Decock, K. M., (A)158, 505
Degrave, W., (A)106A, 108A
Degtiarev, O., (A)94A
Deivasigamani, (A)129A
del Pilar Bilot, M., (A)50A
del Portillo, P. (A)358
dela Cruz, E. C., (A)360, 6A, 9A, 75A, 101A, (O)192
Delamaza, L. M., (A)160
Delamballerie, X., (A)153
Delforge, D., (A)357
Delgado, R., (A)494
Delgado, S. P., (O)581
Demessias, I. J. T., (A)487
Demico, P., (A)153
Deming, A. T., (A)78A
Demissie, A., (A)105A
Deng, E., (A)31A
Deng, Y., (A)9A, 31A, 92A
Deo, M. G., (A)85A, 96A, (O)51, 421
Depiereux, E., (A)357
Desai, S. D., (A)124A
Desfontaines, M., (A)362
Deshmukh, M., (A)96A
Deshpande, S. S., (A)58A
Desikan, K. V., (A)98A
Desikan, P., (A)96A
Desikan, V. K., (A)125A
Desmet, K. A. L., (A)499
DeSousa, J. P. C., (A)137, 159
Despande, R. G., (A)347
Destefano, M. S., (A)166
Desvarieux, F., (A)4A, 24A, 28A, 32A, 48A, 154A
Detoeuf, G., (A)165A
Devadas, I. J., (A)130A
Devadas, J., (A)127A, 156A
Devadas, T. J., (A)48A, 59A
Devanbu, V., (A)32A, 53A
Devasundaram, J. K., (C)296, (O)16
Dewapura, D., (A)129A, 129A, 134A, 134A
Dewit, S., (A)369
Dewitt, L., (A)161
Dhandayuthapani, S., (A)109A, 114A
Dhar, M. M., (A)92A
Dhar, S., (C)292, 467, 473, (E)455
Dhariwal, A. C., (A)167A, (O)428
Dharmshaktu, N. S., (A)60A
Dhople, A., (A)307
Dhople, A. M., (A)312, 312, 361, 485, 77A, 80A, 116A
Diamond, E., (C)460
Dias, E. P., (A)11A, 55A
Dias, L. C., (A)11A, 30A
Diaz, H. B., (A)487
Dietrich, M., (A)12A, 305
Ding, J., (A)13A, 487, 487, 51A
Discini, F., (A)26A
Dixon, J. A., (A)21A
D'Mello, M., (A)8A, 15A
Dockrell, H. M., (A)362, 499, 84A, 84A, 88A, 89A, 104A
Doherty, T. M., (A)652
Doi, T., (A)503
Dolcan, G., (A)26A
Dolzhansky, V. M., (A)173
Dominic I., M., (A)39A
Donelly-Wu, M. K., (A)358
Dong, L., (A)161A
Dooley, S. W., (A)370
Doorly, R., (A)505
Doran, T. J., (A)159
Doucet-Populaire, F., (A)358
Douglas, J., (A)73A, 109A
Douglas, J. T., (A)131, 362, 78A, 94A, 109A, (O)192
Douvas, G. S., (A)337
Dowd, P. M., (A)132
Drakib, A., (A)70A
Draper, P., (A)496, 498
Drijfhout, J. W., (A)133
Drowart, A., (A)495, 653, 653, 660, 662, 89A, 91A, (O)29
Drysdale, P., (A)173
Duerksen, F., (A)4A, 150A, 161A, 162A
Duiko, V., (A)66A
Duncan, M. E., (A)21A, 21A, 21A, 30A, 105A
Duppre, N., (A)94A
Duppre, N. C., (O)204
Dutta, A., (A)339
Dutta, R. N., (A)156A
Dutta, S., (A)156A
Duzgunes, N., (A)168
Dwyer, B., (A)164, 369, 376
Dyachina, M., (A)94A, 113A, 113A, 123A
Dysinger, W., (A)168A

Eastcott, H., (A)362
Ededezie, U. M., (A)58A
Edmonds, K., (A)662
Edstein, M. D., (A)647
Edwards, A., (A)666
Edwards, F. F., (A)367
Egawa, K., (A)344

Eggens, H., (A)60A
Egit, A. S., (A)26A
Ehsan, Q., (A)125
Eiglmeier, K., (A)358, 358
Eisenach, K. D., (A)378
Ekambaram, V., (A)3A
Ekekezie, U. M., (A)130A
El Hamid A. Mohamed, A., (A)17A, 33A
El Hassan, A. M., (A)341
El Regal Khamis, E., (A)17A, 33A, 33A
El Shabrawy, N., (A)17A, 33A, 33A
El Tayeb, S. H. M., (A)17A, 33A, 33A
Elangeswaran, N., (A)89A, 90A
Elias-Zewitch, M., (A)369
Ell, S. R., (A)139A
Ellis, C. J., (A)173
Ellner, J. J., (A)153, 375, 662
Elsaghier, A., (A)130, 159, 159
Elzaatari, F. A. K., (A)190, 177
Emori, M., (A)503
Eng, J., (A)506
Engelhart, S., (A)507
Engers, H. D., (A)134
Enshaie, S., (A)74A
Erasmuson, S. K., (A)502
Erkilic, N., (A)154A
Esaguy, N., (A)160, 652, 110A
Eschanov, T., (A)56A
Escobar-Gutierrez, A., (A)488
Eskina, I., (A)80A
Esparza, J., (A)90A
Espinasse, F., (A)167
Esquenazi, D. A., (A)87A, 95A
Essex, M., (A)97A
Estrada, I., (A)90A, 101A
Estrada, I. C. E., (A)142
Estrada-Parra, I., (O)245
Estrada-Parra, S., (A)90A, 101A
Evans, K. D., (A)160
Ewing, P. A., (O)16

Faber, V., (A)161
Faber, W. R., (A)136, 143, 23A, 25A, 25A, 496, 86A, 161A
Faccioli, L. H., (A)92A, (C)107
Fadeeva, N. I., (A)181
Fafutis, M., (A)101A, 101A
Fafutus-Morris, M., (O)245
Failbus, S., (A)73A, (O)35
Fajardo, T. T., Jr., (A)360, 6A, 9A, 75A, 97A, 101A, 125A, (O)192
Falconi, E., (A)49A, 49A, 63A, 131A
Falkinham, J. O., (A)658
Fan, D.-H., (A)10A, 144A
Fang, C., (A)123
Fanning, A., (A)496
Faria, E., (A)138A
Faucher, J.-F., (A)72A, (O)533
Fauron, P., (A)648
Fauvilledufaux, M., (A)161
Favila, L., (A)101A
Faye, O., (A)6A, 7A
Fedkede, M., (A)118A
Fehrenbach, F. J., (A)175
Feldman, S. T., (O)20
Feldmann, M., (A)156
Felicio-Balagon, M. V., (O)192
Felipe, A. P. L., (A)102A
Feng, X., (A)68A
Fernandez, A. M., (A)647
Fernandez-Vina, M. A., (A)100A
Ferra Torres, T. M., (A)148, 340
Ferraz, A. G., (E)102
Ferraz, M. L., (A)127
Ferreira, A., (A)147A
Ferreira, J., (A)23A, 143A
Ferreira, L., (A)57A
Ferreira, N. M. L. A., (A)132A
Fessehaye, G., (A)16A
Feytmans, E., (A)357
Fiallo, P., (A)141, 145, 107A, (C)464, 471
Fidler, H. M., (A)503
Field, M., (A)156
Figarola, J., (A)146A
Figueiredo, A. A., (A)136A
Filippov, V. I., (A)173
Filley, E., (A)103A
Filley, E. A., (A)132
Fine, P. E. M., (A)343, 68A, 74A, 74A, (O)270, 542
Finiasz, M., (A)91A
Fink, S., (A)91A
Finlay, K., (O)592
Fiorucci, F., (A)368
Flad, H.-D., (A)7A, 309
Flageul, B., (O)214
Flasher, D., (A)168
Fleury, R., (A)121A, 121A, 126A
Fleury, R. N., (A)124A, (C)109
Fliess, E., (A)82A
Flores, O., (A)488, 88A
Flynn, J. L., (A)161
Folgueira, L., (A)494
Fonseca, C., (A)1*58
Fonseca, H. H. R., (A)38A
Forbes, B. A., (A)660
Ford, A. L., (A)488
Forget, A., (A)137
Fortunato, R. M. C., (A)29A
Foss, N. T., (A)30A, 31A, 500, 92A, 102A, 120A, (C)107, (E)102, (O)218
Foster, R., (A)168A
Foucauld, F., (A)4A, 24A, 28A, 32A, 154A
Foundohou, J., (A)63A
Franco, R., (A)82A
Franco, R. J., (A)14A
Franco, S. A., (A)71A
Frankel, R. I., (A)20A
Franzblau, S. G., (A)9A, 17A, 17A, 18A, 308, 315, 671, (O)66

Fraser, J. L., (A)495
Freeman, M. J., (A)157A
Freerksen, E., (A)122, 315
Freire, O., (A)652
Freitas, M. B., (A)55A
Freitas, P., (A)163A
Frieden, T. R., (A)370
Friedland, J. S., (A)347, 370
Friedmann, P. S., (A)121
Friend, D. S., (A)168
Frindt, P., (A)489
Friscia, G., (A)180, 661
Froese, B., (A)4A
Frommel, D., (A)16A, 21A, 21A, 21A, 30A, 105A
Frothingham, R., (A)504
Frucht-Pery, J., (O)20
Fuentes-Ahumada, C., (O)581
Fujii, K., (A)345
Fujita, M., (A)165, 348
Fujiwara, T., (A)131, 348, 73A, 78A, 120A
Fukutomi, Y., (A)348, (O)609
Furney, S. K., (A)132, 375
Furst, V., (A)141
Fuster, E., (A)133A
Fuursted, K., (A)161, 504

Gabay, M. A., (A)50A
Gad El Rab, M. O., (A)365
Gaikwad, A., (A)655
Gaku, K., (A)344
Gala, M., (A)30A
Galenko, N. N., (A)167
Gallo, M. E., (A)12A
Gallo, M. E. M., (A)12A
Gama, C., (A)143A
Gammon, D. W., (A)366
Gan, H., (A)494
Gan, S. C., (A)73A
Ganapati, R., (A)3A, 8A, 15A, 25A, 30A, 38A, 46A, 51A, 58A, 58A, 63A, 69A, 72A, 141A, 141A, 152A, 152A, 166A
Gandewar, K. L., (A)3A, 8A, 30A, 46A, 58A
Gandhi, S., (A)93A
Gandolfo, G. M., (A)368
Gangadharam, P. R. J., (A)361, 371, 80A
Gangal, S., (A)85A
Gangal, S. G., (O)51, 421
Ganguly, N. K., (A)128, 361, 361
Ganju, L., (A)1333
Gao, X., (A)123A
Gao, Y., (A)31A
Garbe, T., (A)349
Garbino, J., (A)82A
Garcia, E., (A)30A
Garcia, I. G., (A)11A
Garcia, J., (A)30A
Garcia, R., (O)581
Garcia, V., (A)103A
Garcia-Flores, E., (A)46A
Gardner, G. D., (A)485
Garg, B. R., (A)352, 651
Garnier, T., (A)358
Gascon, P., (A)371
Gaston, J. S. H., (A)173
Gathua, S., (A)171, 502
Gatt, P., (A)5A, 304
Gaus, W., (A)305
Gautier, N., (A)162
Gehlsen, K. R., (A)174
Gelber, R. H., (A)145, 311, 314, 7A, 76A, 76A, 78A, 81A, 81A, 81A, 82A, 103A, (O)398
Geluk, L., (A)133
Gentile, B., (A)37A
George, R., (A)75A, (O)550
Georges, C., (A)358
Gerdes, J., (A)7A, 309
Gerovitch, L., (A)34A
Gevaudan, M. J., (A)153
Ghalib, H. W., (A)341
Gharaibeh, N. S., (A)338
Gharpure, M. B., (A)485
Ghei, S. K., (A)98A
Gheorghiu, M., (A)142, 179
Ghosh, S., (A)125
Ghulawala, R. G., (A)340
Gibbs, J. H., (A)129
Gicquel, B., (A)142, 378
Gidoh, M., (A)337
Gil, R., (A)57A
Gil, R. E., (A)363
Gil Suarez, R., (A)56A
Gilden, J., (A)157
Gill, O. N., (A)175
Gilleron, M., (A)669
Gillis, T. P., (A)141, 145, 17A, 106A, 108A
Gilot, P., (A)141, 162, 369
Gimi, K., (A)77A
Girdhar, A., (A)16A, 342, 649, 649
Girdhar, B. K., (A)16A, 33A, 342, 649, 649, 85A, 125A
Girija, D., (A)58A, 58A
Githui, W., (A)171, 502
Gitnick, G., (A)169
Glatt, R., (A)53A, 66A
Glaziou, P., (A)2A, 147, 61A, 64A, 72A, (O)199, 533
Glushka, J., (A)152
Goble, M., (A)371
Godard, C. M., (A)656
Godeau, B., (A)660
Godfrey-Faussett, P. D., (A)360, 661
Goes, J. T., (A)106A
Goh, K. S., (A)124, 124, 484
Gokhale, N. R., (A)485
Gokhale, S. K., (C)110
Goldstein, M. M., (A)161
Golovlev, I. R., (A)181
Gomathi, A., (A)650
Gomes, M. K., (A)166A
Gomes de Andrade, V. R., (A)649
Gomez, C. A., (A)148

Gomez, J. R., (A)33A
Gomez, M., (A)101A
Gomez Echevarria, J. R., (A)17A
Goncalves, O. S. J., (A)43A, 47A, 47A, 47A, 165A
Goncalves, S., (A)1'58
Goncharov, L. A., (A)173
Gonzaga, E., (A)73A
Gonzales, A. B., (A)363
Gonzalez, A., (A)101A, 101A
Gonzalez, A. B., (A)13A, 49A, 647
Gonzalez-Abreu, E., (A)363, 49A, 109A
Gonzalez-Amaro, R., (O)581
Gonzalez-Mendosa, A., (O)245
Gonzalez Segredo, A., (A)56A, 109A
Good, R. C., (A)374
Goodfellow, M., (A)495
Goodless, D. R., (A)35A
Gopal, P. K., (A)127A
Gopawar, K., (A)166A
Gormus, B. J., (A)75A, 75A, 79A, 80A, (O)236
Goto, M., (A)120A, 124A
Gottschau, A., (A)152
Goud, A. S., (A)27A, 119A, 167A
Goulart, I. M. B., (A)120A, (C)459
Gow, B. L., (A)378
Graf, P., (A)306, 41A, 65A, 167A, (O)556
Graham, D. Y., (A)170
Grandison, P. M., (A)493
Gratzl, O., (A)486
Grau, G. E., (A)87A
Grauwin, M.-Y., (A)37A, 155A
Grewal, P., (A)129A, 129A, 134A, 134A
Griffin, G. E., (A)347, 370
Griffin, J. P., (A)666
Grillone, S., (A)66A, 107A, (O)389
Grino, S. S., (A)40A
Grisso, C. L., (A)139
Grosset, J.-H., (A)147, 147, 156, 164, 172, 304, 313, 369, 374, 647, 663, 2A, 8A, 54A, 61A, 64A, 108A, (C)629, (O)199, 600
Grossi, A., (A)59A, 158A, 163A, 164A, 1'58
Grossi, M. A., (A)123A
Grugni, A., (O)25
Gruner, M., (A)163A
Gu, C., (A)13A
Gu, L., (A)78A
Guebre-Xabier, M., (A)16A, (C)632
Guedenon, A., (A)63A
Guerra, I. E., (A)48A
Guesdon, J.-L., (A)178
Guido, L. S., (A)360
Guido-Villahermosa, L., (O)192
Guillen-Vargas, C. M., (O)245
Gulle, H., (A)133
Gunawardena, P., (A)129A, 129A, 134A, 134A
Gunzareth, M., (A)41A, 65A, 167A
Guo, S.-G., (A)45A
Gupta, A., (A)89A, 146A, 158A
Gupta, B. K., (A)123A, 146A, 158A
Gupta, H. P., (A)92A
Gupta, N., (A)46A
Gupta, R. K., (A)49A, 50A
Gupta, S., (A)166A
Gupte, M. D., (A)103A, 147A, 147A, (O)563
Gurumurthy, P., (A)372
Gurunath Babu, V. V., (A)25A
Gutierrez, M., (A)23A, 143A
Gwanzura, L., (A)100A, 100A
Gyi, M. M., (A)13A

Ha, Y.-M., (A)96A
Haanen, J. B. A. G., (A)139, 489, 102A
Haas, M., (A)7A, 308, 314, 107A, 110A, 116A
Haas, W. H., (A)372, 505
Habtemariam, H., (C)632
Hackett, M., (A)104A
Hadley, W. K., (A)168
Haeseleer, F., (A)372
Hagio, S., (A)124A
Hahn, M., (A)309
Hamerlijnck, S., (A)16A
Hamerlinck, F. F. V., (A)25A
Hamid, M. E., (A)495
Hance, A. J., (A)178
Haniez, F., (A)369
Hansen, E. B., (A)492
Harboe, M., (A)136, 143, 162, 182, 182, 496, 662, 84A, 87A
Hardie, R. M., (A)163
Harding, D. R. K., (A)652
Hardwicke, P. M. D., (A)79A
Hari, L., (A)5A
Harish, B. N., (A)352
Harris, D., (A)349
Harris, D. P., (A)129, 180, 661
Harris, E. B., (A)143, 15A, 308, 315, 338, 109A, 116A
Harris, G. S., (A)663
Harrison, D. K., (A)657
Hart, R., (A)168A
Hartman, S., (A)374
Hartskeerl, R. A., (A)166, 179, 114A
Hasan, A., (A)667
Hashim, F. A., (A)341
Haskard, D., (A)156
Hastings, R. C., (A)15A, 308, 315, 338, 342, 78A, 78A, 105A, 116A, (O)394, (Ob)112
Hatano, K., (A)151A
Hatfull, G. F., (A)358, 358, 495, 507
Hauhner, C. Z., (A)342
Haumont, M., (A)372
Hayashi, H., (O)609
Hayran, M., (A)663
He, C., (A)9A
He, G., (A)37A, 52A
He, R., (A)15A
He, Y., (A)71A
Hebert, M. F., (A)122
Hector, J. S. R., (A)374
Heerkens, Y. F., (A)340, 143A

Hefta, S. A., (A)115A
Heifets, L., (A)375
Henry, D., (A)135A
Henry, D. E., (A)135A
Herath, U., (A)134A
Herbert, D., (A)142
Hermans, C. J., (A)359
Hermans, P., (A)180, 378
Hermans, P. W. M., (A)166
Hermon-Taylor, J., (A)170
Hernandez, O., (A)57A, 647
Hernandez-Berumen, A., (A)141A
Hernandez Frontera, E., (A)505
Heron, I., (A)152, 365
Herrera, M., (A)63A
Herrera, T., (A)176
Heurich, A. E., (A)155
Heym, B., (A)163, 661
Hicks, K. E. S., (A)660
Hidaka, T., (A)337, 345, 503, 77A
Hieselaar, L., (A)119A
Hill, C., (A)145
Hill, D. F., (A)142
Hinshelwood, S., (A)163
Hioki, K., (A)362
Hirata, T., (O)415
Hirsch, D. S., (A)131
Hirzel, C., (A)155A
Hiwase, N., (A)58A
Hjelm, U., (A)506
Hla-Htut-Lwin, (A)42A
Ho, C. T., (A)355
Hoard, A., (A)162A
Hodgson, A. L. M., (A)159
Hoeksma, A. F., (A)161A
Hoel, T., (A)506
Hoffner, S. E., (A)506
Hogeweg, M., (A)20A, 119A
Holliman, R. E., (A)370
Holobaugh, P., (A)138
Honda, I., (A)506
Hong, B., (A)41A, 55A
Honore, N., (A)358, 358, 359, 108A, (O)600
Hontebeyrie-Joskowicz, M., (A)352
Hoop, R. K., (A)373
Hopfer, R. L., (A)181
Horsburgh, C. R., (A)371
Horwitz, M. A., (A)171
Hosoe, K., (A)337
Hospedales, C. J., (A)65A
Houssaini-Iraqui, M., (A)373
How, W., (A)73A
Howe, R., (A)21A, 30A, 341, 105A
Howe, R. C., (A)105A
Hsieh, P.-C., (A)373
Htoon, M. T., (A)126, 501
Hu, L., (A)10A
Hu, L.-F., (A)118A, 118A
Hu, R., (A)70A
Hua, J.-X., (A)45A, 65A
Huang, C. Y., (A)10A
Huang, H., (A)52A
Huang, L., (A)54A
Huang, W., (A)67A, 70A
Huang, W.-B., (A)5A
Huang, X., (A)32A
Huebner, R. E., (A)374
Hunt, R., (O)394
Hunter, S., (A)76A, 103A
Husain, A., (A)650
Husain, S., (A)649, 650, 151A, 160A
Huson, A., (A)142A
Hussain, R., (A)125, 362, 499, 84A, 88A, 93A, 104A
Hussain, S., (A)342
Hussein, N., (A)125
Huygen, K., (A)134, 495, 653, 653, 660, 662, 86A, 89A, 91A, (O)29

Ibanez, M. A., (A)485, 77A, 116A
Ibe, M., (A)491
Ibragimov, C., (A)113A
Idunov, V., (A)56A
Ieven, M., (O)389
Ignacio, B., (A)17A, 17A, 18A, (O)389
Iguchi, K., (A)145
Ikelo, C., (O)542
Ilagan, R., (A)17A
Iles, P. B., (A)173
Ilias, M. I., (A)167A
Ilunga, N., (A)97A
Imaizumi, M., (A)124A
Imamura, S., (A)348
Imboden, P., (A)497
Inamine, J. M., (A)492, 493
Indira, C., (A)59A
Ingledew, N., (A)94A
Innes, J. A., (A)173
Inoue, T., (A)362
Inui, S., (A)348
Iralu, J. V., (A)662
Iranmanesh, A., (A)81A
Iredell, J., (A)163
Irshaid, Y. M., (A)338
Irtuganova, O., (A)111A
Isa, R. I., (A)28A, 46A, 46A, 133A, 134A, 156A
Iseman, M. D., (A)176, 371
Ishaque, M., (A)112A, (C)294
Ishida, Y., (A)71A, 169A
Ishiko, H., (A)377
Islas, A., (A)90A, 101A, 101A
Islas-Rodriguez, A. E., (O)245
Isukapally, M., (A)125A
Itakura, K., (A)336
Ivanyi, J., (A)130, 159, 159, 180, 349, 661
Izumi, S., (A)145, 348, 355, 356, 362, 67A, 114A, 120A, 120A, 120A

Jabur, R., (A)29A, 29A
Jackson, K., (A)164, 369

Jacob, M., (A)75A, 122A, 125A, (O)550
Jacob, W., (A)487
Jacobs, J. M., (A)489
Jacobs, M R., (A)662
Jacobs, P., (A)372
Jacobs, W. R., Jr., (A)358, 492, 494, 507
Jacobson, R. R., (A)315
Jacobus, D. P., (A)485
Jacyk, W. K., (A)127, 650
Jadhav, V. H., (A)351
Jaffero, G., (A)144A
Jagavkar, C. K., (A)8A
Jagtap, B., (A)8A
Jain, J. K., (A)3A, 8A
Jain, V. K., (A)350
Jaiswal, C. S., (A)166A
Jakeman, N., (A)42A
Jakeman, P., (A)42A, 52A
Jambroes, M., (A)16A
Jamet, P., (A)6A, 7A, 8A, 21A, 647
Jansen, H. M., (A)180, 670
Janson, A., (A)84A
Janson, A. A. M., (A)133
Janvier, F., (A)71A
Jarings, G. H., (A)114A
Jarlier, V., (A)144
Jaswal, S., (A)361
Jautzke, G., (A)175
Jayakumar, J., (A)12A, 650, 650
Jayapal, V., (C)462
Jayaraj, P., (A)140A
Jayaraj, V. P., (A)3A
Jayaraman, R., (A)39A, 51A
Jayasheela, M., (A)353, 89A, 90A
Jeevan, A., (A)77A
Jehin, E., (A)19A
Jennekens, F. G. E., (A)126
Jennekens-Schinkel, A., (A)126
Jenner, P. J., (A)99A, 106A, 115A
Jentoft, J. E., (A)373
Jerskey, R., (A)159A
Jesudasan, K., (A)3A, 20A, 363, 45A, 58A, 64A, 69A, 151A
Jha, P. K., (A)127
Ji, B.-H., (A)164, 310, 374, 647, 8A, 54A
Ji, Y. E., (A)142
Jian, D., (A)10A
Jiang, C., (A)45A, 64A, 65A
Jiang, Z., (A)41A, 55A, 148A
Jimenez, C., (A)17A, 17A, 18A
Jing, B., (A)62A
Job, C. K., (A)12A, 145, 342, 78A, (O)270, 394
Jogaikar, D. G., (A)351
John, A., (A)147A
John, K. R., (A)41A
Johnson, I., (A)163A
Johnson, J. D., (A)370
Johnson, N. M., (A)503
Jones, P., (A)135
Joone, G. K., (A)124
Joseph, A., (A)3A
Joseph, M., (A)163A
Joseph, P., (A)649
Joshi, S., (A)359, 72A, 140A
Josse, R., (A)63A
Jurado, R., (A)30A
Juscenko, A., (A)17A, 66A, 66A, 95A, 95A, 105A

Kadyan, R. S., (A)19A
Kahkonen, M. K., (A)342
Kailash, S., (A)98A
Kakar, S., (A)137A
Kalengayi, M. R., (A)97A
Kalkut, G., (A)507
Kallenius, G., (A)506
Kamala, (A)148A
Kamaludin, F., (A)657
Kamholz, S. L., (A)155
Kampirapap, K., (A)107A, 108A
Kanaujia, G. V., (A)143, 114A
Kandaswami, V., (A)57A
Kang, W., (A)54A
Kannan, K. B., (A)98A
Kannan, N., (A)342
Kansy, M., (A)14A
Kanwar, A. J., (C)467, (E)455
Kaplan, G., (A)349, 353, 489, 102A
Kar, H. K., (A)18A, 18A, 24A, 345, 349, 357, 95A, 126A
Karacorlu, M. A., (A)26A, 117A
Kartikeyan, S., (A)151
Kashala, L. O., (A)97A
Kashala, O., (A)97A
Kashiwabara, Y., (A)362, 109A, 114A
Kashyap, A., (A)123
Kathe, V., (A)72A, 140A
Kathet, B., (A)73A
Katkar, K. N., (A)8A
Katoch, K., (A)2A, 7A, 13A, 19A, 350, 351, 67A, 114A, 114A, 116A, 122A, 1233, (O)433
Katoch, V. M., (A)7A, 13A, 143, 307, 350, 351, 98A, 113A, 114A, 114A, 116A
Kauer, J. M. G., (O)592
Kaufmann, S. H. E., (A)133, 316
Kaulagekar, A. A., (A)131A
Kaur, H., (A)18A, 349, 357, 656, 95A, 123A, 130A
Kaur, I., (A)359, 652
Kaur, S., (A)128, 342, 359, 361, 361, 652, (C)292, 467, 473, (E)455
Kawajira, K., (A)506
Kawamata, K., (A)506
Kawamura, I., (A)165
Kawatsu, K., (A)355, 356, 362, 120A, 120A
Kazda, J., (A)165, 17A, 33A, 376
Kazen, R., (A)16A, 150A, 158A
Kebret, Z., (A)150A, 158A
Kemper, C. A., (A)165
Kempsell, K. E., (A)142
Kent, R. J., (A)165
Kerketta, W., (A)28A

Kern, P., (A)305
Khajuria, A., (E)455
Khan, M. B., (A)347
Khan, M. I., (A)166A
Khan, N. A., (A)127A
Khan, S. A., (A)32A
Khandekar, P. S., (O)227
Khanolkar-Young, S., (A)134
Khare, S., (A)96A
Kharkar, R. D., (A)34A, 57A
Kher, S. K., (A)149
Khuller, G. K., (A)656
Kiber, H., (N)641
Kieser, T., (A)507
Kilburn, J. O., (A)154, 156, 370
Kim, J.-D., (A)155, 360, 97A, (O)236
Kim, K.-H., (A)114A
Kim, N.-H., (A)96A
Kim, S. H., (A)665
Kim, S. K., (A)155
Kinda, K., (A)137A
Kindelan, J., (A)30A
Kinfu, Y., (A)148A
Kingsley, S., (A)46A, 141A, 141A, 142A, 152A, 152A
Kini, M. S., (O)25
Kiran, K. U., (A)22A, 145A
Kiran, U., (A)24A, 154A, 157A
Kirschner, P., (A)372
Kishore, V., (A)23A, 132A
Kitajima, S., (A)120A, 124A
Kittampol, K., (A)656
Kitumba, A. R., (A)65A
Klaczkiewicz, K., (A)492
Klapper, P. J., (A)155
Klatser, P. R., (A)23A, 25A, 359, 362, 498, 67A, 75A, 107A, 108A, 109A, 111A, 114A
Klebnikov, V. S., (A)181
Klein, R., (A)507
Klemens, S. P., (A)166, 166
Klokke, A. H., (O)556
Klopman, G., (A)662
Ko, J. L., (A)139
Kocagoz, S., (A)663
Kocagoz, T., (A)663
Kocaslan, S., (A)135A
Kochar, D. K., (A)146A, 158A
Kochar, V., (A)130A
Kochi, A., (A)668
Kohli, M., (A)361
Kohsaka, K., (O)415
Kolars, J. C., (A)123
Kolattukudy, P. E., (A)168
Kolk, A. H. J., (A)134, 139, 166, 179, 180, 670, 90A
Koller, B., (A)161
Kontochristopoulos, G., (A)35A, (C)634
Kopparty, S. N. M., (A)138A
Kornbluth, R. C., (A)169
Koryakin, V. A., (A)167
Kosuge, K., (A)491
Kothandapani, G., (A)39A
Kotilinek, L., (A)659
Kovindha, A., (A)148A
Kraakman, E. M., (A)489, 102A
Kraft, G. H., (A)148A
Krahenbuhl, J. L., (A)78A, 102A
Krajewska, M. M., (A)486
Krasnoproshina, L. I., (A)181
Kress, Y., (A)665
Krieg, S., (A)143, 174, 496
Kripke, M. L., (A)77A
Krishnamurthy, P., (A)339, 349, 73A
Krishnan, S. A. R., (A)51A
Kronenberg, M., (A)140
Krotoski, W. A., (A)342, 78A
Kubeyinje, E. P., (A)126
Kudalkar, J., (A)85A, 96A
Kudalkar, J. L., (O)421
Kudoh, S., (A)145
Kuijper, S., (A)134, 166, 180, 670
Kulkarni, A., (A)83A
Kultur, A., (A)26A
Kumar, A., (A)368
Kumar, B., (A)128, 361
Kumar, J. S., (A)28A
Kumar, K. S., (A)28A, 28A, 138A
Kumar, N., (A)33A
Kumar, R., (A)3A
Kumar, S. V., (A)125A
Kumar, V., (A)350, 110A
Kumararatne, D. S., (A)173
Kumaresan, J. A., (A)67A, 128A
Kunimoto, D., (A)496
Kunio, K., (A)73A
Kuriyama, T., (A)491
Kurnia, D., (A)165A, 167A
Kurup, A. M., (A)138A
Kuznetsov, A. A., (A)173
Kyaw-Tin, (A)42A
Kyriakis, K., (A)35A

Labrousse, V., (A)124, 137
Lacey, S., (A)43, 38A
Lachat, J. J., (A)120A
Lafratta, T. E., (A)4A
Lagranderie, M., (A)142
Lakerveld-Heyl, K., (A)340
Lal, H., (A)350
Lalande, V., (A)374
Lalu, T., (A)89A
Lam, N. N., (A)64A
Landge, K., (A)51A
Landolt, H., (A)486
Landry, M. T., (A)78A
Laneelle, G., (A)168
Laneelle, M. A., (A)152, 162, 168, 664
Lapierre, S., (A)669
Lapinsky, S. E., (A)126
Larsson, L., (A)152, 173, 176, 658
Lathigra, R., (A)159, 349

Launois, P., (A)134, 350, 358, 495, 653, 653, 86A, 87A, 89A, 91A, (O)29, 214
Lavania, R. K., (A)122A, (O)433
Lawrence, V., (A)127A, 135A
Lawson, A. M., (A)498
Lazard, T., (A)663
Lazovskaya, A., (A)113A
Le, D. K., (A)61A
Le, T. T., (A)61A
Learn, D. B., (A)121
Leboeuf, M. A., (A)59A, 158A, 164A
Lebrun, L., (A)167
Lechat, M. F., (A)68A, 69A
Leclerc, C., (A)142
Ledesma, E., (A)33A
Lee, B. L., (A)665
Lee, J. B., (A)92A
Lee, J. D., (A)167
Lee, J. T., (A)167
Lee, M., (A)20A
Lee, M. G., (A)167
Lee, M.-K., (A)360
Leelabai, G., (A)353
Legua, P., (A)49A, 49A, 63A, 131A
Leguizamon, O. R., (A)314, 14A
Lehman, L., (A)144A, 145A, 147A, 158A, 158A, 163A, 164A, 169A
Lehner, T., (A)667
Lehrer, A., (A)59A, (O)586
Lemmer, J., (A)344
Lenzi, M. E. R., (A)50A
Leonard, R. B., (A)156
Leonardi, C. L., (A)377
Leoture, A., (A)54A, 168A
LeMaitre, C., (A)148A, 150A, 157A
LePoole, C., (A)105A
LePoole, I. C., (A)174
Lessa, Z. L., (A)43A, 47A, 47A, 47A, 165A
Leveille, C. A., (A)4A, 24A, 28A, 32A, 48A, 154A
Lever, P., (A)148, 16A
Leviatan, A., (A)150
Levin, M. E., (A)495
Levy, L., (A)116A, (C)629
Levy-Frebault, V. V., (A)152, 167, 179
Lew, J., (A)92A, 140A
Lew, W., (A)92A
Lewallen, S., (A)341, 118A, 118A
Lewin-Smith, M. R., (A)123A
Lewis, D., (A)126
Li, D., (A)10A
Li, F., (A)61A, 151A, 161A
Li, H., (A)61A
Li, H.-Y., (A)5A, 60A, 118A, 118A, (O)1
Li, J., (A)61A, 123A
Li, M.-H., et al., (A)134
Li, Q., (A)52A
Li, S., (A)31A, 54A
Li, T., (A)61A, 68A
Li, W., (A)27A, 61A, 64A, 67A, 70A, 121A
Li, W.-H., et al., (A)338
Li, W.-Z., (A)501, 10A, 45A, 65A, 68A, 156A
Li, X., (A)67A, 88A, 88A
Li, Y., (A)28A, 32A, 92A
Li, Z., (A)37A
Liang, J., (A)52A
Liang, Z., (A)16A, 32A, 42A
Lienhardt, C., (A)145A, 157A
Lik, W., (A)155A
Lim, J. T.-E., (A)648
Lima, V. J., (E)102
Limb, D. I., (A)663
Limbassa, J., (A)362
Limpaiboon, T., (A)358
Lin, Y., (A)32A
Lindner, B., (A)7A, 310, 107A, 110A, 116A
Ling, X., (A)148A, 161A
Liossi, A., (C)634
Lisboa, Z., (A)34A
Liu, F., (A)67A, 70A
Liu, G., (A)111A
Liu, G. C., (A)52A
Liu, H., (A)28A
Liu, J., (A)82A, 123A
Liu, K., (A)151A
Liu, X., (A)10A
Liu, Z., (A)15A, 79A
Livelo, J., (A)17A, 17A, 18A
Ljungqvist, L., (A)182
Llopis, L., (A)82A
Llorca, J., (A)33A
Lo, J., (A)10A
Lobo, D., (A)11A, 14A, 32A, 39A, 39A, 51A, 53A, 129A, 148A, (C)462
Locksley, R. M., (A)76A, (O)398
Lockwood, D. N. J., (A)23A, 34A, 84A, (O)9
Lombardi, C., (A)56A
Long, Z., (A)62A
Longrono, C., (A)30A
Lopes, V. G. S., (A)122A
Lopez, S. S., (A)148
Lopez Bravo, L., (A)149
Lopez Pla, J., (A)17A
Lora, M., (A)501
Lotz, B. P., (A)127, 650
Louhenapessy, A. A., (A)40A
Louis, S., (A)42
Lounis, N., (A)164
Love, S. G., (A)652
Lowe, J. G., (A)129
Lownie, J. F., (A)344
Lowrie, D., (A)497
Lowrie, D. B., (A)158, 354
Lu, B., (A)346
Lu, D., (A)31A
Lu, J., (A)136A
Lu, M., (A)70A
Lu, P., (A)37A, 61A
Lu, S. Z., (A)366
Lu, X.-H., et al., (A)145
Lu, Z., (A)31A

Lubbers, W. J., (A)20A
Lucas, S. B., (A)158, 343, 104A, (O)270, 542
Lukacs, K., (A)354
Lukey, P. T., (A)175
Luo, J., (A)10A, 62A, 64A, 64A, 68A, 69A, 156A
Luo, X., (A)64A
Luo, X.-G., (A)10A, 62A, 64A, 68A, 69A, 156A
Luquiaud, P., (A)72A, (O)533
Luquin, M., (A)152
Lussow, A. R., (A)135
Luzhnova, S., (A)17A
Lyon, S., (A)1'58

Ma, J., (A)9A, 31A, 92A
Ma, W., (A)9A
Maakaroun, M. J., (A)152A
MacArthur, A., (A)156A
Macedo, P. M., (A)160
MacFarlane, A., (A)362, 89A
Machado, A. M., (A)95A
Machtelinckx, L., (A)108A
Mack, P. A., (A)75A, 79A
Mackall, J. C., (A)664
Mackenzie, C. R., (A)175
Macotela, E., (A)88A
MacPhail, A. P., (A)126
MacRae, M. A., (A)53A
Macrery, R., (A)32A
Madarang, M. G., (A)131
Madjid, B., (A)67A, 75A
Madsen, L. A., (A)371
Maeda, H., (A)503
Maeda, Y., (A)355, 356, 120A, 120A
Maes, P., (A)177
Maestre, J. L., (A)13A, 647
Maestre Mesa, J., (A)109A
Mafoyane, N. A., (A)650
Magalhaes, E., (A)164A
Magalhaes, M. C. C., (A)43A, 69A, 139A, 166A
Maganu, E. T., (A)128A
Magdeleine, J., (A)54A
Maguina, C., (A)49A, 49A, 63A
Maguire, J. H., (A)662
Mahadevan, P. R., (A)15A, 307, 359, 83A, 98A
Mahajan, M. K., (A)19A
Mahajan, P., (A)351
Mahalingam, V. N., (A)147A, 147A
Mahenthiralingam, E., (A)496
Mahesh, S. P., (A)127A
Maini, R. N., (A)156
Maisha, S., (A)164A
Maisonnette, M. J., (A)166A
Majoroh, T. O., (A)42A, 501, 161A
Majumdar, S., (A)168
Makino, M., (A)91A, 114A
Malau, C., (A)47A
Malaviya, G. N., (A)342, 649, 650, 110A, 142A, 151A, 160A
Malo, B., (A)137A
Malo, M., (A)132A
Malta, A. M., (A)12A, 94A
Malta, A. M. C., (A)23A
Mane, G. S., (A)34A, 57A
Mangan, J., (A)111A
Mani Mozhi, N., (A)3A, 20A, 69A
Manini, M., (A)354
Manivannan, K., (A)149A
Mann, S. B. S., (A)342
Manoj, R., (A)142A
Mao, Z., (A)61A
Marchal, G., (A)490
Marchesi, F., (A)377, 497
Margarido-Marchese, L. C., (A)124A
Marin, L. M. L., (A)162, 168, 664
Markesich, D. C., (A)170
Marlink, R., (A)97A
Maroja, M. F., (A)53A, 71A
Marques, A. B., (A)11A, 11A, 29A, 35A, 121A, 121A, 126A
Marques, L. B., (A)56A
Marques, M. A. M., (A)102A
Marques Boechat, A., (A)649
Martelli, C. M. T., (A)127, (C)461
Martin, C., (A)378
Martin, M., (A)647
Martin, P. M. V., (A)147
Martineau-Needham, D., (A)43, 38A
Martinez, A., (A)143A, 168A
Martodihardjo, S., (A)167A
Marzliak, M. C., (A)4A
Masih, M. J., (A)132A
Masih, V. K., (A)166A
Maslov, A., (A)113A, 113A, 113A
Maslow, J. N., (A)658
Mason, P. R., (A)100A, 100A
Mathai, A., (A)668
Mathai, R., (A)75A, (O)550
Mathelier, S., (A)71A
Mathews, M., (A)11A, 39A, 39A, 51A
Mathews, R., (A)162A
Mathur, A., (A)81A
Mathur, M., (A)168
Matoba, A. Y., (A)665
Matos, T. T., (A)53A, 136A
Matsuda, P. M., (A)23A
Matsui, S., (A)32A
Matsuo, K., (A)496
Matsuoka, M., (A)85A, (O)415, 609
Mattan, A., (A)14A
Matter, L., (A)497
Mauch, H., (A)175
Mauff, G., (A)487
Mauron, J., (A)15A
May, M. H., (A)157, 337
Mazumdar, S., (A)92A
Mazurek, G. H., (A)374
Mbayo, Il., (A)97A
McAdam, K. P. W. J., (A)134, 171, 23A, 93A, (O)9
McAdam, R., (A)378

McAuley, D. M., (O)16
McCarthy, P. L., (A)494
McCarthy, R., (A)497
McClean, K., (A)105A
McCormick, G. T., (A)78A
McCormick, J., (A)84A, 115A
McDermott-Lancaster, R. D., (A)111A, (O)605
McDonough, K. A., (A)665
McDougall, A. C., (A)120, 128, 343, (N)332
McFadden, J., (A)169, 362, 375, 503
McGowan, J. E., Jr., (A)666
McKee, J. J., (A)493
McKenzie, K. R., (A)352
McMurray, D. N., (A)505
McNeil, M. R., (A)152, 493
McNerney, R., (A)360
McTavish, D., (A)658
Medine, M. E., (A)148
Meghdadi, M., (A)74A
Mehra, V., (A)88A
Mehra, V. J., (A)103A
Mehta, J. M., (A)351
Meindl, W., (A)312
Melo, I. S., (A)30A, 122A
Meloen, R. H., (A)133
Melsom, R., (A)21A, 21A, 21A, 105A
Menaka, K., (A)89A, 90A
Mendelow, B., (A)126
Mendes, M. F., (A)73A
Mendez-Samperio, P., (A)654
Mendez-Tovar, L. J., (A)46A
Mendonca, L., (A)144A
Meng, M., (A)31A, 32A, 92A
Mengue, S., (A)143A
Menz, B., (A)84A
Menzel, S., (A)21A, 21A, 105A
Merad-Boudia, A., (A)70A
Merlin, V., (A)59A, 94A
Metaphat, C., (A)40A
Metchock, B., (A)666
Metello, H. N., (A)43A, 47A, 47A, 47A, 165A
Meyers, W. M., (A)12A, 305, 75A, 75A, 76A, 79A, 123A, (O)236, 270
Meylan, P. R. A., (A)169
Meyohas, M. D., (A)369
Meziou, T. J., (A)54A
Miao, Z., (A)131A
Miao, Z., et al., (A)9A
Michalany, N. S., (A)29A, 29A
Miguel, C. P., (A)99A, 121A
Miko, R., (A)150A
Miko, T., (A)21A, 21A, 21A, 30A, 654, 105A
Miko, T. L., (A)148A
Mikotawells, S., (A)157
Millan, J., (A)127, 350, 495, 653, 653, 86A, 89A, (O)214
Miller, P., (A)138
Millership, S. E., (A)170
Minagawa, F., (A)346, 346, 78A, 85A
Mincek, M. A., (A)153
Mindermann, T., (A)486
Minnikin, D. E., (A)145, 152, 495, 499, 506, 670
Minnucci, F., (A)91A
Minocha, Y. C., (A)123A
Miorner, H., (A)176
Miranda, A., (A)99A, 121A
Miranda, D., (A)126A
Miranda, G., (A)143A
Mischner-Van Ravensberg, C. D., (A)340
Mishra, B., (A)342
Misonne, M.-C., (A)369
Misra, A. K., (O)428
Misra, R. S., (A)18A, 18A, 22A, 345, 349, 357, 59A, 85A, 89A, 92A, 95A, 99A, 126A, (O)259
Mistry, N., (A)87A, 100A
Mistry, Y., (A)104A
Mitchell, D. M., (A)181
Mitchell, P. D., (E)283
Mitchell, P. S., (A)666
Mitchison, D. A., (A)158
Mitsuda, T., (A)491
Mitsuyama, M., (A)165
Mittal, K., (A)138
Mittal, R. A., (A)350
Miyachi, Y., (A)348
Miyazaki, N., (O)597
Mizushima, M., (A)169A
Mizushima, Y., (A)667
Mobayen, M. H., (C)474
Modlin, R. L., (A)139, 140, 355, 366, 655, 88A
Moet, F. J., (A)19A
Mohagheghpour, N., (A)76A, 103A, (O)398
Mohammed, A. H. A., (A)33A
Mohapatra, D. C., (A)124A
Mohareb, R. W., (A)24A
Molina, J., (O)185
Molvaer, R., (A)137A
Momeni, A., (A)74A
Momotani, E., (A)135
Moncada, B., (O)581
Mong, A., (A)151A
Monizpereira, J., (A)140
Monoharan, A., (A)117A
Monson, V., (A)137A
Monteiro, L., (A)26A, 26A
Montreewasuwat, N., (A)108A
Mor, N., (A)363, 375
Moraila, G., (A)88A
Moraila-Moya, G., (A)141A
Morais, S. J., (A)35A
Morales, R., (A)101A, 101A
Morales-Ortiz, R., (O)245
Moreira, A. L., (A)353, 489, 87A, 95A, 98A, (O)204
Moreira, M. B. R., (A)166A
Moreira, T. A., (A)11A
Moreira Neto, J. A., (A)152A
Moreno, C., (A)129, 159, 179, 180, 368, 661
Morens, D., (A)22A
Morgan, A., (A)46A
Mori, S., (A)143A
Moriarty, K. M., (A)142

Morini, J., (A)94A
Morini, J. C., (C)468
Morita, C. R., (A)136
Morris, S. L., (A)142, 664
Moss, M. T., (A)170
Motta, C. P., (A)71A
Moudgil, K. D., (A)493
Moulia-Pelat, J.-P., (A)147, 64A, (O)199
Mounden, J. C., (A)343
Mous, H. V. H., (A)100A, 100A
Mroczkowski, T. F., (A)342
Mudarikwa, L. C., (A)44A
Mughandira, K., (A)32A
Mukherjee, A., (A)18A, 18A, 22A, 345, 349, 357, 649, 95A, 122A, 126A, (O)433
Mukherjee, R., (A)138, 149, 18A, 18A, 22A, 345, 349, 357, 87A, 90A, 93A, 95A,
104A, 104A, 126A, 1333
Muliyil, J., (A)3A, 24A, 41A, 153A, (C)460
Muller, H. J., (A)165, 376
Muller, K., (A)165, 376
Mullins, R. J., (A)135
Murata, J., (A)356
Murphy, D., (A)374
Murray, A., (A)142
Murray, L., (A)81A
Murray, L. P., (A)7A, 76A, 76A, 78A, 81A, 81A, 82A, 103A, (O)398
Murtaza, A., (A)85A
Murthy, P. A., (A)668
Mutatkar, K., (A)48A, 63A
Mutatkar, R. K., (A)127A, 130A, 135A
Muthusamy, P., (A)42
Mutis, T., (A)351, 489, 102A, 105A
Muzaffarullah, (A)157A
Muzaffer, (A)154A
Myint, T., (A)126, 501

Na, G.-Y., (A)96A
Naafs, B., (A)139, 25A, 36A, 90A, , 100A, 155A
Nadkarni, N. J., (O)25
Nagai, R., (A)377
Nagai, S., (A)152, 182
Nagaraj, K., (A)34A, 57A
Nagarajan, M., (A)5A
Nagaraju, B., (A)147A, 147A
Nagrajan, K., (A)365
Naik, S., (A)4A, 55A, 55A, 72A, 72A, 97A, 140A
Nair, J., (A)142, 664
Nair, S., (A)357
Nair, S. C., (A)359
Nair, S. K., (A)349, 95A
Nakahara, K., (A)377
Nakami, J., (A)45A
Nakamura, K., (A)362
Nakamura, M., (O)415
Nakanaga, K., (A)85A
Nakasone, A. S., (A)160
Nakata, N., (A)348
Nakatani, C., (A)124A
Nakazawa, T., (A)32A
Nakuci, M., (A)27A, 45A
Nakuci, M. M., (A)27A, 45A
Namafoyane, N. A., (A)127
Nambudripa, K., (A)39A
Nambudripad, K., (A)51A
Namiki, M., (A)341
Naoumi, C., (A)35A
Narang, P., (A)96A
Narayan, V., (A)368
Narayana, A., (A)372
Narayanakumar, T. S., (A)149A
Narayanan, P. R., (A)158
Narayanan, R., (A)11A, 53A
Narayanan, R. B., (A)110A, 122A, (O)433
Nascimento, M. L. P., (A)136A
Nasr, E. M., (A)17A, 33A, 33A
Nassos, P., (A)168
Nataraj, A., (A)177
Nath, I., (A)308, 85A, 92A, 99A, (O)259
Natrajan, M., (A)351, 2A, 7A, 13A, 19A
Natu, M. V., (A)19A
Naudin, J.-C., (A)155A, 165A
Naumov, V., (A)34A, 35A, 101A
Navalkar, R. G., (A)347
Navon, L., (A)128A
Nayak, H. V., (A)59A
Nazareno, J. B., (A)75A
N'Diaye-Niang, M., (A)350, 89A
Neelan, P. N., (A)349
Neff, G., (A)151
Negesse, Y., (A)654
Nei, Z., (A)10A
Neimes, R. E., (A)342
Nelson, A., (A)123A
Nelson, D. L., (A)99A
Nelson, K. E., (A)131, (C)460
Nery, J. A. C., (A)12A, 12A, 23A, 86A, 87A, 94A, 95A, 121A, (O)204
Neubert, D., (A)136
Neubert, R., (A)136
Neupane, K., (A)46A
Neupane, K. D., (O)35
Newell, J. N., (O)556
Newman, G., (A)494
Newman, I., (A)183
Newnham, R., (A)171
Newton, S., (A)358
Ngamying, M., (A)108A
Ngoc, L. N., (A)147, (O)199
Nguyen, H. V., (A)41A
Nguyen, N. T., (A)41A
Nguyen, S. X., (A)41A
Nguyen, V. T. J. S., (A)147
Niang, K., (A)358
Niang, M. B. N., (A)653
Niang, M. N., (A)495, 653, 86A
Nicholl, A., (A)144A
Niemczyk, S., (A)658

Nikaido, H., (A)665
Ning, Y., (A)69A
Nishino, H., (A)344
Nishioka, S. A. N., (C)459
Niu, S., (A)151A
Nobleraj, A., (A)32A
Nogueira, A. C., (A)136
Nogueira, J. M., (A)33A
Nogueira, W., (A)4A, 43A, 47A, 47A, 47A, 165A
Nolan, C. M., (A)170
Nolte, F. S., (A)666
Nomaguchi, H., (A)491, 85A
Nomoto, K., (A)165
Nomura, T., (A)362
Nong, Y., (A)70A, (C)631
Noonan, L. C., (A)493
Noordeen, S. K., (A)149
Norelia, M. E., (A)71A
Noriega, A. R., (A)494
Novick, A., (A)364
Nunes, A. S. D., (A)11A
Nunn, P., (A)171
Nunn, P. P., (A)502
Nunzi, E., (C)464, 471
Nyalugwe, S., (A)32A
Nye, P. M., (A)360

Obura, M., (A)36A, (O)542
O'Connor, G. T., (A)658
O'Connor, R., (A)15A, 15A
Odawa, B. A., (A)36A
Odhiambo, J., (A)171
Ogata, K., (A)376
Oh, C.-S., (A)112A, 116A
Ohara, N., (A)496
Ohkawa, S., (A)75A, 79A
Ohkubo, A., (A)377
Ohmen, J. D., (A)139, 140, 355
Ohtaka, K., (A)343
Okello, C. M., (A)36A
O'Kennedy, R., (A)15A, 15A
Oksenhendler, E., (A)660
Okuku, P., (A)36A, (O)542
Okuzumi, K., (A)377
Okwumabua, O., (A)666
Olcen, P., (O)571
Oliveira, E. R., (A)135A
Oliveira, J., (A)136A
Oliveira, M. L. W., (A)55A, 135A, 136A, 166A
Ollivier, J., (A)71A
Olphe-Galliard, P., (N)640
Olsson, B., (A)658
Omwega, M., (A)171
Onozaki, K., (A)348, (O)609
Onunu, A. N., (A)126
Onyi, G. O., (A)154
Oommen, P. K., (A)142A
Oommen, T., (A)19A, (C)636
Oomoto, Y., (O)609
Oostendorp, R., (A)145A
Opromolla, D. W., (A)4A
Orefice, F., (A)26A, 26A, 26A, 26A, 26A, 26A, 27A, 123A, 126A, 152A
Orege, P. A., (A)36A, (O)542
Orme, I. M., (A)132, 375, 666, 666
Orsini, B., (A)144A, 147A, 163A
Osato, M. S., (A)665
Osipov, A., (A)123A
Oskam, L., (A)114A
Ossent, P., (A)373
O'Sullivan, J. F., (A)124, 15A, (O)406
Ottenhoff, T. H. M., (A)133, 351, 489, 86A, 102A, 105A
Ozawa, T., (A)344, 346, 346
Ozel, I., (A)5A
Ozhara, S., (A)663

Pablos Mendez, A., (A)370
Paccaly-Moulin, A., (A)374
Pade, S., (A)3A
Pai, R. R., (A)58A
Pai, V. V., (A)8A, 15A, 30A, 58A
Pal, D., (A)112A
Pal, P. G., (A)171
Palenque, E., (A)494
Palittapongarnpim, P., (A)496
Palla, J., (A)127A
Pallares, F., (A)488
Pan, Y., (A)6A
Pandhi, R. K., (C)293
Pandiaraj, L., (A)39A, 51A
Pandya, S., (A)159A
Pang, H., (A)37A
Panneerselvam, V., (A)149A
Pant, M. C., (A)81A
Panteleos, D., (A)35A, (C)634
Papa, F., (A)502, (O)44
Pappo, O., (A)150
Paranjape, R., (A)355
Pararste, S., (A)166A
Pardo, R. J., (A)35A
Paredes, A. M., (A)63A
Paredes, S., (A)59A
Parida, S. K., (A)87A
Parikh, K., (A)371
Park, B. K., (A)121
Park, C. Y., (A)167
Parkash, O., (A)33A, 85A, 96A
Parreira, V., (A)11A
Parreiras, S., (A)164A
Parrilla, M., (A)17A, 17A, 18A
Parrilla, M. L. R., (O)66
Parshin, M., (A)66A
Partida, S., (A)101A
Pasquier, R., (A)145A, 157A
Pasten, S., (A)488
Pasvol, G., (A)180, 661
Patarroyo, M. E., (A)309

Patel, B. R., (A)357
Patil, K. M., (A)142A, 142A
Patil, M., (A)116A
Patil, M. A., (A)7A, 13A, 143, 113A, 114A, 114A
Patil, V., (A)655
Patki, A. H., (C)472
Patout, C. A., (A)364
Pattanapanyasat, K., (A)104A
Pattyn, S. R., (A)66A, 107A, (E)76, (O)389
Paulraj, K., (A)141A
Pavithran, K., (A)650
Peake, P. W., (A)352
Pean, C., (A)4A, 24A, 28A, 29A, 32A, 48A, 71A, 154A
Pedraza, S., (A)101A
Pedrosa, V. L., (A)53A, 136A
Pedroza, S. C., (A)127
Pelaez, E., (A)486
Penland, R., (A)665
Penna, G. O., (A)38A, 43A, 53A, 66A, 139A, 139A, 166A
Penna, M. L., (A)94A
Penneys, N. S., (A)377
Pennini, S., (A)71A
Pennini, S. N., (A)11A, 122A
Perani, E. G., (A)8A, 108A, 647, (O)600
Pereira, A., (A)486
Pereira, G. F. M., (A)38A, 43A, 53A, 66A, 139A, 139A, 166A
Pereira, G. M. B., (A)87A, 95A
Pereira, J. H., (A)79A, 150A, 150A
Perez, M., (A)12A, 23A, 363, 133A, 133A
Perronne, C., (A)156, 172, 663
Persechini, P. M., (A)102A
Pervin, K., (A)667
Pescher, P., (A)490
Pessolani, C., (A)106A, 115A
Pessolani, M. C. V., (O)381
Peterson, E. M., (A)160
Petrofsky, M., (A)130
Petter, I., (A)159A
Pfau, R., (A)151
Philip, R., (A)153A
Phillips, M., (A)355
Phillips, N. F. B, (A)373
Piccolella, E., (A)368
Pickering, L., (A)139
Pieciak, W. S., (A)662
Piefer, A., (A)145A, 146A, 148A
Pierre Rose, M. C.-D., (A)54A
Piguet, P.-F., (A)87A
Pimentel, M. I. F., (A)98A
Pinardi, M. E., (A)99A
Pinitsoontorn, S., (A)39A, 40A
Pinto Saavedra, I., (A)34A
Pinville-Loger, P., (A)54A
Pirmez, C., (A)138
Pithie, A. D., (A)173
Pitulle, C., (A)165
Piyadasa, R., (A)134A
Plata, J. A., (O)185
Plichart, C., (A)72A, (O)533
Plichart, R., (A)147, 64A, 72A, (O)199, 533
Plikaytis, B. B., (A)173, 666
Plikaytis, B. D., (A)173
Plosker, C. L., (A)658
Pocidalo, J.-J., (A)156, 172, 663
Pohle, H. D., (A)175
Poitineau, Y., (A)648
Pollack, A. H., (A)155
Pollet, J. F., (A)372
Polozov, A. I., (A)173
Polyanskaya, I. S., (A)353
Ponniah, J. A., (A)64A
Ponnighaus, J. M., (A)343, 68A, 74A, 74A, (O)270
Porichha, D., (A)124A, (C)109, (O)428
Portaels, F., (A)173
Portugal, I., (A)140
Possani, M., (A)4A
Poulet, S., (A)661
Pourshafie, M., (A)667
Poveda, J. D., (A)167
Prabhakar, B. R., (A)9A
Prabhakar, R., (A)5A, 142, 649
Prabhakara Rao, V., (A)65A
Prabhakaran, K., (A)143, 15A, 338, 109A, 116A
Pradhan, H. M., (A)14A
Prado, M. G., (A)136A
Prakash, G., (A)104A
Prakash, K., (A)654
Prantera, C., (A)159
Prasad, H. K., (A)85A, 89A, 99A, (O)259
Prasongthrap, P., (A)45A
Prats, G., (A)152
Predasat, P., (A)133A
Premkumar, R., (A)136A, 138A, 141A
Prestidge, R. L., (A)129, 493
Procelli, S., (A)136
Prome, D., (A)168, 664
Prome, J. C., (A)168
Prueksaritanont, T., (A)122
Puche, R. C., (O)586
Pulido, R. M., (A)488
Pushpadass, C., (A)4A
Puzo, G., (A)669, 669

Qian, L., (A)94A, 109A
Qin, S., (A)32A
Qiu, J., (A)79A
Quesada-Pascual, F., (A)90A
Quimpo, R. J., (A)47A

Rachkova, O., (A)113A
Rada, E., (A)89A
Radford, A., (A)86A
Radford, A. J., (A)159
Radhakrishnan, V. V., (A)668
Radotra, B. D., (A)652
Radzioch, D., (A)367

Raes, V., (A)107A, (O)389
Raghunath, D., (A)149
Raghupati Sarma, G., (A)372
Rahelu, M., (A)173
Raheman, F., (A)93A
Rahman, F., (A)372
Rai, N., (A)346
Raios, K., (A)369
Raisys, V. A., (A)156
Raja Rao, B., (A)339
Rajacic, Z., (A)486
Rajan, M. A., (A)117A
Rajan Babu, G., (A)20A, 152A
Rajendran, V., (A)4A
Raju, M. A., (A)134A
Rakotondrajao, J., (A)343
Ramachandran, A., (A)8A
Ramakrishnan, R., (A)53A
Ramana, V., (A)156A
Ramanujam, R., (A)53A
Rambukkana, A., (A)136, 143, 174, 496, 86A
Ramesh, G. R., (A)358
Ramesh, V., (A)18A, 22A, 59A, 130A, (O)259
Rameshwar, P., (A)371
Rami, G., (A)122A
Ramirez, G., (A)101A
Ramkumar, B., (A)357
Ramos-Figueroa, A., (A)152A
Ramprasad, S., (A)153A
Ramu, G., (A)42, 15A, 85A, 99A, (O)433
Ran, S., (A)67A
Ran, S.-P., (A)60A
Ranade, M., (A)51A, 68A, 68A
Randhawa, B., (A)143, 15A, 338, 109A
Rani, R., (A)149, 100A
Rao, B. K., (A)60A
Rao, C. K., (C)106
Rao, D. N., (A)96A
Rao, K., (A)98A
Rao, K. N., (A)72A, 140A
Rao, K. S., (A)149A
Rao, M. R., (A)149
Rao, P. R., (A)82A
Rao, P. S., (A)8A, 339, 349, 73A, 89A, 90A
Rao, P. S. K., (A)147A, 147A
Rao, P. S. S., (A)64A, 69A, 75A, 119A, 119A, 119A, (O)550
Rao, R., (A)48A, 141A
Rao, R. S., (A)352
Rao, S. P., (A)174, 376, 651
Rao, V. P., (A)51A
Rao, X., (A)62A
Raspanti, E. O., (E)102
Rastogi, N., (A)124, 124, 135, 137, 159, 373, 484, 502
Ratcliffe, L. T., (A)175
Ratledge, C., (A)499, 670
Ratliff, T. L., (A)497
Ratnakar, C., (A)651
Ratnaker, P., (A)668
Ratrimoarivony, C., (A)343
Ratterree, M. S., (A)75A, 79A
Rauzier, J., (A)142
Ravi, S., (A)8A
Raviglione, M. C., (A)668
Ravikumar, L., (A)32A
Ravisse, P., (A)135
Rawashdeh, N. M., (A)338
Ray, R., (C)292
Rayner, A. B., (A)663
Raynes, J. G., (A)93A
Rea, T. H., (A)7A, 139, 140, 342, 355, 366, 655
Reategui, H., (A)63A
Rebello, P. B., (A)11A
Rebello, P. F. B., (A)38A, 71A
Recarte, M., (A)59A
Reddi, P., (A)358
Reddi, P. P., (O)227
Reddy, A., (A)164A
Reddy, B. N., (A)339, 124A, (C)109, (O)428
Reddy, B. S. N., (A)352, 651
Reddy, J. V. S., (A)337
Reddy, M. N., (A)82A
Reddy, N., (A)141A
Rees, R. J. W., (A)74A, (N)333
Reis, A., (A)487
Reis do Amaral, R., (A)136A, 139A
Reis Vianna, F., (A)11A, 11A, 29A, 35A, 121A, 121A, 126A
Reisinger, D. M., (A)139
Remacle, J., (A)357
Remick, D. G., (A)347, 370
Remold, H. G., (A)494
Ren, X., (A)51A
Ren, X., et al., (A)60A
Rene-Corail, P., (A)54A
Renuka, G., (A)650
Renzo, S., (A)57A
Ress, S. R., (A)175
Resuello, R. G., (A)75A
Revankar, C. R., (A)8A, 30A, 46A, 58A, 166A
Rhodes, L. E., (A)121
Ribas, C. B. R., (A)11A, 30A
Ribas, J., (A)11A, 122A
Richard, L., (A)137
Richardus, J. H., (A)37A
Richman, D. D., (A)169
Richter, E., (A)309
Ridel, P. R., (A)358
Ridell, M., (A)152, 495
Ridley, M., (A)121A
Rieckmann, K. H., (A)647
Rieder, H. L., (A)668
Rigouts, L., (A)173
Rinke de Wit, T., (A)84A
Rittel, W., (A)365
Rivier, F., (A)495, 653
Riviere, M., (A)669
Rivoire, B., (A)134, 366, 76A, 84A, 115A
Roberts, A. D., (A)132, 375, 666
Roberts, H., (A)147A

Roberts, J. P., (A)122
Robinson, N. M., (A)665
Robinson, P., (A)98A
Robuck, K. G., (A)115A
Rocha Santos, M. R. O., (A)31A
Roche, P., (A)135, (O)597, 592
Roche, P. W., (A)352, (O)35
Rodella, M. E., (A)144A
Rodrigues, A. L., (A)43A, 139A, 166A
Rodrigues, C., (A)26A, 27A, 123A
Rodrigues, L. C., (A)175
Rodrigues, M. L. O., (C)461
Rodrigues, M. M. P., (A)134A
Rodriguez, J., (A)647
Rodriguez, J. C., (A)486
Rodriguez, O., (A)488, 88A
Rodriguez-Dominguez, J., (A)38A, 143A, 168A
Rogers, H. J., (A)498
Rogues, A. M., (A)369
Rom, W. N., (A)671
Romain, F., (A)490
Roman, E., (A)180, 661
Romero, A., (A)56A
Romero, R. C., (A)8A
Rongong, N. T., (A)19A
Ronk, M., (A)115A
Rook, G. A. W., (A)129, 132, 368, 503
Rosa, H., (A)127
Rosa Santos, O. L., (A)136A
Roselino, A. M. F., (A)30A, 31A, (E)102
Rosenberg, E. Y., (A)665
Rosenfeld, M., (A)7A
Rosenkiewicz, J. R., (A)498
Ross, B., (A)369
Ross, B. C., (A)164, 376
Ross, E. R., (A)157
Rotta, O., (A)29A, 29A, (O)44
Rouby, D., (A)648
Rouse, D. A., (A)142, 664
Roux, J., (A)347
Roux, J.-F., (A)61A
Roy, I. S., (A)36A, 118A, (Ob)117A
Roy, P. K., (A)28A, 132A, 140A
Ruf, B., (A)175
Ruiz, G., (A)49A, 49A, 63A, 131A
Ruiz, P., (A)35A
Rupert, S., (A)153A
Rusli Ngatimin, H. M., (A)139A
Russell, D. G., (A)375

Saad, M. H., (A)122A
Saad, M. H. F., (A)80A
Sabharwal, B. D., (A)123A
Sabroza, P. C., (A)71A
Sachedeva, M., (A)663
Sada, E., (A)176
Sadahiro, M., (A)11A, 53A, 66A
Saeed, E. S., (A)365
Sagar Reddy, V. V., (A)137A
Saha, K., (A)123
Sahu, J., (A)168A
Said, G., (A)127, 352
Saikawa, K., (A)336
Saini, V., (A)350
Saint Marc, T., (A)369
Saint-Zeby, J. C., (A)54A, 168A
Saito, H., (A)345, 503, 77A, (O)250, 255
Saito, M., (A)362
Sakamoto, Y., (A)362, 78A
Salafia, A., (A)14A, 486, 149A, 160A
Salerni, G., (C)468
Salfinger, M., (A)373
Salgado, A., (O)185
Salgado, J. L., (A)87A
Salgado, S., (A)134A
Salgame, P., (A)655, 87A
Saltini, C., (A)368
Samadpour, M., (A)156
Samal, R. C., (O)428
Samant, G., (A)22A
Samanta, S. K., (A)36A, 118A, (Ob)117A
Sampaio, A. A., (A)166A
Sampaio, E., (A)98A
Sampaio, E. P., (A)353, 489, 86A, 99A, 102A, (O)204
Sampson, C., (A)99A, 103A, (O)185
Samson, P., (A)96A, 126A
Samson, P. D., (A)3A, 140A, (C)474, (O)51
Samson, R. C., (A)10A
Samuel, J., (A)28A, 28A, 28A
Sanchez, A., (A)168A
Sanchez, L. N., (A)487
Sanchez, R. M., (A)78A, (O)394
Sanchez-Garcia, J., (A)106A
Sanderson, J. D., (A)170
Sankariah, P., (A)141A
Sanlorenzo, M., (A)343
Sano, S., (A)138
Sansarricq, H., (A)54A, 63A
Santaella, C., (A)89A
Santamaria, J., (A)487
Santiago, S., (A)59A
Santos, A. R., (A)106A
Santos, W. C. S., (A)132A
Santoscoy, L., (A)101A
Saral, S., (A)127A
Sarathchandra, K. G., (A)104A
Saravanabavan, V., (A)50A, 54A, 137A
Sardinha, J. C. G., (A)11A, 122A, 122A
Sareen, M., (A)656
Sarin, R. C., (A)9A
Sarkis, G. J., (A)358, 507
Sarno, E. N., (A)12A, 12A, 86A, 87A, 94A, 95A, 98A, 99A, 102A, 121A, 122A, 126A, (O)204
Saroyants, L., (A)95A, 95A, 101A, 105A
Saroyants, L. V., (A)353
Sarthou, J.-L., (A)350, 495, 653, 653, 86A, 89A
Sarv, A., (A)70A
Sasaki, D. T., (A)76A, (O)398
Sasiain, M., (A)91A

Sastrulus, M. V., (A)339
Sathe, S. S., (A)371
Satish Kumar, A., (A)166A
Sato, E., (A)124A
Sato, K., (A)345, 503, 503
Sauch, J., (A)12A
Sauwen, A. C. C., (A)29A
Save, M., (A)18A
Savic, B., (A)176
Saxena, M., (A)130A
Saxena, U., (A)59A
Saylan, T., (A)5A, 26A, 26A, 364, 95A, 100A, 135A
Sbarbaro, J. A., (A)176
Scandella, B., (A)362
Scat, Y., (A)54A
Schaper, K.-J., (A)312
Schauf, V., (A)138
Scheepers, A., (A)344
Schepers, P., (A)107A, 111A
Schettini, A. P., (A)30A, 122A, 122A
Schettini, M. C., (A)122A
Schipper, A., (A)20A
Schlesinger, L. S., (A)490
Schmiedlin-Ren, P., (A)123
Schoel, B., (A)133
Schopfer, K., (A)497
Schreuder, P. A. M., (A)39A
Schreuders, T., (A)145A, 146A
Schroder, K. H., (A)376
Schuetz, J. D., (A)123
Schuitema, A. R. J., (A)166
Schulz, E. J., (A)126
Schurmann, D., (A)175
Schuurman, M. E., (A)39A, 40A
Schwerer, B., (A)80A
Sciulli, R., (A)109A
Scollard, D. M., (A)22A, 98A, 99A, 104A
Scott, A. K., (A)121
Sehgal, V., (A)654
Sehgal, V. N., (A)123, 27A
Sekar, B., (A)8A, 353, 73A
Sekaran, N. G., (A)98A
Sela, S., (A)86A
Selmaj, K., (A)86A
Selvin, S. J., (A)153A
Sen, A., (A)80A, 112A
Sengupta, U., (A)33A, 85A, 98A, (E)439
Senguttavan, A., (A)129A
Senthilkumar, S., (A)89A, 90A
Sepulveda-Amor, J., (A)46A
Sequeira, E., (A)55A, 97A
Serfling, U., (A)377
Serrano-Jaen, L. G., (A)141A
Serruys, E., (A)161, 660
Sethna, K., (A)87A
Setogawa, T., (A)503
Setterquist, S., (A)181
Settinayake, S., (A)129A, 129A, 134A, 134A, 157A
Seydel, J. K., (A)7A, 122, 14A, 306, 312, 315
Seydel, U., (A)7A, 310, 107A, 110A, 116A
Shah, A., (A)38A, 51A, 141A, 141A, 142A, 149A, 151A, 152A, 152A, 157A
Shah, D., (A)72A, 97A
Shah, J. S., (A)160A
Shah, N., (A)141A, 141A, 152A, 152A
Shah, P. B., (A)169A
Shankar, V., (A)156A
Shankar Narayanan, N. P., (A)85A, 99A
Shanker Narayan, N. P., (A)42, 149A
Shanmuganandan, S., (A)50A, 54A, 137A
Shannon, E. J., (A)16A, 105A
Shanson, D. C., (A)165
Shantaraman, R., (A)352
Shanti, J., (A)142A
Shao, K., (A)41A, 55A
Shariati, (A)74A
Sharma, A. K., (A)18A, 24A, 345, 349, 357, 95A, 126A
Sharma, B. L., (A)33A
Sharma, R. K., (A)113A, 114A, 114A
Sharma, R. N., (A)353
Sharma, V. D., (A)7A, 13A, 143, 113A, 114A, 114A, 116A
Sharma, V. K., (A)342, 359, 652, (C)292
Shats, E., (A)34A, 35A
Shattock, R., (A)347
Shattock, R. J., (A)370
Shaw, R. J., (A)181
Shawar, R. M., (A)177
Shegokar, S., (A)140A
Shen, D., (A)15A
Shen, J., (A)88A, 121A
Shen, P.-Z., (A)45A
Shende, R. K., (A)655
Shenoy, B. C., (A)373
Sheppard, C. C., (A)98A
Sherif, A., (A)42A
Sheriff, M. O., (A)352, 651
Shetty, V., (A)4A, 6A, 18A, 22A, 100A, 100A
Shetty, V. P., (A)138, 344, 489, (O)70
Shi, M., (A)82A
Shi, Z., et al., (A)354
Shi, Z. R., (A)346
Shi, Z.-R., et al., (A)145
Shimizu, H., (A)491
Shin, J. S., (A)155
Shin, K. H., (A)167
Shinde, S. R., (O)51
Shinnick, T. M., (A)173, 378, 494, 666, 667, 98A, (O)59, 406
Shinzo, I., (A)73A
Shiratsuchi, H., (A)375
Shivannavar, C., (A)116A
Shivannavar, C. T., (A)7A, 13A, 143, 113A, 114A, 114A
Shong, B., (A)111A
Shrestha, I., (O)597
Shute, J., (A)21A
Shwe, T., (A)344, 501
Sidddalingaswamy, M. K., (A)149A
Sieling, P. A., (A)139, 366, 655

Sievers, A., (A)164, 369
Signorelle, M., (A)12A
Silva, C. L., (A)354, 92A, 102A, (C)107, (O)218
Silva, J., (O)185
Silveira, V. N., (A)53A
Simoni, M. C., (A)34A
Simono, F., (A)46A, 134A, 156A
Simpson, K. E., (A)152
Singay, J., (A)42A
Singh, I. G., (A)22A
Singh, M., (A)134
Singh, N., (A)77A
Singh, N. B., (A)83A, 88A, 91A, 92A
Singh, R. P., (A)648
Singh, S., (A)99A
Sinha, H., (A)70A
Sinha, S., (A)88A, 91A
Sittisombut, N., (A)358
Siu, P., (A)7A, 76A, 76A, 78A, 81A, 81A, 81A, 82A, 103A
SivaSai, K. S. R., (A)89A, (O)259
Sivaram, M., (A)342, 138A
Sivasankaran, (A)128A
Sjobring, U., (A)176
Skamene, E., (A)367
Skinner, P. S., (A)132, 375
Skinsnes, O. K., (A)98A
Skinsnes-Law, A., (A)128A
Slutsky, A., (A)658
Small, P. M., (A)378
Smith, D., (A)168A
Smith, I., (A)141
Smith, K. A., (A)489
Smith, P. G., (A)150, 175, 103A, (O)185
Smith, T., (A)22A, 148A
Smith, T. C., (A)37A
Smith, W. C. S., (A)19A, 363, 58A, 66A
Smits, J., (A)70A
Soares, D., (A)45A, (O)592
Soares, D. J., (A)73A
Sobel, J. D., (A)179
Soeparlan, A. G., (A)167A
Soloman, V., (A)24A
Soloman, V. K., (A)145A
Solomon, (A)157A
Solomon, S., (A)141A, 143A, 151A
Solomon, V. K., (A)154A
Sommerfeld, P., (A)165A
Soni, N. K., (A)127
Sood, R. K., (A)366
Soong, F. X. A., (A)9A
Soro, B., (A)158
Sosne, G., (A)507
Sosseloir, Y., (A)177
Soto, I., (A)14A
Sow, S., (A)7A, (O)214
Soydan, M., (A)364, 135A
Spanier, J. M., (A)120
Speelman, P., (A)180, 670
Spencer, L., (A)165A
Spencer, R. C., (A)663
Spiegel, A., (A)147, 147
Spinaci, S., (A)668
Spink, M. J., (A)132A
Spits, H., (A)489
Sreevatsa, (A)13A, 110A
Srinath, M. S., (A)142A
Srinivasan, H., (A)147A, 147A
Srisaenpang, S., (A)39A, 40A
Sritharan, V. K., (A)662
Stackebrandt, E., (A)165
Stahl, A., (A)162A
Stanford, J. L., (A)368, 94A, 103A, (C)474
Stanley, A., (A)106A
Stanley, J., (A)23A, 84A, 125A
Stanley, J. N. A., (A)24A, 93A, (O)9
Stanley-Blackwell, L. C. C., (E)619
Stastny, P., (A)100A
Steenbergen, G. J., (O)192
Stelandre, M., (A)177
Stella, X., (A)149A
Stephens, D. M., (A)502
Sterling, T., (A)370
Sterne, J. A. C., (A)343, 68A, 74A, 74A, (O)270
Stetter, M., (A)157
Steven, L. M., (A)131
Sticht-Groh, V., (A)112A
Stoker, N., (A)84A
Stoker, N. G., (A)163, 360, 499, 661, 84A, 88A
Storrs, E. E., (A)83A, 83A
Stuyvesant, W., (A)168A
Styblo, K., (A)177
Style, A., (A)138A
Su, H., (A)67A
Suarez-Moreno, O., (A)146, 56A, 109A
Subramanian, A., (A)149A
Subramanian, M., (A)349, 353, 73A
Subramanian, P. T. K., (A)50A, 137A
Subuddhi, K. B., (A)36A
Suchitra, K., (A)344
Sudha, R., (A)93A
Sudhakar, K. S., (A)98A
Sudhakar, S., (A)137A
Sudre, P., (A)668
Suffys, P., (A)106A
Suga, M., (A)503
Sujai, S., (A)24A
Sukanto, H., (A)167A
Sule, R. R., (A)485
Sullivan, L., (A)138
Sun, C., (A)32A, 92A
Sun, S., (A)61A
Sun, X., (A)92A, 162A
Sundaram, P., (A)668
Sundaresan, T. K., (A)149, 150
Sunderarajan, (A)28A
Suneetha, S., (A)136A, 166A
Sunisha, (A)135A
Surcel, H. M., (A)180, 661
Suresh Kumar, S. K., (A)349
Suri Babu, C. S., (A)98A
Sutherland, P. A., (A)160

Sutlas, M., (A)5A
Suzuki, K., (O)609
Suzuki, Y., (A)91A, 114A
Syed, M., (A)145A
Sylla, P. M., (A)165A

Tadesse, A., (A)16A
Taffessework, G., (A)118A
Takahashi, D., (A)354
Takewaki, S., (A)377
Takii, T., (O)609
Talwar, G. P., (A)18A, 18A, 22A, 345, 349, 357, 95A, 104A, 126A, 1333, (O)227
Talwar, S., (A)127
Tan, E. V., (A)106A
Tan, T., (A)648
Tan, Y., (A)61A
Tanaka, M., (A)344
Tanaka, S., (A)32A
Tang, G., (A)32A
Tang, Q.-C., (A)651
Tang, Y., (A)2A
Tank, B., (A)36A, 90A
Tao, M., (A)64A
Tao, M.-B., (A)10A, 62A, 64A, 68A, 69A, 156A
Taranekar, R. S., (A)8A, 58A
Tasaka, H., (A)496
Taylor, I. K., (A)181
Tazi, A., (A)178
Tedesco Marchese, J., (A)124A
Teeling, P., (A)143, 496
Teixeira, M. J. O., (A)135A
Telenti, A., (A)377, 497, 108A, (O)600
Telle, W. B., (A)497
ten Ham, P. B. G., (A)44A
Tenberg, R., (A)662
Teng, T., (A)70A
Terencio de las Aguas, J., (A)364, 5A, 17A, 33A, (Ob)113
Testa, J., (A)362
Thakar, U. H., (A)55A
Thangaraj, H. S., (A)115A
Thawani, G., (A)655
Theetranont, C., (A)22A, 99A, 104A
Thet, A. T., (A)126
Theuvenet, W. J., (A)135, 45A, (O)35, 592, 597
Thiagarajan, N., (A)129A
Thibert, L., (A)154, 669
Thierry, D., (A)178
Thirunavakarasu, S., (A)11A, 39A, 39A
Thoen, C. O., (A)179
Thole, J. E. R., (A)136, 143, 84A, 86A
Thomas, A., (A)5A, 649, 127A
Thomas, A., (A)135A
Thomas, C. J., (A)11A
Thomas, E. L., (A)121
Thomas, M. V., (A)128A
Thomas, S., (A)122A
Thomas, T. J., (A)179
Thompson, C. W., (A)65A
Thompson, J. K., (A)499, 84A
Thompson, P. J., (A)378
Thurman, P. F., (A)498
Thurmond, C., (A)666
Thyagarajan, S. P., (C)462
Ti, T. K., (A)647
Tiendrebeogo, A., (A)43A, 48A
Timm, J., (A)142
Tiwari, V. D., (A)127, 648
Tizard, M. L. V., (A)170
Toida, I., (A)506
Tokars, J. I., (A)374
Tollefson, J. E., (A)65A
Tomioka, H., (A)345, 503, 77A, (O)250, 255
Tong, W., (A)367
Torii, K., (O)609
Torrecilla, M. A. A., (A)53A, 55A
Torregrossa, F., (C)471
Torrencilla, M. A., (A)55A
Torres, M., (A)176
Torres, P., (A)33A
Torres-Alvarez, M. B., (O)581
Torrez, D., (A)148
Tout-Puissant, K., (A)71A
Tran, K. H., (A)61A
Traore, I., (A)6A, 8A
Traple, G., (A)144A
Trias, J., (A)144
Trias, J. Q., (A)498
Triebold, K. J., (A)161
Trindade, M. A. B., (C)109
Trivedi, M. P., (A)25A, 49A, 50A, 69A
Truffot-Pernot, C., (A)156, 164, 172, 374
Truman, R. W., (A)67A, (O)394
Tsang, M., (A)7A, 76A, 76A, 78A, 81A, 81A, 81A, 82A, 103A
Tsubaki, K., (A)491
Tsukada, H., (A)165
Tsutsumi, S., (A)337
Tuosto, L., (A)368
Turcotte, R. A., (A)137
Turk, J. L., (A)79A, 150A, 150A
Tyagi, P. K., (A)28A, (C)636
Tzourio, C., (A)127

Udani, R., (A)507
Ulrich, M., (A)99A, 103A, (O)185
Uplekar, M., (A)4A, 6A, 22A
Uplekar, M. W., (A)344
Urbanczik, R., (A)304
Urlyapova, N., (A)17A, 80A
Ursi, D., (A)107A, (O)389
Utaipat, U., (A)99A, 104A
Uyemura, K., (A)139, 140, 355

Vaishnavi, C., (A)128, 361, 361
Valdez, R., (A)91A
Valdez, R. P., (A)56A
Valdez-Valenzuela, F., (A)141A

Valencia, E., (A)131A
Valeyre, D., (A)178
Vallishayee, R. S., (A)158, 103A, 147A, (O)563
Van Acterveld, M., (A)84A
van Beers, S., (A)16A, 67A, 75A
van Brakel, W. H., (A)124, 128, 21A
van Embden, J. D. A., (A)135, 166, 378, 652
Van Grieken, R., (A)487
Van Halbeek, H., (A)152
Van Harsselaar, B., (A)180
Van Joost, T., (A)139, 36A, 90A
Van Landingham, R. M., (O)59, 406
Van Leeuwen, J., (A)166
Van Meijgaarden, K. E., (A)133
Van Rensburg, C. E. J., (A)124, 378
van Schooten, W. C. A., (A)139
Van Soest, A., (A)151
Van Staden, A. M., (A)378
Van Vooren, J.-P., (A)161, 495, 653, 653, 660, 662, 89A, 91A, (O)29
van den Akker, T. W., (A)139, 90A
van den Broek, J., (O)556
van den Elsen, P., (A)139
van den Wijngaard, R. M. J., (A)105A
Vandenbussche, P., (A)653, 86A
Vandeputte, D., (A)487
van der Stoep, N., (A)139
van der Vliet, G. M. E., (A)359, 498, 107A, 111A
Vanderzee, R., (A)667
Vanfleteren, B., (A)161
Vardy, D. A., (A)150
Varnerot, A., (A)179
Vartak, R., (A)55A, 72A, 97A
Vasanthi, B., (A)353
Vasilyev, A., (A)123A
Vaughan, R., (A)667
Vazquez, J. A., (A)179
Vega-Lopez, F., (A)499, 46A, 84A, 88A, 141A, 152A
Vellut, C., (A)4A
Vemuri, N., (A)93A
Venisse, A., (A)669
Venkatesan, K., (A)143, 16A, 649, 81A
Vennemann, M., (A)53A
Ventura, D. R. V., (A)139A, 139A, 166A
Verbon, A., (A)179, 180, 670
Verbov, J. L., (A)121
Vercauteren, J., (A)669
Verfuin, P. R. N., (C)628
Vergara-Vargas, M. G., (A)152A
Verhage, R., (A)37A, 41A
Veringa, E., (A)180
Verma, K. K., (C)293
Verma, S. N., (A)3A, 8A
Vesin, C., (A)87A
Viana, S. M., (A)12A
Vianna, F. R., (A)649
Viciana, A. L., (A)35A
Vidal, M. C., (O)586
Viera, L. M., (A)93A
Vignoli, C., (A)153
Vignon-Pennamen, M.-D., (O)214
Vijayakumar, D., (A)147A
Vijayakumaran, P., (A)3A, 20A, 64A, 69A, 128A, 143A, 151A
Vikerfors, T., (O)571
Vilchis, M., (A)90A
Vilde, J.-L., (A)156, 172, 663
Vilela de Castro, A., (A)152A
Villahermosa, L. G., (A)6A, 9A, 75A, 97A, 101A, 106A, 125A
Villishayee, R. S., (A)147A
Vinayakumar, S., (A)23A, 34A, (O)9
Vincke, J. P., (A)161
Vinnick, L., (A)34A
Virmond, M., (A)82A, 150A, 159A, 161A
Vishnevetsky, F., (A)123A
Vishvanathan, N., (A)365
Visser, K., (A)14A, 306
Viyakumar, C., (A)153A
Vladimirsky, M. A., (A)173
Voller, A., (A)360
von Ballestrem, W. G., (A)309, 341, 14A
Von Pessolani, M. C., (A)144
Von Reyn, C. F., (A)658
Von Runbinder, G., (A)35A
Vordermeier, H. M., (A)180, 661
Vordermeier, M., (A)349
Vorobyev, A. A., (A)181

Wadhwa, S., (A)126A
Wadnerkar, S. D., (A)134A
Wahab, S., (A)93A
Waite, D., (A)371
Waiyaki, P., (A)502
Wakamatsu, A., (A)354
Walavalkar, S., (A)46A
Walia, R., (A)345, 104A
Walker, D. A., (A)181
Walker, K. B., (A)158
Walker, L. L., (O)59, 406
Wallace, P. A., (A)495
Wallace, R. J., (A)154
Wallace, R. J., Jr., (A)374
Wallis, C. K., (A)156
Wallis, R. S., (A)355
Walsh, G. P., (A)360, 6A, 9A, 73A, 75A, 75A, 79A, 97A, 101A, 106A, 125A, (O)192, 236
Walter, C. S., (A)43A, 52A
Wang, F., (A)61A
Wang, G., (A)162A
Wang, H., (A)146, 54A, 82A
Wang, J., (A)162A
Wang, L., (A)6A
Wang, R., (A)164A
Wang, S., (A)31A, 662
Wang, T., (A)355, 356, 120A, 120A
Wang, W., (A)54A
Wang, X., (A)162A

Wang, X.-H., (A)140
Wang, Y., (A)9A
Wang, Z., (A)54A, 92A, 161A
Wang, Z.-M., (A)651
Want, S. V., (A)170
Wanzeller, M. E. A., (A)23A
Wasunna, K., (A)171
Watanabe, M., (A)145, 506
Waters, M. F. R., (A)311, 362, 18A, 103A, 121A
Wathanadilokkol, U., (A)148A
Watkins, P. B., (A)123
Watson, J. D., (A)129, 316, 493, 652, (O)571
Watson, J. M., (A)163, 63A, 153A, 153A, 154A, 165A
Watt, B., (A)663
Weber, M. W., (A)151
Wei, G., (A)52A
Wei, W., (A)67A, 88A, 88A
Weiser, W. Y., (A)375
Wempe, E., (A)7A
Wen, S.-F., (A)144A
Wen, Z., (A)37A
Weng, X., (A)61A
Wentzel, L., (A)31A
Were, M., (A)36A
Werner, L., (A)26A
Wery, W., (A)165A
Westerhof, W., (A)105A, 161A
Westfall, K., (A)181
Weverling, G. J., (A)670
Wheat, P. F., (A)663
Wheeler, J., (A)145A, 157A
Wheeler, P. R., (A)313, 499, 670, 93A
Whitby, M., (A)163
White, F. M. M., (A)65A
Whittier, P. S., (A)181
Wiebel, M., (A)507
Wieles, B., (A)84A
Wiens, C., (A)162A
Wiese, M., (A)14A, 313
Wiher, H., (A)42A
Wiker, H., (O)571
Wiker, H. G., (A)162, 182, 182
Wilfred, D., (O)259
Wilkinson, P. C., (A)183
Williams, D. L., (A)141, 145, 493, 17A, 106A, 108A
Williams, H., (A)94A
Williamson, B. H., (A)378
Wilshire, E., (A)369
Wilson, K. H., (A)504
Wilson, R. J., (A)68A
Wilson, S. B., (A)657
Wilson, S. M., (A)360
Win, M., (A)126
Winter, N., (A)142
Wirth, D. F., (A)662
Wisingerova, E., (A)669
Witzig, R. S., (A)671
Woel, G., (A)29A
Wondimu, A., (A)76A
Wondimus, A., (A)654
Woodley, C. L., (A)505
Woods, S. A., (A)358
Woods, W., (A)55A
Woods, W. J., (A)56A, 57A
Wright, E. L., (A)484
Wu, G., (A)15A
Wu, H., (A)346, 98A
Wu, M., (A)130
Wu, Q., (A)348, 67A, 67A, 73A, 88A
Wu, Q., et al., (A)356, 356, 356
Wu, X., (A)32A, 69A, 92A
Wu, Y., (A)27A
Wu, Z., (A)88A
Wu, Z., et al., (A)123A
Wu-Hunter, S., (A)358, (O)381
Wuscher, N., (A)135
Wyzykowski, R., (A)139

Xie, C., (A)54A
Xie, J., (A)13A
Xie, Z., (A)13A, 487, 487
Xu, H., (A)13A
Xu, K., (A)75A, 79A, (O)236
Xu, S., (A)151A, 153A, 153A
Xu, W., (A)2A, 6A

Yadav, V. S., (A)2A, 19A, 67A, 1233
Yadava, A., (A)90A
Yajima, M., (A)356
Yajko, D., (A)168
Yamada, N., (A)356
Yamada, T., (A)496
Yamada, Y., (A)145
Yamaguchi, R., (A)496
Yamamura, M., (A)655
Yamane, T., (A)337
Yamashita, J. T., (A)29A, 29A, (O)44
Yamashita, K., (A)337
Yamazaki, A., (A)496
Yan, L., (A)27A, 64A, 155A
Yan, L.-B., (A)501, 156A
Yan, X., (A)9A
Yan, Z., (A)162A
Yanez, L. B., (A)143A
Yanez Velasco, L. B., (A)38A
Yang, J., (A)65A
Yang, L.-H., (A)10A, 62A, 144A
Yang, W. I., (A)167
Yang, Z.-M., (A)10A, 45A, 62A, 64A, 65A, 68A, 69A, 156A
Yashodhara, S., (A)59A
Yates, G. R., (A)502
Yates, M. D., (A)161
Ye, G.-Y., (A)10A, 45A, 62A, 64A, 64A, 65A, 67A, 67A, 68A, 69A, 70A, 73A, 88A, 88A, 121A, 123A, (N)327
Yebakima, A., (A)168A
Yernault, J.-C., (A)660, 91A, (O)29

Yi, S., (A)131A
Yilmaz, E., (A)663
Yin, B., (A)62A
Yin, Y., (A)88A
Yin, Y.-P., (A)91A, 114A
Ying, Z., (A)54A
Yoder, L. J., (B)114, 326
Yogi, Y., (A)362
Yokota, S., (A)491, 85A
Yonadi, V., (A)14A
Yong, S., (A)136, 174, 86A
Yoo, H. S., (A)167
Yoon, K.-H., (A)360
Yoshie, Y., (A)345
Yoshikawa, H., (A)165
Yoshino, Y., (A)346, 346
Young, D., (A)349, 661, 84A
Young, D. B., (A)361, 104A
Young, L. S., (A)130
Young, S., (A)362, 84A
Yu, A., (A)54A
Yu, B., (A)55A, 161A
Yu, J., (A)61A
Yu, X., (A)2A
Yu, X.-L., (A)5A
Yu, Y., (A)123A
Yuksel, A., (A)26A, 364, 154A
Yun, L., (A)82A
Yuschenko, A. A., (A)353
Yushin, M., (A)80A, 111A
Yusuff, G., (A)353

Zahaf, A., (A)54A
Zaheer, A., (A)95A
Zaheer, S. A., (A)149, 18A, 18A, 22A, 24A, 345, 349, 357, 100A, 126A
Zamora, D., (A)148
Zandotti, C., (A)153
Zeliger, L. R., (A)167
Zewge, S., (A)144A
Zhang, D., (A)70A
Zhang, G., (A)27A, 155A, 155A
Zhang, G.-C., (A)501, 156A
Zhang, H., (A)37A, 52A
Zhang, J., (A)37A, 52A, 61A
Zhang, M., (A)32A, 79A
Zhang, S., (A)67A, 70A
Zhang, S., et al., (A)340
Zhang, W., (A)82A
Zhang, X., (A)92A, 151A
Zhang, Y., (A)28A, 661, 671
Zhang, Y. S., (A)374
Zhao, D., (A)70A, (C)631
Zhao, G., (A)98A
Zhao, J., (A)32A
Zhao, T., (A)2A, 6A, 28A
Zhao, Z., (A)32A
Zhen, D., (A)61A
Zheng, D.-Y., (A)60A
Zheng, R., (A)2A
Zheng, T., (A)155A
Zheng, Z.-J., (A)156A
Zhong, J., (C)631
Zhou, D., et al., (A)2A
Zhou, H. M., (A)346
Zhou, L., (A)71A
Zhou, W., (A)121A
Zhu, Q., (A)9A
Zhu, S., (A)98A
Zhu, Y., (A)32A
Zicker, F., (A)127
Ziegler, T., (A)183
Ziesing, S., (A)372
Zijlstra, E. E., (A)341
Zimin, A. E., (A)181
Zimmerli, W., (A)486
Zlotogorski, A., (A)150
Zmuidzinas, A., (A)489
Zong, J., (A)70A
Zuiderhoek, B., (A)484
Zuniga, M., (A)99A, 103A, (O)185

SUBJECT INDEX

Original articles are indicated by (O), editorial (E), correspondence (C), obituaries (Ob), abstracts (A), book reviews (B). Page numbers followed by A are abstracts of the 14th International Leprosy Congress.

Acid, fatty,
Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against *M. avium*. Barrow, W. W., *et al.* ..... (A) 484
Biochemical properties and fatty acid composition of *M. haemophilum*—study of 16 isolates from Australian patients. Portaels, F., *et al.* ..... (A) 173
Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ..... (A) 168

Acid-fast bacilli,
Antigenic similarity of a cultivable acid-fast bacterium to *M. leprae*. Joshi, S., *et al.* ... (A) 359
Viability of acid-fast bacilli from gamma-irradiated and UV irradiated lepromatous armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ... (A) 158

Acquired immunodeficiency syndrome (AIDS),
Clarithromycin and other antimicrobial agents in the treatment of disseminated *M. avium* infections in patients with acquired immunodeficiency syndrome. Dautzenberg, B., *et al.* ..... (A) 369
Clarithromycin—a review of its pharmacological properties and therapeutic use in *M. avium* intracellulare complex infection in patients with acquired immune deficiency syndrome. Barradell, L. B., *et al.* ..... (A) 658
Genetic diversity among strains of *M. avium* causing monoclonal and polyclonal bacteremia in patiens with AIDS. Arbeit, R. F., *et al.* ..... (A) 658
Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated *M. avium* complex. Gascon, P., *et al.* ..... (A) 371
Improvement of hand impairment and life quality by field delivered splints and grip aids in deformed leprosy patients. Shah, A., *et al.* ..... (A) 141A
Islation of a fastidious Mycobacterium species from two AIDS patients. Jackson, K., *et al.* ..... (A) 164
Laboratory aspects of *M. genavense*, a proposed species isolated from AIDS patients. Coyle, M. B., *et al.* ..... (A) 156
Leprosy and AIDS; beyond the stigma. Skinsnes-Law, A. ..... (A) 128A
Rehabilitation of leprosy handicap by Modulan grip aids; an evaluation. Shah, A., *et al.* ..... (A) 152A

Adenosine triphosphate (ATP),
ATP measurement and thymidine uptake in patient monitoring and in *in vitro* drug screening. Dhople, A. ..... (A) 307
Adenosine triphosphate content of *M. leprae* by Percoll buoyant density centrifugation. Sharma, V. K., *et al.* ..... (A) 359
Purification of polyphosphate and ATP glucose phosphotransferase from *M. tuberculosis* H37Ra: evidence that poly(P) and ATP glucokinase activities are catalyzed by the same enzyme. Hsieh, P.-C., *et al.* ..... (A) 373

Africa,
Aspects of tuberculosis in Africa. 3. Genetic "fingerprinting" for clues to the pathogenesis of tuberculosis. Godfrey-Faussett, P. and Stoker, N. G. ..... (A) 661
Fight against leprosy in French-speaking Africa. Olphe Galliard, P. ..... (N) 640
La lepre vue par le lepreux africain. Kinda, K. ..... (A) 137A
[Leprosy survey conducted in the Central African Republic from 1982 to 1985 among the B-Benzele Pygmies.] Baquillon, G., *et al.* ..... (A) 362
MDT for leprosy in 8 francophone countries of West Africa: 10 years' implementation (1982-1991). Tiendrebeogo, A. and Blanc, L. ..... (A) 43A
Tuberculosis and HIV infection in sub-saharan Africa. Decock, K. M., *et al.* ..... (A) 158

Albania,
Delenda Lepra; organization of the struggle for eradication of leprosy in Albania. Nakuci, M. and Nakuci, M. M. ..... (A) 45A
Dermatoglyphic aspects in leprosy patients and their relatives in Albania. Nakuci, M. M. and Nakuci, M. ..... (A) 27A

Algeria,
Leprosy in Algeria. Boudghene-Stambouli, O. and Merad-Boudia, A. ..... (A) 70A

American Leprosy Missions (ALM),
A model for eradication of leprosy from rural South India at Ambilikkai during the last 3 1/2 decades among 1.5 lakhs of population in 1965 later on supported by ALM. Cherian, J. ..... (A) 40A

Anemia,
Anaemia, iron-related measurements and erythropoietin levels in untreated patients with active leprosy. Lapinsky, S. E., *et al.* ..... (A) 126

Ansamycin,
In vitro synergistic activity between ofloxacin and ansamycin against *M. leprae*. Dhople, A. M., *et al.* ..... (A) 485

Antibody,
A prospective immunoepidemiologic study using MLSA and ELISA for antibodies against PGL-I. Krishnamurthy, P., *et al.* ..... (A) 73A
A rapid latex agglutination test for detection of antibodies in tuberculosis and Hansen's disease. Ganju, L., *et al.* ..... (A) 133
Anti-peripheral nerve antibodies in leprosy patients recognize an epitope shared by the *M. leprae* 65 kDa heat shock protein. Launois, P., *et al.* ..... (A) 350
Antibodies against secreted and nonsecreted antigens in mice after infection with live *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 180
Antibodies to *M. paratuberculosis*-specific protein antigens in Crohn's disease. Elsaghier, A., *et al.* ..... (A) 159
Antibodies to *M. tuberculosis*-specific epitopes in lepromatous leprosy. Bothamley, G., *et al.* ..... (A) 130
Antibodies to a nerve lipid extract (NLE) in sera of leprosy patients. Vartak, R., *et al.* (A) 97A
Antibodies to cerebroside-sulfate in leprosy. Wheeler, P. R., *et al.* ..... (A) 93A
Antibody response of patient with borderline lepromatous and borderline tuberculoid leprosy to mycobacterial 29/33-kDa doublet and 65-kDa singlet antigens. Burggraaf, J. D., *et al.* ..... (A) 86A
Antibody responses to various antigens of *M. leprae* in borderline leprosy with or in reaction. Sudha, R. and Stanley, J. N. A. ..... (A) 93A
Autoantibodies to neural antigens in leprosy. Vemuri, N., *et al.* ..... (A) 93A
Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* ..... (O) 44
Clinical significance of anti-PGL-I antibody in multibacillary leprosy patients. Ma, J., *et al.* ..... (A) 31A
Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* ..... (A) 488
Comparative evaluation of antibodies in the serum and urine of leprosy patients through diversified mycobacterial antigens. Gupta, H. P., *et al.* ..... (A) 92A
[Comparison between MI- and Ms-ELISA in the determination of serum antibodies in leprosy.] Li, M.-H., *et al.* ..... (A) 134
Comparison of a gelatin particle agglutination test and ELISA for detection of antibody to *M. leprae*. Qian, L., *et al.* ..... (A) 94A
Detection of antibodies to phenolic glycolipid by ELISA in leprosy patients. Lal, H., *et al.* ..... (A) 350
[Determination of antiphenolic glycolipid antibodies in a general population of an area endemic for leprosy.] Mor, N., *et al.* ..... (A) 363
Does antibody to mycobacterial antigens including lipoarabinomannan, limit dissemination in childhood tuberculosis. Costello, A. M. D., *et al.* ..... (A) 368

Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Drowart, A., *et al.* ..... (O) 29
Gelatin particle agglutination assay to detect anti-PGL-I antibodies in leprosy patients and in household contacts: a preliminary study. Mahajan, P., *et al.* ..... (A) 351
Higher specificity in the serodiagnosis of leprosy by combined titration of antiphenolic glycolipid-I and antiphospholipid antibodies. Fiallo, P., *et al.* ..... (C) 464
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
IgM serum antibodies to PGL-I by ELISA in healthy subjects and leprosy patients. Meng, M., *et al.* ..... (A) 92A
Immunoscintigraphy in the detection of tuberculosis with radiolabelled antibody fragment against *M. bovis* bacillus Calmette-Guerin—a preliminary study in a rabbit model. Lee, J. D., *et al.* ..... (A) 167
Infection with *M. avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Bermudez, L. E. and Champsi, J. ..... (A) 659
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
Is nerve damage in leprosy an autoimmune phenomenon involving antiperipheral nerve antibodies? Desikan, P., *et al.* ..... (A) 96A
M. leprae LAM and PGL-I antibodies crossreact with HIV-1 antibodies in sera from HIV-1-seronegative leprosy patients and their contacts. Kashala, O., *et al.* ..... (A) 97A
M. leprae infection triggers synthesis of stress-inducible HSP70 in Schwann cells and anti-HSP antibodies in sera. Mistry, Y., *et al.* ..... (A) 104A
Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen. Yokota, S., *et al.* (A) 491
Prevalence of antineural antibodies among leprosy patients. Cho, S.-N., *et al.* ..... (A) 97A
Recognition of 21-kDa and 14-kDa antigens of mycobacterium ICRC by anti-*M. leprae* antibodies. Chiplunkar, S., *et al.* ..... (A) 85A
Recognition of *M. leprae* antigens with antibodies present in sera from patients with lepromatous leprosy. Islas Rodriguez, A. E., *et al.* ..... (O) 245
Relationship between anti-PGL-I antibody (IgM) level and relapses in cured leprosy patients. Sun, C., *et al.* ..... (A) 32A
Results in serological assays for detection of the prevalence of antibodies to HIV-1 leprosy cases in Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (A) 35A
Role of anti-*M. leprae* PGL-I antibodies in assessing the contacts of leprosy patients in a low-endemic area. Soares, D. J., *et al.* ..... (A) 73A
Significance of antibodies to phenolic glycolipid-I in leprosy diagnosis. Prakash, K., *et al.* ..... (A) 654
[Survey of the antibody to HCV in National Leprosarium Suruga.] Tanaka, M., *et al.* (A) 344

Antibodies, monoclonal,
Characterization of the specific recognition sites of monoclonal antibodies to the PGL-I of *M. leprae*. Fujiwara, T., *et al.* ..... (A) 78A
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kDa-region proteins and the secreted antigen-85 complex and demonstration of antigen-85B on the *M. leprae* cell wall surface. Rambukkana, A., *et al.* ..... (A) 136
Immunoreactivity of mycobacterial strain ICRC and *M. leprae* antigens with polyclonal and monoclonal antibodies. Chiplunkar, S. V., *et al.* ..... (O) 421
Production of monoclonal antibodies against *M. leprae*. Wu, Q., *et al.* ..... (A) 88A
Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ..... (A) 155
Results of the 3rd Immunology of Leprosy/Immunology of Tuberculosis Antimycobacterial Monoclonal Antibody Workshop. Khanolkar-Young, S., *et al.* ..... (A) 134
[Study on monoclonal antibody in leprosy. (II) Preliminary report on production of monoclonal antibody against supersonic products of *M. leprae*.] Wu, Q., *et al.* ..... (A) 356
[Study on monoclonal antibody in leprosy. (III) Production of monoclonal antibody to entire *M. leprae*.] Wu, Q., *et al.* ..... (A) 356

[Study on monoclonal antibody in leprosy. (IV) Basic conditions for the production of monoclonal antibody.] Wu, Q., *et al.* ..... (A) 356
Survey of monoclonal antibodies against *M. leprae* for use in immunohistochemical and immunoultrastructural localization studies. Krotoski, W. A., *et al.* ..... (A) 78A

Antigen(s),
A 15-kDa antigen of *M. leprae* that is recognized by both humoral and cellular immune systems in leprosy patients. Sela, S., *et al.* ..... (A) 86A
A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemoautotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* ..... (A) 112A
A comparison of the T-cell delayed-type hypersensitivity epitopes of the 19-kD antigens from *M. tuberculosis* and *M. intracellulare* using overlapping synthetic peptides. Mackall, J. C., *et al.* ..... (A) 664
A molecular analysis of mycobacterial antigens which stimulate gamma/delta T cells. Sanchez-Garcia, J., *et al.* ..... (A) 106A
A novel protein antigen secreted by *M. leprae*: the homolog of *M. tuberculosis* MPT32. Wieles, B., *et al.* ..... (A) 84A
A seroepidemiological study of leprosy in household contacts and healthy population based on ELISA using ND-O-BSA and PGL I as antigens. Li, W., *et al.* ..... (A) 67A
An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ..... (A) 90A
Anergy and Mitsuda responses toward chemoautotrophic nocardioform antigens run parallel to lepromin across the leprosy spectrum. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 117A
Antibodies against secreted and nonsecreted antigens in mice after infection with live *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 180
Antibodies to *M. paratuberculosis*-specific protein antigens in Crohn's disease. Elsaghier, A., *et al.* ..... (A) 159
Antibody response of patient with borderline lepromatous and borderline tuberculoid leprosy to mycobacterial 29/33-kDa doublet and 65-kDa singlet antigens. Burggraaf, J. D., *et al.* ..... (A) 86A
Antibody responses to various antigens of *M. leprae* in borderline leprosy with or in reaction. Sudha, R. and Stanley, J. N. A. ..... (A) 93A
Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor. Mendez-Samperio, P. ..... (A) 654
Antigenic glycolipids of *M. fortuitum* based on trehalose acylated with 2-methyloctadec-2-enoic acid. Hamid, M. E., *et al.* ..... (A) 495
Antigenic similarity may be responsible for immune reactivity in leprosy. Chin-A-Lien, R. A. M., *et al.* ..... (A) 90A
Antigenic similarity of a cultivable acid-fast bacterium to *M. leprae*. Joshi, S., *et al.* ..... (A) 359
Association of HLA-A,-B,-C, and DR antigens with leprosy. Ghei, S. K., *et al.* ..... (A) 98A
Autoantibodies to neural antigens in leprosy. Vemuri, N., *et al.* ..... (A) 93A
CD1b restricts the response of human CD4-8-T lymphoyctes to a microbial antigen. Procelli, S., *et al.* ..... (A) 136
Characterization of B cell epitopes on the 16K antigen of *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 179
Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* ..... (O) 44
Cloning and characterization of a 42-kDa serine-rich antigen from *M. leprae*. Vega-Lopez, F., *et al.* ..... (A) 84A
Cloning and characterization of the genes coding for the 85 complex antigens of *M. leprae*. de Mendonca Lima, L., *et al.* ..... (A) 108A
Cloning and sequencing of the gene for alpha-antigen from *M. avium* and mapping of B-cell epitopes. Ohara, N., *et al.* ..... (A) 496
Comparative evaluation of antibodies in the serum and urine of leprosy patients through diversified mycobacterial antigens. Gupta, H. P., *et al.* ..... (A) 92A
Comparison of polymerase chain reaction amplification of two mycobacterial DNA

sequences, IS6110 and the 65-kDa antigen gene, in the diagnosis of tuberculosis. Walker, D. A., *et al.* ..... (A) 181
Composition and immunological properties of the protein fraction of A36, a major antigen complex of *M. paratuberculosis*. DeKesel, M., *et al.* ..... (A) 141
Cross-sectional assessment of ELISA reactivity in leprosy patient, contacts, and normal population using the semisynthetic antigen natural disaccharide octyl bovine serum albumin (ND-O-BSA) in Cebu, The Philippines. Cellona, R. V., *et al.* ..... (O) 192
Crossreactive recognition of human T-cell epitopes in the M. *leprae* 18-kDa antigen. Menz, B., *et al.* ..... (A) 84A
Demonstration of mycobacterial antigens in the skin smears of tuberculoid patients of leprosy. Sengupta, U., *et al.* ..... (A) 85A
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Detection of 65-kDa heat-shock protein from sera of leprosy patients- mycobacterial or autoantigen origin. Elangeswaran, N., *et al.* ..... (A) 90A
Detection of *M. leprae*-specific antigen with M-dot-ELISA in sera from household contacts of leprosy patients. Cao, Y., *et al.* ..... (A) 73A
Detection of mycobacterial antigens in sputum by an enzyme immunoassay. Al-Orainey, I. O., *et al.* ..... (A) 365
Detection of mycobacterial antigens present in short-term culture media using particle counting immunoassay. Drowart, A., *et al.* ..... (A) 660
Do human leukocyte antigens have a role to play in differential manifestation of multibacillary leprosy—a study on multibacillary leprosy patients from India. Rani, R., *et al.* ..... (A) 149
Does antibody to mycobacterial antigens including lipoarabinomannan, limit dissemination in childhood tuberculosis. Costello, A. M. D., *et al.* ..... (A) 368
Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Drowart, A., *et al.* ..... (O) 29
Evaluation of four semi-synthetic *M. leprae* antigens with sera from healthy populations in endemic and non-endemic areas. Douglas, J. T., *et al.* ..... (A) 131
Expression of the *M. tuberculosis* 19-kilodalton antigen in *M. smegmatis*—immunological analysis and evidence of glycosylation. Garbe, T., *et al.* ..... (A) 349
Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of *M. avium*. Belisle, J. T., *et al.* ..... (A) 493
Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of *M. tuberculosis* by human and murine T cells. Harris, D. P., *et al.* ..... (A) 661
[HLA antigens in lepromatous leprosy.] Saroyants, L. V., *et al.* ..... (A) 353
HLA class-II+ human keratinocytes present *M. leprae* antigens to CD4+ Th1-like cells. Mutis, T., *et al.* ..... (A) 351
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kDa-region proteins and the secreted antigen-85 complex and demonstration of antigen-85B on the *M. leprae* cell wall surface. Rambukkana, A., *et al.* ..... (A) 136
Homologs of *M. leprae* 18-kilodalton and *M. tuberculosis* 19 kilodalton antigens in other mycobacteria. Booth, R. J., *et al.* ..... (A) 493
IL-6 production in response to purified mycobacterial heat shock proteins and to antigen 85 in leprosy. Launois, P., *et al.* ..... (A) 653
Identification and characterization of epitopes shared between the mycobacterial 65-kilodalton heat shock protein and the actively secreted antigen-85 complex—their *in situ* expression on the cell wall surface of *M. leprae*. Rambukkana, A., *et al.* ..... (A) 143
Identification of immunodominant antigens during infection with *M. tuberculosis*. Andersen, P., *et al.* ..... (A) 152
IgG activity toward purified heat-shock proteins and antigen 86/5 in leprosy patients and their contacts. Launois, P., *et al.* ..... (A) 89A
IgG humoral response against the antigen 85 complex homologs in leprosy. Drowart, A., *et al.* ..... (A) 91A
Immunogenicity and protection studies with recombinant vaccinia and BCG each expressing the 18-kDa antigen of *M. leprae*. Baumgart, K. W., *et al.* ..... (A) 86A
Immunohistochemical demonstration of PGL-I antigen in the skin and nervous system of leprosy patients. Goto, M., *et al.* ..... (A) 120A

Immunoreactivity of mycobacterial strain ICRC and *M. leprae* antigens with polyclonal and monoclonal antibodies. Chiplunkar, S. V., *et al.* ..... (O) 421
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* (A) 74A
Induction of cellular immune reactions by A36, an antigen complex of *M. paratuberculosis*—comparison of A36 and Johin components. Gilot, P., *et al.* ..... (A) 162
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
M. leprae 10-kDa heat-shock protein is a major T-cell antigen. Mehra, V., *et al.* ..... (A) 88A
M. leprae antigens can be recognized by both Th1-like and Th2-like human T cells. MacFarlane, A. and Dockrell, H. ..... (A) 89A
M. leprae produces extracellular homologs of the antigen-85 complex. Von Pessolani, M. C. and Brennan, P. J. ..... (A) 144
M. leprae soluble antigen (Rees) skin test responses in an endemic population in India. Krishnamurthy, P., *et al.* ..... (A) 349
Major antigens of *M. habana* recognized by sera of patients with lepromatous leprosy. Vilchis, M., *et al.* ..... (A) 90A
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Modulation of MHC class-II antigen expression on antigen presenting cells of leprosy patients by *M. leprae*. SivaSai, K. S. R., *et al.* ..... (A) 89A
Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Carlucci, S., *et al.* ..... (A) 368
New leprosy skin-test antigens. Rivoire, B., *et al.* ..... (A) 84A
Overexpression and seroreactivity of 15-kDa antigen of *M. leprae*. Banu, M. J., *et al.* (A) 114A
Overexpression of *M. leprae* antigens in *Escherichia coli*. Oskam, L., *et al.* ..... (A) 114A
PGL-I-like antigen in renal carcinoma. Makino, M., *et al.* ..... (A) 91A
Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen. Yokota, S., *et al.* (A) 491
Problems in detection of secretory antigens of intracellular mycobacteria in macrophage and Schwann cell tissue culture. Mistry, N., *et al.* ..... (A) 87A
Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ..... (A) 155
Rapid detection of tuberculous and non-tuberculous mycobacteria by polymerase chain reaction amplification of a 162 bp DNA fragment from antigen-85. Fauvilledufaux, M., *et al.* ..... (A) 161
Reactivity of leprosy and control sera to crude and recombinant *M. leprae* antigens. Vega-Lopez, F., *et al.* ..... (A) 88A
Recognition of 21-kDa and 14-kDa antigens of mycobacterium ICRC by anti-*M. leprae* antibodies. Chiplunkar, S., *et al.* ..... (A) 85A
Recognition of *M. leprae* antigens with antibodies present in sera from patients with lepromatous leprosy. Islas Rodriguez, A. E., *et al.* ..... (O) 245
Reconocimiento de antigenos de *M. leprae* en pacientes hansenianos. Santaella, C., *et al.* ..... (A) 89A
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma-delta T cells activated by live *M. tuberculosis*. Boom, W. H., *et al.* ..... (A) 153
Schwann cells are able to present exogenous mycobacterial hsp70 to antigen-specific T lymphocytes. Ford, A. L., *et al.* ..... (A) 488
Sequence and immunological characterization of a serine-rich antigen from *M. leprae*. Vega Lopez, F., *et al.* ..... (A) 499
Serologic responses to nerve antigens in sooty mangabey monkeys with experimental leprosy. Cho, S.-N., *et al.* ..... (O) 236
Serological response against crossreactive cell-wall antigens (65-kDa protein and LAM-B) in leprosy. Elangeswaran, N., *et al.* ..... (A) 89A
Serological response in leprosy and tuberculosis patients to the 18-kDa antigen of *M. leprae* and antigen 85B of *M. bovis* BCG. Vikerfors, T., *et al.* ..... (O) 571

Serological response of leprosy patients to *M. leprae* specific and mycobacteria specific antigens: possibility of using these assays in combinations. Sekar, B., *et al.* ..... (A) 353
Similarity between mycobacterial and human epidermal antigens. Vandenakker, T. H. W., *et al.* ..... (A) 139
Soluble *M. leprae* antigen skin testing and lepromin positivity in children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 105A
Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. Birnbaum, G., *et al.* ..... (A) 659
Structure of a novel glycopeptidolipid antigen containing a O methylated serine isolated from *M. xenopi* complete H-1-NMR and C-13-NMR assignment. Riviere, M., *et al.* ..... (A) 669
Structures of glycopeptidolipid antigens of serovar-25 and serovar-26 of the *M. avium* serocomplex, synthesis of allyl glycosides of the outer disaccharide units and serology of the derived neoglycoproteins. Aspinall, G. O., *et al.* ..... (A) 366
Structures of the glycopeptidolipid antigens of two animal pathogens—*M. senegalense* and *M. procinum*. Marin, L. M. L., *et al.* ..... (A) 664
Studies of alpha-antigen genes in *M. leprae*. Yin, Y.-P., *et al.* ..... (A) 114A
Subplasmalemmal linear densities in mononuclear cells induced by an antigen in human sensory peripheral nerve. Crawford, C. L. and Hardwicke, P. M. D. ..... (A) 79A
T-cell receptor beta-chain gene usage in the T-cell recognition of *M. leprae* antigens in one tuberculoid leprosy patient. van Schooten, W. C. A., *et al.* ..... (A) 139
T-cell repertoire in tuberculosis—selective anergy to an immunodominant epitope of the 38-kDa antigen in patients with active disease. Vordermeier, H. M., *et al.* ..... (A) 180
T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with *M. leprae* secreted antigen-85 is another immunodominant antigen. Launois, P., *et al.* ..... (A) 653
The antigen-85 complex—a major secretion product of *M. tuberculosis*. Wiker, H. G. and Harboe, M. ..... (A) 182
The major secreted antigen complex (Ag-85) from *M. bovis* bacille Calmette-Guerin is associated with protective T cells in leprosy—a follow-up study of 45 household contacts. Launois, P., *et al.* ..... (A) 495
The mycobacterial secreted antigen-85 complex possesses epitopes that are differentially expressed in human leprosy lesions and *M. leprae*-infected armadillo tissues. Rambukkana, A., *et al.* ..... (A) 496
The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guerin (BCG) vaccination in either South India or London. Das, S., *et al.* ..... (A) 158
The structure of an antigenic glycolipid (SL-IV) from *M. tuberculosis*. Baer, H. H. .... (A) 492
Tuberculosis and leprosy—attempts to identify T-cell antigens of potential value for vaccine design. Kaufmann, S. H. E., *et al.* ..... (A) 133
[Use of enzyme immunoassay and immunoblotting for the serological characterization of mycobacterial antigens.] Vorobyev, A. A., *et al.* ..... (A) 181

Argentina,
Books by Prof. Meny Bergel available. ..... (N) 116
Experimental leprosy in *Dasypus hybridus* in Argentina. Franco, R., *et al.* ..... (A) 82A
Leprosy control program in Santa Fe Province, Argentina: results after 30 years. Merlin, V., *et al.* ..... (A) 59A

Armadillo(s),
Armadillos (*Dasypus novemcinctus*) as a model to test antileprosy vaccines; a preliminary report. Job, C. K., *et al.* ..... (O) 394
Leprosy in wild armadillos. Storrs, E. E. ..... (A) 83A
Nerve condition study technique in the armadillo. Garbino, J., *et al.* ..... (A) 82A
Relationship between host histones and armadillo-derived *M. leprae*. Pessolani, M. C. V., *et al.* ..... (O) 381
Spatial analysis of the origins and risks of armadillo leprosy. Truman, R. W., *et al.* ... (A) 67A
The armadillo as a model for leprosy. Storrs, E. E. ..... (A) 83A
The mycobacterial secreted antigen-85 complex possesses epitopes that are differentially expressed in human leprosy lesions and *M. leprae*-infected armadillo tissues. Rambukkana, A., *et al.* ..... (A) 496

Viability of acid-fast bacilli from gamma-irradiated and UV irradiated lepromatous armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ...(A) 158

Arthritis,
Lactoferrin triggers *in vitro* proliferation of T cells of Lewis rats submitted to mycobacteria-induced adjuvant arthritis. Esaguy, N., *et al.* .....(A) 652

Assay(s) (see also **ELISA**),
A bioassay to detect nanogram concentrations of rifampin. Guebre Xabier, M., *et al.* .(A) 16A
A prognostic value of serological assays in regressed leprosy. Degtiarev, O. and Dyachina, M. .....(A) 94A
A rapid *in vitro* microassay for the viability and drug sensitivity of *M. leprae*. Butcher, P. D., *et al.* .....(A) 111A
A simple colorimetric assay for detection of amplified *M. leprae* DNA. van der Vliet, G. M. E., *et al.* .....(A) 498
Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* .....(A) 488
Detection of mycobacterial antigens in sputum by an enzyme immunoassay. Al-Orainey, I. O., *et al.* .....(A) 365
Detection of mycobacterial antigens present in short-term culture media using particle counting immunoassay. Drowart, A., *et al.* .....(A) 660
Enhanced chemiluminescent assay (ECL): a highly sensitive method for the detection of *M. leprae* infection in nasal secretions. Sciulli, R., *et al.* .....(A) 109A
Gelatin particle agglutination assay to detect anti-PGL-I antibodies in leprosy patients and in household contacts: a preliminary study. Mahajan, P., *et al.* .....(A) 351
Lipoarabinomannan (LAM)-based enzyme-linked immunosorbent assay in serodiagnosis of leprosy. Gandhi, S., *et al.* .....(A) 93A
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* .....(O) 227
Preliminary exploration of leprosy relapse surveillance with immunologic assays. Weng, X., *et al.* .....(A) 61A
Results in serological assays for detection of the prevalence of antibodies to HIV-1 leprosy cases in Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* .....(A) 35A
Serological response of leprosy patients to *M. leprae* specific and mycobacteria specific antigens: possibility of using these assays in combinations. Sekar, B., *et al.* .....(A) 353
Simple colorimetric microtiter plate hybridization assay for detection of amplified *M. leprae*. van der Vliet, G. M. E., *et al.* .....(A) 359
Use of PGL-immunoassays in seroepidemiological studies of *M. leprae* infection in Malaysia. Gan, S. C. and Fujiwara, T. .....(A) 73A
[Use of enzyme immunoassay and immunoblotting for the serological characterization of mycobacterial antigens.] Vorobyev, A. A., *et al.* .....(A) 181

Australia,
Biochemical properties and fatty acid composition of *M. haemophilum*—study of 16 isolates from Australian patients. Portaels, F., *et al.* .....(A) 173
M. marinum infection—epidemiology and presentation in Queensland (Australia) 1971-1990. Iredell, J., *et al.* .....(A) 163

Autopsy,
Analysis of 98 autopsy cases in a Japanese leprosarium. Kitajima, S., *et al.* .....(A) 124A
Reaction type 2 of HD (ENL) with visceral involvement: index for the severity of the disease, clinical, laboratorial and autopsy study of 34 patients. Margarido-Marchese, L. C., *et al.* .....(A) 124A

B663 (see also **Clofazimine**), **Bacilli,**
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* .....(A) 5A
Leprosy bacilli in smears from nasal mucosa. MaCrery, R., *et al.* .....(A) 32A
Presence of Hansen's bacilli in conjunctive, vitreous body and retina in an eye of a patient bearing the Virchowian form of Hansen's disease. Orefice, F., *et al.* .....(A) 126A

T cell response to purified filtrate antegen 85 from *M. bovis* bacilli Calmette-Guerin (BCG) in leprosy patients. Launois, P., *et al.* ..... (A) 134
Viability of acid-fast bacilli from gamma-irradiated and UV irradiated lepromatous armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ... (A) 158

Bacilli, ICRC,
Immunoreactivity of mycobacterial strain ICRC and *M. leprae* antigens with polyclonal and monoclonal antibodies. Chiplunkar, S. V., *et al.* ..... (O) 421
Immunotherapeutic potential of ICRC vaccine: a case control study. Bhatki, W. S. and Ghulawala, R. G. ..... (A) 340
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
Postvaccination sensitization with ICRC vaccine. Gupte, M. D., *et al.* ..... (A) 103A
Recognition of 21-kDa and 14-kDa antigens of mycobacterium ICRC by anti-*M. leprae* antibodies. Chiplunkar, S., *et al.* ..... (A) 85A

Bacterial index (BI),
Clinical assessment, BI, MI, relapse rate. Waters, M. F. R. ..... (A) 311

Bacteremia,
Diagnosis of *M. avium* bacteremia by polymerase chain reaction. Iralu, J. V., *et al.* ... (A) 662
Genetic diversity among strains of *M. avium* causing monoclonal and polyclonal bacteremia in patients with AIDS. Arbeit, R. F., *et al.* ..... (A) 658

Bacteriology,
Bacteriological and immunological studies on active leprosy in Cairo. El Tayeb, S. H. M., *et al.* ..... (A) 33A
Bacteriological response of BL/LL patients to MDT for varied duration: a retrospective five-year follow up. Bhatki, W. and Pade, S. ..... (A) 3A
Clinical and bacteriological effect of tryptophan-enriched diet in multibacillary leprosy-a preliminary communication. Ganapati, R., *et al.* ..... (A) 15A
Clinical, electrophysiological and bacteriological evaluation of nerve damage after regular MDT in leprosy. Antia, N., *et al.* ..... (A) 22A
Current practices in mycobacteriology: results of a survey of state public health laboratories. Huebner, R. E., *et al.* ..... (A) 374
Etudes de l'indice bacteriologique chez les patients multibacillaires. Dambreville, M., *et al.* ..... (A) 32A
Histo-bacteriological investigation of borderline tuberculoid leprosy. Wang, T., *et al.* .. (A) 355

Bacteriophage,
DNA sequence, structure and gene expression of mycobacteriophage-L5—a phage system for mycobacterial genetics. Hatfull, G. F. and Sarkis, G. J. ..... (A) 358
Insertion into the *M. smegmatis* genome of the aph gene through lysogenization with the temperate mycobacteriophage Ms6. Anes, E., *et al.* ..... (A) 140
Superinfection immunity of mycobacteriophage-L5—applications for genetic transformation of mycobacteria. Donelly-Wu, M. K., *et al.* ..... (A) 358

Bangladesh,
Leprosy in Bangladesh 1984-88. Choudhury, A. M. ..... (A) 500

BCG (bacille Calmette-Guerin),
Annual immunotherapy in treated lepromatous leprosy with three different BCG-based vaccines- a 6-year assessment. Waters, M. F. R., *et al.* ..... (A) 103A
Assessment of BCG protective efficacy by case-control studies. Nishioka, S. A. N. and Goulart, I. M. B. ..... (C) 459
BCG vaccination as protection against leprosy. Alvim, M. F. S., *et al.* ..... (A) 94A
BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ..... (A) 175
BCG vaccination protects against leprosy in Venezuela. Convit, J., *et al.* ..... (A) 103A
BCG vaccination protects against leprosy in Venezuela: a case control study. Convit, J., *et al.* ..... (O) 185
BCG vaccine and leprosy. Baker, D. M. and Nguyen, V. T. J. S. ..... (A) 147

Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Orege, P., *et al.* ..... (O) 542
Cloning and sequence analysis of the gene encoding an NADP dependent alcohol dehydrogenase in *M. bovis* BCG. Stelandre, M., *et al.* ..... (A) 177
[Correlation between vaccination with BCG and the clinical forms of leprosy.] Castro Chavez, R., *et al.* ..... (A) 148
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with *M. leprae* and *M. bovis* BCG. Suzuki, K., *et al.* ..... (O) 609
Drs. Muliyil, *et al.* reply to the letter from Drs. Nishioka and Goulart. Muliyil, *et al.* ..... (C) 460
Early clinical and pathological results of *M. leprae* challenge of monkeys after attempted protective immunization with live BCG or BCG + heat-killed *M. leprae*. Xu, K., *et al.* ..... (A) 79A
Early immunological results of experimental *M. leprae* challenge of monkeys after attempted immunization with live BCG or BCG + heat-killed *M. leprae*. Gormus, B. J., *et al.* ..... (A) 75A
Expression of *Escherichia coli* beta-galactosidase in *M. bovis* BCG using an expression system isolated from M. paratuberculosis which induced humoral and cellular immune responses. Murray, A., *et al.* ..... (A) 142
Generation of cytolytic T-cells in individuals infected by *M. tuberculosis* and vaccinated with BCG. Pithie, A. D., *et al.* ..... (A) 173
Histopathological analyses of lepromin tests performed at BCG-ized and nonBCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
Histopathological analysis of specimens of BCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
IFN-gamma-producing ability as a possible marker for the protective T cells against *M. bovis* BCG in mice. Kawamura, I., *et al.* ..... (A) 165
Immunogenicity and protection studies with recombinant vaccinia and BCG each expressing the 18-kDa antigen of *M. leprae*. Baumgart, K. W., *et al.* ..... (A) 86A
Immunoscintigraphy in the detection of tuberculosis with radiolabelled antibody fragment against *M. bovis* bacillus Calmette-Guerin—a preliminary study in a rabbit model. Lee, J. D., *et al.* ..... (A) 167
Influence of BCG vaccination and close contact with leprosy patients on the results of skin test with four new tuberculins. Bottasso, O., *et al.* ..... (A) 94A
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ..... (A) 168
Pilot study to determine acceptability and ability of heat killed *M. leprae* plus BCG (HKML + BCG) vaccine to induce skin test conversion. Chen, Z.-L., *et al.* ..... (A) 651
Pulsed field gel electrophoresis of representatives of *M. tuberculosis* and *M. bovis* BCG strains. Varnerot, A., *et al.* ..... (A) 179
Rodrigues, *et al.* reply to letter from Drs. Nishioka and Goulart. Rodrigues, M. L. O., *et al.* ..... (C) 461
Sensitization potential and reactogenicity of varying doses of BCG plus killed *M. leprae*: an extended study. Gupte, M. D., *et al.* ..... (O) 563
Serological response in leprosy and tuberculosis patients to the 18-kDa antigen of *M. leprae* and antigen 85B of *M. bovis* BCG. Vikerfors, T., *et al.* ..... (O) 571
Structural features of lipoarabinomannan from *M. bovis* BCG; determination of molecular mass by laser desorption mass spectrometry. Venisse, A., *et al.* ..... (A) 669
T cell response to purified filtrate antigen 85 from *M. bovis* bacilli Calmette-Guerin (BCG) in leprosy patients. Launois, P., *et al.* ..... (A) 134
The major secreted antigen complex (Ag-85) from *M. bovis* bacille Calmette-Guerin is asociated with protective T cells in leprosy—a follow-up study of 45 household contacts. Launois, P., *et al.* ..... (A) 495

The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guerin (BCG) vaccination in either South India or London. Das, S., *et al.* ....(A) 158
The protective role of BCG in Hansen's disease. Magalhaes, M. C. C. ....(A) 69A

Behcet's syndrome,
T-cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. Pervin, K., *et al.* ....(A) 667

Belgium,
Beatification of Father Damien. ....(N) 478

Biopsy,
A morphological study of nerve biopsies from cases of multibacillary leprosy given multidrug therapy. Jacobs, J. M., *et al.* ....(A) 489
Conjunctival biopsy in patients bearing Hansen's disease. Campos, W., *et al.* ....(A) 123A
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ....(A) 145
Evaluation of polymerase chain reaction amplification of *M. leprae*-specific repetitive sequence in biopsy specimens from leprosy patients. Yoon, K.-H., *et al.* ....(A) 360
Histopathological analysis of skin biopsies performed in leprosy patients: reaction or relapse? Schettini, A. P., *et al.* ....(A) 122A
Immunohistochemical identification of ferritin, lactoferrin and transferrin in leprosy lesions of human skin biopsies. Momotani, E., *et al.* ....(A) 135
Nucleic acid sequence-based amplification (NASBA) for identification and viability assessment of *M. leprae* in skin biopsy specimens. van der Vliet, G. M. E., *et al.* ....(A) 107A
Role of skin and cutaneous nerve biopsies in paucibacillary borderline tuberculoid Hansen's disease. Thomas, S., *et al.* ....(A) 122A
Treated indeterminate leprosy: a search for predictive histopathological and immunohistochemical parameters in skin biopsies taken from patients at admission and at clinical discharge. Takahashi, D., *et al.* ....(A) 354

Blood,
Acetylation of dapsone by human whole blood. Irshaid, Y. M., *et al.* ....(A) 338
Analysis of cytokine production by mycobacterium-reactive T cells—failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ....(A) 489
Analysis of cytokine production by mycobacterium-reactive T cells: failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ....(A) 102A
Characterization of gamma/delta lymphocytes-T in the peripheral blood of patients with active tuberculosis—a comparison with normal subjects and patients in sarcoidosis. Tazi, A., *et al.* ....(A) 178
Digital blood circulation in paucibacillary leprosy. Ghosh, S. and Biswas, A. ....(A) 125
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium-M. intracellulare* complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ....(A) 168
Hematologic data of old patients with leprosy. Matsui, *et al.* ....(A) 32A
Hematological and biochemical investigations on active and treated patients. El Tayeb, S. H. M., *et al.* ....(A) 32A
Interleukin-1beta production by peripheral blood mononuclear cells from leprosy patients. Jayapal, V., *et al.* ....(C) 462
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ....(A) 95A
Reduced fingertip blood flow and peripheral dysautonomia in leprosy patients in Iranian Azerbaijan and in Maharashtra, India. Abbot, N. C., *et al.* ....(C) 474
Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ....(A) 138
T-cell receptor usage in blood and skin lesions in leprosy. Cross, C., *et al.* ....(A) 104A
Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Neubert, R., *et al.* ....(A) 136

Ultrastructural observations of small blood vessels in leprosy patients. Yajima, M., *et al.* ..... (A) 356

Bone,

Application of electroactivated solutions for treatment of osteomyelitis in leprosy patients. Shats, E. ..... (A) 34A
Bone infarction and leprosy. Carpintero, P., *et al.* ..... (A) 30A

Book Reviews,

Leprosy for Medical Practitioners and Paramedical Workers by S. J. Yawalker. Yoder, L. J. ..... (B) 326
Prevention of Disabilities in Patients with Leprosy by H. Srinivasan. ..... (B) 637
Prevention of Disability; Guidelines for Leprosy Control Programmes published by ILEP. (B) 477
Solapur Comprehensive Leprosy Project: Prospect and Retrospect by J. M. Mehta, S. S. Dhamangaonkar and D. G. Jogaikar. ..... (B) 477

Borderline leprosy,

Antibody response of patient with borderline lepromatous and borderline tuberculoid leprosy to mycobacterial 29/33-kDa doublet and 65-kDa singlet antigens. Burggraaf, J. D., *et al.* ..... (A) 86A
Antibody responses to various antigens of *M. leprae* in borderline leprosy with or in reaction. Sudha, R. and Stanley, J. N. A. ..... (A) 93A
Bacteriological response of BL/LL patients to MDT for varied duration: a retrospective five-year follow up. Bhatki, W. and Pade, S. ..... (A) 3A
Borderline tuberculoid hanseniasis; parameters of immunological activity. Pimentel, M. I. F., *et al.* ..... (A) 98A
Borderline tuberculoid leprosy in an HIV+ patient; clinical, histologic and immunohistologic evaluation. Goodless, D. R., *et al.* ..... (A) 35A
Borderline tuberculoid relapse in lepromatous leprosy. Girdhar, B. K., *et al.* ..... (A) 649
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with *M. avium*. Lazard, T., *et al.* ..... (A) 663
Clinical and histological picture of very early indeterminate and BT leprosy in adolescents. Duncan, M. E., *et al.* ..... (A) 30A
Combined chemotherapy and immunotherapy for treatment of highly bacillated BL/LL cases. Katoch, K., *et al.* ..... (A) 13A
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* ..... (A) 5A
Cutaneous sarcoidosis masquerading as relapsed borderline tuberculoid leprosy? Kaur, S., *et al.* ..... (E) 455
Extensive progressive new lesions in a BT case while on regular MB-MDT. Kiran, K. U. ..... (A) 22A
Histo-bacteriological investigation of borderline tuberculoid leprosy. Wang, T., *et al.* ..... (A) 355
Paralysis of occipitofrontalis in a borderline case of leprosy. Mishra, B., *et al.* ..... (A) 342
Reaction in borderline tuberculoid leprosy presenting with multiple subcutaneous nodules. Jayakumar, J., *et al.* ..... (A) 650
Role of skin and cutaneous nerve biopsies in paucibacillary borderline tuberculoid Hansen's disease. Thomas, S., *et al.* ..... (A) 122A
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated *M. avium* complex infection of normal C57BL/6 mice. Perronne, C., *et al.* (A) 172
Treatment of highly bacillated BL/LL cases with a pyrazinamide containing regimen. Katoch, K., *et al.* ..... (A) 7A
Zoster-form borderline-lepromatous leprosy. Yamashita, J. T., *et al.* ..... (A) 29A

Brazil,

Action of the social assistant and improvement of leprosy patients' treatment regularity-Duque de Caxias Project, Rio de Janeiro, Brazil. Reis do Amaral, R ..... (A) 136A
Association between leprosy and hepatitis-B infection—a survey in Goiana, Central Brazil. Rosa, H., *et al.* ..... (A) 127
Current situation of Hansen's disease control program in the Amazon Region of Brazil. Oliveira, M. L. W., *et al.* ..... (A) 55A
Development and adaptation of the Semmes-Weinstein light touch/deep pressure sensory test in Brazil. Lehman, L., *et al.* ..... (A) 144A

Development of multiprofessional prevention and control of disability courses in Minas Gerais, Brazil, from 1988 to 1992. Lehman, L., *et al.* ..... (A) 163A
Disability in new cases of Hansen's disease in the State of Minas Gerais, Brazil, from 1988 to 1992 by regions of epidemiological priority and training. Lehman, L., *et al.* (A) 158A
Drug support to the use of multidrug therapy (WHO) in Brazil between 1986 and 1992. Rodrigues, A. L., *et al.* ..... (A) 43A
Educative actions and Hansen's disease control program in the State of Sao Paulo, Brazil. Lessa, Z. L., *et al.* ..... (A) 165A
Evaluation of the health educational methods and effects of a wound reduction program for 72 workers with Hansen's disease in Bambui, Minas Gerais, Brazil. Lehman, L. (A) 169A
Factors influencing patient's compliance to MDT/WHO in Rio de Janeiro. Moreira, T. A., *et al.* ..... (A) 11A
Guidelines and strategies of the program for the control and elimination of Hansen's disease in Brazil in the period 1990 1994. Penna, G. O., *et al.* ..... (A) 38A
Hansen's disease in children in the State of Amazonas, Brazil, 1980 to 1990. Pennini, S., *et al.* ..... (A) 71A
Impact of personnel training on the epidemiological and operational indicators- Brazil, 1986 to 1991. Rodrigues, A. L., *et al.* ..... (A) 166A
Impact of personnel training on the indicators of the Hansen's disease control program in the Federal District of Brazil, 1990-1992. Sampaio, A. A. and Moreira, M. B. R. (A) 166A
Impact of the implementation of MDT/WHO on the control of Hansen's disease in Brazil in the period 1986-1992. Penna, G. O., *et al.* ..... (A) 53A
Implanting multiple drug therapy in Sao Paulo, Brazil- strategies, operation and results. Nogueira, W., *et al.* ..... (A) 43A
MDT in Manaus: readmission after release from treatment. Ribas, C. B. R., *et al.* ..... (A) 11A
Management strategies in the control of Hansen's disease in the State of Minas Gerais, Brazil, from 1988 to 1992. Grossi, A., *et al.* ..... (A) 164A
Participation of Hansen's disease patients in the governmental Hansen's disease control policy—Hansen's Disease and the Constitutional Assembly—a Brazilian Ministry of Health's experience. Ventura, D. R. V., *et al.* ..... (A) 139A
Participation of the "Movimento de Reitegracao de Hansenianos" (MORHAN) in the leprosy control program in Brazil. Reis do Amaral, R. ..... (A) 139A
Preliminary evaluation to measure the future effects of decentalization on the control of Hansen's disease in the metropolitan regional area of Belo Horizonte, Minas Gerais, Brazil, from 1990 to 1992. Leboeuf, M. A., *et al.* ..... (A) 59A
Project for implanting integrated health attention centers for rehabilitation in the 65 health subregions of the State of Sao Paulo, Brazil, for the period 1993 to 1995. Nogueira, W., *et al.* ..... (A) 47A
Results in serological assays for detection of the prevalence of antibodies to HIV-1 leprosy cases in Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (A) 35A
Situation diagnosis and reorganization of social actions for Hansen's disease in the State of Sao Paulo, Brazil. Goncalves, O. S. J., *et al.* ..... (A) 47A
Studies of trends of Hansen's disease in Brazil. Penna, G. O., *et al.* ..... (A) 66A
Upgrading of human resources for Hansen's disease control actions in the State of Sao Paulo, Brazil, during 1988 to 1992. Metello, H. N., *et al.* ..... (A) 47A

Burma (see **Myanmar**).

Cambodia,
Comprehensive care of Cambodians with Hansen's disease in a large American city. Style, A. ..... (A) 138A

Canada,
A singular obsession: New Brunswick's leprosy doctor. Stanley-Blackwell, L. C. C. .... (E) 619

Cancer,
The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines *in vitro* by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Van Rensburg, C. E. J., *et al.* ..... (A) 378

Caribbean,
The epidemiology of Hansen's disease in the English-speaking Caribbean and Suriname: current status and trends. Tollefson, J. E., *et al.* ..... (A) 65A

Catalase,
Characterization of the katG gene encoding a catalase peroxidase required for the isoniazid susceptibility of *M. tuberculosis*. Heym, B., *et al.* ..... (A) 661
The catalase-peroxidase of *M. intracellulare*: nucleotide sequence analysis and expression in *Escherichia coli*. Morris, S. L., *et al.* ..... (A) 142

Cell(s),
An investigation of mast cells in two basic leprosy groups. Aroni, K., *et al.* ..... (C) 634
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*—effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159
Determination of subcellular location of the immunoprotective moieties in *M. habana*. Chaturvedi, V., *et al.* ..... (A) 88A
Differential cytokine gene expression and secretion after phagocytosis by a human monocytic cell line of *Toxoplasma gondii* compared with *M. tuberculosis*. Friedland, J. S., *et al.* ..... (A) 370
Differential mechanism of intracellular killing of *M. avium* and *Listeria monocytogenes* by activated human and murine macrophages—the role of nitric oxide. Bermudez, L. E. ..... (A) 367
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
Killing of mycobacteria-infected macrophages by LAK cells from leprosy patients. Chiplunkar, S., *et al.* ..... (A) 96A
Lack of expression of intercellular adhesion molecule ICAM-1 in lepromatous leprosy patients. Moncada, B., *et al.* ..... (O) 581
M. leprae in mast cells in histoid leproma. Liu, J., *et al.* ..... (A) 123A
M. leprae produces extracellular homologs of the antigen-85 complex. Von Pessolani, M. C. and Brennan, P. J. ..... (A) 144
Mast cells in histoid leproma. Wu, Z., *et al.* ..... (A) 123A
Modulation of MHC class-II antigen expression on antigen presenting cells of leprosy patients by *M. leprae*. SivaSai, K. S. R., *et al.* ..... (A) 89A
Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Friedland, J. S., *et al.* ..... (A) 347
Observation on subcutaneous immune cells *in situ* in leprous nonreactive skin lesions. Zhu, S., *et al.* ..... (A) 98A
Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. Mindermann, T., *et al.* ..... (A) 486
Physical organization of lipids in the cell wall of *M. chelonae*. Nikaido, H., *et al.* ..... (A) 665
Porins in the cell wall of mycobacterial. Trias, J., *et al.* ..... (A) 144
Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Meylan, P. R. A., *et al.* ..... (A) 169
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma-delta T cells activated by live *M. tuberculosis*. Boom, W. H., *et al.* ..... (A) 153
Serological response against crossreactive cell-wall antigens (65-kDa protein and LAM-B) in leprosy. Elangeswaran, N., *et al.* ..... (A) 89A
Significance of cellular morphology of Mitsuda lepromin response. Desikan, V. K. and Girdhar, B. K. ..... (A) 125A
Squamous cell carcinoma in chronic ulcers of leprosy patients. Richardus, J. H. and Smith, T. C. ..... (A) 37A
Stimulation of mycolic acid biosynthesis by incorporation of cis-tetracos-5-enoic acid in a cell-wall preparation of *M. smegmatis*. Wheeler, P. R., *et al.* ..... (A) 499
Study of intracellular deposition of the anti-leprosy drug clofazimine in mouse spleen using laser microprobe mass analysis. Vandeputte, D., *et al.* ..... (A) 487
Subcellular fractionation of *M. leprae* and the search for new proteins. Chitale, S. and Brennan, P. J ..... (A) 115A
Subcellular localization of DDS and rifampin in the skin and nerve of multidrug-treated cases of leprosy. Shetty, V., *et al.* ..... (A) 18A
Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Neubert, R., *et al.* ..... (A) 136

Thalidomide does not affect selected immunomodulating surface receptor molecules on cells with immune potential. Shannon, E. J., *et al.* ..... (A) 105A
The effect of *M. tuberculosis* on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Filley, E. A., *et al.* ..... (A) 132
The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines *in vitro* by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Van Rensburg, C. E. J., *et al.* ..... (A) 378
Whole-cell protein electrophoresis for typing *M. tuberculosis*. Millership, S. E. and Want, S. V. ..... (A) 170

Cells, B,
An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ..... (A) 90A
Analysis of B-cell epitopes on the variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein. Peake, P. W., *et al.* ..... (A) 352
B-cell epitopes of HSP65 in the autoimmune diseases. Nomaguchi, H., *et al.* ..... (A) 85A
Characterization of B cell epitopes on the 16K antigen of *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 179
Cloning and sequencing of the gene for alpha-antigen from *M. avium* and mapping of B-cell epitopes. Ohara, N., *et al.* ..... (A) 496

Cells, mononuclear,
Comparative effects of *M. avium* glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells. Pourshafie, M., *et al.* ..... (A) 667
Identification of IL-8 as a locomotor attractant for activated human lymphocytes in mononuclear cell cultures with anti-CD3 or purified protein derivative of *M. tuberculosis*. Wilkinson, P. C. and Newman, I. ..... (A) 183
Interleukin-1beta production by peripheral blood mononuclear cells from leprosy patients. Jayapal, V., *et al.* ..... (C) 462
Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ..... (A) 138
Subplasmalemmal linear densities in mononuclear cells induced by an antigen in human sensory peripheral nerve. Crawford, C. L. and Hardwicke, P. M. D. ..... (A) 79A

Cells, natural killer (NK),
Association of NK (CD16+) cells and cytokines with *M. leprae* specific responses in type 1 reactions. Esquenazi, D. A., *et al.* ..... (A) 87A
Reduced natural killer cell activity in multi-drug resistant pulmonary tuberculosis. Ratcliffe, L. T., *et al.* ..... (A) 175

Cells, Schwann,
Lipoarabinomannan (LAM)- a possible immunoregulatory molecule of *M. leprae*-infected Schwann cells? Mistry, N., *et al.* ..... (A) 100A
M. leprae infection triggers synthesis of stress-inducible HSP70 in Schwann cells and anti-HSP antibodies in sera. Mistry, Y., *et al.* ..... (A) 104A
Murine strain variation in *M. leprae*-infected Schwann cell functions and their modulation by macrophages. Birdi, T., *et al.* ..... (A) 77A
Observation on phagocytosis to *M. leprae* by cultured human Schwann cells. Qiu, J., *et al.* ..... (A) 79A
Problems in detection of secretory antigens of intracellular mycobacteria in macrophage and Schwann cell tissue culture. Mistry, N., *et al.* ..... (A) 87A
Schwann cells are able to present exogenous mycobcterial hsp70 to antigen-specific T lymphocytes. Ford, A. L., *et al.* ..... (A) 488

Cells, T,
A comparison of the T-cell delayed-type hypersensitivity epitopes of the 19-kD antigens from *M. tuberculosis* and *M. intracellulare* using overlapping synthetic peptides. Mackall, J. C., *et al.* ..... (A) 664
A molecular analysis of mycobacterial antigens which stimulate gamma/delta T cells. Sanchez-Garcia, J., *et al.* ..... (A) 106A
A role for gamma interferon, tumor necrosis factor, and soluble T-cell receptors in the

depressed blastogenic response of spleen cells of *M. lepraemurium*-infected mice. Richard, L., *et al.* ..... (A) 137
Analysis of cytokine production by mycobacterium-reactive T cells—failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 489
Analysis of cytokine production by mycobacterium-reactive T cells: failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 102A
Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor. Mendez-Samperio, P. ..... (A) 654
Appearance of delta-gamma T cell receptor-positive cells following alpha-beta T cell receptor-positive cells in the lepromin reaction of human skin. Fujita, M., *et al.* ..... (A) 348
Crossreactive recognition of human T-cell epitopes in the *M. leprae* 18-kDa antigen. Menz, B., *et al.* ..... (A) 84A
FACS analysis of CD4+ T-cell subsets in reacting and nonreacting leprosy skin lesions. Utaipat, U., *et al.* ..... (A) 104A
Functional analysis of DR17-(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. Geluk, L., *et al.* ..... (A) 133
Generation of cytolytic T-cells in individuals infected by *M. tuberculosis* and vaccinated with BCG. Pithie, A. D., *et al.* ..... (A) 173
Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of *M. tuberculosis* by human and murine T cells. Harris, D. P., *et al.* ..... (A) 661
Human T-cell clones recognize mycobacterial specific and shared epitopes on *M. leprae* 70-kDa protein. Adams, E., *et al.* ..... (A) 104A
IFN-gamma-producing ability as a possible marker for the protective T cells against *M. bovis* BCG in mice. Kawamura, I., *et al.* ..... (A) 165
Identification of T-cell stimulatory epitopes from the 18-kDa protein of *M. leprae*. Doherty, T. M., *et al.* ..... (A) 652
Immunosupressive roles for IL-10 and IL-4 in human infection–*in vitro* modulation of T-cell responses in leprosy. Sieling, P. A., *et al.* ..... (A) 655
Lactoferrin triggers *in vitro* proliferation of T cells of Lewis rats submitted to mycobacteria-induced adjuvant arthritis. Esaguy, N., *et al.* ..... (A) 652
Limited T-cell receptor beta-chain diversity of a T-helper cell type-1-like response to *M. leprae*. Uyemura, K., *et al.* ..... (A) 139
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
M. leprae 10-kDa heat-shock protein is a major T-cell antigen. Mehra, V., *et al.* ..... (A) 88A
M. leprae antigens can be recognized by both Th1-like and Th2 like human T cells. MacFarlane, A. and Dockrell, H. ..... (A) 89A
M. leprae in mast cells in histoid leproma. Liu, J., *et al.* ..... (A) 123A
Major histocompatibility complex class I-restricted T cells are required for resistance to *M. tuberculosis* infection. Flynn, J. L., *et al.* ..... (A) 161
Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Carlucci, S., *et al.* ..... (A) 368
Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Barnes, P. F., *et al.* ..... (A) 366
Reconstitution of *M. leprae* immunity in severe combined immunodeficient mice using a T-cell line. Azouaou, N., *et al.* ..... (O) 398
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma-delta T cells activated by live *M. tuberculosis*. Boom, W. H., *et al.* ..... (A) 153
Selection of T lymphocytes bearing limited T-cell receptor beta chains in the response to a human pathogen. Wang, X. H., *et al.* ..... (A) 140
Selective expansion of Vdelta1 + T-cells from leprosy skin lesions. Uyemura, K., *et al.* ..... (A) 355
T cell response to purified filtrate antegen 85 from *M. bovis* bacilli Calmette-Guerin (BCG) in leprosy patients. Launois, P., *et al.* ..... (A) 134
T-cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. Pervin, K., *et al.* ..... (A) 667

T-cell receptor beta-chain gene usage in the T-cell recognition of *M. leprae* antigens in one tuberculoid leprosy patient. van Schooten, W. C. A., *et al.* ..... (A) 139
T-cell receptor usage in blood and skin lesions in leprosy. Cross, C., *et al.* ..... (A) 104A
T-cell repertoire in tuberculosis—selective anergy to an immunodominant epitope of the 38-kDa antigen in patients with active disease. Vordermeier, H. M., *et al.* ..... (A) 180
T-cell response to *M. tuberculosis*. Orme, I. M., *et al.* ..... (A) 666
T-cell responses to synthetic peptides in human leprosy. Murtaza, A., *et al.* ..... (A) 85A
T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with *M. leprae* secreted antigen-85 is another immunodominant antigen. Launois, P., *et al.* ..... (A) 653
The major secreted antigen complex (Ag-85) from *M. bovis* bacille Calmette-Guerin is asociated with protective T cells in leprosy—a follow-up study of 45 household contacts. Launois, P., *et al.* ..... (A) 495
Tuberculosis and leprosy—attempts to identify T-cell antigens of potential value for vaccine design. Kaufmann, S. H. E., *et al.* ..... (A) 133

Cell-mediated immunity (CMI),
Cell-mediated immunity in leprosy; an update. Sengupta, U. ..... (E) 439
Cell-mediated immunity in trachomatous scarring—evidence from a leprosy population. Courtright, P., *et al.* ..... (A) 341

Chemotherapy (see also **Therapy**),
Application of fluorescent staining to assessment of the chemotherapy responses/drug susceptibility testing in leprosy. Katoch, V. M. ..... (A) 307
Combined chemotherapy and immunotherapy for treatment of highly bacillated BL/LL cases. Katoch, K., *et al.* ..... (A) 13A
Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Drowart, A., *et al.* ..... (O) 29
Fixed duration combined chemotherapy in multibacillary leprosy. Cunha, M. G. S., *et al.* ..... (A) 11A
Histological changes with combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Natarajan, M., *et al.* ..... (A) 351
Histopathological evaluation of chemotherapy and chemoimmunotherapy in MB leprosy. Mukherjee, A., *et al.* ..... (A) 126A
II Wurzburg Symposium on the Chemotherapy of Leprosy. ..... (A) 298
Leprosy: Short-Term Treatment—A Quantitative Scientific Basis for Anti-microbial Chemotherapy in Control Programmes by Joel G. Almeida. McDougall, A. C. ..... (A) 120
Neonatally thymectomized Lewis rat as a model for the elimination of "persisters" by chemotherapy. Siu, P., *et al.* ..... (A) 78A
Progress in chemotherapy research of leprosy. Ji, B., *et al.* ..... (A) 8A
Search for effective short-course regimens for the treatment of leprosy. Pattyn, S. R. .. (E) 76
Serological monitoring of the response to chemotherapy in leprosy patients. Roche, P. W., *et al.* ..... (O) 35
Short-term chemotherapy with rifampin + cotrimoxazol + isoniazid (cotrifazide). Freerksen, E. ..... (A) 315
Study of field trials of combined chemotherapy and fixed duration combined chemotherapy in multibacillary leprosy in MDT project, Bharuch District, Gujarat, India. Chopra, N. K. ..... (A) 49A
The neonatally thymectomized Lewis rat as a tool for chemotherapy research. Gelber, R. H. ..... (A) 311
Ultrastructural parameters indicating viability of *M. leprae* after chemotherapy. Kumar, V., *et al.* ..... (A) 110A
Utility of the beige mouse in chemotherapeutic studies in leprosy. Gangadharam, P. R. J. and Dhople, A. M. ..... (A) 80A

Children,
A clinical analysis of 187 children with leprosy. Wu, Y. ..... (A) 27A
A longitudinal study of the predictive value of the lepromin response and anti-PGL-I serology in children. Naik, S., *et al.* ..... (A) 72A
A sponsorship program for leprosy-affected children. Joshi, S., *et al.* ..... (A) 72A
BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ..... (A) 175

Growth and development of children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 21A
Hansen's disease in children in the State of Amazonas, Brazil, 1980 to 1990. Pennini, S., *et al.* ..... (A) 71A
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346
Leprosy- study of 20 placentas and the repercussion on the newborn. Lopes, V. G. S., *et al.* ..... (A) 122A
Leprosy and children: future perspectives. Mutatkar, K. and Ganapati, R. ..... (A) 63A
Leprosy in children of mothers with leprosy and healthy controls studied prospectively from birth. Duncan, M. E., *et al.* ..... (A) 21A
Leprosy in children. Sehgal, V. N. ..... (A) 27A
Nutrition, growth and mental development of children of urban leprosy patients. Rao, K. N ..... (A) 140A
Soluble *M. leprae* antigen skin testing and lepromin positivity in children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 105A
Study of leprosy in children in multidrug therapy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* ..... (A) 69A

China, People's Republic of,

An evaluation of retreatment of 13, 477 leprosy patient cured with DDS in Jiangsu Province, China. Xie, J. and Ding, J. ..... (A) 13A
An evaluation of the achievements of community-based leprosy control for 35 years in Chenggu County, Shaanxi Province, China. Wang, H., *et al.* ..... (A) 54A
An observation on the effect of MDT in the treatment of 1095 leprosy patients in Shaanxi Province, China. Deng, Y., *et al.* ..... (A) 9A
Analyses of delay for 19, 472 leprosy cases in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 62A
Analyses of logistic regression for 593 MB cases with WHO MDT or modified MDT in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 68A
Analyses of stepwise regression and indicators for reflecting leprosy decline in Yangzhou, China. Yang, Z.-M., *et al.* ..... (A) 69A
Analyses of treatment time for leprosy cases cured with DDS and MDT in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 10A
Analysis of 1096 newly registered cases of leprosy found in Jiangsu Province, China. Ren, X., *et al.* ..... (A) 60A
Application of circular distribution method to analysis of 14, 258 leprosy cases for deformities survey in Yangzhou, China. Yang, Z.-M., *et al.* ..... (A) 156A
Application of optical mark reader (OMR) to China leprosy surveillance system. Yang, Z.-M., *et al.* ..... (A) 65A
Basic elimination of leprosy in Shanghai, China. Chen, J., *et al.* ..... (A) 61A
China leprosy surveillance system. Dai, Z.-C., *et al.* ..... (A) 45A
Contribution of MDT to the prevention of eye disease in leprosy; results from a cross-sectional survey in the People's Republic of China. Courtright, P., *et al.* ..... (A) 118A
Effect and surveillance of 1076 leprosy patients treated with MDT in Shandong Province of China. Yu, X., *et al.* ..... (A) 2A
Epidemiological survey of leprosy in Yichun Prefecture of Jiangxi Province, China. He, Y. and Zhou, L. ..... (A) 71A
Long-term effect on patient detection after 30 years of leprosy control in prefectures of two provinces in China, 1980-1992. Li, H.-Y., *et al.* ..... (A) 60A
National Expert Advisory Committee on Leprosy established. Ye, G.-Y. ..... (N) 327
National Seminar on Ocular Leprosy held. ..... (N) 478
Problems of leprosy relapse in China. Li, H.-Y. ..... (O) 1
Relapses after dapsone monotherapy; an analysis of 769 cases in Jiangsu Province, China. Xie, Z., *et al.* ..... (A) 13A
Relapses in 20,091 cured leprosy cases in Shandong Province of China. Pan, Y., *et al.* (A) 6A
Rick factors for cataract in leprosy patients; results from a cross-sectional survey in the People's Republic of China. Lewallen, S., *et al.* ..... (A) 118A
Study on leprosy seroepidemiology in China. Wu, Q., *et al.* ..... (A) 67A

The impact of multidrug therapy on epidemiological trends of leprosy in Guizhou, China. Li, Q. and Liu, G. C. ..... (A) 52A

Cholesterol,
Effect of multidrug therapy on plasma level of high density lipoprotein cholesterol (HDL-C) in patients of lepromatous leprosy. Kumar, N. and Sharma, B. L. ..... (A) 33A

Chromatography,
Detection of 2-eicosanol by gas chromatography-mass spectrometry in sputa from patients with pulmonary mycobacterial infections. Alugupalli, S., *et al.* ..... (A) 658
Identification of *M. avium* complex strains and some similar species by high-performance liquid chromatography. Butler, W. R., *et al.* ..... (A) 154
Routine application of high-performance liquid chromatography for identification of mycobacteria. Thibert, L. and Lapierre, S. ..... (A) 669

Cimetidine,
The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Coleman, M. D., *et al.* ..... (A) 121

Ciprofloxacin,
Effects of rifampin and ciprofloxacin on mycolic acid levels in human tissue-derived *M. leprae* and its correlation with viability. Patil, M., *et al.* ..... (A) 116A
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium-M. intracellulare* complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ..... (A) 168

Classification,
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (O) 433
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (A) 122A
Concurrent skin and nerve histology in leprosy and its role in the classification of leprosy. Kaur, S., *et al.* ..... (A) 652
Lepromin skin testing in the classification of Hansen's disease in the United States. Krotoski, W. A., *et al.* ..... (A) 342

Clinic(s),
Deformity care clinics- a new approach to integrate care after cure concept in routine MDT program. Dave, P. V., *et al.* ..... (A) 51A
Variables influencing regularity of leprosy patients in attending treatment clinics. Kannan, N. and Sivaram, M. ..... (A) 342

Clinical,
A clinical analysis of 187 children with leprosy. Wu, Y. ..... (A) 27A
A clinical and radiological study of maxillary antrum in lepromatous leprosy. Hauhner, C. Z., *et al.* ..... (A) 342
A comparison of clinical features in tuberculosis associated with infection with human immunodeficiency virus-1 and virus 2. Doorly, R., *et al.* ..... (A) 505
An analysis of 70 newly detected leprosy patients. Liu, H., *et al.* ..... (A) 28A
Analysis of potential prognostic factors in paucibacillary leprosy. Bhatia, A. S., *et al.* ..... (A) 19A
Analysis of 392 leprosy cases newly detected in 1985-1991 in South-East Prefecture of Guizhou Province. Chen, Y., *et al.* ..... (A) 62A
Asymptomatic nerve hypertrophy in lepromatous leprosy—a clinical, electrophysiological and morphological study. Tzourio, C., *et al.* ..... (A) 127
Borderline tuberculoid leprosy in an HIV+ patient; clinical, histologic and immunohistologic evaluation. Goodless, D. R., *et al.* ..... (A) 35A
Cervical lymphadenitis in a child caused by a previously unknown mycobacterium. Haas, W. H., *et al.* ..... (A) 372
Chaulmoogra oil was already used to treat leprosy by traditional Chinese medical doctors in the period of the Southern Song Dynasty. Liang, Z. ..... (A) 16A
Clinical Leprosy by Virendra N. Sehgal. Yoder, L. J. ..... (B) 114
Clinical and bacteriological effect of tryptophan-enriched diet in multibacillary leprosy-a preliminary communication. Ganapati, R., *et al.* ..... (A) 15A

Clinical and histological picture of very early indeterminate and BT leprosy in adolescents. Duncan, M. E., *et al.* ..... (A) 30A
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (O) 433
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (A) 122A
Clinical assessment of early leprous neuropathy with electrophysiologic correlation. Brown, T. R., *et al.* ..... (A) 148A
Clinical assessment of monolesion leprosy cases. Pai, V. V., *et al.* ..... (A) 30A
Clinical assessment, BI, MI, relapse rate. Waters, M. F. R. ..... (A) 311
Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Lockwood, D. N. J., *et al.* ..... (O) 9
Clinical significance of anti-PGL-I antibody in multibacillary leprosy patients. Ma, J., *et al.* ..... (A) 31A
Clinical study of lepra reactions in 123 cases treated by MDT. Mohareb, R. W. ..... (A) 24A
Clinical trials of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 7A
Clinical, electrophysiological and bacteriological evaluation of nerve damage after regular MDT in leprosy. Antia, N., *et al.* ..... (A) 22A
Clinical-histopathological correlation in patients suspected of having leprosy. Schettini, A. P., *et al.* ..... (A) 30A
Clinically atypical relapses in multibacillary patients. Jamet, P. and Bobin, P. ..... (A) 21A
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* ..... (A) 5A
[Correlation between vaccination with BCG and the clinical forms of leprosy.] Castro Chavez, R., *et al.* ..... (A) 148
Detection of *M. tuberculosis* DNA in clinical samples by using a simple lysis method and polymerase chain reaction. Folgueira, L., *et al.* ..... (A) 494
Detection of *M. tuberculosis* in clinical samples by 2-step polymerase chain reaction and nonistropic hybridization methods. Shawar, R. M., *et al.* ..... (A) 177
Detection of *M. tuberculosis* in clinical samples by using polymerase chain reaction and a nonradioactive detection system. Kolk, A. H. J., *et al.* ..... (A) 166
Determinant about irregularity on ambulatorial treatment of leprosy in a university hospital. Rosa Santos, O. L., *et al.* ..... (A) 136A
Early clinical and pathological results of *M. leprae* challenge of monkeys after attempted protective immunization with live BCG or BCG + heat-killed *M. leprae*. Xu, K., *et al.* ..... (A) 79A
Effect of HIV infection on clinical response of leprosy patients to multidrug therapy in Kenya. Orege, P. A., *et al.* ..... (A) 36A
Frequency and clinical features of erythema nodosum leprosum in Hyderabad, India. Vinayakumar, S., *et al.* ..... (A) 34A
Frequency of leprosy neuropathy in hyperendemic areas of Mexico and its correlation with clinical, epidemiological and structural findings. Valdez-Valenzuela, F., *et al.* ..... (A) 141A
Glucorticoids and regulatory peptides in leprosy pathogenesis. Naumov, V., *et al.* ..... (A) 101A
Granuloma persistance after clinical inactivity. Porichha, D., *et al.* ..... (A) 124A
Hematologic data of old patients with leprosy. Matsui, S., *et al.* ..... (A) 32A
Hematological and biochemical investigations on active and treated patients. El Tayeb, S. H. M., *et al.* ..... (A) 33A
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
Immunoepidemiological studies on subclinical infection in leprosy. II. Geographical distribution of seropositive responders with special reference to their possible source of infection. Abe, M., *et al.* ..... (A) 346
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346
Incidence of special events among patients with multibacillary leprosy during surveillance. Vijayakuaran, P., *et al.* ..... (A) 20A
Leprosy- study of 20 placentas and the repercussion on the newborn. Lopes, V. G. S., *et al.* ..... (A) 122A

Leprosy clinical trial of clarithromycin. Chan, G., *et al.* ..... (A) 17A
Leprosy clinical trial of fusidic acid. Franzblau, S. G., *et al.* ..... (A) 17A
Leprosy clinical trial of sparfloxacin. Chan, G., *et al.* ..... (A) 18A
Leprosy in women: clinical and immunological aspects. Ulrich, M., *et al.* ..... (A) 99A
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H. ..... (A) 310
Mycetomas in leprosy. Jayakumar, J., *et al.* ..... (A) 650
Myiasis in leprosy. Husain, A., *et al.* ..... (A) 650
Myokymia in leprosy patients. Kaur, S. and Dhar, S. ..... (A) 473
Natural history and clinical features of reversal reaction in Hyderabad, India. Lockwood, D., *et al.* ..... (A) 23A
Nerve function assessment in leprosy- comparison of various clinical methods. van Brakel, W. H., *et al.* ..... (A) 21A
On the necessity of alternative therapies for the treatment of leprosy. Alvarenga, A., *et al.* ..... (A) 14A
Oral manifestations of leprosy. Scheepers, A., *et al.* ..... (A) 344
Polymerase chain reaction to detect *M. tuberculosis* in a clinical microbiology laboratory. Veringa, E., *et al.* ..... (A) 180
Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ..... (A) 155
Reaction type 2 of HD (ENL) with visceral involvement: index for the severity of the disease, clinical, laboratorial and autopsy study of 34 patients. Margarido-Marchese, L. C., *et al.* ..... (A) 124A
Recaidas en hansenianos multibacilares tratados con monoterapia sulfonica. Terencio de las Aguas, J. ..... (A) 5A
Significance of taking care of leprosy inpatients with complications in a general hospital. Nguyen, S. X., *et al.* ..... (A) 41A
Somatosensory-evoked potentials in leprosy. Gupta, B. K., *et al.* ..... (A) 158A
Strengthening of active case-finding strategies and clinical study of household leprosy contacts in Mexico. Garcia Flores, E., *et al.* ..... (A) 46A
Study of fungal infection in Hansen's disease. Tyagi, P. K. ..... (A) 28A
Testicular insufficiency in multibacillary Hansen's disease—a five-year follow-up study. Frankel, R. I., *et al.* ..... (A) 20A
Thalidomide- a clinical study of 33 cases of type 2 lepra reaction. Kishore, V. ..... (A) 23A
The detection of *M. tuberculosis* in uncultured clinical specimens using the polymerase chain reaction and a non radioactive DNA probe. Thierry, D., *et al.* ..... (A) 178
The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of *M. avium* intracellulare. Kent, R. J., *et al.* ..... (A) 165
Treated indeterminate leprosy: a search for predictive histopathological and immunohistochemical parameters in skin biopsies taken from patients at admission and at clinical discharge. Takahashi, D., *et al.* ..... (A) 354

Clofazimine,
Agranulocytosis supposed caused by clofazimine in a lepromatous patient. Pinto Saavedra, I., *et al.* ..... (A) 34A
An *in vitro* comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase-A2 activity and superoxide generation. Krajewska, M. M. and Anderson, R. ..... (A) 486
Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Van Rensburg, C. E. J., *et al.* ..... (A) 124
Clofazimine distribution in human milk. Venkatesan, K., *et al.* ..... (A) 16A
Conjunctival and scleral pigmentation due to clofazimine. Campos, W., *et al.* ..... (A) 26A
Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Freerksen, E. and Seydel, J. K. ..... (A) 122
Hypersensitivity to dapsone, rifampin and clofazimine in a lepromatous leprosy patient. Kumar, J. S., *et al.* ..... (A) 28A
Improved high-performance liquid chromatographic analysis of snythetic phenazine compounds including clofazimine. O'Connor, R. and O'Kennedy, R. ..... (A) 15A
In-vitro activity of streptomycin and clofazimine against established infections of *M. avium* complex in beige mice. Gangadharam, P. R. J. and Parikh, K. ..... (A) 371

Investigation of lymphoedema as an adverse effect of clofazimine therapy in leprosy. Oommen, T., *et al.* ..... (A) 19A
Pedal edema following clofazimine therapy; a case report. Tyagi, P. K. and Oommen, T. ..... (C) 636
Penetration of dapsone, rifampin and clofazimine into macrophages and mycobacteria. Mathur, A., *et al.* ..... (A) 81A
Pseudo acute abdomen due to use of clofazimine. Discini, F., *et al.* ..... (A) 26A
Severe abdominal pain in low dosage clofazimine. Chong, P. Y. and Ti, T. K. ..... (A) 647
Study of intracellular deposition of the anti-leprosy drug clofazimine in mouse spleen using laser microprobe mass analysis. Vandeputte, D., *et al.* ..... (A) 487
The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines *in vitro* by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Van Rensburg, C. E. J., *et al.* ..... (A) 378
Use of clofazimine in patients with oculo-cutaneous albinism in bearers of Virchow's form of Hansen's disease. Campos, W., *et al.* ..... (A) 26A

Cloning,
Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor. Mendez-Samperio, P. ..... (A) 654
Cloning and characterization of a 42-kDa serine-rich antigen from *M. leprae*. Vega-Lopez, F., *et al.* ..... (A) 84A
Cloning and characterization of the genes coding for the 85 complex antigens of *M. leprae*. de Mendonca Lima, L., *et al.* ..... (A) 108A
Cloning and expression of portions of the 34-kilodalton protein gene to *M. paratuberculosis*: its application to serological analysis of Johne's disease. De Kesel, M., *et al.* (A) 369
Cloning and sequence analysis of the gene encoding an NADP dependent alcohol dehydrogenase in *M. bovis* BCG. Stelandre, M., *et al.* ..... (A) 177
Cloning and sequencing of the Tuf gene coding for the elongation factor Tu of *M. leprae*. Dhandayuthapani, S., *et al.* ..... (A) 109A
Cloning and sequencing of the gene for alpha-antigen from *M. avium* and mapping of B-cell epitopes. Ohara, N., *et al.* ..... (A) 496
Cloning and sequencing of the gene which encodes the highly inducible acetamidase of *M. smegmatis*. Mahenthiralingam, E., *et al.* ..... (A) 496
Cloning of mycobacterial histidine synthesis genes by complementation of a *M. smegmatis* auxotroph. Hinshelwood, S. and Stoker, N. G. ..... (A) 163
Cloning of the lsyA gene from *M. tuberculosis*. Andersen, A. B. and Hansen, E. B. .... (A) 492
Human T-cell clones recognize mycobacterial specific and shared epitopes on *M. leprae* 70-kDa protein. Adams, E., *et al.* ..... (A) 104A
Molecular cloning and characterization of *M. paratuberculosis* promoters in *Escherichia coli*. Thomas, T. J., *et al.* ..... (A) 179
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* ..... (O) 227
Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ..... (A) 168
Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Barnes, P. F., *et al.* ..... (A) 366

Commonwealth of Independent States,
Leprosy in the former USSR. Juscenko, A. ..... (A) 66A
Leprosy prevalence in Russia. Juscenko, A., *et al.* ..... (A) 66A

Complement,
Cloning of mycobacterial histidine synthesis genes by complementation of a *M. smegmatis* auxotroph. Hinshelwood, S. and Stoker, N. G. ..... (A) 163
Macrophage phagocytosis of virulent but not attenuated strains of *M. tuberculosis* is mediated by mannose receptors in addition to complement receptors. Schlesinger, L. S. ..... (A) 490
Reconstruction of antileprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and C(rat)EDTA (a source of C3-C9). Kashyap, A., *et al.* ..... (A) 123

Concanavalin A (ConA),
Correlation between TNK production, increase of plasma C reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Foss, N. T., *et al.* ..... (O) 218

Congresses,
4th Congress of Microbiology and Parasitology and 1st Congress of Tropical Medicine. (N) 327
II Wurzburg Symposium on the Chemotherapy of Leprosy. ..... (A) 298
6th International Congress for Infectious Diseases. ..... (N) 327
The International Congresses and other outstanding events in the study, epidemiology, and elimination of leprosy. Balina, L. M. and Valdez, R. P. ..... (A) 56A
Transactions of the Fourteenth International Leprosy Congress. ..... (S) 676

Control of leprosy,
[A focus of leprosy in San Francisco Libre, Nicaragua—1990.] Gomez, C. A., *et al.* ..... (A) 148
A 20-year review of amputations in the National Leprosy Control Program in Paraguay. Duerksen, F., *et al.* ..... (A) 162A
A trial based on PGL-I serology for leprosy control; preliminary results. Gonzalez-Abreu, E. and Gonzalez, A. B. ..... (A) 49A
An evaluation of the achievements of community-based leprosy control for 35 years in Chenggu County, Shaanxi Province, China. Wang, H., *et al.* ..... (A) 54A
An experimental study of involvement of general health workers in leprosy work. Bandyopadhyay, S. K. ..... (A) 50A
Behavior health change intervention on leprosy control in South Sulawesi, Indonesia. Rusli Ngatimin, H. M. ..... (A) 139A
Better community participation in leprosy. Alatkar, I. ..... (A) 39A
Changes in leprosy profile in a hyperendemic Bombay slum over 15 years. Ganapati, R., *et al.* ..... (A) 58A
Cohort study in the leprosy control program in Amazonas. Torrecilla, M. A. A., *et al.* (A) 55A
Communication for leprosy awareness in a country in transition. Cheriyan, C. S. and Devadas, J. ..... (A) 127A
Community-based leprosy control program; a case study in Nakhonratchasima Province, Thailand. Prasongthrap, P. ..... (A) 45A
Comparative case output through different case-detection methods in urban areas. Mathews, M., *et al.* ..... (A) 39A
Comprehensive leprosy care project, "Borsad model"- a new approach to leprosy elimination. Shah, A. and Ganapati, R. ..... (A) 38A
Computerized monitoring of leprosy program. Revankar, C. R., *et al.* ..... (A) 46A
Control and elimination of leprosy; a rural/urban strategy analysis. Devadas, T. J. and Abraham, T. ..... (A) 59A
Cost and effectiveness of integrating leprosy with primary care. John, K. R. and Muliyil, J. ..... (A) 41A
Costing of leprosy control programs before and after introduction of MDT. Daniel, J. and Walter, C. S. ..... (A) 43A
Efficient program monitoring; developments from the MURLEP project. Schuurman, M. E., *et al.* ..... (A) 40A
Epidemic and control of leprosy in Tibet. Yang, L.-H., *et al.* ..... (A) 62A
Epidemiological changes in urban leprosy control project—14 years' observations in Bombay. Revankar, C. R., *et al.* ..... (A) 58A
Erradicar la transmision de la lepra para 1994; politica para la accion en Mexico. Rodriguez-Dominguez, *et al.* ..... (A) 38A
Evaluation of MDT implementation for leprosy control in Bendel State of Nigeria (1985-1990). Majoroh, T. O. ..... (A) 42A
Evolution of the ILEP information system for leprosy control projects 1966-1993. Martineau-Needham, D. and Lacey, S. ..... (A) 38A
Experiences with evaluation of leprosy control. Jesudasan, K., *et al.* ..... (A) 58A
Formulation of a new leprosy control program in the Republic of Yemen as cooperation between GLRA and MOPH. Al Qubati, Y. and Al Nabhani, M. G. ..... (A) 45A
Fourteen years of HD control in Acre State. Woods, W. J., *et al.* ..... (A) 56A
Hansen's disease and its elimination. de Mallac, M. J. ..... (A) 62A
HLA-linked genetic control of leprosy. Kher, S. K., *et al.* ..... (A) 149

Impact of health education in the prevention of plantar ulcers in a leprosy control project-preliminary findings. Basskaran, E., *et al.* ..... (A) 153A
Impairments and disabilities; the difference and implications for leprosy control. Brandsma, J. W. and Heerkens, Y. F. ..... (A) 143A
Implementation of leprosy control program through basic health care network. Shao, K., *et al.* ..... (A) 41A
Importance of social rehabilitation of the patients in leprosy control. Soydan, M., *et al.* ..... (A) 135A
Integration of eye care in leprosy control in northern Nigeria. Verhage, R. ..... (A) 41A
Integration of leprosy control program into primary health care; 4-year preliminary study in Ogun State of Nigeria. Krishnan, S. A. R., *et al.* ..... (A) 51A
Involvement of scouting movement in leprosy control. Mutatkar, K. and Rao, R. ..... (A) 48A
July 1992 meeting of WHO Working Group on Leprosy Control. ..... (N) 332
La plan e acion estrategica de mercadotecnia utilizada para erradicar la transmision de la lepra en Mexico. Barocio, A. and Castellanos, F. ..... (A) 48A
Leprosy and socioeconomic development: between and within country comparisons. Smith, W. C. S. ..... (A) 66A
Leprosy control in 7 districts of South Sulawesi, Indonesia, 1986-91. Day, R., *et al.* ..... (A) 148
Leprosy control in Karakalpakstan. Eschanov, T. and Idunov, V. ..... (A) 56A
Leprosy control program (LCP) in Alto Amazonas Province, Loreto Region, Peru, October 1987-September 1990. Legua, P., *et al.* ..... (A) 49A
Leprosy control program in Loreto Region, Peru, October 1990 March 1992. Falconi, E., *et al.* ..... (A) 63A
Leprosy control program in Santa Fe Province, Argentina: results after 30 years. Merlin, V., *et al.* ..... (A) 59A
Leprosy control program in Thailand. Chantraprachoom, C. and Kittampol, K. ..... (A) 656
Leprosy control programme in Malaysia. Kamaludin, F. ..... (A) 657
Leprosy in Bangladesh 1984-88. Choudhury, A. M. ..... (A) 500
Leprosy eradication program in metropolitan cities: critical evaluation. Misra, R. S., *et al.* ..... (A) 59A
Leprosy teaching at medical schools through community-based leprosy control in a slum area. Oliveira, M. L. W., *et al.* ..... (A) 166A
Long-term active surveillance of leprosy suspects—what are the likely returns? Ponnighaus, J. M., *et al.* ..... (A) 343
Long-term effect on patient detection after 30 years of leprosy control in prefectures of two provinces in China, 1980-1992. Li, H.-Y., *et al.* ..... (A) 60A
Long-term evaluation of a province-wide clue survey for leprosy in Liaoning. Yu, A., *et al.* ..... (A) 54A
Maintaining a national Hansen's disease program in a budget-deficit reduction era. Guerra, I. E. ..... (A) 48A
Measuring epidemiological impact of multidrug therapy in leprosy control area. Rao, P. S. S., *et al.* ..... (A) 64A
Moolgaokar Leprosy Ward of BLP. ..... (N) 641
Multi-drug therapy, leprosy and leprosy control in west Nepal. van Brakel, W. H. ..... (A) 124
1972-1992: 20 years after starting the eradication project Malta. Gatt, P. ..... (A) 304
On reflections on the elimination of leprosy. Rao, C. K ..... (A) 106
On the role of the government in leprosy control. Zhang, H., *et al.* ..... (A) 37A
Participation of the "Movimento de Reitegracao de Hansenianos" (MORHAN) in the leprosy control program in Brazil. Reis do Amaral, R. ..... (A) 139A
Predictive value of gelatin particle agglutination test (GPAT) in leprosy control. Le, D. K., *et al.* ..... (A) 61A
Prevention of Disability; Guidelines for Leprosy Control Programmes published by ILEP. ..... (B) 477
Priorities for the future and prospects for leprosy control. Becx-Bleumink ..... (E) 82
Progress in leprosy control through multidrug therapy. ..... (A) 339
Promocion para la salud en el programa contra la lepra en Mexico. Castellanos, F., *et al.* ..... (A) 168A
Pros and cons of combining tuberculosis and leprosy control activities (based on 15 years' experience of the National TB Leprosy Program in Tanzania). Chum, H., *et al.* ..... (A) 41A

Prospects of global elimination of leprosy as a public health problem by the year 2000. Bechelli, L. M. ..... (A) 44A
Rapid photo survey as a tool for case detection in leprosy in urban areas. Lobo, D., *et al.* ..... (A) 39A
Rapid village survey (RVS), an alternative method in the estimation of leprosy prevalence. Pinitsoontorn, S., *et al.* ..... (A) 39A
Results of MDT implementation in the Mile Four Leprosy Control Project, Abakaliki, Enugu State, Nigeria. MacRae, M. A. and Vennemann, M. ..... (A) 53A
Revised estimates of global leprosy numbers. Smith, P. G. ..... (A) 150
Role de l'agent de sane dans un project de controle de la lepre; experience d'une annee. Blanc, G., *et al.* ..... (A) 48A
Self-assessment tools in monitoring of leprosy control programs. Eggens, H. ..... (A) 60A
"Simulation game" as a model of health education in leprosy; an experience from the rural leprosy control project in Nganjuk Regency, East Java. Agusni, I., *et al.* ..... (A) 167A
Situation of leprosy elimination in the Americas. Lombardi, C. ..... (A) 56A
Sixty years of leprosy control in southeastern Nigeria: the Uzuakoli experience. Chukwu, J. N. and Ededezie, U. M. ..... (A) 58A
Social action for leprosy control. Mutatkar, R. K. ..... (A) 130A
Solapur Comprehensive Leprosy Project: Prospect and Retrospect by J. M. Mehta, S. S. Dhamangaonkar and D. G. Jogaikar. ..... (B) 477
Some points on the elimination of leprosy. Sansarricq, H. ..... (A) 63A
Strengthening of active case-finding strategies and clinical study of household leprosy contacts in Mexico. Garcia Flores, E., *et al.* ..... (A) 46A
Surveillance system for leprosy; a field approach. Blanc, L., *et al.* ..... (A) 48A
The National Leprosy Control Program of Bhutan: factors in a successful MDT program. Jakeman, P. ..... (A) 52A
[The Netherlands Foundation for Leprosy Control: medical work under adverse conditions.] Spanier, J. M. ..... (A) 120
The approach to the leprosy problem in the past in Indonesia-a historical review of leprosy control activities in Indonesia during the last centuries. Zuiderhoek, B. ..... (A) 484
The disabled leprosy patient as partner in leprosy control: stigma as a sign post. Verhage, R. ..... (A) 37A
Training and education strategy in leprosy control program in Senegal. Naudin, J.-C., *et al.* ..... (A) 165A
Treatment compliance in the South Sulawesi Leprosy Control Program, Indonesia. Lever, P., *et al.* ..... (A) 16A
Twenty years after starting the eradication project in Malta. Gatt, P. ..... (A) 5A
Utilization of Barangay health volunteers in the implementation of the leprosy control program. Grino, S. S. ..... (A) 40A

Corticosteriods,
Colchicine in type 2 lepra reaction and its comparison with corticosteroids. Katkar, K. N. and Jagavkar, C. K. ..... (A) 8A
Quiet nerve paralysis assessment with respect to MDT and corticosteroid therapy. Gupte, M. D., *et al.* ..... (A) 147A

Cuba,
A health education intervention in Cuba to diminish the delay in diagnosis of leprosy. de Rojas, V., *et al.* ..... (A) 57A
4th Congress of Microbiology and Parasitology and 1st Congress of Tropical Medicine. (N) 327
Labor del Laboratorio Nacional de Referencia de Baciloscopia de Lepra en Cuba. Suarez Moreno, O., *et al.* ..... (A) 56A
[Ocular leprosy in the city of Camaguey, Cuba.] Cardoso Guillen, E., *et al.* ..... (A) 340
Survey for secondary dapsone and rifampicin resistance in Cuba. Gonzalez, A. B., *et al.* ..... (A) 647

Cultivation,
Attempts to cultivate *M. leprae* in fat tissue. Godard, C. M. ..... (A) 656
Cultivation of *M. leprae* in artificial culture medium. Biswas, S. K. ..... (A) 111A
In vitro cultivation of *M. leprae*—existence of a growth factor. Dhople, A. M. and Ibanez, M. A. ..... (A) 116A

In vitro cultivation of *M. leprae* with cytokines. Oh, C.-S. ..... (A) 112A
Observations on attempted leprosy cultures in two media. Bhatia, V. N. and Thawani, G. ..... (A) 655
Observations on the cultivation of *M. leprae* and M. tuberculosis in medium "V" and "V1.". Herbert, D. and Prabhakar, R. ..... (A) 142

Cutaneous,
Chronic planta ulcer of a leprosy patient treated by fasciocutaneous instep flap transfer—preliminary result. Majoroh, T. O. ..... (A) 501
Chronic plantar ulcers of leprosy patients treated by musculo cutaneous instep flap transfer. Majoroh, T. O. ..... (A) 161A
[Cutaneous neoplasia in two cases of leprosy.] Sanlorenzo, M., *et al.* ..... (A) 343
Cutaneous sarcoidosis masquerading as relapsed borderline tuberculoid leprosy? Kaur, S., *et al.* ..... (E) 455
[Distribution of single cutaneous lesions in paucibacillary leprosy.] Avelleira, J. C. R., *et al.* ..... (A) 649
Histopathological alterations in areas of cutaneous sensory loss in the diagnosis of leprosy. Pennini, S. N., *et al.* ..... (A) 122A
Neuritis of the lateral femoral cutaneous nerve in leprosy. Theuvenet, W. J., *et al.* ..... (O) 592
Observation on subcutaneous immune cells *in situ* in leprous nonreactive skin lesions. Zhu, S., *et al.* ..... (A) 98A
Reaction in borderline tuberculoid leprosy presenting with multiple subcutaneous nodules. Jayakumar, J., *et al.* ..... (A) 650
Role of skin and cutaneous nerve biopsies in paucibacillary borderline tuberculoid Hansen's disease. Thomas, S., *et al.* ..... (A) 122A
Ultrastructural alterations of dermal nerves in early cutaneous leprous macules. Antunes, S. L. G. and Sarno, E. N. ..... (A) 126A
Use of clofazimine in patients with oculo-cutaneous albinism in bearers of Virchow's form of Hansen's disease. Campos, W., *et al.* ..... (A) 26A

Cyclosporine,
Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of *M. avium* complex in rats treated with cyclosporine. Brown, S. T., *et al.* ..... (A) 367

Damien-Dutton Society,
1992 Damien-Dutton Award Recipient Anwei Skinsnes Law. ..... (N) 115
Dr. Charles K. Job is 1993 Damien-Dutton Award recipient. ..... (N) 638

Dapsone (DDS),
A 20-year follow-up study of incidence rates of leprosy in DDS prophylaxis and control groups. Prabhakara Rao, V. ..... (A) 65A
Acetylation of dapsone by human whole blood. Irshaid, Y. M., *et al.* ..... (A) 338
An evaluation of retreatment of 13, 477 leprosy patient cured with DDS in Jiangsu Province, China. Xie, J. and Ding, J. ..... (A) 13A
Analyses of treatment time for leprosy cases cured with DDS and MDT in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 10A
Bioavailability of dapsone on oral administration of Dapsomine-a comparative evaluation. Venkatesan, K., *et al.* ..... (A) 649
Brodimoprim-DDS and brodimporim-DDS/rifampin; *in vitro* and in vivo results for a newly developed effective MDT against leprosy. Seydel, J. K., *et al.* ..... (A) 7A
Brodimoprim-dapsone and brodimporim/dapsone/rifampin; *in vitro* and *in vivo* results. Seydel, J. K. ..... (A) 315
Clarithromycin is bactericidal against strains of *M. leprae* resistant and susceptible to dapsone and rifampin. Walker, L. L., *et al.* ..... (O) 59
Dapsone for autoimmune thromobocytopenic purpura. Godeau, B., *et al.* ..... (A) 660
Dapsone syndrome. Gokhale, N. R., *et al.* ..... (A) 485
Dapsone-induced lupoid photodermatitis in leprosy. Roselino, A. M. F., *et al.* ..... (A) 31A
Dapsone-induced pulmonary eosinophilia. Kumar, K. S., *et al.* ..... (A) 28A
Disability grading of patients in a MDT program—comparison with a similar group treated with dapsone alone and five year follow up. Duerksen, F., *et al.* ..... (A) 4A

Effects of glucocorticoids, dapsone and thalidomide on interleukin-1 production. Lew, W., *et al.* (A) 92A
[Evaluation of MDT retreatment in 13, 477 leprosy patients cured by DDS.] Xie, Z. and Ding, J. (A) 487
Hypersensitivity to dapsone, rifampin and clofazimine in a lepromatous leprosy patient. Kumar, J. S., *et al.* (A) 28A
Improving patient compliance—a multicenter evaluation of the DDS tile test. Naik, S., *et al.* (A) 55A
Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Bozeman, P. M., *et al.* (A) 121
Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteer. Edstein, M. D. and Rieckmann, K. H. (A) 647
Long-term effects of dapsone on immune responses in BALB/c mice. Reddy, M. N. and Rao, P. R. (A) 82A
Multidrug therapy versus dapsone monotherapy in leprosy: an international randomized study with long-term follow up. Dietrich, M., *et al.* (A) 305
Penetration of dapsone, rifampin and clofazimine into macrophages and mycobacteria. Mathur, A., *et al.* (A) 81A
Primary dapsone resistance in Cebu, The Philippines: recent findings. Cellona, R. V., *et al.* (A) 6A
Primary resistance to dapsone and rifampin. Damasco, M. H. S., *et al.* (A) 12A
Reduction of dapsone hydroxylamine to dapsone during methemoglobin formation in human erythrocytes *in vitro*. Coleman, M. D. and Jacobus, D. P. (A) 485
Relapses after dapsone monotherapy; an analysis of 769 cases in Jiangsu Province, China. Xie, Z., *et al.* (A) 13A
Relapses of 1455 leprosy cases cured with DDS monotherapy. Liu, Z., *et al.* (A) 15A
Single dose rifampin cannot prevent relapse in skin-smear negative multibacillary leprosy patients after dapsone monotherapy. Jamet, P., *et al.* (A) 6A
Subcellular localization of DDS and rifampin in the skin and nerve of multidrug-treated cases of leprosy. Shetty, V., *et al.* (A) 18A
Survey for secondary dapsone and rifampicin resistance in Cuba. Gonzalez, A. B., *et al.* (A) 647
Survey for secondary dapsone and rifampin resistance in Cuba. Gonzalez, A. B. and Maestre, J. L. (A) 13A
The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Coleman, M. D., *et al.* (A) 121
Treatment of paucibacillary leprosy with a regimen containing rifampicin, dapsone and prothionamide. Katoch, K., *et al.* (A) 123
Treatment of paucibacillary patients with MDT containing rifampin, dapsone and prothionamide. Katoch, K., *et al.* (A) 2A

Deformity, disability,

A 10-year observation on the curative effect of surgical operations for correction of leprosy deformities—a report of 86 cases. Niu, S., *et al.* (A) 151A
A modification of surgical procedure to prevent postoperative sublimis minus deformity at the donor finger. Beine, A.-O. (A) 160A
A study on nondehabilitated and dehabilitated leprosy patients. Gopal, P. K. (A) 127A
A study on the effects of prevention of physical disabilities in Hansen's disease and treatment by simple techniques at a control program on the stigma. Traple, G., *et al.* (A) 144A
A study to assess social disability and economic loss to leprosy patients on MDT in north India—preliminary study. Palla, J., *et al.* (A) 127A
A systematic program for disability prevention at Karigiri (DISLEP); a preliminary report. Solomon, S. and Vijayakumaran, P. (A) 143A
An epidemiological survey of deformities and disabilities among 14, 257 cases of leprosy. Zhang, G., *et al.* (A) 155A
An epidemiological survey of deformities and disabilities among 14, 257 leprosy patients in 11 countries. Zhang, G. C., *et al.* (A) 501
An impairment scoring system. Watson, J. M. (A) 63A
Application of circular distribution method to analysis of 14, 258 leprosy cases for deformities survey in Yangzhou, China. Yang, Z.-M., *et al.* (A) 156A

Correction of mild and moderate saddle nose deformity in leprosy by a one-stage procedure. Malaviya, G. N. and Husain, S. ..... (A) 151A
Deformity care clinics—a new approach to integrate care after cure concept in routine MDT program. Dave, P. V., *et al.* ..... (A) 51A
Development of multiprofessional prevention and control of disability courses in Minas Gerais, Brazil, from 1988 to 1992. Lehman, L., *et al.* ..... (A) 163A
Disability grading of patients in a MDT program—comparison with a similar group treated with dapsone alone and five year follow up. Duerksen, F., *et al.* ..... (A) 4A
Disability in new cases of Hansen's disease in the State of Minas Gerais, Brazil, from 1988 to 1992 by regions of epidemiological priority and training. Lehman, L., *et al.* (A) 158A
Effectiveness of protective orthopedic shoes in neuropathic and deformed feet in leprosy. Yuksel, A. and Erkilic, N. ..... (A) 154A
Extent of leprosy-related disabilities in Turkey. Cakiner, T., *et al.* ..... (A) 26A
Field-based deformity care services in Sri Lanka. Settinayake, S. and Shah, A. ..... (A) 157A
Finger dynamography—bedside method for evaluation of paralytic finger deformities before and after correction. Malaviya, G. N. and Husain, S. ..... (A) 160A
Impact of MDT on disability profile: CULES experience in an urban cumrural project. Abraham, T., *et al.* ..... (A) 156A
Impairments and disabilities; the difference and implications for leprosy control. Brandsma, J. W. and Heerkens, Y. F. ..... (A) 143A
Improvement of hand impairment and life quality by field delivered splints and grip aids in deformed leprosy patients. Shah, A., *et al.* ..... (A) 141A
Incapacity of leprosy patients; a ten-year analysis. Castellazzi, Z., *et al.* ..... (A) 501
Influence of MDT on the incidence of disabilities in Hansen's disease. Chen, Z., *et al.* (A) 144A
Measurement of dehabilitation in patients of leprosy- a scale. Anandaraj, H. ..... (A) 131A
Modified disability gradings—a new classification for disability evaluation. Shah, A. and Kingsley, S. ..... (A) 142A
Monitoring of peripheral nerve involvement underlying disability of the hand in HD: a 7-year follow up in a U.S. population. Bell-Krotoski, J. ..... (A) 146A
Pattern of leprosy deformities among agricultural labourers in an endemic district: a pilot study. Kartikeyan, S. and Chaturvedi, R. M. ..... (A) 151
Plan para prevencion de incapacidades en Mexico. Rodriguez Dominguez, J., *et al.* ..... (A) 143A
Prevalence of deformities in the leprosy patients in Mozambique. Compostella, L., *et al.* ..... (A) 156A
Prevention of Disabilities in Patients with Leprosy by H. Srinivasan. ..... (B) 637
Prevention of Disability; Guidelines for Leprosy Control Programmes published by ILEP. ..... (B) 477
Prevention of functional impairment, disabilities and deformities. Hirzel, C., *et al.* .... (A) 155A
Problems and coping strategy of families with deformed and normal leprosy patients. Kopparty, S. N. M., *et al.* ..... (A) 138A
Relation of skin lesions with deformitites in nonlepromatous leprosy. Subuddhi, K. B. (A) 36A
Risk factors for developing disability before the diagnosis of Hansen's disease. Ferreira, J., *et al.* ..... (A) 143A
Social aspects of disability and rehabilitation in leprosy. Saxena, M. and Kochar, V. ..(A) 130A
[Stepwise regression analysis of the factors affecting the disability of leprosy.] Chen, X.-S., *et al.* ..... (A) 151
The international classification of impairments, disabilities and handicaps in leprosy-control projects. Brandsma, J. W., *et al.* ..... (A) 340

Dehydrogenase,

Cloning and sequence analysis of the gene encoding an NADP dependent alcohol dehydrogenase in *M. bovis* BCG. Stelandre, M., *et al.* ..... (A) 177
Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Klein, R., *et al.* ..... (A) 507
Similarities between alanine dehydrogenase and the N-terminal part of pyridine nucleotide transhydrogenase and their possible implication in the virulence mechanism of *M. tuberculosis.* Delforge, D., *et al.* ..... (A) 357

Dermal,

Distinguishing post-kala-azar dermal leishmaniasis from leprosy: experience in the Sudan. El Hassan, A. M., *et al.* ..... (A) 341

Mycobacterial 65,000 MW heat-shock protein shares a carboxy terminal epitope with human epidermal cytokeratin-1/2. Rambukkana, A., *et al.* ..... (A) 174
Similarity between mycobacterial and human epidermal antigens. Vandenakker, T. H. W., *et al.* ..... (A) 139
Ultrastructural alterations of dermal nerves in early cutaneous leprous macules. Antunes, S. L. G. and Sarno, E. N. ..... (A) 126A

Diabetes,
Healing rates of plantar ulcers in leprosy and diabetes. Birke, J. A., *et al.* ..... (A) 364

DNA,
A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemo-autotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* ..... (A) 112A
A simple colorimetric assay for detection of amplified M. leprae DNA. van der Vliet, G. M. E., *et al.* ..... (A) 498
Characterisation of a novel repetitive DNA sequence from *M. bovis*. Doran, T. J., *et al.* (A) 159
Characterization of *M. leprae* strains by RFLP analysis of amplified rDNA. Katoch, V. M., *et al.* ..... (A) 114A
Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65-kDa antigen gene, in the diagnosis of tuberculosis. Walker, D. A., *et al.* ..... (A) 181
Computer recognition of possible functional or structural sites on *M. leprae* DNA. Cardo, P. P., *et al.* ..... (A) 107A
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Detection of *M. tuberculosis* DNA in clinical samples by using a simple lysis method and polymerase chain reaction. Folgueira, L., *et al.* ..... (A) 494
Direct detection of *M. tuberculosis* in sputum by polymerase chain reaction and DNA hybridization. Nolte, F. S., *et al.* ..... (A) 666
DNA fingerprinting of *M. bovis* strains by restriction fragment analysis and hybidization with insertion elements IS1081 and IS6110. Collins, D. M., *et al.* ..... (A) 502
DNA fragment length polymorphism analysis of *M. tuberculosis* isolated by arbitrarily primed polymerase chain reaction. Palittapongarnpim, P., *et al.* ..... (A) 496
DNA restriction fragment analysis to define an extended cluster of tuberculosis in homeless men and their associates. Dwyer, B., *et al.* ..... (A) 369
DNA sequence, structure and gene expression of mycobacteriophage-L5—a phage system for mycobacterial genetics. Hatfull, G. F. and Sarkis, G. J. ..... (A) 358
Evaluation of nonradioactive DNA probes for identification of mycobacteria. Lebrun, L., *et al.* ..... (A) 167
Identification of *M. tuberculosis* DNA in a case of lupus vulgaris. Serfling, U., *et al.* ..... (A) 377
Identification of *M. tuberculosis* and *M. avium-intracellulare* directly from primary BACTEC cultures by using acridinium ester-labeled DNA probes. Evans, K. D., *et al.* ..... (A) 160
Large DNA restriction fragment polymorphism in the *M. avium-M. intracellulare* complex—a potential epidemiologic tool. Mazurek, G. H., *et al.* ..... (A) 374
M. smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Levin, M. E. and Hatfull, G. F. ..... (A) 495
M. tuberculosis DNA in tissue affected by sarcoidosis. Fidler, H. M., *et al.* ..... (A) 503
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* ..... (O) 227
Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ..... (A) 169
Rapid detection of tuberculous and non-tuberculous mycobacteria by polymerase chain reaction amplification of a 162 bp DNA fragment from antigen-85. Fauvilledufaux, M., *et al.* ..... (A) 161
Strain identification of *M. tuberculosis* by DNA fingerprinting: recommendations for a standard methodology. van Embden, J. D., *et al.* ..... (A) 378
The detection of *M. tuberculosis* in uncultured clinical specimens using the polymerase chain reaction and a non radioactive DNA probe. Thierry, D., *et al.* ..... (A) 178

Trifluoperazine inhibits the incorporation of labeled precursors into lipids, proteins and DNA of *M. tuberculosis* H37Rv. Ratnaker, P. and Murthy, P. A. ..... (A) 668

Dominican Republic,
Discapacidades en el enfermo de lepra, Dominican Republic, 1979-1992. Isa, R. I., *et al.* ..... (A) 156A
Evolucion de la endemia leprosa en Republica Dominicana 1966 1992. Bogaert, H., *et al.* ..... (A) 134A
Integracion social y economica de un grupo de pacientes de lepra en la zona rural de Dominicana con gran participacion de la comunidad. Isa, R. I., *et al.* ..... (A) 133A
Lucha antileprosa en la region suroeste de la Republica Dominicana; programa modelo con participacion de la comunidad. Bogaert, H., *et al.* ..... (A) 46A
Recidivas en enfermos de lepra multibacilares y paucibacilares tratados con tres drogas Republica Dominicana, Octubre 1982-Diciembre 1992. Isa, R. I., *et al.* ..... (A) 46A

Drugs (see also specific drugs),
A rapid *in vitro* microassay for the viability and drug sensitivity of *M. leprae*. Butcher, P. D., *et al.* ..... (A) 111A
Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against *M. avium*. Barrow, W. W., *et al.* ..... (A) 484
Activities of WIN-57272 minocycline, clarithromycin, and 14 hydroxy-clarithromycin against *M. avium* complex in human macrophages. Cohen, Y., *et al.* ..... (A) 156
Activity of clarithromycin compared with those of other drugs against *M. paratuberculosis* and further enhancement of its extracellular and intracellular activities of ethambutol. Rastogi, N., *et al.* ..... (A) 124
Alternative treatment for drug-resistant leprosy and tuberculosis. Prabhakaran, K., *et al.* ..... (A) 15A
Application of fluorescent staining to assessment of the chemotherapy responses/drug susceptibility testing in leprosy. Katoch, V. M. ..... (A) 307
Application of laser microprobe mass analysis to *in vitro* drug screening. Lindner, B., *et al.* ..... (A) 110A
ATP measurement and thymidine uptake in patient monitoring and in *in vitro* drug screening. Dhople, A. ..... (A) 307
Benzylamines and related compounds. Meindl, W. ..... (A) 312
Chaulmoogra oil was already used to treat leprosy by traditional Chinese medical doctors in the period of the Southern Song Dynasty. Liang, Z. ..... (A) 16A
Chlorpromazine—a drug potentially useful for treating mycobacterial infections. Crowle, A. J., *et al.* ..... (A) 337
Combination drug testing of *M. chelonae*. Matoba, A. Y., *et al.* ..... (A) 665
Combined distribution toxicity study of two novel phenazines. O'Connor, R., *et al.* ..... (A) 15A
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ..... (A) 145
Dr. Almeida replies (rifampin). Almeida, J. G. ..... (C) 630
Dr. Grosset replies for the Isoprodian Study Group. Grosset, J.-H. ..... (C) 629
Drug resistance in Nepali leprosy patients. Butlin, C. R., *et al.* ..... (A) 46A
Effect of antileprosy drugs on biological rhythms. Urlyapova, N., *et al.* ..... (A) 17A
Fluoroquinolones. Grosset, J. ..... (A) 313
India—the use of the fixed drug combination Isoprodian rifampin under field conditions. Graf, P. ..... (A) 306
M. leprae viability in skin and nerve after MDT and their sensitivity to antileprosy drugs. Shetty, V., *et al.* ..... (A) 4A
Macrolides, fusidic acid, lincosamides, and quinolones. Franzblau, S. G., *et al.* ..... (A) 315
Medico International issues fourth edition of Sources for Essential Drugs. ..... (O) 328
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H. ..... (A) 310
Mycobacterial model strains in drug screening. Visser, K. and Seydel, J. K. ..... (A) 306
New antileprosy drugs: phenazine derivatives. Dhople, A. M. ..... (A) 312
New dihydorfolate reductase inhibitors. Wiese, M. ..... (A) 313

Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 8A
On the necessity of alternative therapies for the treatment of leprosy. Alvarenga, A., *et al.* ..... (A) 14A
Patients' compliance and drug trials: an analysis of efficiency of monotherapy and multidrug therapy (MDT) treatment. Saravanabavan, V. and Shanmuganandan, S. ..... (A) 54A
Possible new targets for drug action. Wheeler, P. R. ..... (A) 313
Rapid assessment of drug susceptibilities of *M. tuberculosis* by means of luciferase reporter phages. Jacobs, W. R., Jr., *et al.* ..... (A) 507
Recaidas en hansenianos multibacilares tratados con monoterapia sulfonica. Terencio de las Aguas, J. ..... (A) 5A
Recent results on *in vivo* drug efficacies from mass analysis of individual *M. leprae* organisms. Seydel, U., *et al.* ..... (A) 116A
Reconstruction of antileprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and C(rat)EDTA (a source of C3-C9). Kashyap, A., *et al.* ..... (A) 123
Reversal of drug resistance in *M. leprae* by ampicillin/sulbactam. Prabhakaran, K., *et al.* ..... (A) 338
Study of intracellular deposition of the anti-leprosy drug clofazimine in mouse spleen using laser microprobe mass analysis. Vandeputte, D., *et al.* ..... (A) 487
Susceptibility of *M. malmoense* to antibacterial drugs and drug combinations. Hoffner, S. E., *et al.* ..... (A) 506

Edema,
Investigation of lymphoedema as an adverse effect of clofazimine therapy in leprosy. Oommen, T., *et al.* ..... (A) 19A
Pedal edema following clofazimine therapy; a case report. Tyagi, P. K. and Oommen, T. ..... (C) 636

Electron microscopy (see also **Ultrastructure**),
Electron microscopic study of *M. leprae* passed on laboratory animals. Maslov, A. and Dyachina, M. ..... (A) 113A
Electron microscopy, polymerase chain reaction and serodiagnosis as tools for assessing leprosy treatment. Nasr, E. M., *et al.* ..... (A) 17A

ELISA (enzyme-linked immunosorbent assay) tests,
A prospective immunoepidemiologic study using MLSA and ELISA for antibodies against PGL-I. Krishnamurthy, P., *et al.* ..... (A) 73A
A seroepidemiological study of leprosy in household contacts and healthy population based on ELISA using ND-O-BSA and PGL I as antigens. Li, W., *et al.* ..... (A) 67A
Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* ..... (A) 488
[Comparison between Ml- and Ms-ELISA in the determination of serum antibodies in leprosy.] Li, M.-H., *et al.* ..... (A) 134
Comparison of a gelatin particle agglutination test and ELISA for detection of antibody to *M. leprae*. Qian, L., *et al.* ..... (A) 94A
Cross-sectional assessment of ELISA reactivity in leprosy patient, contacts, and normal population using the semisynthetic antigen natural disaccharide octyl bovine serum albumin (ND-O-BSA) in Cebu, The Philippines. Cellona, R. V., *et al.* ..... (O) 192
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Detection of *M. leprae*-specific antigen with M-dot-ELISA in sera from household contacts of leprosy patients. Cao, Y., *et al.* ..... (A) 73A
Detection of antibodies to phenolic glycolipid by ELISA in leprosy patients. Lal, H., *et al.* ..... (A) 350
IgM serum antibodies to PGL-I by ELISA in healthy subjects and leprosy patients. Meng, M., *et al.* ..... (A) 92A
Lipoarabinomannan (LAM)-based enzyme-linked immunosorbent assay in serodiagnosis of leprosy. Gandhi, S., *et al.* ..... (A) 93A

Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: ELISA. De Lange, W. E., *et al.* ..... (A) 100A

Enzyme(s),

A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemo-autotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* ..... (A) 112A

Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Hebert, M. F., *et al.* ..... (A) 122

Detection of mycobacterial antigens in sputum by an enzyme immunoassay. Al-Orainey, I. O., *et al.* ..... (A) 365

Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Bozeman, P. M., *et al.* ..... (A) 121

Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ..... (A) 168

Purification of polyphosphate and ATP glucose phosphotransferase from *M. tuberculosis* H37Ra: evidence that poly(P) and ATP glucokinase activities are catalyzed by the same enzyme. Hsieh, P.-C., *et al.* ..... (A) 373

Rapid identification of mycobacteria to the species level of polymerase chain reaction and restriction enzyme analysis. Telenti, A., *et al.* ..... (A) 377

Studies of lymphocyte physiology—a study of marker enzymes of metabolic pathways. Suri Babu, C. S., *et al.* ..... (A) 98A

[Use of enzyme immunoassay and immunoblotting for the serological characterization of mycobacterial antigens.] Vorobyev, A. A., *et al.* ..... (A) 181

Epidemiology,

A prospective immunoepidemiologic study using MLSA and ELISA for antibodies against PGL-I. Krishnamurthy, P., *et al.* ..... (A) 73A

A seroepidemiological study of leprosy in household contacts and healthy population based on ELISA using ND-O-BSA and PGL I as antigens. Li, W., *et al.* ..... (A) 67A

An epidemiological survey of deformities and disabilities among 14, 257 cases of leprosy. Zhang, G., *et al.* ..... (A) 155A

An epidemiological survey of deformities and disabilities among 14, 257 leprosy patients in 11 countries. Zhang, G. C., *et al.* ..... (A) 501

Analysis of factors affecting leprosy epidemic with stepwise regression model. Li, T. and Feng, X. ..... (A) 68A

Applications of molecular methods to epidemiology of tuberculosis. Crawford, J. T. ..... (A) 494

Detection of leprosy infection by serology and polymerase chain reaction; an epidemiological study in South Sulawesi, Indonesia. van Beers, S., *et al.* ..... (A) 67A

Disability in new cases of Hansen's disease in the State of Minas Gerais, Brazil, from 1988 to 1992 by regions of epidemiological priority and training. Lehman, L., *et al.* (A) 158A

Effect of natural demographic characters on incidence of leprosy- a case study. Ranade, M. ..... (A) 68A

Epidemic and control of leprosy in Tibet. Yang, L.-H., *et al.* ..... (A) 62A

Epidemic situation of leprosy after MDT implementation and prediction of basic eradication in Yangzhou Prefecture. Jiang, C., *et al.* ..... (A) 64A

Epidemiological and ecological aspects of leprosy: an analysis of major dimensions of disease ecology and health care management. Shanmuganandan, S., *et al.* ..... (A) 50A

Epidemiological changes in urban leprosy control project—14 years' observations in Bombay. Revankar, C. R., *et al.* ..... (A) 58A

Epidemiological impact of multidrug therapy of leprosy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* ..... (A) 49A

Epidemiological survey of leprosy in Yichun Prefecture of Jiangxi Province, China. He, Y. and Zhou, L. ..... (A) 71A

Epidemiologie *et* polychimiotherapie appliquees au programme de la lepre en Tunisie. Zahaf, A. and Meziou, T. J. ..... (A) 54A

Epidemiology of leprosy in relation to control. ..... (A) 500

Estimated number of leprosy cases in the world. Noordeen, S. K., *et al.* ..... (A) 149
Evolution of the leprosy detection rate in Anjouan (Comores) from 1981 to 1992. Grillone, S. and Pattyn, S. ..... (A) 66A
Evolution of the leprosy endemicity in Benin (1982-1992). Guedenon, A., *et al.* ..... (A) 63A
Frequency of leprosy neuropathy in hyperendemic areas of Mexico and its correlation with clinical, epidemiological and structural findings. Valdez-Valenzuela, F., *et al.* ..... (A) 141A
Global estimates of the number of people needing medical treatment and care as a result of leprosy. ..... (A) 657
Immunoepidemiological studies on subclinical infection in leprosy. II. Geographical distribution of seropositive responders with special reference to their possible source of infection. Abe, M., *et al.* ..... (A) 346
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346
Impact of a vertical program on leprosy in Lalitpur 1986-1992: epidemiological and managerial implications. Soares, D., *et al.* ..... (A) 45A
Impact of personnel training on the epidemiological and operational indicators—Brazil, 1986 to 1991. Rodrigues, A. L., *et al.* ..... (A) 166A
International Meeting on Epidemiology of Leprosy in Relation to Control held in Jakarta, Indonesia, 17-21 June 1992. ..... (A) 148
Large DNA restriction fragment polymorphism in the *M. avium-M. intracellulare* complex—a potential epidemiologic tool. Mazurek, G. H., *et al.* ..... (A) 374
Leprosy–economy–environment; might we predict leprosy incidence from this point of view? Zhao, D., *et al.* ..... (A) 631
Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Cartel, J.-L., *et al.* ..... (A) 147
M. marinum infection—epidemiology and presentation in Queensland (Australia) 1971-1990. Iredell, J., *et al.* ..... (A) 163
Measuring epidemiological impact of multidrug therapy in leprosy control area. Rao, P. S. S., *et al.* ..... (A) 64A
Microlevel analysis of leprosy in Vadodara District. De, J. and Sinha, H. ..... (A) 70A
Neuritic leprosy: epidemiology and therapeutic responsiveness. Talwar, S., *et al.* ..... (A) 127
Prevalence rate of leprosy in Khulna, south of Bangladesh. Ishida, Y. and Ahsan Ali, A. K. ..... (A) 71A
Profil epidemiologique de la lepre en Haiti. Pean, C., *et al.* ..... (A) 71A
Revised estimates of global leprosy numbers. Smith, P. G. ..... (A) 150
Seroepidemiological assessment of leprosy in Culion, The Philippines. Cunanan, A., Jr., *et al.* ..... (A) 73A
Study of applying age-specific prevalence rates. Yang, Z.-M., *et al.* ..... (A) 64A
Study on leprosy seroepidemiology in China. Wu, Q., *et al.* ..... (A) 67A
The actual state of leprosy in the Baltic States. Drakib, A., *et al.* ..... (A) 70A
The epidemiological impact of MDT on leprosy in Guangdong Province. Chen, J. and Liang, Z. ..... (A) 42A
The epidemiology of Hansen's disease in the English-speaking Caribbean and Suriname: current status and trends. Tollefson, J. E., *et al.* ..... (A) 65A
The impact of HIV infection on the global epidemiology of tuberculosis. Styblo, K. ..... (A) 177
The impact of multidrug therapy on epidemiological trends of leprosy in Guizhou, China. Li, Q. and Liu, G. C. ..... (A) 52A
The International Congresses and other outstanding events in the study, epidemiology, and elimination of leprosy. Balina, L. M. and Valdez, R. P. ..... (A) 56A
The relationship between leprosy incidence and economic development. Zhao, D., *et al.* ..... (A) 70A
Use of PGL-immunoassays in seroepidemiological studies of *M. leprae* infection in Malaysia. Gan, S. C. and Fujiwara, T. ..... (A) 73A

Erythema nodosum leprosum (ENL),
A potential marker for the prediction of ENL reactions. Singh, S., *et al.* ..... (A) 99A
Association of C4B deficiency (C4B*Q0) with erythema nodosum leprosum in leprosy. Demessias, I. J. T., *et al.* ..... (A) 487
Correlation between TNF production, increase of CRP level, and suppression of T lymphocytes during ENL reaction. Foss, N. T. and Silva, C. L. ..... (A) 102A

Correlation between TNK production, increase of plasma C reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Foss, N. T., *et al.* ..... (O) 218
Erythema nodosum leprosum in a case of histoid leprosy. Kaur, S., *et al.* ..... (C) 292
Frequency and clinical features of erythema nodosum leprosum in Hyderabad, India. Vinayakumar, S., *et al.* ..... (A) 34A
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ..... (A) 345
Influence of thalidomide on the histological manifestations of ENL. Miranda, A., *et al.* (A) 99A
Levels and composition of circulating immune complexes in patients with erythema nodosum leprosum and acute anterior uveitis. Cakiner, T., *et al.* ..... (A) 100A
Levels of Il-6 and TNF receptors in ENL. Sampaio, E. P., *et al.* ..... (A) 86A
Necrotic erythema nodosum leprosum; a presenting manifestation of lepromatous leprosy. Verma, K. K. and Pandhi, R. K. ..... (C) 293
Onset of leprosy in adolescence carries highest risk of later ENL. Scollard, D. M., *et al.* (A) 22A
Reaction type 2 of HD (ENL) with visceral involvement: index for the severity of the disease, clinical, laboratorial and autopsy study of 34 patients. Margarido-Marchese, L. C., *et al.* ..... (A) 124A
Roles of lymphocyte subpopulations in erythema nodosum leprosum and acute anterior uveitis. Bahceci, E., *et al.* ..... (A) 95A

Escherichia coli,
Expression of *Escherichia coli* beta-glactosidase in *M. bovis* BCG using an expression system isolated from *M. paratuberculosis* which induced humoral and cellular immune responses. Murray, A., *et al.* ..... (A) 142
Molecular cloning and characterization of *M. paratuberculosis* promoters in *Escherichia coli*. Thomas, T. J., *et al.* ..... (A) 179
Overexpression of *M. leprae* antigens in *Escherichia coli*. Oskam, L., *et al.* ..... (A) 114A
The catalase-peroxidase of *M. intracellulare*: nucleotide sequence analysis and expression in *Escherichia coli*. Morris, S. L., *et al.* ..... (A) 142

Ethambutol,
Activity of clarithromycin compared with those of other drugs against *M. paratuberculosis* and further enhancement of its extracellular and intracellular activities of ethambutol. Rastogi, N., *et al.* ..... (A) 124
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated *M. avium* complex infection of normal C57BL/6 mice. Perronne, C., *et al.* (A) 172

Ethiopia,
Comparability of ball pen and nylon filaments in testing sensory function of patients with leprosy in Nepal and Ethiopia. Lienhardt, C., *et al.* ..... (A) 157A
Footsole sensation in normal subjects in Ethiopia. Currie, H. and Byass, P. ..... (A) 158A
Future of ILEP—focusing on the example of Ethiopia. Kiber, H. ..... (N) 641
Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia and Nepal. Lienhardt, C., *et al.* ..... (A) 145A
Reasons why leprosy is different in Eritrea when compared with Ethiopia. Berhe, D. ..(A) 61A

Experimental leprosy,
Experimental leprosy in *Dasypus hybridus* in Argentina. Franco, R., *et al.* ..... (A) 82A
Respiratory burst metabolic status of macrophages in experimental leprosy. Kohli, M., *et al.* ..... (A) 361
Serologic responses to nerve antigens in sooty mangabey monkeys with experimental leprosy. Cho, S.-N., *et al.* ..... (O) 236

Eye(s),
A case analysis of the pattern of cataract and postoperative outcome of cataract extraction in leprosy patients as compared to nonleprosy patients. Taffessework, G. and Fedkede, M. ..... (A) 118A
A histological study of the eye lesions in 12 leprosy patients with tuberculoid lesion in 4 eyes. Brandt, F., *et al.* ..... (A) 346

A longitudinal follow-up study of eyes in 649 leprosy patients. Rajan, M. A. and Monoharan, A. ..... (A) 117A
Analysis of lagophthalmos among 2144 cases of leprosy. Yan, L., *et al.* ..... (A) 27A
Bilaterial iridocyclitis caused by *M. leprae* diagnosed through paracentesis. Campos, W., *et al.* ..... (A) 27A
Cataract surgery in a leprosy population in Liberia. Frucht-Pery, J. and Feldman, S. T. (O) 20
Contribution of MDT to the prevention of eye disease in leprosy; results from a cross-sectional survey in the People's Republic of China. Courtright, P., *et al.* ..... (A) 118A
Corneal sensitivity in leprosy patients and controls. Hieselaar, L., *et al.* ..... (A) 119A
Current eye health care delivery system for leprosy in leprosy endemic zone of eastern India. Samanta, S. K. and Roy, I. S. ..... (A) 36A
Dacryocistographical study of patients bearing Hansen's disease. Boratto, L., *et al.* ..... (A) 26A
Early detection of ocular leprosy. Goud, A. S. ..... (A) 167A
Early diagnosis iritis in leprosy patients. Goud, A. S. ..... (A) 119A
Evaluation of precorneal film in leprosy. Goud, A. S. ..... (A) 27A
Follow up of posterior chamber intraocular lenses in five lepromatous patients. Daniel, E. ..... (A) 160A
[Histopathological study of six eye specimens of leprosy patients.] Shi, Z., *et* al ..... (A) 354
Integration of eye care in leprosy control in northern Nigeria. Verhage, R. ..... (A) 41A
[Intraocular experimental infection with *M. leprae* in nude rats.] Shi, Z.-R., *et al.* ..... (A) 145
Intraocular lens in leprosy. Panneerselvam, V. and Shanker Narayan, N. P. ..... (A) 149A
Intraocular pressure decrease in household contacts of patients with Hansen's disease and endemic control subject. Hussein, N., *et al.* ..... (A) 125
Intraocular pressure in leprosy patients without apparent anterior segment pathology. Daniel, E., *et al.* ..... (A) 119A
Levels and composition of circulating immune complexes in patients with erythema nodosum leprosum and acute anterior uveitis. Cakiner, T., *et al.* ..... (A) 100A
National Seminar on Ocular Leprosy held. ..... (N) 478
Ocular leprosy in patients with facial patches. Samanta, S. K. and Roy, I. S. ..... (A) 118A
[Ocular leprosy in the city of Camaguey, Cuba.] Cardoso Guillen, E., *et al.* ..... (A) 340
Ocular problems in cases released from treatment. Samanta, S. K. and Roy, I. S. ..... (O) 117A
Ocular study of Hansen's disease at a dermatological hospital; the prevention in our hands. Orefice, F. and Boratto, L. ..... (A) 26A
Paralysis of facial muscles in lagophthalmos. Lubbers, W. J., *et al.* ..... (A) 20A
Pattern and spread of ocular lesions in multibacillary leprosy; a histopathological study. Jacob, M. ..... (A) 125A
Presence of Hansen's bacilli in conjunctive, vitreous body and retina in an eye of a patient bearing the Virchowiane form of Hansen's disease. Orefice, F., *et al.* ..... (A) 126A
Prevalence of color blindness among patients with leprosy. Shwe, T. ..... (A) 344
Pupil cycle time in leprosy. Daniel, E. and Rao, P. S. S. ..... (A) 119A
Results of surgical correction of lagophthalmos (Gillies technique) in leprosy patients. Baccarelli, R., *et al.* ..... (A) 161A
Risk factors for cataract in leprosy patients; results from a cross-sectional survey in the People's Republic of China. Lewallen, S., *et al.* ..... (A) 118A
Roles of lymphocyte subpopulaions in erythema nodosum leprosum and acute anterior uveitis. Bahceci, E., *et al.* ..... (A) 95A
Study of ocular lesions in leprous outpatients. Monteiro, L., *et al.* ..... (A) 26A
Visible corneal nerves in leprosy. Daniel, E. and Rao, P. S. S. ..... (A) 119A

Face,

Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of *M. avium*. Belisle, J. T., *et al.* ..... (A) 493
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kDa-region proteins and the secreted antigen-85 complex and demonstration of antigen-85B on the *M. leprae* cell wall surface. Rambukkana, A., *et al.* ..... (A) 136
Identification and characterization of epitopes shared between the mycobacterial 65-kilodalton heat shock protein and the actively secreted antigen-85 complex—their *in situ* expression on the cell wall surface of *M. leprae*. Rambukkana, A., *et al.* ..... (A) 143
Ocular leprosy in patients with facial patches. Samanta, S. K. and Roy, I. S. ..... (A) 118A
Paralysis of facial muscles in lagophthalmos. Lubbers, W. J., *et al.* ..... (A) 20A

Serum transferrin (Tf) concentration and Tf receptors (R) on the surface of T lymphocytes in lepromatous leprosy (LL). Fafutis, M., *et al.* ....(A) 101A
Surgical treatment for the bilateral facial palsy in leprosy. Zhang, G. and Zheng, T. ...(A) 155A
Thalidomide does not affect selected immunomodulating surface receptor molecules on cells with immune potential. Shannon, E. J., *et al.* ....(A) 105A

Family,
An analysis of familial clustering of leprosy infection using the models of theoretical probability. Chen, X., *et al.* ....(A) 70A
Intrafamilial transmission of leprosy in Vellore town, India. George, R., *et al.* ....(O) 550
Intrafamiliar transmission of leprosy in Vellore town, India. George, R., *et al.* ....(A) 75A
Low predictive value of PGL-I serology for the early diagnosis of leprosy in family contacts: results of a 10 year prospective field study in French Polynesia. Chanteau, S., *et al.* ....(O) 533
Problems and coping strategy of families with deformed and normal leprosy patients. Kopparty, S. N. M., *et al.* ....(A) 138A
The importance of the examination of all family members in field work. de Oliveira Cortes, J. L., *et al.* ....(A) 50A

Finger(s),
A modification of surgical procedure to prevent postoperative sublimis minus deformity at the donor finger. Beine, A.-O. ....(A) 160A
Correction of claw fingers by lasso procedure in Hansen's disease. Sidddalingaswamy, M. K. and Rao, K. S. ....(A) 149A
Customized latex finger caps for insensitive hand. Freeman, M. J. ....(A) 157A
Finger dynamography—bedside method for evaluation of paralytic finger deformities before and after correction. Malaviya, G. N. and Husain, S. ....(A) 160A
Reduced fingertip blood flow and peripheral dysautonomia in leprosy patients in Iranian Azerbaijan and in Maharashtra, India. Abbot, N. C., *et al.* ....(C) 474

FLA-ABS test,
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ....(A) 346
Ten-twelve years follow up of healthy contacts of leprosy cases using FLA-ABS and lepromin tests. Bharadwaj, V. P., *et al.* ....(A) 67A

Foot,
A long-term observation on the effect of tendon transplant of the posterior tibial muscle in the correction of foot drop of leprosy. Jiang, Z. and Ling, X. ....(A) 148A
Analysis of static and dynamic foot pressure in leprosy patients. Patil, K. M., *et al.* ...(A) 142A
Analysis of stresses in two-dimensional model of leprotic foot. Patil, K. M., *et al.* ....(A) 142A
Development of plastic footwear for anesthetic feet in leprosy. Antia, N. and Arolkar, S. ....(A) 143A
Effectiveness of protective orthopedic shoes in neuropathic and deformed feet in leprosy. Yuksel, A. and Erkilic, N. ....(A) 154A
Footsole sensation in normal subjects in Ethiopia. Currie, H. and Byass, P. ....(A) 158A
Management of common peroneal nerve damage (foot drop) in Hansen's disease—Dhoopet Leprosy Research Center approach. Solomon, V. K., *et al.* ....(A) 154A
Replacement of the main sensory nerves of hands and feet in leprosy patients with freeze-thawed muscle as graft material. Kazen, R., *et al.* ....(A) 150A
Results of surgical procedues for the correction of footdrop and of lagophthalmus due to leprosy. Weber, M. W., *et al.* ....(A) 151
Semmes-Weinstein monofilament testing to determine normal sensory thresholds in the foot and hand: a comparative study in India. Jerskey, R. ....(A) 159A
Tendo-achiles lengthening along with tibialis posterior transfer for correction of foot drop—a 5-year follow up. Lobo, D., *et al.* ....(A) 148A
The test track: a useful tool in testing sensitivity of feet? Kazen, R., *et al.* ....(A) 158A
WLEREC protective footwear. Naafs, B. and Brandsma, J. W. ....(A) 155A

Foot pad(s),
Bactericidal action at low doses of a new rifamycin derivative, 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ....(A) 337

[Experience with the mouse foot pad technique to obtain *M. leprae*.] Suarez-Moreno, O. ..... (A) 146
[Influence of feeding on the multiplication of *M. leprae* in the mouse foot pad.] Wang, H. ..... (A) 146
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H. ..... (A) 310
[Nude mouse foot pad model of leprosy infection.] Lu, X.-H., *et* al ..... (A) 145
Studies of macrophage traffic into the experimental lepromatous lesion of the *M. leprae*-infected nu/nu mouse foot pad. Krahenbuhl, J. L., *et al.* ..... (A) 78A
TNF-alpha-mediated tissue damage in mouse footpads primed with mycobacterial preparations. Al-Attouaj. R., *et al.* ..... (A) 129

France,
Dr. le Gonidec retires. ..... (N) 479
Recipon steps down as President of Association Francaise Raoul Follereau. ..... (N) 327

Genetics,
An immunogenetic study of differential manifestations of leprosy in north India. Rani, R., *et al.* ..... (A) 100A
Aspects of tuberculosis in Africa. 3. Genetic "fingerprinting" for clues to the pathogenesis of tuberculosis. Godfrey-Faussett, P. and Stoker, N. G. ..... (A) 661
Cloning and sequence analysis of the gene encoding an NADP dependent alcohol dehydrogenase in *M. bovis* BCG. Stelandre, M., *et al.* ..... (A) 177
DNA sequence, structure and gene expression of mycobacteriophage-L5—a phage system for mycobacterial genetics. Hatfull, G. F. and Sarkis, G. J. ..... (A) 358
Genetic control of immune responses to the 18-kDa protein of *M. leprae*; different TH1 subsets may be involved in proliferative and delayed-type hypersensitivity. Backstrom, B. T., *et al.* ..... (A) 129
Genetic diversity among strains of *M. avium* causing monoclonal and polyclonal bacteremia in patiens with AIDS. Arbeit, R. F., *et al.* ..... (A) 658
Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of *M. tuberculosis* by human and murine T cells. Harris, D. P., *et al.* ..... (A) 661
HLA-linked genetic control of leprosy. Kher, S. K., *et al.* ..... (A) 149
Immunogenetic aspects of susceptibility to leprosy. Saroyants, L., *et al.* ..... (A) 95A
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
Leprosy, tuberculosis, and the new genetics. Young, D. B. and Cole, S. T. ..... (A) 361
Superinfection immunity of mycobacteriophage-L5—applications for genetic transformation of mycobacteria. Donelly-Wu, M. K., *et al.* ..... (A) 358

Genome,
Insertion into the *M. smegmatis* genome of the aph gene through lysogenization with the temperate mycobacteriophage Ms6. Anes, E., *et al.* ..... (A) 140
Nucleotide sequence of the first cosmid from the *M. leprae* genome project: structure and function of the Rif-Str regions. Honore, N., *et al.* ..... (A) 358
Rough morphological variants of *M. avium*; characterization of genomic deletions resulting in the loss of glycopeptidolipid expression. Belisle, J. T., *et al.* ..... (A) 492
Use of an ordered cosmic library to deduce the genomic organization of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 358

Germany,
Dr. W. H. van Brakel wins Dr. Minoo Mehta International Prize ..... (N) 327
Medico International issues fourth edition of Sources for Essential Drugs. ..... (O) 328
II Wurzburg Symposium on the Chemotherapy of Leprosy. ..... (A) 298

Granuloma(s),
A preliminary study of correlation of immuno-histological and ultrastructural characteristics of neural granuloma in leprosy patients. Kumar, V., *et al.* ..... (A) 350
Granuloma persistance after clinical inactivity. Porichha, D., *et al.* ..... (A) 124A
In vitro labeling and function of granuloma macrophages from lepromatous leprosy. Chae, G.-T., *et al.* ..... (A) 96A

Hair,
Eyebrow reconstruction by means of a free graft taken from the hair-bearing scalp of lepromatous patients. Maakaroun, M. J., *et al.* ..... (A) 152A
Observation on the effect of eyebrow transplantation by single autologous hair—a report of 274 cases. Wang, X., *et al.* ..... (A) 162A

Haiti,
Aspect clinique differentiel de la lepre en Haiti. Woel, G., *et al.* ..... (A) 29A
Aspects cliniques particuliers de la maladie de Hansen en Haiti. Desvarieux, F., *et al.* (A) 28A
Effets secondaires des medicaments, observations faites chez des patients Haitiens. Foucauld, F., *et al.* ..... (A) 4A
Frequence *et* evolution des maux perforants plantaires: experience Haitienne. Beliard, N., *et al.* ..... (A) 154A
Profil epidemiologique de la lepre en Haiti. Pean, C., *et al.* ..... (A) 71A

Hand(s),
A "quick" VMT and ST for the hands compared to a standard VMT and ST. Jehin, E., *et al.* ..... (A) 19A
An improved method of assessing work and hand function in leprosy. Premkumar, R., *et al.* ..... (A) 141A
Correction of claw hand and restoration of metacarpal arch by intrinsic reactivation; long-term follow-up study of 158 hands. Narayanakumar, T. S., *et al.* ..... (A) 149A
Customized latex finger caps for insensitive hand. Freeman, M. J. ..... (A) 157A
Effect of hand soaking on sensory testing. McAuley, D. M., *et al.* ..... (O) 16
Elimination of leprosy and its complications: the case of hand neuropathy. Vergara-Vargas, M. G., *et al.* ..... (A) 152A
Improvement of hand impairment and life quality by field delivered splints and grip aids in deformed leprosy patients. Shah, A., *et al.* ..... (A) 141A
Ink impression technique—a new method for recording the improvement in claw hand. Shah, A., *et al.* ..... (A) 152A
Monitoring of peripheral nerve involvement underlying disability of the hand in HD: a 7-year follow up in a U.S. population. Bell-Krotoski, J. ..... (A) 146A
Ocular study of Hansen's disease at a dermatological hospital; the prevention in our hands. Orefice, F. and Boratto, L. ..... (A) 26A
Rehabilitation of leprosy handicap by Modulan grip aids; an evaluation. Shah, A., *et al.* ..... (A) 152A
Replacement of the main sensory nerves of hands and feet in leprosy patients with freeze-thawed muscle as graft material. Kazen, R., *et al.* ..... (A) 150A
Semmes-Weinstein monofilament testing to determine normal sensory thresholds in the foot and hand: a comparative study in India. Jerskey, R. ..... (A) 159A
The social identity of the physically handicapped. Rodrigues, M. M. P. and Aranha, M. S. F. ..... (A) 134A
"Trac operation"—a new technique for reconstruction of transverse metacarpal arch along with correction of ulnar claw hand. Shah, A. ..... (A) 149A

Hepatitis,
Association between leprosy and hepatitis-B infection—a survey in Goiana, Central Brazil. Rosa, H., *et al.* ..... (A) 127
Hepatitis C and hepatitis B virus serum markers in Greek leprosy patients. Kontochristopoulos, G., *et al.* ..... (A) 35A

Hepatotoxicity,
Isoniazid and hepatotoxicity. Verduin, P. R. N. ..... (C) 628

Histoid leprosy,
Erythema nodosum leprosum in a case of histoid leprosy. Kaur, S., *et al.* ..... (C) 292
Histoid leprosy at Westfort Hospital, South Africa. Wentzel, L. ..... (A) 31A
Histoid leprosy in early macular lepromatous leprosy: incidental finding or sign of augmented local immunity? Fiallo, P., *et al.* ..... (C) 471

Histology,
Clinical and histological picture of very early indeterminate and BT leprosy in adolescents. Duncan, M. E., *et al.* ..... (A) 30A

Concurrent skin and nerve histology in leprosy and its role in the classification of leprosy. Kaur, S., *et al.* ..... (A) 652
Histological and immunohistochemical changes of eccrine sweat glands in leprosy. Wang, T., *et al.* ..... (A) 120A

Histopathology,
Ambiguities in leprosy histopathology. Porichha, D., *et al.* ..... (O) 428
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (O) 433
Clinical and histopathological correlation in the classification of leprosy. Bhatia, A. S., *et al.* ..... (A) 122A
Clinical-histopathological correlation in patients suspected of having leprosy. Schettini, A. P., *et al.* ..... (A) 30A
Extent, origin, and implications of observer variation in the histopathological diagnosis of suspected leprosy. Fine, P. E. M., *et al.* ..... (O) 270
Histopathological alterations in areas of cutaneous sensory loss in the diagnosis of leprosy. Pennini, S. N., *et al.* ..... (A) 122A
Histopathological analyses of lepromin tests performed at BCG-ized and nonBCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
Histopathological analysis of skin biopsies performed in leprosy patients: reaction or relapse? Schettini, A. P., *et al.* ..... (A) 122A
Histopathological analysis of specimens of BCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
Histopathological evaluation of chemotherapy and chemoimmunotherapy in MB leprosy. Mukherjee, A., *et al.* ..... (A) 126A
Histopathological evoluation of PB patients under WHO regimen. Reis Vianna, F., *et al.* ..... (A) 126A
[Histopathological study of six eye specimens of leprosy patients.] Shi, Z., *et* al ..... (A) 354
Liver and leprosy: histopathological/bronchial changes. China, R. A., *et al.* ..... (A) 123A
On histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w.* Reddy, B. N. and Porichha, D. ..... (C) 109
Pattern and spread of ocular lesions in multibacillary leprosy; a histopathological study. Jacob, M. ..... (A) 125A
Pre- and post-histopathological evaluation of 50 leprosy patients under multidrug therapy. Desai, S. D. ..... (A) 124A
Treated indeterminate leprosy: a search for predictive histopathological and immunohistochemical parameters in skin biopsies taken from patients at admission and at clinical discharge. Takahashi, D., *et al.* ..... (A) 354

History of leprosy,
A singular obsession: New Brunswick's leprosy doctor. Stanley-Blackwell, L. C. C. .... (E) 619
Summary and research of leprosy accounts in the Bible. Lu, J. ..... (A) 136A
The medieval leprosarium: its place in medical history. Ell, S. R. ..... (A) 139A

HLA (see also **Genetics**),
Association of HLA-A, -B, -C, and DR antigens with leprosy. Ghei, S. K., *et al.* ..... (A) 98A
[HLA antigens in lepromatous leprosy.] Saroyants, L. V., *et al.* ..... (A) 353
HLA class-II+ human keratinocytes present *M. leprae* antigens to CD4+ Th1-like cells. Mutis, T., *et al.* ..... (A) 351
HLA-linked genetic control of leprosy. Kher, S. K., *et al.* ..... (A) 149

Human immunodeficiency virus (HIV),
A comparison of clinical features in tuberculosis associated with infection with human immunodeficiency virus-1 and virus-2. Doorly, R., *et al.* ..... (A) 505
A semiquantitative assessment of the cellular immune response to *M. tuberculosis* in HIV-infected patients. Lewin-Smith, M. R., *et al.* ..... (A) 123A
Borderline tuberculoid leprosy in an HIV+ patient; clinical, histologic and immunohistologic evaluation. Goodless, D. R., *et al.* ..... (A) 35A
Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya–analysis of early 6 month) mortality. Nunn, P., *et al.* ..... (A) 171
Comparison of the abilities of *M. avium* and *M. intracellulare* to infect and multiply in

cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Crowle, A. J., *et al.* ..... (A) 157
Drug resistant tuberculosis in an urban population including patients at risk from human immunodeficiency virus infection. Chawla, P. K., *et al.* ..... (A) 155
Effect of HIV infection on clinical response of leprosy patients to multidrug therapy in Kenya. Orege, P. A., *et al.* ..... (A) 36A
Effectiveness of the macrolide clarithromycin in the treatment of *M. avium* complex infection in HIV-infected patients. Ruf, B., *et al.* ..... (A) 175
Failure of therapy for tuberculosis in human immunodeficiency virus infection. Nolan, C. M. ..... (A) 170
HIV-1 infection as a risk factor for leprosy; a case-control study in Tanzania. Borgdorff, M. W., *et al.* ..... (O) 556
Human immunodeficiency virus (HIV) and leprosy. Naafs, B., *et al.* ..... (A) 36A
Leprosy and HIV in Tanzania. Chum, H. J., *et al.* ..... (A) 65A
Leprosy in an HIV-positive and syphilitic young Paraguayan man. von Ballestrem, W., *et al.* ..... (A) 341
Leprosy reversal reaction in HIV-positive patients. Blum, L., *et al.* ..... (O) 214
M. leprae LAM and PGL-I antibodies crossreact with HIV-1 antibodies in sera from HIV-1-seronegative leprosy patients and their contacts. Kashala, O., *et al.* ..... (A) 97A
Qualitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Brindle, R. J., *et al.* ..... (A) 502
Report of a Meeting on HIV Infection in Leprosy. ..... (N) 642
Results in serological assays for detection of the prevalence of antibodies to HIV-1 leprosy cases in Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (A) 35A
Seroprofile of HBV, HIV and HTLV infections in Zairian leprosy patients and their contacts. Ilunga, N., *et al.* ..... (A) 97A
The impact of HIV infection on the global epidemiology of tuberculosis. Stylbo, K. ... (A) 177
Tuberculosis and HIV infection in sub-saharan Africa. Decock, K. M., *et al.* ..... (A) 158

Hypersensitivity,
A comparison of the T-cell delayed-type hypersensitivity epitopes of the 19-kD antigens from *M. tuberculosis* and *M. intracellulare* using overlapping synthetic peptides. Mackall, J. C., *et al.* ..... (A) 664
Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Chu, C. Q., *et al.* ..... (A) 156
Dietary vitamin-D affects cell-mediated hypersensitivity but not resistance to experimental pulmonary tuberculosis in guinea pigs. Hernandez Frontera, E. and McMurray, D. N. ..... (A) 505
Genetic control of immune responses to the 18-kDa protein of *M. leprae*; different TH1 subsets may be involved in proliferative and delayed-type hypersensitivity. Backstrom, B. T., *et al.* ..... (A) 129
Hypersensitivity to dapsone, rifampin and clofazimine in a lepromatous leprosy patient. Kumar, J. S., *et al.* ..... (A) 28A
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* ..... (A) 74A
Isolation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunized with living mycobacteria. Romain, F., *et al.* (A) 490
Topically applied verapamil hydrochloride inhibits tuberculin induced delayed-type hypersensitivity reactions in human skin. McFadden, J., *et al.* ..... (A) 375

ILEP (International Federation of Anti-Leprosy Associations),
Evolution of the ILEP information system for leprosy control projects 1966-1993. Martineau-Needham, D. and Lacey, S. ..... (A) 38A
Future of ILEP—focusing on the example of Ethiopia. Kiber, H. ..... (N) 641
ILEP Medical Bulletins available. ..... (N) 334
ILEP new appointments. ..... (N) 481
ILEP sponsorship of medical research. ..... (N) 334
Implementation of multidrug therapy in projects sponsored by ILEP members 1984-1991. Martineau-Needham, D. and Lacey, S. ..... (A) 43

Prevention of Disability; Guidelines for Leprosy Control Programmes published by ILEP. ..... (B) 477
The effect of the ILEP joint study project on sole wound prevalence. Watson, J. M. ..... (A) 154A

Immune complexes,
Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* ..... (O) 44
Diagnostic significance of circulating immune complexes in patients with pulmonary tuberculosis. Radhakrishnan, V. V., *et al.* ..... (A) 668
Levels and composition of circulating immune complexes in patients with erythema nodosum leprosum and acute anterior uveitis. Cakiner, T., *et al.* ..... (A) 100A
Suppression of ADCC by immune complexes formed *in vitro* in *M. leprae*-infected mice. Vaishnavi, C., *et al.* ..... (A) 361

Immune responses,
A semiquantitative assessment of the cellular immune response to *M. tuberculosis* in HIV-infected patients. Lewin-Smith, M. R., *et al.* ..... (A) 123A
Expression of *Escherichia coli* beta-glactosidase in *M. bovis* BCG using an expression system isolated from *M. paratuberculosis* which induced humoral and cellular immune responses. Murray, A., *et al.* ..... (A) 142
Genetic control of immune responses to the 18-kDa protein of *M. leprae*; different TH1 subsets may be involved in proliferative and delayed-type hypersensitivity. Backstrom, B. T., *et al.* ..... (A) 129
Immunization with extracellular proteins of *M. tuberculosis* includes cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Pal, P. G. and Horwitz, M. A. ..... (A) 171
Long-term effects of dapsone on immune responses in BALB/c mice. Reddy, M. N. and Rao, P. R. ..... (A) 82A
Specificity of a protective memory immune response against *M. tuberculosis*. Anderson, P. and Heron, I. ..... (A) 365

Immunoglobulins,
Detection of IgA anti-PGL-I in mangabey monkey inoculated with *M. leprae*. Saad, M. H. F., *et al.* ..... (A) 80A
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and inerleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
IgG activity toward purified heat-shock proteins and antigen 86\5 in leprosy patients and their contacts. Launois, P., *et al.* ..... (A) 89A
IgG humoral response against the antigen 85 complex homologs in leprosy. Drowart, A., *et al.* ..... (A) 91A
IgM serum antibodies to PGL-I by ELISA in healthy subjects and leprosy patients. Meng, M., *et al.* ..... (A) 92A
Relationship between anti-PGL-I antibody (IgM) level and relapses in cured leprosy patients. Sun, C., *et al.* ..... (A) 32A

Immunology,
Acute phase reactants in leprosy. Vaishnavi, C., *et al.* ..... (A) 128
Adenosine deaminase activity in leprosy. Shende, R. K., *et al.* ..... (A) 655
Bacteriological and immunological studies on active leprosy in Cairo. El Tayeb, S. H. M., *et al.* ..... (A) 33A
Borderline tuberculoid hanseniasis; parameters of immunological activity. Pimentel, M. I. F., *et al.* ..... (A) 98A
Composition and immunological properties of the protein fraction of A36, a major antigen complex of M. paratuberculosis. DeKesel, M., *et al.* ..... (A) 141
Cytokine patterns in leprosy. Salgame, P. and Bloom, B. R. ..... (A) 87A
Early immunological results of experimental *M. leprae* challenge of monkeys after attempted immunization with live BCG or BCG + heat-killed *M. leprae*. Gormus, B. J., *et al.* ..... (A) 75A
Efecto del ionoforo A23187 y 12, 13-forbol miriacetato sobre la proliferacion de linfocitos T de pacientes con lepra lepromatosa. Alfaro, F., *et al.* ..... (A) 101A

Expression of the *M. tuberculosis* 19-kilodalton antigen in *M. smegmatis*—immunological analysis and evidence of glycosylation. Garbe, T., *et al.* ..... (A) 349
Immunology. Kaufmann, S. H. E. ..... (A) 316
Leprosy in women: clinical and immunological aspects. Ulrich, M., *et al.* ..... (A) 99A
Limiting dilution analysis in leprosy. Mullins, R. J., *et al.* ..... (A) 135
Morphological and immunohistochemical findings in erythema multiforme in leprosy. Miranda, A., *et al.* ..... (A) 121A
Preliminary exploration of leprosy relapse surveillance with immunologic assays. Weng, X., *et al.* ..... (A) 61A
RBS immuno-adhering function in leprosy patients and their households–a preliminary study. Lu, D., *et al.* ..... (A) 31A
Reactions immunologiques observees a l'Institut Cardinal Leger pendant une periode de 8 ans. Leveille, C. A., *et al.* ..... (A) 24A
Receptor selective encephalins as effective immunomodulators in leprosy. Mazumdar, S., *et al.* ..... (A) 92A
Results of the 3rd Immunology of Leprosy/Immunology of Tuberculosis Antimycobacterial Monoclonal Antibody Workshop. Khanolkar-Young, S., *et al.* ..... (A) 134
Sequence and immunological characterization of a serine-rich antigen from *M. leprae*. Vega Lopez, F., *et al.* ..... (A) 499
Synthesis of species-specific *M. avium* trisaccharide (serovar 21) for the preparation of a neoglycoprotein for immunological studies. Ziegler, T. ..... (A) 183
Transforming growth factor-beta in leprosy. Goulart, I. M. B., *et al.* ..... (A) 120A
Understanding protective immunity to leprosy. Watson, J. D. ..... (A) 316

Immunotherapy,

Annual immunotherapy in treated lepromatous leprosy with three different BCG-based vaccines—a 6-year assessment. Waters, M. F. R., *et al.* ..... (A) 103A
Combined chemotherapy and immunotherapy for treatment of highly bacillated BL/LL cases. Katoch, K., *et al.* ..... (A) 13A
Histological changes with combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Natarajan, M., *et al.* ..... (A) 351
Histopathological evaluation of chemotherapy and chemoimmunotherapy in MB leprosy. Mukherjee, A., *et al.* ..... (A) 126A
Immunotherapy of MB leprosy patients with the antileprosy vaccine *Mycobacterium w*. Zaheer, S. A., *et al.* ..... (A) 18A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ..... (A) 345
Immunotherapy with *Mycobacterium w* vaccine in MB leprosy patients showing slow responses to MDT. Ramesh, V., *et al.* ..... (A) 18A
Localized lepromatous leprosy and its response to chemo immunotherapy. Beena, K. R., *et al.* ..... (A) 22A
Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w*. Sharma, A. K., *et al.* ..... (A) 24A

Indeterminate leprosy,

Treated indeterminate leprosy: a search for predictive histopathological and immunohistochemical parameters in skin biopsies taken from patients at admission and at clinical discharge. Takahashi, D., *et al.* ..... (A) 354

India,

A beneficiary study of leprosy services among the tribal and nontribal population in three selected districts of Madhya Pradesh in India. Dharmshaktu, N. S., *et al.* ..... (A) 60A
A comparative study on the effectiveness of different methods of case detection in north India. Casabianca, M. N., *et al.* ..... (A) 28A
A model for eradication of leprosy from rural South India at Ambilikkai during the last 3 1/2 decades among 1.5 lakhs of population in 1965 later on supported by ALM. Cherian, J. ..... (A) 40A
A study of the dehabilitation process of leprosy patients: India. Kaulagekar, A. A. ..... (A) 131A
A study to assess social disability and economic loss to leprosy patients on MDT in north India—preliminary study. Palla, J., *et al.* ..... (A) 127A

An immunogenetic study of differential manifestations of leprosy in north India. Rani, R., *et al.* ..... (A) 100A
Assessing effectiveness of leprosy education in rural India; a randomized-controlled community-based intervention trial. Dhariwal, A. C. ..... (A) 167A
BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ..... (A) 175
Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Lockwood, D. N. J., *et al.* ..... (O) 9
Community perception of leprosy in Kerala, South India. Thomas, A., *et al.* ..... (A) 127A
Community-based rehabilitation program of The Leprosy Mission, India. Samson, P. D., *et al.* ..... (A) 140A
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* ..... (A) 5A
Current eye health care delivery system for leprosy in leprosy endemic zone of eastern India. Samanta, S. K. and Roy, I. S. ..... (A) 36A
Dayapuram Leprosy Hospital Platinum Jubilee ..... (N) 479
Do human leukocyte antigens have a role to play in differential manifestation of multibacillary leprosy—a study on multibacillary leprosy patients from India. Rani, R., *et al.* ..... (A) 149
Dr. Bakhta Reddy replaces Dr. Vellut at DFB. ..... (N) 328
Epidemiological impact of multidrug therapy of leprosy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* ..... (A) 49A
Evaluation of community-based rehabilitation for leprosy patients in the South India experience. Rajan Babu, G. ..... (A) 152A
Five years' experience of MDT in Amritsar (Punjab). Bharti, R., *et al.* ..... (A) 9A
Fixed duration multidrug therapy (FDT) for multibacillary (MB) leprosy in Indian rural pograms. Ganapati, R., *et al.* ..... (A) 3A
Frequency and clinical features of erythema nodosum leprosum in Hyderabad, India. Vinayakumar, S., *et al.* ..... (A) 34A
GRECALTES 1993 Antileprosy Day ceremony. ..... (N) 329
Health and human resource mobilization: an assessment of staffing pattern in NLEP at operational level. Reddy, J. V. S. ..... (A) 337
India—the use of the fixed drug combination Isoprodian rifampin under field conditions. Graf, P. ..... (A) 306
Integration follow-up study of general health staff trained in leprosy in Wardha District, India. Landge, K., *et al.* ..... (A) 51A
International Gandhi Award. Gokhale, S. K. ..... (C) 110
Intrafamilial transmission of leprosy in Vellore town, India. George, R., *et al.* ..... (O) 550
Intrafamiliar transmission of leprosy in Vellore town, India. George, R., *et al.* ..... (A) 75A
Leprosy patients honored on World Disabled Day. ..... (N) 479
M. leprae soluble antigen (Rees) skin test responses in an endemic population in India. Krishnamurthy, P., *et al.* ..... (A) 349
Moolgaokar Leprosy Ward of BLP ..... (N) 641
Natural history and clinical features of reversal reaction in Hyderabad, India. Lockwood, D., *et al.* ..... (A) 23A
New simulation model for predicting incidence and prevalence trends in Sevagram area of Wardha District, Maharashtra, India. Ranade, M. ..... (A) 68A
1989 Dr. Farooq Abdullah Oration Award to Dr. Katoch. ..... (N) 116
1991 Acworth RRE Society Award for Best Presented Paper to Dr. Chaturvedi and Mr. Patil. ..... (N) 116
1991 Acworth RRE Society Award for Best Published Work to Dr. Patil. ..... (N) 117
1991 Dr. C. G. S. Iyer Oration Award to Dr. Venkatesan. ..... (N) 116
1992 Erwin Stindl Memorial Oration Award to Dr. Kurup. ..... (N) 117
1993 Bombay Leprosy Project's Antileprosy Week Celebration. ..... (N) 328
PDLC receives RCI International Award. ..... (N) 329
PDLC's film receives award. ..... (N) 480
Poona District Leprosy Committee receives award. ..... (N) 329
Projection of demand for leprosy services in India after WHO MDT. Almeida, J. ..... (A) 44A
Reduced fingertip blood flow and peripheral dysautonomia in leprosy patients in Iranian Azerbaijan and in Maharashtra, India. Abbot, N. C., *et al.* ..... (C) 474

Response of newly diagnosed patients to leprosy in Kerala, South India. Alexander, R., *et al.* ..... (A) 135A
SLR&TC, Karigiri 1993 courses. ..... (N) 330
Sample survey for prevalence of leprosy in three slums of Delhi, India. Rao, K. N. ..... (A) 72A
Sample survey of leprosy after 3 years of MDT in Bhavani Taluk of Periyar District, Tamil Nadu, South India. Shanker Narayan, N. P., *et al.* ..... (A) 42
Semmes-Weinstein monofilament testing to determine normal sensory thresholds in the foot and hand: a comparative study in India. Jerskey, R. ..... (A) 159A
Skin disease diagnostic, treatment and education (SDDTE) camps: a tool for community education in the tribal district Bharuch (Guajrat), India. Chopra, N. K., *et al.* ..... (A) 50A
Social action for leprosy eradication; an inexpensive Indian model. Devadas, T. J. and Cheriyan, C. S. ..... (A) 48A
Study of field trials of combined chemotherapy and fixed duration combined chemotherapy in multibacillary leprosy in MDT project, Bharuch District, Gujarat, India. Chopra, N. K. ..... (A) 49A
Study of leprosy in children in multidrug therapy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* ..... (A) 69A
Study of relapse in paucibacillary leprosy patients in multidrug therapy project in Bharuch District, Gujarat, India. Chopra, N. K. ..... (A) 6A
Teaching of leprosy in medical colleges of Orissa, India. Sahu, J. ..... (A) 168A
The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guerin (BCG) vaccination in either South India or London. Das, S., *et al.* ..... (A) 158
Workshop on Social Science Research on Health Education in Leprosy. ..... (N) 117

Indonesia,
Behavior health change intervention on leprosy control in South Sulawesi, Indonesia. Rusli Ngatimin, H. M. ..... (A) 139A
Detection of leprosy infection by serology and polymerase chain reaction; an epidemiological study in South Sulawesi, Indonesia. van Beers, S., *et al.* ..... (A) 67A
Field testing of the community health education leaflet developed at the National Leprosy Training Center, Ujungpadang, Indonesia. Kurnia, D. and Aspar, N. ..... (A) 167A
International Meeting on Epidemiology of Leprosy in Relation to Control held in Jakarta, Indonesia, 17-21 June 1992. ..... (A) 148
Leprosy control in 7 districts of South Sulawesi, Indonesia, 1986-91. Day, R., *et al.* ..... (A) 148
The approach to the leprosy problem in the past in Indonesia-a historical review of leprosy control activities in Indonesia during the last centuries. Zuiderhoek, B. ..... (A) 484
Treatment compliance in the South Sulawesi Leprosy Control Program, Indonesia. Lever, P., *et al.* ..... (A) 16A

Indomethacin,
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*—effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159

Inoculation,
Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ..... (A) 337
Detection of IgA anti-PGL-I in mangabey monkey inoculated with *M. leprae*. Saad, M. H. F., *et al.* ..... (A) 80A
Study on nude mice inoculated with *M. leprae* by multiple routes. Wang, H., *et al.* ..... (A) 82A

Interferon,
A role for gamma interferon, tumor necrosis factor, and soluble T-cell receptors in the depressed blastogenic response of spleen cells of *M. lepraemurium*-infected mice. Richard, L., *et al.* ..... (A) 137
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*—effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159
Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. SivaSai, K. S. R., *et al.* ..... (O) 259

IFN-gamma-producing ability as a possible marker for the protective T cells against *M. bovis* BCG in mice. Kawamura, I., *et al.* ..... (A) 165
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
M. leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. Sampaio, E. P., *et al.* ..... (A) 353

Interleukin(s),
Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with *M. leprae* and *M. bovis* BCG. Suzuki, K., *et al.* ..... (O) 609
Effects of glucocorticoids, dapsone and thalidomide on interleukin-1 production. Lew, W., *et al.* ..... (A) 92A
Immunosupressive roles for IL-10 and IL-4 in human infection-*in vitro* modulation of T-cell responses in leprosy. Sieling, P. A., *et al.* ..... (A) 655
Inactivation of interleukin-2 by the culture isolate from *M. leprae* in Ogawa media with cytokines. Oh, C.-S. ..... (A) 116A
Infection with *M. avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Bermudez, L. E. and Champsi, J. ..... (A) 659
Interleukin-1beta production by peripheral blood mononuclear cells from leprosy patients. Jayapal, V., *et al.* ..... (C) 462
Interleukin-6 antagonizes tumor necrosis factor-related mycobacteriostatic and mycobactericidal activities in macrophages. Bermudez, L. E., *et al.* ..... (A) 130
Recombinant IL-2 in untreated and treated lepromatous leprosy patients. Villahermosa, L. G., *et al.* ..... (A) 101A
Regulation of interleukin-1-beta (IL-1-beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs. Zhang, Y. and Rom, W. N. ..... (A) 671

International Journal of Leprosy (IJL),
Index to Volume 61. ..... (S) 773
Reviewers for Volume 61. ..... (-) 672
Statement of Financial Condition. ..... (-) 529
Statement of Ownership, Management, and Circulation. ..... (-) 673

International Leprosy Association (ILA),
List of Members. ..... (S) 709
Minutes of General Meeting of ILA Members. ..... (S) 697
Minutes of ILA Council Meeting, 4 September 1993. ..... (S) 721
Officers and Councillors (1993-1998). ..... (S) 708

Intestine(s),
Identification of rifampin-inducible P450-IIIA4 (CYP3A4) in human small bowel enterocytes. Kolars, J. C., *et al.* ..... (A) 123

Iran,
Leprosy in Isfahan, a province of Iran. Asilian, A., *et al.* ..... (A) 74A
Reduced fingertip blood flow and peripheral dysautonomia in leprosy patients in Iranian Azerbaijan and in Maharashtra, India. Abbot, N. C., *et al.* ..... (C) 474

Isoniazid,
Characterization of the katG gene encoding a catalase peroxidase required for the isoniazid susceptibility of *M. tuberculosis.* Heym, B., *et al.* ..... (A) 661
Isolation and characterization of isoniazid-resistant mutants of *M. smegmatis* and *M. aurum.* Heym, B. and Cole, S. T. ..... (A) 163
Isoniazid and hepatotoxicity. Verfuin, P. R. N. ..... (C) 628
Salivary levels of isoniazid and rifampicin in tuberculous patients. Gurumurthy, P., *et al.* ..... (A) 372
Short-term chemotherapy with rifampin + cotrimoxazol + isoniazid (cotrifazide). Freerksen, E. ..... (A) 315
The risk of isoniazid in the Isoprodian-rifampin regimen. Grosset, J. ..... (A) 304

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Goble, M., *et al.* ..... (A) 371

Israel,
Leprosy acquired in Israel. Vardy, D. A., *et al.* ..... (A) 150

Italy,
Rehabilitation organizations initiate coordination process. ..... (N) 480

Japan,
Analysis of 98 autopsy cases in a Japanese leprosarium. Kitajima, S., *et al.* ..... (A) 124A
[Biwasaki Leprosarium—a century of dedication.] Itakura, K. ..... (A) 336
[The progress of National Leprosarium.] Saikawa, K. ..... (A) 336

Kenya,
Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Orege, P., *et al.* ..... (O) 542
Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya–analysis of early (6 month) mortality. Nunn, P., *et al.* ..... (A) 171
Effect of HIV infection on clinical response of leprosy patients to multidrug therapy in Kenya. Orege, P. A., *et al.* ..... (A) 36A
Rehabilitation International Working Group on Leprosy. ..... (N) 331

Kidney(s),
Acute renal failure caused by two single doses of rifampicin with a year of interval. Pelaez, E., *et al.* ..... (A) 486
PGL-I-like antigen in renal carcinoma. Makino, M., *et al.* ..... (A) 91A
Renal transplantation in leprosy patients. Roselino, A. M. F., *et al.* ..... (E) 102

Korea,
A model for the healing of leprosy in Korea. Lew, J. ..... (A) 140A

Leishmaniasis,
Distinguishing post-kala-azar dermal leishmaniasis from leprosy: experience in the Sudan. El Hassan, A. M., *et al.* ..... (A) 341
Leishmaniasis difusa anergica de Republica Dominicana; participacion del personal auxiliar delprograma de lepra en el descubrimiento de casos. Bogaert, H. and Isa, R. I. ..... (A) 28A

Lepromatous leprosy,
A clinical and radiological study of maxillary antrum in lepromatous leprosy. Hauhner, C. Z., *et al.* ..... (A) 342
Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A
Altered calcium-binding ability of plasma proteins as the cause of hypocalcemia in lepromatous leprosy. Vidal, M. C., *et al.* ..... (O) 586
Analysis of cytokine production by mycobacterium-reactive T cells—failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 489
Analysis of cytokine production by mycobacterium-reactive T cells: failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 102A
Annual immunotherapy in treated lepromatous leprosy with three different BCG-based vaccines—a 6-year assessment. Waters, M. F. R., *et al.* ..... (A) 103A
Antibodies to *M. tuberculosis*-specific epitopes in lepromatous leprosy. Bothamley, G., *et al.* ..... (A) 130
Asymptomatic nerve hypertrophy in lepromatous leprosy—a clinical, electrophysiological and morphological study. Tzourio, C., *et al.* ..... (A) 127
Autoaggressive lepromatous leprosy. Dhar, S., *et al.* ..... (C) 467
Bacteriological response of BL/LL patients to MDT for varied duration: a retrospective five-year follow up. Bhatki, W. and Pade, S. ..... (A) 3A
Borderline tuberculoid relapse in lepromatous leprosy. Girdhar, B. K., *et al.* ..... (A) 649
Clinical trials of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 7A

Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* ..... (A) 488
Cytokine mRNA expression in lepromatous leprosy and the reactional states in leprosy. Sampaio, E. P., *et al.* ..... (A) 102A
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (O) 204
Effect of multidrug therapy on plasma level of high density lipoprotein cholesterol (HDL-C) in patients of lepromatous leprosy. Kumar, N. and Sharma, B. L. ..... (A) 33A
Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. SivaSai, K. S. R., *et al.* ..... (O) 259
Electrocardiographic alterations in lepromatous leprosy patients with concomitant *Trypanosoma cruzi* infection. Bottasso, O. A., *et al.* ..... (C) 468
[HLA antigens in lepromatous leprosy.] Saroyants, L. V., *et al.* ..... (A) 353
Histoid leprosy in early macular lepromatous leprosy: incidental finding or sign of augmented local immunity? Fiallo, P., *et al.* ..... (C) 471
Histological changes with combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Natarajan, M., *et al.* ..... (A) 351
Hypersensitivity to dapsone, rifampin and clofazimine in a lepromatous leprosy patient. Kumar, J. S., *et al.* ..... (A) 28A
In vitro labeling and function of granuloma macrophages from lepromatous leprosy. Chae, G.-T., *et al.* ..... (A) 96A
In vitro test systems to determine susceptibility to lepromatous leprosy. Mahadevan, P. R. and Robinson, P. ..... (A) 98A
Lack of expression of intercellular adhesion molecule ICAM-1 in lepromatous leprosy patients. Moncada, B., *et al.* ..... (O) 581
Localized lepromatous leprosy and its response to chemo immunotherapy. Beena, K. R., *et al.* ..... (A) 22A
Lymphocyte subpopulations and their functional properties in lepromatous leprosy. Saroyants, L., *et al.* ..... (A) 95A
Major antigens of *M. habana* recognized by sera of patients with lepromatous leprosy. Vilchis, M., *et al.* ..... (A) 90A
Minocycline in lepromatous leprosy. Fajardo, T., Jr., *et al.* ..... (A) 9A
Minocycline in the treatment of lepromatous leprosy—pilot studies of possible regimens. Waters, M. F. R. ..... (A) 18A
Natural killers in lepromatous leprosy. Saroyants, L., *et al.* ..... (A) 105A
Necrotic erythema nodosum leprosum; a presenting manifestation of lepromatous leprosy. Verma, K. K. and Pandhi, R. K. ..... (C) 293
Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 8A
Powerful bactericidal activities of clarithromycin and minocycline against *M. leprae* in lepromatous leprosy. Ji, B. H., *et al.* ..... (A) 647
Recognition of *M. leprae* antigens with antibodies present in sera from patients with lepromatous leprosy. Islas Rodriguez, A. E., *et al.* ..... (O) 245
Recombinant IL-2 in untreated and treated lepromatous leprosy patients. Villahermosa, L. G., *et al.* ..... (A) 101A
Serum lactoferrin in lepromatous leprosy patients. Parkash, O., *et al.* ..... (A) 33A
Serum transferrin (Tf) concentration and Tf receptors (R) on the surface of T lymphocytes in lepromatous leprosy (LL). Fafutis, M., *et al.* ..... (A) 101A
Systemic lupus erythematosus in a lepromatous leprosy patient; a diagnostic and therapeutic problem. Arunthathi, S., *et al.* ..... (A) 28A

Lepromin,

A longitudinal study of the predictive value of the lepromin response and anti-PGL-I serology in children. Naik, S., *et al.* ..... (A) 72A
Anergy and Mitsuda responses toward chemoautotrophic nocardiofirm antigens run parallel to lepromin across the leprosy spectrum. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 117A
Appearance of delta-gamma T cell receptor-positive cells following alpha-beta T cell receptor-positive cells in the lepromin reaction of human skin. Fujita, M., *et al.* ..... (A) 348

Histopathological analyses of lepromin tests performed at BCG-ized and nonBCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346
Induction of lepromin positivity by a candidate antileprosy vaccine *Mycobacterium w* and its immunoprophylactic effect in lepromin-negative healthy contacts or multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 95A
Induction of lepromin positivity by a candidate antileprosy vaccine, *Mycobacterium w*, in lepromin negative healthy contacts of multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 349
Lepromin skin testing in the classification of Hansen's disease in the United States. Krotoski, W. A., *et al.* ..... (A) 342
Significance of cellular morphology of Mitsuda lepromin response. Desikan, V. K. and Girdhar, B. K. ..... (A) 125A
Soluble *M. leprae* antigen skin testing and lepromin positivity in children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 105A
Ten-twelve years follow up of healthy contacts of leprosy cases using FLA-ABS and lepromin tests. Bharadwaj, V. P., *et al.* ..... (A) 67A

Lesion(s),
A histological study of the eye lesions in 12 leprosy patients with tuberculoid lesion in 4 eyes. Brandt, F., *et al.* ..... (A) 3466
Clinical assessment of monolesion leprosy cases. Pai, V. V., *et al.* ..... (A) 30A
Demonstration of PGL-I and LAM-B in paraffin sections of leprosy skin lesions. Wang, T., *et al.* ..... (A) 120A
Development of improved techniques for extraction of nucleic acids from leprosy lesions. Katoch, V. M., *et al.* ..... (A) 114A
[Distribution of single cutaneous lesions in paucibacillary leprosy.] Avelleira, J. C. R., *et al.* ..... (A) 649
Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. SivaSai, K. S. R., *et al.* ..... (O) 259
Expression of adhesion molecules in leprosy lesions. Sullivan, L., *et al.* ..... (A) 138
Extensive progressive new lesions in a BT case while on regular MB-MDT. Kiran, K. U. ..... (A) 22A
FACS analysis of CD4+ T-cell subsets in reacting and nonreacting leprosy skin lesions. Utaipat, U., *et al.* ..... (A) 104A
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* ..... (A) 99A
Immunohistochemical identification of ferritin, lactoferrin and transferrin in leprosy lesions of human skin biopsies. Momotani, E., *et al.* ..... (A) 135
Localization of single lesions in leprosy. Avelleira, J. C., *et al.* ..... (A) 29A
Nerve lesions induced by macrophage activation. Said, G. and Hontebeyrie-Joskowicz, M. ..... (A) 352
Observation on subcutaneous immune cells *in situ* in leprous nonreactive skin lesions. Zhu, S., *et al.* ..... (A) 98A
Pattern and spread of ocular lesions in multibacillary leprosy; a histopathological study. Jacob, M. ..... (A) 125A
Relation of skin lesions with deformitites in nonlepromatous leprosy. Subuddhi, K. B. ... (A) 36A
Selective expansion of Vdelta1 + T-cells from leprosy skin lesions. Uyemura, K., *et al.* .. (A) 355
Studies of macrophage traffic into the experimental lepromatous lesion of the *M. leprae*-infected nu/nu mouse foot pad. Krahenbuhl, J. L., *et al.* ..... (A) 78A
Study of ocular lesions in leprous outpatients. Monteiro, L., *et al.* ..... (A) 26A
T-cell receptor usage in blood and skin lesions in leprosy. Cross, C., *et al.* ..... (A) 104A
The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. van Brakel, W. H., *et al.* ..... (A) 128

The mycobacterial secreted antigen-85 complex possesses epitopes that are differentially expressed in human leprosy lesions and *M. leprae*-infected armadillo tissues. Rambukkana, A., *et al.* ..... (A) 496

Leukocyte(s),

Do human leukocyte antigens have a role to play in differential manifestation of multibacillary leprosy—a study on multibacillary leprosy patients from India. Rani, R., *et al.* ..... (A) 149

Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Bozeman, P. M., *et al.* ..... (A) 121

Lipid(s),

A new glycolipid from *M. avium-M. intracellulare* complex. Watanabe, M., *et al.* ..... (A) 145

Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A

Antibodies to a nerve lipid extract (NLE) in sera of leprosy patients. Vartak, R., *et al.* (A) 97A

Antigenic glycolipids of *M. fortuitum* based on trehalose acylated with 2-methyloctadec-2-enoic acid. Hamid, M. E., *et al.* ..... (A) 495

Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Van Rensburg, C. E. J., *et al.* ..... (A) 124

Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes—demonstration of voltage gating and of negative point charges at the channel mouth. Trias, J. Q. and Benz, R. ..... (A) 498

Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* ..... (O) 44

Comparative effects of *M. avium* glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells. Pourshafie, M., *et al.* ..... (A) 667

Detection of antibodies to phenolic glycolipid by ELISA in leprosy patients. Lal, H., *et al.* ..... (A) 350

[Determination of antiphenolic glycolipid antibodies in a general population of an area endemic for leprosy.] Mor, N., *et al.* ..... (A) 363

Does the difference of the properties of trisaccharide-BSA conjugate (NT-P-BSA) of *M. leprae* phenolic glycolipid influence its seroreactivity? Fujiwara, T., *et al.* ..... (A) 348

Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of *M. avium*. Belisle, J. T., *et al.* ..... (A) 493

Higher specificity in the serodiagnosis of leprosy by combined titration of antiphenolic glycolipid-I and antiphospholipid antibodies. Fiallo, P., *et al.* ..... (C) 464

Leprosy-derived chemoautotrophic nocardioform (CAN) bacteria closely resemble, or are idential with, *M. leprae* on mycolate and other lipid profiles. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 357

Physical organization of lipids in the cell wall of *M. chelonae*. Nikaido, H., *et al.* ..... (A) 665

Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ..... (A) 155

Regulation of phospholipid synthesis in *M. smegmatis* by cyclic adenosine monophosphate. Sareen, M., *et al.* ..... (A) 656

Rough morphological variants of *M. avium*; characterization of genomic deletions resulting in the loss of glycopeptidolipid expression. Belisle, J. T., *et al.* ..... (A) 492

Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ..... (A) 138

Significance of antibodies to phenolic glycolipid-I in leprosy diagnosis. Prakash, K., *et al.* ..... (A) 654

Structure of a novel glycopeptidolipid antigen containing a O methylated serine isolated from *M. xenopi* complete H-1-NMR and C-13-NMR assignment. Riviere, M., *et al.* (A) 669

Structure of a novel sulfate containing mycobacterial glycolipid. Marin, L. M. L., *et al.* (A) 168

Structure of mycoside-F, a family of trehalose-containing glycolipids of *M. fortuitum*. Gautier, N., *et al.* ..... (A) 162

Structures of glycopeptidolipid antigens of serovar-25 and serovar-26 of the *M. avium* serocomplex, synthesis of allyl glycosides of the outer disaccharide units and serology of the derived neoglycoproteins. Aspinall, G. O., *et al.* ..... (A) 366

Structures of the glycopeptidolipid antigens of two animal pathogens—*M. senegalense* and *M. procinum*. Marin, L. M. L., *et al.* ..... (A) 664
Suppression of human monocyte cytokine release by phenolic glycolipid-I of *M. leprae*. Silva, C. L., *et al.* ..... (C) 107
The structure of an antigenic glycolipid (SL-IV) from *M. tuberculosis*. Baer, H. H. ..... (A) 492
Trifluoperazine inhibits the incorporation of labeled precursors into lipids, proteins and DNA of *M. tuberculosis* H37Rv. Ratnaker, P. and Murthy, P. A. ..... (A) 668

Lipoarabinomannan (LAM),
Demonstration of PGL-I and LAM-B in paraffin sections of leprosy skin lesions. Wang, T., *et al.* ..... (A) 120A
Detection of lipoarabinomannan as a diagnostic test for tuberculosis. Sada, E., *et al.* ..... (A) 176
Does antibody to mycobacterial antigens including lipoarabinomannan, limit dissemination in childhood tuberculosis. Costello, A. M. D., *et al.* ..... (A) 368
Lipoarabinomannan (LAM)—a possible immunoregulatory molecule of *M. leprae*-infected Schwann cells? Mistry, N., *et al.* ..... (A) 100A
Lipoarabinomannan (LAM)-based enzyme-linked immunosorbent assay in serodiagnosis of leprosy. Gandhi, S., *et al.* ..... (A) 93A
M. leprae LAM and PGL-I antibodies crossreact with HIV-1 antibodies in sera from HIV-1-seronegative leprosy patients and their contacts. Kashala, O., *et al.* ..... (A) 97A
Serological response against crossreactive cell-wall antigens (65-kDa protein and LAM-B) in leprosy. Elangeswaran, N., *et al.* ..... (A) 89A
Structural definition of lipoarabinomannan: its biological significance in host-parasite interaction. Chatterjee, D., *et al.* ..... (A) 115A
Structural features of lipoarabinomannan from *M. bovis* BCG; determination of molecular mass by laser desorption mass spectrometry. Venisse, A., *et al.* ..... (A) 669

Lipoprotein,
Effect of multidrug therapy on plasma level of high density lipoprotein cholesterol (HDL-C) in patients of lepromatous leprosy. Kumar, N. and Sharma, B. L. ..... (A) 33A

Liposome,
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium-M. intracellulare* complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ..... (A) 168
Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ..... (A) 138

Liver,
Association between leprosy and hepatitis-B infection—a survey in Goiana, Central Brazil. Rosa, H., *et al.* ..... (A) 127
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Hebert, M. F., *et al.* ..... (A) 122
Hepatitis C and hepatitis B virus serum markers in Greek leprosy patients. Kontochristopoulos, G., *et al.* ..... (A) 35A
Immunoreactivity of mammalian liver component with leprosy sera. Despande, R. G., *et al.* ..... (A) 347
Improvement of hand impairment and life quality by field delivered splints and grip aids in deformed leprosy patients. Shah, A., *et al.* ..... (A) 141A
Isoniazid and hepatotoxicity. Verfuin, P. R. N. ..... (C) 628
Liver and leprosy: histopathological/bronchial changes. China, R. A., *et al.* ..... (A) 123A

Lucio phenomenon,
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ..... (A) 95A

Lupus,
Identification of *M. tuberculosis* DNA in a case of lupus vulgaris. Serfling, U., *et al.* ..... (A) 377
Systemic lupus erythematosus in a lepromatous leprosy patient; a diagnostic and therapeutic problem. Arunthathi, S., *et al.* ..... (A) 28A

Lymphocyte(s),
Characterization of gamma/delta lymphocytes-T in the peripheral blood of patients with active tuberculosis—a comparison with normal subjects and patients in sarcoidosis. Tazi, A., *et al.* ..... (A) 178
Correlation between TNF production, increase of CRP level, and suppression of T lymphocytes during ENL reaction. Foss, N. T. and Silva, C. L. ..... (A) 102A
Correlation between TNK production, increase of plasma C reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Foss, N. T., *et al.* ..... (O) 218
Cytokine secretion by CD4 T-lymphocytes acquired in response to *M. tuberculosis* infection. Orme, I. M., *et al.* ..... (A) 666
Efecto del ionoforo A23187 y 12, 13-forbol miriacetato sobre la proliferacion de linfocitos T de pacientes con lepra lepromatosa. Alfaro, F., *et al.* ..... (A) 101A
Identification of IL-8 as a locomotor attractant for activated human lymphocytes in mononuclear cell cultures with anti-CD3 or purified protein derivative of *M. tuberculosis*. Wilkinson, P. C. and Newman, I. ..... (A) 183
Lymphocyte proliferation and cytokine secretion in response to purified mycobacterial HSP and to Ag85 during infection with *M. leprae*. Launois, P., *et al.* ..... (A) 86A
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
Lymphocyte subpopulations and their functional properties in lepromatous leprosy. Saroyants, L., *et al.* ..... (A) 95A
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ..... (A) 95A
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Roles of lymphocyte subpopulations in erythema nodosum leprosum and acute anterior uveitis. Bahceci, E., *et al.* ..... (A) 95A
Schwann cells are able to present exogenous mycobacterial hsp70 to antigen-specific T lymphocytes. Ford, A. L., *et al.* ..... (A) 488
Selection of T lymphocytes bearing limited T-cell receptor beta chains in the response to a human pathogen. Wang, X. H., *et al.* ..... (A) 140
Serum transferrin (Tf) concentration and Tf receptors (R) on the surface of T lymphocytes in lepromatous leprosy (LL). Fafutis, M., *et al.* ..... (A) 101A
Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. Birnbaum, G., *et al.* ..... (A) 659
Studies of lymphocyte physiology—a study of marker enzymes of metabolic pathways. Suri Babu, C. S., *et al.* ..... (A) 98A

Macrophage(s),
Activities of WIN-57272, minocycline, clarithromycin, and 14 hydroxy-clarithromycin against *M. avium* complex in human macrophages. Cohen, Y., *et al.* ..... (A) 156
Assessment of mycobacterial infection and multiplication in macrophages of polymerase chain reaction. Barrera, L. F., *et al.* ..... (A) 367
Capacity of *M. avium* isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Furney, S. K., *et al.* ..... (A) 132
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*--effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159
Comparison of the abilities of *M. avium* and *M. intracellulare* to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Crowle, A. J., *et al.* ..... (A) 157
Differential mechanism of intracellular killing of *M. avium* and *Listeria monocytogenes* by activated human and murine macrophages—the role of nitric oxide. Bermudez, L. E. ..... (A) 367
Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. SivaSai, K. S. R., *et al.* ..... (O) 259
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium*-

M. intracellulare complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ..... (A) 168
Evaluation of the activity of a number of antimicrobial agents against mycobacteria within mouse macrophages by a radiometric method. Banerjee, D. K. and Patel, B. R. ..... (A) 357
In vitro labeling and function of granuloma macrophages from lepromatous leprosy. Chae, G.-T., *et al.* ..... (A) 96A
Interleukin-6 antagonizes tumor necrosis factor-related mycobacteriostatic and mycobactericidal activities in macrophages. Bermudez, L. E., *et al.* ..... (A) 130
Killing of mycobacteria-infected macrophages by LAK cells from leprosy patients. Chiplunkar, S., *et al.* ..... (A) 96A
M. avium-M. intracellulare binds to the integrin receptor alpha(v)beta3 on human monocytes and monocyte-derived macrophages. Rao, S. P., *et al.* ..... (A) 376
MICs and MBCs of clarithromycin against *M. avium* within human macrophages. Mor, N. and Heifets, L. ..... (A) 375
Macrophage phagocytosis of virulent but not attenuated strains of *M. tuberculosis* is mediated by mannose receptors in addition to complement receptors. Schlesinger, L. S. ..... (A) 490
Macrophage system. Mahadevan, P. R. ..... (A) 307
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Modulation of monocytes/macrophages of leprosy patients by tuftsin for biochemical and immunogenic functions. Khare, S., *et al.* ..... (A) 96A
[Monokine production by mouse peritoneal macrophages after phagocytosis of mycobacteria.] Fukutomi, Y., *et al.* ..... (A) 348
Murine strain variation in *M. leprae*-infected Schwann cell functions and their modulation by macrophages. Birdi, T., *et al.* ..... (A) 77A
Mycobacterial growth and ultrastructure in mouse L-929 fibroblasts and bone marrow-derived macrophages—evidence that infected fibroblasts secrete mediators capable of modulating bacterial growth in macrophages. Rastogi, N., *et al.* ..... (A) 137
Nerve lesions induced by macrophage activation. Said, G. and Hontebeyrie-Joskowicz, M. ..... (A) 352
Pathogenesis of tuberculosis—interaction of *M. tuberculosis* with macrophages. McDonough, K. A., *et al.* ..... (A) 665
Penetration of dapsone, rifampin and clofazimine into macrophages and mycobacteria. Mathur, A., *et al.* ..... (A) 81A
Problems in detection of secretory antigens of intracellular mycobacteria in macrophage and Schwann cell tissue culture. Mistry, N., *et al.* ..... (A) 87A
Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Meylan, P. R. A., *et al.* ..... (A) 169
Respiratory burst metabolic status of macrophages in experimental leprosy. Kohli, M., *et al.* ..... (A) 361
Responses of cytokine-treated human monocyte-derived macrophages to challenge with *M. leprae*. Adams, L. B. and Krahenbuhl, J. L. ..... (A) 102A
Studies of macrophage traffic into the experimental lepromatous lesion of the *M. leprae*-infected nu/nu mouse foot pad. Krahenbuhl, J. L., *et al.* ..... (A) 78A
TNF-alpha response to human monocyte-derived macrophages to *M. avium*, serovar 4, is a brief duration and protein kinase C dependent. Gan, H., *et al.* ..... (A) 494
The combined effect of rifampin and pyrazinamide with the human macrophage. Sbarbaro, J. A., *et al.* ..... (A) 176
UV-B irradiation of mice impairs the phagocytic ability of macrophages, decreases immunity to *M. lepra*emurium, and increases disease pathogenesis. Jeevan, A. and Kripke, M. L. ..... (A) 77A

Malawi,
Association of geographic factors with leprosy incidence rates in Karonga District, northern Malawi. Sterne, J. A. C., *et al.* ..... (A) 74A
Computing in the field. ..... (N) 331
Drs. Boerrigter and Ponnighaus make changes. ..... (N) 331

Incidence rates of leprosy decline with increasing duration of schooling and with improving standards of housing in Karonga District, northern Malawi. Ponnighaus, J. M., *et al.* ..... (A) 68A

Malaysia,

Leprosy control programme in Malaysia. Kamaludin, F. ..... (A) 657

Use of PGL-immunoassays in seroepidemiological studies of *M. leprae* infection in Malaysia. Gan, S. C. and Fujiwara, T. ..... (A) 73A

Malta,

1972-1992: 20 years after starting the eradication project in Malta. Gatt, P. ..... (A) 304

Twenty years after starting the eradication project in Malta. Gatt, P. ..... (A) 5A

Martinique,

Education sanitaire lepre; enquete devaluation des connaissances *et* de la perception de la lepre a la Martinique. Carolina, J. C., *et al.* ..... (A) 168A

Martinique: Evaluation de 1980 a 1992 de la polyantibiotherapie (PAT) ou polychimiotherapie (PCT) traitment de la lepre. Pierre Rose, M. C.-D., *et al.* ..... (A) 54A

Metabolism,

Circulatory adaptation to the increased metabolism in the skin at the site of the tuberculin reaction. Abbot, N. C., *et al.* ..... (A) 129

Correlation between inhibitory effect of quinolones and mycolic acid metabolism in mycobacteria. Patil, M. A., *et al.* ..... (A) 143

M. leprae metabolism: *in vitro* utilization of glucose, uridine 5′-diphosphoglucose and gutamate. Harris, E. B., *et al.* ..... (A) 116A

Respiratory burst metabolic status of macrophages in experimental leprosy. Kohli, M., *et al.* ..... (A) 361

Studies of lymphocyte physiology—a study of marker enzymes of metabolic pathways. Suri Babu, C. S., *et al.* ..... (A) 98A

Mexico,

Erradicar la transmision de la lepra para 1994; politica para la accion en Mexico. Rodriguez-Dominguez, J., *et al.* ..... (A) 38A

Frequency of leprosy neuropathy in hyperendemic areas of Mexico and its correlation with clinical, epidemiological and structural findings. Valdez-Valenzuela, F., *et al.* ..... (A) 141A

La plan e action estrategica de mercadotecnia utilizada para erradicar la transmision de la lepra en Mexico. Barocio, A. and Castellanos, F. ..... (A) 48A

Plan para prevencion de incapacidades en Mexico. Rodriguez Dominguez, J., *et al.* ..... (A) 143A

Promocion para la salud en el programa contra la lepra en Mexico. Castellanos, F., *et al.* ..... (A) 168A

Strengthening of active case-finding strategies and clinical study of household leprosy contacts in Mexico. Garcia Flores, E., *et al.* ..... (A) 46A

Mice, murine,

A new pathogenicity model of leprosy: mutiliation of toes in mice experimentally infected with *M. leprae*/CAN bacteria. Chakrabarty, A. N., *et al.* ..... (A) 80A

A role for gamma interferon, tumor necrosis factor, and soluble T-cell receptors in the depressed blastogenic response of spleen cells of *M. lepra*emurium-infected mice. Richard, L., *et al.* ..... (A) 137

Acquisition of autoimmunity genes by New Zealand mice is associated with natural resistance to infection by mycobacteria. Esaguy, N., *et al.* ..... (A) 160

Activity of certain newer quinolone antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (A) 81A

Activity of clarithromycin against *M. avium* complex infection in beige mice. Klemens, S. P., *et al.* ..... (A) 166

Activity of combinations of effective antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (A) 81A

Activity of macrolide antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (A) 81A

Activity of phenazine analogs against *M. leprae* infections in mice. Van Landingham, R. M., *et al.* ..... (O) 406

Activity of rifapentine against *M. avium* infection in beige mice. Klemens, S. P. and Cynamon, M. H. ..... (A) 166

Antibodies against secreted and nonsecreted antigens in mice after infection with live *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 180
Bacillary persisters in murine leprosy. Chang, Y. T. ..... (A) 76A
Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ..... (A) 337
Capacity of *M. avium* isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Furney, S. K., *et al.* ..... (A) 132
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with *M. avium*. Lazard, T., *et al.* ..... (A) 663
Differential mechanism of intracellular killing of *M. avium* and *Listeria monocytogenes* by activated human and murine macrophages—the role of nitric oxide. Bermudez, L. E. ..... (A) 367
Evaluation of sodium stibogluconate and ureastibamine on mice experimentally infected with *M. leprae* from human leproma. Dastidar, S. G., *et al.* ..... (A) 80A
Evaluation of the activity of a number of antimicrobial agents against mycobacteria within mouse macrophages by a radiometric method. Banerjee, D. K. and Patel, B. R. ..... (A) 357
[Experience with the mouse foot pad technique to obtain *M. leprae*.] Suarez-Moreno, O. ..... (A) 146
Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of *M. tuberculosis* by human and murine T cells. Harris, D. P., *et al.* ..... (A) 661
IFN-gamma-producing ability as a possible marker for the protective T cells against *M. bovis* BCG in mice. Kawamura, I., *et al.* ..... (A) 165
In-vitro activity of streptomycin and clofazimine against established infections of *M. avium* complex in beige mice. Gangadharam, P. R. J. and Parikh, K. ..... (A) 371
Infection with *M. avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Bermudez, L. E. and Champsi, J. ..... (A) 659
[Influence of feeding on the multiplication of *M. leprae* in the mouse foot pad.] Wang, H. ..... (A) 146
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
Inhibition of growth of *M. avium* in murine and human mononuclear phagocytes by migration inhibitory factor. Orme, I. M., *et al.* ..... (A) 375
Long-term effects of dapsone on immune responses in BALB/c mice. Reddy, M. N. and Rao, P. R. ..... (A) 82A
[Monokine production by mouse peritoneal macrophages after phagocytosis of mycobacteria.] Fukutomi, Y., *et al.* ..... (A) 348
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H ..... (A) 310
Mouse vaccination against leprosy with *M. leprae* subunit vaccines are more effective than with whole sonicated *M. leprae*. Gelber, R. H., *et al.* ..... (A) 76A
Murine strain variation in *M. leprae*-infected Schwann cell functions and their modulation by macrophages. Birdi, T., *et al.* ..... (A) 77A
Mycobacterial growth and ultrastructure in mouse L-929 fibroblasts and bone marrow-derived macrophages—evidence that infected fibroblasts secrete mediators capable of modulating bacterial growth in macrophages. Rastogi, N., *et al.* ..... (A) 137
[Nude mouse foot pad model of leprosy infection.] Lu, X.-H., *et* al ..... (A) 145
On the potential of the SCID mouse as an animal model for leprosy. Converse, P. J., *et al.* ..... (A) 76A
Powerful bactericidal activity of sparfloxacin (AT-4140) against *M. tuberculosis* in mice. Lalande, V., *et al.* ..... (A) 374
Protection of mice by vaccination with purified and recombinant major *M. leprae* proteins and polypeptides. Gelber, R. H., *et al.* ..... (A) 103A
Reconstitution of *M. leprae* immunity in severe combined immunodeficient (SCID) mice. Azouaou, N., *et al.* ..... (A) 76A
Reconstitution of *M. leprae* immunity in severe combined immunodeficient mice using a T-cell line. Azouaou, N., *et al.* ..... (O) 398

Selection of resistant mutants of *M. avium* in beige mice by clarithromycin monotherapy. Ji, B.-H., *et al.* ..... (A) 164
Simulation of leprosy infection in mice. Yushin, M., *et al.* ..... (A) 80A
Sparfloxacin is more bactericidal than ofloxacin against *M. leprae* in mice. Franzblau, S. G., *et al.* ..... (O) 66
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU 40 555 treatment for disseminated *M. avium* complex infection of normal C57BL/6 mice. Perronne, C., *et al.* ..... (A) 172
Studies of macrophage traffic into the experimental lepromatous lesion of the *M. leprae*-infected nu/nu mouse foot pad. Krahenbuhl, J. L., *et al.* ..... (A) 78A
Studies on the activity of minocycline against *M. leprae* infected mice. Gelber, R. H., *et al.* ..... (A) 82A
Study of intracellular deposition of the anti-leprosy drug clofazimine in mouse spleen using laser microprobe mass analysis. Vandeputte, D., *et al.* ..... (A) 487
Study on nude mice inoculated with *M. leprae* by multiple routes. Wang, H., *et al.* ..... (A) 82A
Suppression of ADCC by immune complexes formed *in vitro* in *M. leprae*-infected mice. Vaishnavi, C., *et al.* ..... (A) 361
Susceptibility of severe combined immunodeficient (SCID) mice to *M. leprae*: multiplication of the bacillus and dissemination of the infection at an early stage. Yogi, Y., *et al.* ..... (A) 362
TNF-alpha-mediated tissue damage in mouse footpads primed with mycobacterial preparations. Al-Attouaj. R., *et al.* ..... (A) 129
Therapeutic efficacy of KRM-1648 in combination with other antimicrobials against *M. leprae* infection induced in mice. Tomioka, H., *et al.* ..... (A) 77A
Therapeutic efficacy of some new quinolones and a combination of ofloxacin and rifampin against *M. leprae* infection induced in athymic nude mice. Tomioka, H. and Saito, H. ..... (O) 250
Transmission of leprosy through thorn pricks in nude mice. Job, C. K., *et al.* ..... (A) 78A
UV-B irradiation of mice impairs the phagocytic ability of macrophages, decreases immunity to *M. lepra*emurium, and increases disease pathogenesis. Jeevan, A. and Kripke, M. L. ..... (A) 77A
Ultrastructural study of mouse dorsal root ganglion cultures infected long term with *M. leprae*. Shetty, V. P., *et al.* ..... (A) 138
Utility of beige mouse in leprosy research. Gangadharam, P. R. J. and Dhople, A. M. (A) 361
Utility of the beige mouse in chemotherapeutic studies in leprosy. Gangadharam, P. R. J. and Dhople, A. M. ..... (A) 80A

Mice, nude,
Bactericidal action at low doses of a new rifamycin derivative, 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ..... (A) 337
[Intraocular experimental infection with *M. leprae* in nude rats.] Shi, Z.-R., *et al.* ..... (A) 145
[Nude mouse foot pad model of leprosy infection.] Lu, X.-H., *et al* ..... *(A)* *145*
Study on nude mice inoculated with M. leprae by multiple routes. Wang, H., *et al.* ..... (A) 82A
Therapeutic efficacy of some new quinolones and a combination of ofloxacin and rifampin against *M. leprae* infection induced in athymic nude mice. Tomioka, H. and Saito, H. ..... (O) 250
Transmission of leprosy through thorn pricks in nude mice. Job, C. K., *et al.* ..... (A) 78A

Microbiology,
D. B. Young new Professor of Medical Microbiology. Rees, R. J. W. ..... (N) 333
4th Congress of Microbiology and Parasitology and 1st Congress of Tropical Medicine. ..... (N) 327
Polymerase chain reaction to detect *M. tuberculosis* in a clinical microbiology laboratory. Veringa, E., *et al.* ..... (A) 180

Microscopy,
Electron microscopy, polymerase chain reaction and serodiagnosis as tools for assessing leprosy treatment. Nasr, E. M., *et al.* ..... (A) 17A
Evaluation of polymerase chain reactions, tuberculostearic acid analysis, and direct microscopy for the detection of *M. tuberculosis* in sputum. Savic, B., *et al.* ..... (A) 176

Minocycline,
Activities of WIN-57272, minocycline, clarithromycin, and 14 hydroxy-clarithromycin against *M. avium* complex in human macrophages. Cohen, Y., *et al.* ..... (A) 156
Activity of minocycline and aminoglycosides for *M. leprae*. Gelber, R. H. ..... (A) 314
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with *M. avium*. Lazard, T., *et al.* ..... (A) 663
Clinical trials of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 7A
Minocycline and rifampin in leprosy. Romero, R. C. ..... (A) 8A
Minocycline in lepromatous leprosy. Fajardo, T., Jr., *et al.* ..... (A) 9A
Minocycline in the treatment of lepromatous leprosy—pilot studies of possible regimens. Waters, M. F. R. ..... (A) 18A
Powerful bactericidal activities of clarithromycin and minocycline against *M. leprae* in lepromatous leprosy. Ji, B. H., *et al.* ..... (A) 647
Studies on the activity of minocycline against *M. leprae* infected mice. Gelber, R. H., *et al.* ..... (A) 82A

Mitsuda reaction,
Histological analysis of the Mitsuda reaction in contacts of multibacillary leprosy patients. Trindade, M. A. B. and Fleury, R. N. ..... (C) 109

Molecular biology,
A molecular analysis of mycobacterial antigens which stimulate gamma/delta T cells. Sanchez-Garcia, J., *et al.* ..... (A) 106A
Applications of molecular methods to epidemiology of tuberculosis. Crawford, J. T. ..... (A) 494
Expression of adhesion molecules in leprosy lesions. Sullivan, L., *et al.* ..... (A) 138
Lack of expression of intercellular adhesion molecule ICAM-1 in lepromatous leprosy patients. Moncada, B., *et al.* ..... (O) 581
Lipoarabinomannan (LAM)—a possible immunoregulatory molecule of *M. leprae*-infected Schwann cells? Mistry, N., *et al.* ..... (A) 100A
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. ..... (A) 359
Molecular biology. Cole, S. ..... (A) 317
Molecular characterization of rifampin resistance in pathogenic mycobacteria. Williams, D. L. and Gillis, T. P. ..... (A) 108A
Molecular cloning and characterization of *M. paratuberculosis* promoters in *Escherichia coli*. Thomas, T. J., *et al.* ..... (A) 179
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* ..... (O) 227
Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ..... (A) 168
Mycobacterial heat-shock proteins as carrier molecules. Lussow, A. R., *et al.* ..... (A) 135
Structural features of lipoarabinomannan from *M. bovis* BCG; determination of molecular mass by lase desorption mass spectrometry. Venisse, A., *et al.* ..... (A) 669
Thalidomide does not affect selected immunomodulating surface receptor molecules on cells with immune potential. Shannon, E. J., *et al.* ..... (A) 105A

Monkey(s),
Detection of IgA anti-PGL-I in mangabey monkey inoculated with *M. leprae*. Saad, M. H. F., *et al.* ..... (A) 80A
Early clinical and pathological results of *M. leprae* challenge of monkeys after attempted protective immunization with live BCG or BCG + heat-killed *M. leprae*. Xu, K., *et al.* ..... (A) 79A
Early immunological results of experimental *M. leprae* challenge of monkeys after attempted immunization with live BCG or BCG + heat-killed *M. leprae*. Gormus, B. J., *et al.* ..... (A) 75A
Leprosy in Philippine cynomolgus monkeys (*Macaca fasicularis*). dela Cruz, E. C., *et al.* ..... (A) 75A
Serologic responses to nerve antigens in sooty mangabey monkeys with experimental leprosy. Cho, S.-N., *et al.* ..... (O) 236

Monocyte(s),
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*—effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159
Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with *M. leprae* and *M. bovis* BCG. Suzuki, K., *et al.* ..... (O) 609
Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. SivaSai, K. S. R., *et al.* ..... (O) 259
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium-M. intracellulare* complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ..... (A) 168
M. avium-M. intracellulare binds to the integrin receptor alpha(v)beta3 on human monocytes and monocyte-derived macrophages. Rao, S. P., *et al.* ..... (A) 376
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ..... (A) 95A
Modulation of monocytes/macrophages of leprosy patients by tuftsin for biochemical and immunogenic functions. Khare, S., *et al.* ..... (A) 96A
Responses of cytokine-treated human monocyte-derived macrophages to challenge with *M. leprae*. Adams, L. B. and Krahenbuhl, J. L. ..... (A) 102A
Suppression of human monocyte cytokine release by PGL-I of *M. leprae*. Silva, C. L., *et al.* ..... (A) 92A
Suppression of human monocyte cytokine release by phenolic glycolipid-I of *M. leprae*. Silva, C. L., *et al.* ..... (C) 107
TNF-alpha response to human monocyte-derived macrophages to *M. avium*, serovar 4, is a brief duration and protein kinase C dependent. Gan, H., *et al.* ..... (A) 494

Morbidity,
Study of psychiatric morbidity in Hansen's disease at a rehabilitation center. Sagar Reddy, V. V., *et al.* ..... (A) 137A

Morphology,
A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemoautotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* ..... (A) 112A
Significance of cellular morphology of Mitsuda lepromin response. Desikan, V. K. and Girdhar, B. K. ..... (A) 125A

Morphological index (MI),
Clinical assessment, BI, MI, relapse rate. Waters, M. F. R. ..... (A) 311

Multidrug therapy (MDT),
A morphological study of nerve biopsies from cases of multibacillary leprosy given multidrug therapy. Jacobs, J. M., *et al.* ..... (A) 489
A study to assess social disability and economic loss to leprosy patients on MDT in north India—preliminary study. Palla, J., *et al.* ..... (A) 127A
Accelerated program for MDT implementation. Casabianca, M. N. and Walter, C. S. (A) 52A
An analysis of the incidence of leprosy for leprosy contacts after MDT in Liangshan and Panzhihua Prefectures, Sichuan Province. Wu, X. and Ning, Y. ..... (A) 69A
An observation on the effect of MDT in the treatment of 1095 leprosy patients in Shaanxi Province, China. Deng, Y., *et al.* ..... (A) 9A
Analyses of logistic regression for 593 MB cases with WHO MDT or modified MDT in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 68A
Analyses of treatment time for leprosy cases cured with DDS and MDT in Yangzhou Prefecture, China. Yang, Z.-M., *et al.* ..... (A) 10A
Application of control theory in the management of MDT. Ren, X. and Ding, J. ..... (A) 51A
Assessing the viability of *M. leprae* on 28 cases on MDT by the FDA/EB staining technique. Liu, G. and Shong, B. ..... (A) 111A
Bacteriological response of BL/LL patients to MDT for varied duration: a retrospective five-year follow up. Bhatki, W. and Pade, S. ..... (A) 3A
Brodimoprim-DDS and brodimporim-DDS/rifampin; *in vitro* and in vivo results for a newly developed effective MDT against leprosy. Seydel, J. K., *et al.* ..... (A) 7A

Clinical study of lepra reactions in 123 cases treated by MDT. Mohareb, R. W. .....(A) 24A
Clinical, electrophysiological and bacteriological evaluation of nerve damage after regular MDT in leprosy. Antia, N., *et al.* .....(A) 22A
Contribution of MDT to the prevention of eye disease in leprosy; results from a cross-sectional survey in the People's Republic of China. Courtright, P., *et al.* .....(A) 118A
Costing of leprosy control programs before and after introduction of MDT. Daniel, J. and Walter, C. S. .....(A) 43A
Deformity care clinics—a new approach to integrate care after cure concept in routine MDT program. Dave, P. V., *et al.* .....(A) 51A
Disability grading of patients in a MDT program—comparison with a similar group treated with dapsone alone and five year follow up. Duerksen, F., *et al.* .....(A) 4A
Drug support to the use of multidrug therapy (WHO) in Brazil between 1986 and 1992. Rodrigues, A. L., *et al.* .....(A) 43A
Effect and surveillance of 1076 leprosy patients treated with MDT in Shandong Province of China. Yu, X., *et al.* .....(A) 2A
Effect of HIV infection on clinical response of leprosy patients to multidrug therapy in Kenya. Orege, P. A., *et al.* .....(A) 36A
[Effect of MDT on MB leprosy over 27 months and follow up of 56 months thereafter.] Zhang, S., *et* al .....(A) 340
Effect of multidrug therapy on plasma level of high density lipoprotein cholesterol (HDL-C) in patients of lepromatous leprosy. Kumar, N. and Sharma, B. L. .....(A) 33A
Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore. Lim, J. T.-E. and Tan, T. .....(A) 648
Eight-year follow up of multibacillary leprosy after 24-27 months of multidrug therapy. Li, H.-Y., *et al.* .....(A) 5A
Epidemic situation of leprosy after MDT implementation and prediction of basic eradication in Yangzhou Prefecture. Jiang, C., *et al.* .....(A) 64A
Epidemiological impact of multidrug therapy of leprosy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* .....(A) 49A
Evaluation of MDT implementation for leprosy control in Bendel State of Nigeria (1985-1990). Majoroh, T. O. .....(A) 42A
[Evaluation of MDT retreatment in 13, 477 leprosy patients cured by DDS.] Xie, Z. and Ding, J. .....(A) 487
Extensive progressive new lesions in a BT case while on regular MB-MDT. Kiran, K. U. .....(A) 22A
Factor influencing patient's compliance to MDT/WHO in Rio de Janeiro. Moreira, T. A., *et al.* .....(A) 11A
Factors associated with rate of healing in paucibacillary leprosy treated with MDT. Kumar, R., *et al.* .....(A) 3A
Five years' experience of MDT in Amritsar (Punjab). Bharti, R., *et al.* .....(A) 9A
Fixed duration MDT in paucibacillary leprosy (classical and modified). Nadkarni, N. J., *et al.* .....(O) 25
Fixed duration multidrug therapy (FDT) for multibacillary (MB) leprosy in Indian rural pograms. Ganapati, R., *et al.* .....(A) 3A
Fixed-duration MDT in multibacillary patients; two years of surveillance. Nery, J. A. C., *et al.* .....(A) 12A
Follow-up study of 81 leprosy cases treated by short-term MDT in Turkey. Sutlas, M., *et al.* .....(A) 5A
Histopathological analyses of lepromin tests performed at BCG ized and nonBCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* .....(A) 121A
Histopathological analysis of specimens of BCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* .....(A) 121A
Immunotherapy with *Mycobacterium w* vaccine in MB leprosy patients showing slow responses to MDT. Ramesh, V., *et al.* .....(A) 18A
Impact of MDT on disability profile: CULES experience in an urban cumrural project. Abraham, T., *et al.* .....(A) 156A
Impact of multidrug therapy on field workers in leprosy and their future prospects. Kharkar, R. D., *et al.* .....(A) 57A

Impact of the implementatin of MDT/WHO on the control of Hansen's disease in Brazil in the period 1986-1992. Penna, G. O., *et al.* (A) 53A
Implementation of MDT in a low-endemic region; an operational strategy. Kandaswami, V. (A) 57A
Implementation of multidrug therapy in projects sponsored by ILEP members 1984-1991. Martineau-Needham, D. and Lacey, S. (A) 43
In-factory MDT. Nascimento, M. L. P., *et al.* (A) 136A
Influence of MDT on the incidence of disabilities in Hansen's disease. Chen, Z., *et al.* (A) 144A
Influence of multidrug therapy on smear-positive cases in Taluka Panvel. Chongate, P. N., *et al.* (A) 55A
Integration of care of the highly disabled in MDT program—a field experiment on rehabiliation in districts hyperendemic for leprosy. Ganapati, R., *et al.* (A) 141A
Lack of response to WHO/MDT; a case report. Habtemariam, H. and Guebre-Xabier, M. (C) 632
Late reversal reaction in paucibacillary patients after MDT—its incidence rate, time of onset, modes or presentation. Ananth Reddy, S., *et al.* (A) 25A
Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Cartel, J.-L., *et al.* (A) 147
Life after MDT. Faria, E. (A) 138A
M. leprae viability in skin and nerve after MDT and their sensitivity to antileprosy drugs. Shetty, V., *et al.* (A) 4A
MDT for leprosy in 8 francophone countries of West Africa: 10 years' implementation (1982-1991). Tiendrebeogo, A. and Blanc, L. (A) 43A
MDT in Manaus: readmission after release from treatment. Ribas, C. B. R., *et al.* (A) 11A
MDT in remote areas of Acre State. Woods, W. J., *et al.* (A) 57A
Measuring epidemiological impact of multidrug therapy in leprosy control area. Rao, P. S. S., *et al.* (A) 64A
Multidrug therapy for treatment of leprosy patients in New Caledonia and French Polynesia; results after 10 years. Crouzat, M., *et al.* (A) 2A
Multidrug therapy in the state of Amazonas, 1982-1992. Cunha, M. G. S., *et al.* (A) 53A
Multidrug therapy of multibacillary leprosy patients—a 10 year follow-up study. Jayakumar, J., *et al.* (A) 12A
Multidrug therapy versus dapsone monotherapy in leprosy: an international randomized study with long-term follow up. Dietrich, M., *et al.* (A) 305
Observation of 328 MB cases treated with MDT and follow-up study. Miao, Z., *et* al (A) 9A
Observation of 607 patients of multibacillary leprosy under surveillance of three years after completion of multidrug therapy. Hu, L., *et al.* (A) 10A
On the cost-effectiveness of MDT for leprosy. Zhang, H., *et al.* (A) 52A
Patients' compliance and drug trials: an analysis of efficiency of monotherapy and multidrug therapy (MDT) treatment. Saravanabavan, V. and Shanmuganandan, S. (A) 54A
Pre- and post-histopathological evaluation of 50 leprosy patients under multidrug therapy. Desai, S. D. (A) 124A
Pregnancy is a risk factor for relapse and new nerve damage even after MDT. Duncan, M. E., *et al.* (A) 21A
Preliminary results of the evaluation of a surveillance system of side effects of MDT. Brasil, M. T. L. R. F., *et al.* (A) 4A
Progress in leprosy control through multidrug therapy. (A) 339
Projection of demand for leprosy services in India after WHO MDT. Almeida, J. (A) 44A
Quiet nerve paralysis assessment with respect to MDT and corticosteroid therapy. Gupte, M. D., *et al.* (A) 147A
Results of MDT implementation in the Mile Four Leprosy Control Project, Abakaliki, Enugu State, Nigeria. MacRae, M. A. and Vennemann, M. (A) 53A
Results of skin smears from 84 multibacillary patients on MDT MB regimen recommended by WHO. Cheng, Z. Q., *et al.* (A) 10A
Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w.* Sharma, A. K., *et al.* (A) 24A
Risk of neuritis among multibacillary patients during multidrug therapy. Rajan Babu, G. (A) 20A

Sample survey of leprosy after 3 years of MDT in Bhavani Taluk of Periyar District, Tamil Nadu, South India. Shanker Narayan, N. P., *et al.* ....(A) 42
Seven-year surveillance of 657 cured MB patients retreated with MDT. Zhou, D., *et al.* (A) 2A
Study of 315 multibacillary cases of leprosy under MDT at JNRMH, Tala, Rizal, The Philippines. Samson, R. C. and Dayunghirang, J. ....(A) 10A
Study of field trials of combined chemotherapy and fixed duration combined chemotherapy in multibacillary leprosy in MDT project, Bharuch District, Gujarat, India. Chopra, N. K. ....(A) 49A
Study of leprosy in children in multidrug therapy in Bharuch District, Gujarat, India. Chopra, N. K., *et al.* ....(A) 69A
Study of relapse in paucibacillary leprosy patients in multidrug therapy project in Bharuch District, Gujarat, India. Chopra, N. K. ....(A) 6A
Ten years of multidrug therapy in Zimbabwe. Mudarikwa, L. C. and ten Ham, P. B. G. (A) 44A
Ten-year cohort analysis of multibacillary leprosy patients who received multidrug therapy. Ramakrishnan, R., *et al.* ....(A) 53A
Ten-year cohort analysis of paucibacillary leprosy patients who received multidrug therapy. Thirunavakarasu, S., *et al.* ....(A) 11A
The National Leprosy Control Program of Bhutan: factors in a successful MDT program. Jakeman, P. ....(A) 52A
The Philippines' Manual of Training; MDT for Leprosy available. ....(N) 118
The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. van Brakel, W. H., *et al.* ....(A) 128
The effect of ofloxacin to MDT resistance—a case report. Ishida, Y. and Mizushima, M. ....(A) 169A
The epidemiological impact of MDT on leprosy in Guangdong Province. Chen, J. and Liang, Z. ....(A) 42A
The impact of multidrug therapy on epidemiological trends of leprosy in Guizhou, China. Li, Q. and Liu, G. C. ....(A) 52A
The slit-skin smear in leprosy—an impediment to MDT? de Soldenhoff, R. ....(A) 12A
[Therapeutic effect analysis of 2900 leprosy patients cured by MDT.] Xie, Z., *et al.* ...(A) 487
Treatment of paucibacillary patients with MDT containing rifampin, dapsone and prothionamide. Katoch, K., *et al.* ....(A) 2A
Trend of leprosy in multidrug therapy area of Myanmar. Kyaw Tin and Hla-Htut-Lwin. ....(A) 42A
Trends in prevalence and other rates during a decade of multidrug therapy in Bhutan. Jakeman, P., *et al.* ....(A) 42A
Trends of leprosy during the MDT era. Vijayakumaran, P., *et al.* ....(A) 69A

Muscle(s),

A long-term observation on the effect of tendon transplant of the posterior tibial muscle in the correction of foot drop of leprosy. Jiang, Z. and Ling, X. ....(A) 148A
Comparative study of a herbal oil preparation with an oil massage with plain exercises in wasting of muscles. Dutta, R. N. and Dutta, S. ....(A) 156A
Denatured muscle autografts in peripheral nerve repair in a model of leprosy. de Blaquiere, G., *et al.* ....(A) 79A
Denatured muscle autografts in peripheral nerve repair. 1. Surgical technique. Pereira, J. H., *et al.* ....(A) 150A
Denatured muscle autografts in peripheral nerve repair. 2. Results on leprosy patients. Pereira, J. H., *et al.* ....(A) 150A
Myokymia in leprosy patients. Kaur, S. and Dhar, S. ....(C) 473
Paralysis of facial muscles in lagophthalmos. Lubbers, W. J., *et al.* ....(A) 20A
Reliability of manual muscle strength testing in the evaluation of peripheral nerve dysfunction in leprosy patients. Brandsma, J. W., *et al.* ....(A) 145A
Replacement of the main sensory nerves of hands and feet in leprosy patients with freeze-thawed muscle as graft material. Kazen, R., *et al.* ....(A) 150A

Myanmar (Burma),

A comparative KAP study of leprosy patients and members of the community in Hlaing and Laung-Lon Townships [Myanmar (Burma)]. Myint, T., *et al.* ....(A) 126

Estimation of leprosy prevalence in Bago and Kawa Townships [in Myanmar] using 2-stage probability proportionate to size sampling technique. Myint, T., *et al.* .....(A) 501
Trend of leprosy in multidrug therapy area of Myanmar. Kyaw Tin and Hla-Htut-Lwin .....(A) 42A

Mycobacteria (see also individual species),
A simple and rapid method for the detection and identification of mycobacteria using mycobactin. Barclay, R., *et al.* .....(A) 141
A simple and reliable EDDA method for mycobactin production in mycobacteria—optimal conditions and use in mycobacterial speciation. Bosne, S., *et al.* .....(A) 502
Acquisition of autoimmunity genes by New Zealand mice is associated with natural resistance to infection by mycobacteria. Esaguy, N., *et al.* .....(A) 160
Activities of clarithromycin against 8 slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Brown, B. A., *et al.* .....(A) 154
Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor. Mendez-Samperio, P. .....(A) 654
Assessment of mycobacterial infection and multiplication in macrophages of polymerase chain reaction. Barrera, L. F., *et al.* .....(A) 367
Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes—demonstration of voltage gating and of negative point charges at the channel mouth. Trias, J. Q. and Benz, R. .....(A) 498
Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* .....(O) 44
Cloning of mycobacterial histidine synthesis genes by complementation of a *M. smegmatis* auxotroph. Hinshelwood, S. and Stoker, N. G. .....(A) 163
Comparison of techniques for antimicrobial susceptibility testing of mycobacteria. Limb, D. I., *et al.* .....(A) 663
Computer-assisted pattern recognition model for the identification of slowly growing mycobacteria including *M. tuberculosis.* Plikaytis, B. D., *et al.* .....(A) 173
Correlation between inhibitory effect of quinolones and mycolic acid metabolism in mycobacteria. Patil, M. A., *et al.* .....(A) 143
Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Freerksen, E. and Seydel, J. K. .....(A) 122
Detection of 16S rRNA for viability assessment of mycobacteria. Schepers, P., *et al.* ..(A) 111A
Detection of 2-eicosanol by gas chromatography-mass spectrometry in sputa from patients with pulmonary mycobacterial infections. Alugupalli, S., *et al.* .....(A) 658
Detection of 65-kDa heat-shock protein from sera of leprosy patients—mycobacterial or autoantigen origin. Elangeswaran, N., *et al.* .....(A) 90A
Detection of mycobacteria in tissue by polymerase chain reaction. Gerdes, J., *et al.* ...(A) 309
Determination of the adenylate energy charge (AEC). Haas, M. .....(A) 107A
Determination of the adenylate energy charge (AEC). Haas, M. .....(A) 308
DNA sequence, structure and gene expression of mycobacteriophage-L5—a phage system for mycobacterial genetics. Hatfull, G. F. and Sarkis, G. J. .....(A) 358
Effect of electrochemically activated liquids on mycobacterial viability. Irtuganova, O. and Yushin, M. .....(A) 111A
Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Rastogi, N. and Goh, K. S. .....(A) 124
Evaluation of nonradioactive DNA probes for identification of mycobacteria. Lebrun, L., *et al.* .....(A) 167
Evaluation of the Septi-Chek AFB system in the recovery of mycobacteria. Whittier, P. S., *et al.* .....(A) 181
Evaluation of the activity of a number of antimicrobial agents against mycobacteria within mouse macrophages by a radiometric method. Banerjee, D. K. and Patel, B. R. .....(A) 357
Genus-specific polymerase chain reaction for the mycobacterial dnaJ gene and species-specific oligonucleotide probes. Takewaki, S., *et al.* .....(A) 377
Homologs of *M. leprae* 18-kilodalton and *M. tuberculosis* 19 kilodalton antigens in other mycobacteria. Booth, R. J., *et al.* .....(A) 493

Human T-cell clones recognize mycobacterial specific and shared epitopes on *M. leprae* 70-kDa protein. Adams, E., *et al.* ..... (A) 104A
Immunoreactivity of mycobacterial strain ICRC and *M. leprae* antigens with polyclonal and monoclonal antibodies. Chiplunkar, S. V., *et al.* ..... (O) 421
In leprosy the presence of mycobacteria in the nerve is an essential factor in the cycle and spectrum of *M. leprae* infection. Negesse, Y., *et al.* ..... (A) 654
In vitro antimicrobial susceptibility testing of rapid growing mycobacteria using the tablet diffusion method—resistance pattern of Norwegian *M. fortuitum* and *M. chelonae* isolates. Hoel, T., *et al.* ..... (A) 506
Inhibition of mycobacterial growth by hydrazones. Schaper, K. J., *et al.* ..... (A) 312
Isolation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunized with living mycobacteria. Romain, F., *et al.* (A) 490
Killing of mycobacteria-infected macrophages by LAK cells from leprosy patients. Chiplunkar, S., *et al.* ..... (A) 96A
Labeling of the 65-kDa heat-shock protein in *M. leprae* and other mycobacterial species. Esaguy, N. ..... (A) 110A
Lactoferrin triggers *in vitro* proliferation of T cells of Lewis rats submitted to mycobacteria-induced adjuvant arthritis. Esaguy, N., *et al.* ..... (A) 652
Leprosy and the case of King Baldwin IV of Jerusalem: mycobacterial disease in the Crusader States of the 12th and 13th centuries. Mitchell, P. D. ..... (E) 283
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Molecular characterization of rifampin resistance in pathogenic mycobacteria. Williams, D. L. and Gillis, T. P. ..... (A) 108A
[Monokine production by mouse peritoneal macrophages after phagocytosis of mycobacteria.] Fukutomi, Y., *et al.* ..... (A) 348
Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ..... (A) 169
Mycobacterial growth and ultrastructure in mouse L-929 fibroblasts and bone marrow-derived macrophages—evidence that infected fibroblasts secrete mediators capable of modulating bacterial growth in macrophages. Rastogi, N., *et al.* ..... (A) 137
Mycobacterial model strains in drug screening. Visser, K. and Seydel, J. K. ..... (A) 306
Mycobacteriosis is due to *M. genavense* in six pet birds. Hoop, R. K., *et al.* ..... (A) 373
Penetration of dapsone, rifampin and clofazimine into macrophages and mycobacteria. Mathur, A., *et al.* ..... (A) 81A
Porins in the cell wall of mycobacterial. Trias, J., *et al.* ..... (A) 144
Problems in detection of secretory antigens of intracellular mycobacteria in macrophage and Schwann cell tissue culture. Mistry, N., *et al.* ..... (A) 87A
Purification of a mycobacterial adhesin for fibronectin. Ratliff, T. L., *et al.* ..... (A) 497
Rapid detection of tuberculous and non-tuberculous mycobacteria by polymerase chain reaction amplification of a 162 bp DNA fragment from antigen-85. Fauvilledufaux, M., *et al.* ..... (A) 161
Rapid identification of mycobacteria to the species level of polymerase chain reaction and restriction enzyme analysis. Telenti, A., *et al.* ..... (A) 377
Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Meylan, P. R. A., *et al.* ..... (A) 169
Regulation of interleukin-1-beta (IL-1-beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs. Zhang, Y. and Rom, W. N. ..... (A) 671
Routine application of high-performance liquid chromatography for identification of mycobacteria. Thibert, L. and Lapierre, S. ..... (A) 669
Seals, seal trainers, and mycobacterial infection. Thompson, P. J., *et al.* ..... (A) 378
Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: ELISA. De Lange, W. E., *et al.* ..... (A) 100A
Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: skin tests. Mous, H. V. H., *et al.* ..... (A) 100A
Serological response of leprosy patients to *M. leprae* specific and mycobacteria specific antigens: possibility of using these assays in combinations. Sekar, B., *et al.* ..... (A) 353

Similarity between mycobacterial and human epidermal antigens. Vandenakker, T. H. W., *et al.* ..... (A) 139
Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. Birnbaum, G., *et al.* ..... (A) 659
Stable integration and expression of *Plasmodium falciparum* circumsporozoite protein coding sequence in mycobacteria. Haeseleer, F., *et al.* ..... (A) 372
Structure of a novel sulfate containing mycobacterial glycolipid. Marin, L. M. L., *et al.* (A) 168
Superinfection immunity of mycobacteriophage-L5—applications for genetic transformation of mycobacteria. Donelly-Wu, M. K., *et al.* ..... (A) 358
TNF-alpha-mediated tissue damage in mouse footpads primed with mycobacterial preparations. Al-Attouaj. R., *et al.* ..... (A) 129
The abnormal structure of mycobacterial recA genes. Davis, E. O., *et al.* ..... (A) 115A
Toward developing a new scheme for rapid characterization of mycobacteria with special reference to *M. leprae*. Sharma, V. D., *et al.* ..... (A) 113A
[Use of enzyme immunoassay and immunoblotting for the serological characterization of mycobacterial antigens.] Vorobyev, A. A., *et al.* ..... (A) 181
[Use of highly dispersed ferroparticles for raising sensitivity of the luminescence microscopic method to determine tuberculosis mycobacteria.] Polozov, A. I., *et al.* ..... (A) 173

Mycobacterium alvei,
M. alvei sp. nov. Ausina, V., *et al.* ..... (A) 152

Mycobacterium aurum,
Isolation and characterization of isoniazid-resistant mutants of *M. smegmatis* and *M. aurum*. Heym, B. and Cole, S. T. ..... (A) 163
Partial physical and functional map of a *M. aurum* carotenogenesis operon. Houssaini-Iraqui, M., *et al.* ..... (A) 373

Mycobacterium avium,
Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against *M. avium*. Barrow, W. W., *et al.* ..... (A) 484
Activity of rifapentine against *M. avium* infection in beige mice. Klemens, S. P. and Cynamon, M. H. ..... (A) 166
Anti-*M. avium* activity of quinolones: *in vitro* activities. Klopman, G., *et al.* ..... (A) 662
Capacity of *M. avium* isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Furney, S. K., *et al.* ..... (A) 132
Clarithromycin and other antimicrobial agents in the treatment of disseminated *M. avium* infections in patients with acquired immunodeficiency syndrome. Dautzenberg, B., *et al.* ..... (A) 369
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with *M. avium*. Lazard, T., *et al.* ..... (A) 663
Cloning and sequencing of the gene for alpha-antigen from *M. avium* and mapping of B-cell epitopes. Ohara, N., *et al.* ..... (A) 496
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*—effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 159
Comparative effects of *M. avium* glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells. Pourshafie, M., *et al.* ..... (A) 667
Comparison of the abilities of *M. avium* and *M. intracellulare* to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Crowle, A. J., *et al.* ..... (A) 157
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Diagnosis of *M. avium* bacteremia by polymerase chain reaction. Iralu, J. V., *et al.* ..... (A) 662
Differential mechanism of intracellular killing of *M. avium* and *Listeria monocytogenes* by activated human and murine macrophages—the role of nitric oxide. Bermudez, L. E. ..... (A) 367
Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of *M. avium*. Belisle, J. T., *et al.* ..... (A) 493

Genetic diversity among strains of *M. avium* causing monoclonal and polyclonal bacteremia in patiens with AIDS. Arbeit, R. F., *et al.* ..... (A) 658
Infection with *M. avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Bermudez, L. E. and Champsi, J. ..... (A) 659
Inhibition of growth of *M. avium* in murine and human mononuclear phagocytes by migration inhibitory factor. Orme, I. M., *et al.* ..... (A) 375
MICs and MBCs of clarithromycin against *M. avium* within human macrophages. Mor, N. and Heifets, L. ..... (A) 375
Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ..... (A) 169
Polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp *silvaticum* in long term cultures from Crohn's disease. Moss, M. T., *et al.* ..... (A) 170
Rifabutin and the *M. avium* complex. Kemper, C. A. ..... (A) 165
Rough morphological variants of *M. avium*; characterization of genomic deletions resulting in the loss of glycopeptidolipid expression. Belisle, J. T., *et al.* ..... (A) 492
Selection of resistant mutants of *M. avium* in beige mice by clarithromycin monotherapy. Ji, B.-H., *et al.* ..... (A) 164
Synthesis of species-specific *M. avium* trisaccharide (serovar 21) for the preparation of a neoglycoprotein for immunological studies. Ziegler, T. ..... (A) 183
TNF-alpha response to human monocyte-derived macrophages to *M. avium*, serovar 4, is a brief duration and protein kinase C dependent. Gan, H., *et al.* ..... (A) 494
Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental *M. avium* infections induced in rabbits. Emori, M., *et al.* ..... (A) 503

***Mycobacterium avium* complex,**
Activities of WIN-57272, minocycline, clarithromycin, and 14 hydroxy-clarithromycin against *M. avium* complex in human macrophages. Cohen, Y., *et al.* ..... (A) 156
Activity of clarithromycin against *M. avium* complex infection in beige mice. Klemens, S. P., *et al.* ..... (A) 166
Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of *M. avium* complex in rats treated with cyclosporine. Brown, S. T., *et al.* ..... (A) 367
Effectiveness of the macrolide clarithromycin in the treatment of *M. avium* complex infection in HIV-infected patients. Ruf, B., *et al.* ..... (A) 175
Evaluation of the use of 5-mycoloyl-beta-arabinofuranosyl-(1 2)-5-mycoloyl-alpha-arabinof uranosyl-(1-1')-glycerol in serodiangosis of *M. avium*-intracellulare complex infection. Honda, I., *et al.* ..... (A) 506
Identification of *M. avium* complex strains and some similar species by high-performance liquid chromatography. Butler, W. R., *et al.* ..... (A) 154
Identification of *M. tuberculosis* and *M. avium-intracellulare* directly from primary BACTEC cultures by using acridinium ester-labeled DNA probes. Evans, K. D., *et al.* ..... (A) 160
Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated *M. avium* complex. Gascon, P., *et al.* ..... (A) 371
In vitro antimicrobial activity of benzoxazinorifamycin, KRM 1648, against *M. avium* complex, determined by the radiometric method. Tomioka, H., *et al.* ..... (A) 345
In-vitro activity of streptomycin and clofazimine against established infections of *M. avium* complex in beige mice. Gangadharam, P. R. J. and Parikh, K. ..... (A) 371
Resistance to nitric oxide in *M. avium* complex and its implication in pathogenesis. Doi, T., *et al.* ..... (A) 503
Rifabutin and the *M. avium* complex. Kemper, C. A. ..... (A) 165
Sequence-based differentiation of strains in the *M. avium* complex. Frothingham, R. and Wilson, K. H. ..... (A) 504
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated *M. avium* complex infection of normal C57BL/6 mice. Perronne, C., *et al.* (A) 172
The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of *M. avium* intracellulare. Kent, R. J., *et al.* ..... (A) 165

Mycobacterium bovis (see also **BCG**),
Characterisation of a novel repetitive DNA sequence from *M. bovis*. Doran, T. J., *et al.* ..... (A) 159

Cloning and sequence analysis of the gene encoding an NADP dependent alcohol dehydrogenase in *M. bovis* BCG. Stelandre, M., *et al.* ..... (A) 177
DNA fingerprinting of *M. bovis* strains by restriction fragment analysis and hybidization with insertion elements IS1081 and IS6110. Collins, D. M., *et al.* ..... (A) 502
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with *M. leprae* and *M. bovis* BCG. Suzuki, K., *et al.* ..... (O) 609
Expression of *Escherichia coli* beta-galactosidase in *M. bovis* BCG using an expression system isolated from *M. paratuberculosis* which induced humoral and cellular immune responses. Murray, A., *et al.* ..... (A) 142
IFN-gamma-producing ability as a possible marker for the protective T cells against *M. bovis* BCG in mice. Kawamura, I., *et al.* ..... (A) 165
Immunoscintigraphy in the detection of tuberculosis with radiolabelled antibody fragment against *M. bovis* bacillus Calmette-Guerin—a preliminary study in a rabbit model. Lee, J. D., *et al.* ..... (A) 167
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live *M. bovis* BCG. Huygen, K., *et al.* ..... (A) 662
M. bovis in England and Wales—past, present and future. Hardie, R. M. and Watson, J. M. ..... (A) 163
Pulsed field gel electrophoresis of representatives of *M. tuberculosis* and *M. bovis* BCG strains. Varnerot, A., *et al.* ..... (A) 179
Rhinoceros' rhinorrhea—cause of an outbreak of infection due to airborne *M. bovis* in zookeepers. Dalovisio, J. R., *et al.* ..... (A) 157
Serological response in leprosy and tuberculosis patients to the 18-kDa antigen of *M. leprae* and antigen 85B of *M. bovis* BCG. Vikerfors, T., *et al.* ..... (O) 571
Structural features of lipoarabinomannan from *M. bovis* BCG; determination of molecular mass by laser desorption mass spectrometry. Venisse, A., *et al.* ..... (A) 669
T cell response to purified filtrate antegen 85 from *M. bovis* bacilli Calmette-Guerin (BCG) in leprosy patients. Launois, P., *et al.* ..... (A) 134
The major secreted antigen complex (Ag-85) from *M. bovis* bacille Calmette-Guerin is associated with protective T cells in leprosy—a follow-up study of 45 household contacts. Launois, P., *et al.* ..... (A) 495

Mycobacterium chelonae,

Combination drug testing of *M. chelonae*. Matoba, A. Y., *et al.* ..... (A) 665
In vitro antimicrobial susceptibility testing of rapid growing mycobacteria using the tablet diffusion method—resistance pattern of Norwegian *M. fortuitum* and *M. chelonae* isolates. Hoel, T., *et al.* ..... (A) 506
Physical organization of lipids in the cell wall of *M. chelonae*. Nikaido, H., *et al.* ..... (A) 665

Mycobacterium fortuitum,

Antigenic glycolipids of *M. fortuitum* based on trehalose acylated with 2-methyloctadec-2-enoic acid. Hamid, M. E., *et al.* ..... (A) 495
In vitro antimicrobial susceptibility testing of rapid growing mycobacteria using the tablet diffusion method—resistance pattern of Norwegian *M. fortuitum* and *M. chelonae* isolates. Hoel, T., *et al.* ..... (A) 506
Structure of mycoside-F, a family of trehalose-containing glycolipids of *M. fortuitum*. Gautier, N., *et al.* ..... (A) 162

Mycobacterium genavense,

Mycobacteriosis due to *M. genavense* in six pet birds. Hoop, R. K., *et al.* ..... (A) 373

Mycobacterium habana,

Determination of subcellular location of the immunoprotective moieties in *M. habana*. Chaturvedi, V., *et al.* ..... (A) 88A
Immunochemical characterization of 32-kDa cytosolic protein of *M. habana*: a candidate vaccine. Sinha, S., *et al.* ..... (A) 91A
Major antigens of *M. habana* recognized by sera of patients with lepromatous leprosy. Vilchis, M., *et al.* ..... (A) 90A

The 65-kDa protein of *M. habana* and its putative role in immunity against *M. tuberculosis*. Singh, N. B. ..... (A) 83A

Mycobacterium haemophilum,

Biochemical properties and fatty acid composition of *M. haemophilum*–study of 16 isolates from Australian patients. Portaels, F., *et al.* ..... (A) 173

Mycobacterium intracellulare,

A comparison of the T-cell delayed-type hypersensitivity epitopes of the 19-kD antigens from *M. tuberculosis* and *M. intracellulare* using overlapping synthetic peptides. Mackall, J. C., *et al.* ..... (A) 664

Comparison of the abilities of *M. avium* and *M. intracellulare* to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Crowle, A. J., *et al.* ..... (A) 157

The catalase-peroxidase of *M. intracellulare*: nucleotide sequence analysis and expression in *Escherichia coli*. Morris, S. L., *et al.* ..... (A) 142

Mycobacterium kansasii,

In vitro susceptibility of *M. kansasii* to clarithromycin. Biehle, J. and Cavalieri, S. J. ..(A) 153

Susceptibility of *M. kansasii* to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Witzig, R. S. and Franzblau, S. G. ..... (A) 671

Mycobacterium leprae,

A 15-kDa antigen of *M. leprae* that is recognized by both humoral and cellular immune systems in leprosy patients. Sela, S., *et al.* ..... (A) 86A

A 25-kDa portion of the 65-kDa protein of *M. leprae* has immunoprotective properties. Mahadevan, P. R. and Kulkarni, A. ..... (A) 83A

A new pathogenicity model of leprosy: mutiliation of toes in mice experimentally infected with *M. leprae*/CAN bacteria. Chakrabarty, A. N., *et al.* ..... (A) 80A

A novel protein antigen secreted by *M. leprae*: the homolog of *M. tuberculosis* MPT32. Wieles, B., *et al.* ..... (A) 84A

A rapid *in vitro* microassay for the viability and drug sensitivity of *M. leprae*. Butcher, P. D., *et al.* ..... (A) 111A

A simple and rapid technique for the detection of rifampin resistance in *M. leprae*. Honore, N., *et al.* ..... (A) 108A

A simple and rapid technique for the detection of rifampin resistance in *M. leprae*. Honore, N., *et al.* ..... (O) 600

A simple colorimetric assay for detection of amplified *M. leprae* DNA. van der Vliet, G. M. E., *et al.* ..... (A) 498

A unique type of GABA binding by *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 143

Activity of certain newer quinolone antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (A) 81A

Activity of combinations of effective antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (A) 81A

Activity of macrolide antibiotics against *M. leprae*-infected mice. Gelber, R. H., *et al.* (A) 81A

Activity of minocycline and aminoglycosides for *M. leprae*. Gelber, R. H. ..... (A) 314

Activity of phenazine analogs against *M. leprae* infections in mice. Van Landingham, R. M., *et al.* ..... (O) 406

Activity of sparfloxacin against *M. leprae* measured by the proportional bactericidal test. McDermott-Lancaster, R. D. and Banerjee, D. K. ..... (O) 605

Adenosine triphosphate content of *M. leprae* by Percoll buoyant density centrifugation. Sharma, V. K., *et al.* ..... (A) 359

An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ..... (A) 90A

Analysis of B-cell epitopes on the variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein. Peake, P. W., *et al.* ..... (A) 352

Analysis of cytokine production by mycobacterium-reactive T cells—failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 489

Analysis of cytokine production by mycobacterium-reactive T cells: failure to explain *M. leprae*-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis, T., *et al.* ..... (A) 102A

Anti-peripheral nerve antibodies in leprosy patients recognize an epitope shared by the *M. leprae* 65 kDa heat shock protein. Launois, P., *et al.* ..... (A) 350
Antibody responses to various antigens of *M. leprae* in borderline leprosy with or in reaction. Sudha, R. and Stanley, J. N. A. ..... (A) 93A
Antigenic similarity of a cultivable acid-fast bacterium to *M. leprae*. Joshi, S., *et al.* ..... (A) 359
Application of a polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. Douglas, J. T., *et al.* ..... (A) 109A
Assessing the viability of *M. leprae* on 28 cases on MDT by the FDA/EB staining technique. Liu, G. and Shong, B. ..... (A) 111A
Association of NK (CD16+) cells and cytokines with *M. leprae* specific responses in type 1 reactions. Esquenazi, D. A., *et al.* ..... (A) 87A
Attempts to cultivate *M. leprae* in fat tissue. Godard, C. M. ..... (A) 656
Attempts to grow *M. leprae* in a medium with palmitic acid as the substrate. Ishaque, M. ..... (C) 294
Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ..... (A) 337
Bactericidal activity of ofloxacin against *M. leprae*. Franco, R. J., *et al.* ..... (A) 14A
Bilaterial iridocyclitis caused by *M. leprae* diagnosed through paracentesis. Campos, W., *et al.* ..... (A) 27A
Biochemical characterization of two new major proteins of *M. leprae*. Pessolani, C., *et al.* ..... (A) 115A
Biological properties of *M. leprae* passed on laboratory animals. Dyachina, M., *et al.* ..... (A) 113A
Characterization of *M. leprae* strains by RFLP analysis of amplified rDNA. Katoch, V. M., *et al.* ..... (A) 114A
Characterization of the specific recognition sites of monoclonal antibodies to the PGL-I of *M. leprae*. Fujiwara, T., *et al.* ..... (A) 78A
Clarithromycin is bactericidal against strains of *M. leprae* resistant and susceptible to dapsone and rifampin. Walker, L. L., *et al.* ..... (O) 59
Cloning and characterization of a 42-kDa serine-rich antigen from *M. leprae*. Vega-Lopez, F., *et al.* ..... (A) 84A
Cloning and characterization of the genes coding for the 85 complex antigens of *M. leprae*. de Mendonca Lima, L., *et al.* ..... (A) 108A
Cloning and sequencing of the Tuf gene coding for the elongation factor Tu of *M. leprae*. Dhandayuthapani, S., *et al.* ..... (A) 109A
Combinations of rifampin or rifabutin plus fluoroquinolones against *M. leprae*. Dhople, A. M. and Ibanez, M. A. ..... (A) 77A
Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* ..... (A) 488
Comparison of a gelatin particle agglutination test and ELISA for detection of antibody to *M. leprae*. Qian, L., *et al.* ..... (A) 94A
Computer recognition of possible functional or structural sites on *M. leprae* DNA. Cardo, P. P., *et al.* ..... (A) 107A
Crossreactive recognition of human T-cell epitopes in the *M. leprae* 18-kDa antigen. Menz, B., *et al.* ..... (A) 84A
Cultivation of *M. leprae* in artificial culture medium. Biswas, S. K. ..... (A) 111A
Detection of IgA anti-PGL-I in mangabey monkey inoculated with *M. leprae*. Saad, M. H. F., *et al.* ..... (A) 80A
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ..... (A) 145
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of leprosy patients and their contacts. Pattyn, S. R., *et al.* ..... (O) 389
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of patients and their contacts. Pattyn, S., *et al.* ..... (A) 107A
Detection of *M. leprae* nasal carriage in a leprosy-endemic population. Klatser, P. R., *et al.* ..... (A) 75A
Detection of *M. leprae*-specific antigen with M-dot-ELISA in sera from household contacts of leprosy patients. Cao, Y., *et al.* ..... (A) 73A

Determination of the adenylate energy charge (AEC). Haas, M. ..... (A) 107A
Determination of the adenylate energy charge (AEC). Haas, M. ..... (A) 308
Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with *M. leprae* and *M. bovis* BCG. Suzuki, K., *et al.* ..... (O) 609
Does the difference of the properties of trisaccharide-BSA conjugate (NT-P-BSA) of *M. leprae* phenolic glycolipid influence its seroreactivity? Fujiwara, T., *et al.* ..... (A) 348
Early clinical and pathological results of *M. leprae* challenge of monkeys after attempted protective immunization with live BCG or BCG + heat-killed *M. leprae*. Xu, K., *et al.* ..... (A) 79A
Early immunological results of experimental *M. leprae* challenge of monkeys after attempted immunization with live BCG or BCG + heat-killed *M. leprae*. Gormus, B. J., *et al.* ..... (A) 75A
Effect of *M. leprae* in peripheral nerve on the skin of patients with leprosy. Ridley, M. and Waters, M. F. R. ..... (A) 121A
Effects of fixation on polymerase chain reaction detection of *M. leprae*. Fiallo, P., *et al.* ..... (A) 141
Effects of palmitate on the growth of *M. leprae* under different gaseous environments. Ishaque, M. and Sticht-Groh, V. ..... (A) 112A
Effects of rifampin and ciprofloxacin on mycolic acid levels in human tissue-derived *M. leprae* and its correlation with viability. Patil, M., *et al.* ..... (A) 116A
Electron microscopic study of *M. leprae* passed on laboratory animals. Maslov, A. and Dyachina, M. ..... (A) 113A
Enhanced chemiluminescent assay (ECL): a highly sensitive method for the detection of *M. leprae* infection in nasal secretions. Sciulli, R., *et al.* ..... (A) 109A
Evaluation of four semi-synthetic *M. leprae* antigens with sera from healthy populations in endemic and non-endemic areas. Douglas, J. T., *et al.* ..... (A) 131
Evaluation of polymerase chain reaction amplification of *M. leprae*-specific repetitive sequence in biopsy specimens from leprosy patients. Yoon, K.-H., *et al.* ..... (A) 360
Evaluation of sodium stibogluconate and ureastibamine on mice experimentally infected with *M. leprae* from human leproma. Dastidar, S. G., *et al.* ..... (A) 80A
[Experience with the mouse foot pad technique to obtain *M. leprae*.] Suarez-Moreno, O. ..... (A) 146
Experiences with LAMMA in leprosy. Seydel, U. ..... (A) 310
Extracorporeal viability of *M. leprae*. Sreevatsa ..... (A) 110A
Genetic control of immune responses to the 18-kDa protein of *M. leprae*; different TH1 subsets may be involved in proliferative and delayed-type hypersensitivity. Backstrom, B. T., *et al.* ..... (A) 129
HLA class-II+ human keratinocytes present *M. leprae* antigens to CD4+ Th1-like cells. Mutis, T., *et al.* ..... (A) 351
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kDa-region proteins and the secreted antigen-85 complex and demonstration of antigen-85B on the *M. leprae* cell wall surface. Rambukkana, A., *et al.* ..... (A) 136
Homologs of *M. leprae* 18-kilodalton and *M. tuberculosis* 19 kilodalton antigens in other mycobacteria. Booth, R. J., *et al.* ..... (A) 493
Human T-cell clones recognize mycobacterial specific and shared epitopes on *M. leprae* 70-kDa protein. Adams, E., *et al.* ..... (A) 104A
Identification and characterization of epitopes shared between the mycobacterial 65-kilodalton heat shock protein and the actively secreted antigen-85 complex—their *in situ* expression on the cell wall surface of *M. leprae*. Rambukkana, A., *et al.* ..... (A) 143
Identification of T-cell stimulatory epitopes from the 18-kDa protein of *M. leprae*. Doherty, T. M., *et al.* ..... (A) 652
Immunogenicity and protection studies with recombinant vaccinia and BCG each expressing the 18-kDa antigen of *M. leprae*. Baumgart, K. W., *et al.* ..... (A) 86A
Immunoreactivity of mycobacterial strain ICRC and *M. leprae* antigens with polyclonal and monoclonal antibodies. Chiplunkar, S. V., *et al.* ..... (O) 421
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* (A) 74A
In leprosy the presence of mycobacteria in the nerve is an essential factor in the cycle and spectrum of *M. leprae* infection. Negesse, Y., *et al.* ..... (A) 654

In vitro cultivation of *M. leprae*—existence of a growth factor. Dhople, A. M. and Ibanez, M. A. ..... (A) 116A
In vitro cultivation of *M. leprae* with cytokines. Oh, C.-S ..... (A) 112A
In vitro synergistic activity between ofloxacin and ansamycin against *M. leprae*. Dhople, A. M., *et al.* ..... (A) 485
Inactivation of interleukin-2 by the culture isolate from *M. leprae* in Ogawa media with cytokines. Oh, C.-S. ..... (A) 116A
[Influence of feeding on the multiplication of *M. leprae* in the mouse foot pad.] Wang, H. ..... (A) 146
[Intraocular experimental infection with *M. leprae* in nude rats.] Shi, Z.-R., *et al.* ..... (A) 145
K-130: a new inhibitor of *M. leprae* dihydrofolate reductase. Visser, K., *et al.* ..... (A) 14A
Labeling of the 65-kDa heat-shock protein in *M. leprae* and other mycobacterial species. Esaguy, N. ..... (A) 110A
Leprosy-derived chemoautotrophic nocardioform (CAN) bacteria closely resemble, or are idential with, *M. leprae* on mycolate and other lipid profiles. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 357
Liguefying nodular paniculitis caused by *M. leprae*. Azulay, R. D., *et al.* ..... (A) 23A
Limited T-cell receptor beta-chain diversity of a T-helper cell type-1-like response to *M. leprae*. Uyemura, K., *et al.* ..... (A) 139
Lipoarabinomannan (LAM)—a possible immunoregulatory molecule of *M. leprae*-infected Schwann cells? Mistry, N., *et al.* ..... (A) 100A
Lymphocyte proliferation and cytokine secretion in response to purified mycobacterial HSP and to Ag85 during infection with *M. leprae*. Launois, P., *et al.* ..... (A) 86A
Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and *M. leprae* antigens in leprosy patients. Shinde, S. R., *et al.* ..... (O) 51
M. leprae 10-kDa heat-shock protein is a major T-cell antigen. Mehra, V., *et al.* ..... (A) 88A
M. leprae antigens can be recognized by both Th1-like and Th2 like human T cells. MacFarlane, A. and Dockrell, H. ..... (A) 89A
M. leprae in mast cells in histoid leproma. Liu, J., *et al.* ..... (A) 123A
M. leprae infection triggers synthesis of stress-inducible HSP70 in Schwann cells and anti-HSP antibodies in sera. Mistry, Y., *et al.* ..... (A) 104A
M. leprae LAM and PGL-I antibodies crossreact with HIV-1 antibodies in sera from HIV-1-seronegative leprosy patients and their contacts. Kashala, O., *et al.* ..... (A) 97A
M. leprae metabolism: *in vitro* utilization of glucose, uridine 5′-diphosphoglucose and gutamate. Harris, E. B., *et al.* ..... (A) 116A
M. leprae produces extracellular homologs of the antigen-85 complex. Von Pessolani, M. C. and Brennan, P. J. ..... (A) 144
M. leprae soluble antigen (Rees) skin test responses in an endemic population in India. Krishnamurthy, P., *et al.* ..... (A) 349
M. leprae viability in skin and nerve after MDT and their sensitivity to antileprosy drugs. Shetty, V., *et al.* ..... (A) 4A
M. leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. Sampaio, E. P., *et al.* ..... (A) 353
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ..... (A) 95A
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Mechanism of energy transduction in *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 109A
Modulation of MHC class-II antigen expression on antigen presenting cells of leprosy patients by *M. leprae*. SivaSai, K. S. R., *et al.* ..... (A) 89A
Modulation of cytotoxicity against *M. leprae* by cytokines in leprosy patients. Sasiain, M., *et al.* ..... (A) 91A
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. ..... (A) 359
Mouse vaccination against leprosy with *M. leprae* subunit vaccines are more effective than with whole sonicated *M. leprae*. Gelber, R. H., *et al.* ..... (A) 76A
Murine strain variation in *M. leprae*-infected Schwann cell functions and their modulation by macrophages. Birdi, T., *et al.* ..... (A) 77A

N-Terminal amino-acid sequencing of *M. leprae* proteins: definition of the L12 ribosomal protein. Pessolani, C., *et al.* ..... (A) 106A
Nucleic acid sequence-based amplification (NASBA) for identification and viability assessment of *M. leprae* in skin biopsy specimens. van der Vliet, G. M. E., *et al.* ... (A) 107A
Nucleotide sequence of the first cosmid from the *M. leprae* genome project: structure and function of the Rif-Str regions. Honore, N., *et al.* ..... (A) 358
Observation on phagocytosis to *M. leprae* by cultured human Schwann cells. Qiu, J., *et al.* ..... (A) 79A
Observations on the cultivation of *M. leprae* and M. tuberculosis in medium "V" and "V1." Herbert, D. and Prabhakar, R. ..... (A) 142
Overexpression and seroreactivity of 15-kDa antigen of *M. leprae*. Banu, M. J., *et al.* (A) 114A
Overexpression of *M. leprae* antigens in *Escherichia coli*. Oskam, L., *et al.* ..... (A) 114A
Persistence of *M. leprae* in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Shetty, V. P., *et al.* ..... (A) 344
Phagocytic myeloperoxidase as a killing factor for *M. leprae*. Maslov, A. ..... (A) 113A
Pilot study to determine acceptability and ability of heat killed *M. leprae* plus BCG (HKML + BCG) vaccine to induce skin test conversion. Chen, Z.-L., *et al.* ..... (A) 651
Polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. De Wit, M. Y. L., *et al.* ..... (A) 362
Polymerase chain reaction for the detection of *M. leprae* in skin tissue. Kampirapap, K., *et al.* ..... (A) 108A
Possible transmission of *M. leprae* in a group of U.K. leprosy contacts. Dockrell, H. M., *et al.* ..... (A) 362
Powerful bactericidal activities of clarithromycin and minocycline against *M. leprae* in lepromatous leprosy. Ji, B. H., *et al.* ..... (A) 647
Preservation of *M. leprae in vitro* for four years by lyophilization. Kohsaka, K., *et al.* (O) 415
Production of monoclonal antibodies against *M. leprae*. Wu, Q., *et al.* ..... (A) 88A
Protection of mice by vaccination with purified and recombinant major *M. leprae* proteins and polypeptides. Gelber, R. H., *et al.* ..... (A) 103A
Recent results on *in vivo* drug efficacies from mass analysis of individual *M. leprae* organisms. Seydel, U., *et al.* ..... (A) 116A
Reactivity of leprosy and control sera to crude and recombinant *M. leprae* antigens. Vega-Lopez, F., *et al.* ..... (A) 88A
Recognition of 21-kDa and 14-kDa antigens of mycobacterium ICRC by anti-*M. leprae* antibodies. Chiplunkar, S., *et al.* ..... (A) 85A
Recognition of *M. leprae* antigens with antibodies present in sera from patients with lepromatous leprosy. Islas Rodriguez, A. E., *et al.* ..... (O) 245
Reconocimiento de antigenos de *M. leprae* en pacientes hansenianos. Santaella, C., *et al.* ..... (A) 89A
Reconstitution of *M. leprae* immunity in severe combined immunodeficient (SCID) mice. Azouaou, N., *et al.* ..... (A) 76A
Reconstitution of *M. leprae* immunity in severe combined immunodeficient mice using a T-cell line. Azouaou, N., *et al.* ..... (O) 398
Relationship between host histones and armadillo-derived *M. leprae*. Pessolani, M. C. V., *et al.* ..... (O) 381
Responses of cytokine-treated human monocyte-derived macrophages to challenge with *M. leprae*. Adams, L. B. and Krahenbuhl, J. L. ..... (A) 102A
Reversal of drug resistance in *M. leprae* by ampicillin/sulbactam. Prabhakaran, K., *et al.* ..... (A) 338
Role of anti-*M. leprae* PGL-I antibodies in assessing the contacts of leprosy patients in a low-endemic area. Soares, D. J., *et al.* ..... (A) 73A
Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ..... (A) 138
Sensitization potential and reactogenicity of varying doses of BCG plus killed *M. leprae*: an extended study. Gupte, M. D., *et al.* ..... (O) 563
Sequence and immunological characterization of a serine-rich antigen from *M. leprae*. Vega Lopez, F., *et al.* ..... (A) 499
Serological response in leprosy and tuberculosis patients to the 18-kDa antigen of *M. leprae* and antigen 85B of *M. bovis* BCG. Vikerfors, T., *et al.* ..... (O) 571
Serological response of leprosy patients to *M. leprae* specific and mycobacteria specific antigens: possibility of using these assays in combinations. Sekar, B., *et al.* ..... (A) 353

Simple colorimetric microtiter plate hybridization assay for detection of amplified *M. leprae*. van der Vliet, G. M. E., *et al.* ..... (A) 359
Soluble *M. leprae* antigen skin testing and lepromin positivity in children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 105A
Sparfloxacin is more bactericidal than ofloxacin against *M. leprae* in mice. Franzblau, S. G., *et al.* ..... (O) 66
Strain differences identified within *M. leprae*. de Wit, M. Y. L. and Klatser, P. R. ..... (A) 108A
Studies of alpha-antigen genes in *M. leprae*. Yin, Y.-P., *et al.* ..... (A) 114A
Studies of macrophage traffic into the experimental lepromatous lesion of the *M. leprae*-infected nu/nu mouse foot pad. Krahenbuhl, J. L., *et al.* ..... (A) 78A
Studies on the activity of minocycline against *M. leprae* infected mice. Gelber, R. H., *et al.* ..... (A) 82A
[Study on monoclonal antibody in leprosy. (II) Preliminary report on production of monoclonal antibody against supersonic products of *M. leprae*.] Wu, Q., *et al.* ..... (A) 356
[Study on monoclonal antibody in leprosy. (III) Production of monoclonal antibody to entire *M. leprae*.] Wu, Q., *et al.* ..... (A) 356
Study on nude mice inoculated with *M. leprae* by multiple routes. Wang, H., *et al.* ..... (A) 82A
Subcellular fractionation of *M. leprae* and the search for new proteins. Chitale, S. and Brennan, P. J. ..... (A) 115A
Suppression of ADCC by immune complexes formed *in vitro* in *M. leprae*-infected mice. Vaishnavi, C., *et al.* ..... (A) 361
Suppression of human monocyte cytokine release by PGL-I of *M. leprae*. Silva, C. L., *et al.* ..... (A) 92A
Suppression of human monocyte cytokine release by phenolic glycolipid-I of *M. leprae*. Silva, C. L., *et al.* ..... (C) 107
Survey of monoclonal antibodies against *M. leprae* for use in immunohistochemical and immunoultrastructural localization studies. Krotoski, W. A., *et al.* ..... (A) 78A
Susceptibility of severe combined immunodeficient (SCID) mice to *M. leprae*: multiplication of the bacillus and dissemination of the infection at an early stage. Yogi, Y., *et al.* ..... (A) 362
T-cell receptor beta-chain gene usage in the T-cell recognition of *M. leprae* antigens in one tuberculoid leprosy patient. van Schooten, W. C. A., *et al.* ..... (A) 139
T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with *M. leprae* secreted antigen-85 is another immunodominant antigen. Launois, P., *et al.* ..... (A) 653
The laser microprobe mass analysis (LAMMA) method. Lindner, B. ..... (A) 309
The mycobacterial secreted antigen-85 complex possesses epitopes that are differentially expressed in human leprosy lesions and *M. leprae*-infected armadillo tissues. Rambukkana, A., *et al.* ..... (A) 496
The nucleotide sequence of the promoter, 16S rRNA and space region of the ribosomal RNA operon of *M. leprae* precursor rRNA and comparison with *M. leprae* precursor. Kempsell, K. E., *et al.* ..... (A) 142
Therapeutic efficacy of KRM-1648 in combination with other antimicrobials against *M. leprae* infection induced in mice. Tomioka, H., *et al.* ..... (A) 77A
Therapeutic efficacy of some new quinolones and a combination of ofloxacin and rifampin against *M. leprae* infection induced in athymic nude mice. Tomioka, H. and Saito, H. ..... (O) 250
Toward developing a new scheme for rapid characterization of mycobacterial with special reference to *M. leprae*. Sharma, V. D., *et al.* ..... (A) 113A
Ultrastructural parameters indicating viability of *M. leprae* after chemotherapy. Kumar, V., *et al.* ..... (A) 110A
Ultrastructural study of mouse dorsal root ganglion cultures infected long term with *M. leprae*. Shetty, V. P., *et al.* ..... (A) 138
Use of PGL-immunoassays in seroepidemiological studies of *M. leprae* infection in Malaysia. Gan, S. C. and Fujiwara, T. ..... (A) 73A
Use of an ordered cosmic library to deduce the genomic organization of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 358
Use of radiolabeled substrates. Nath, I. ..... (A) 308
Utilizacion de 3 sistemas de PCR para la deteccion de ADN de *M. leprae* en muestras quimicas. Maestre Mesa, J., *et al.* ..... (A) 109A

Viability of acid-fast bacilli from gamma-irradiated and UV irradiated lepromatous armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ...(A) 158

Mycobacterium lepraemurium,

A role for gamma interferon, tumor necrosis factor, and soluble T-cell receptors in the depressed blastogenic response of spleen cells of *M. lepra*emurium-infected mice. Richard, L., *et al.* ...(A) 137

UV-B irradiation of mice impairs the phagocytic ability of macrophages, decreases immunity to *M. lepra*emurium, and increases disease pathogenesis. Jeevan, A. and Kripke, M. L. ...(A) 77A

Mycobacterium malmoense,

Susceptibility of *M. malmoense* to antibacterial drugs and drug combinations. Hoffner, S. E., *et al.* ...(A) 506

Mycobacterium marinum,

A case of disseminated *M. marinum* infection in an immunocompent patient. Vazquez, J. A. and Sobel, J. D. ...(A) 179

M. marinum infection—epidemiology and presentation in Queensland (Australia) 1971-1990. Iredell, J., *et al.* ...(A) 163

Mycobacterium microti,

Possible intermediates in the biosynthesis of mycoside-B by *M. microti*. Thurman, P. F., *et al.* ...(A) 498

Mycobacterium paratuberculosis,

Activity of clarithromycin compared with those of other drugs against *M. paratuberculosis* and further enhancement of its extracellular and intracellular activities of ethambutol. Rastogi, N., *et al.* ...(A) 124

Antibodies to *M. paratuberculosis*-specific protein antigens in Crohn's disease. Elsaghier, A., *et al.* ...(A) 159

Cloning and expression of portions of the 34-kilodalton protein gene to *M. paratuberculosis*: its application to serological analysis of Johne's disease. De Kesel, M., *et al.* (A) 369

Composition and immunological properties of the protein fraction of A36, a major antigen complex of *M. paratuberculosis*. DeKesel, M., *et al.* ...(A) 141

Expression of *Escherichia coli* beta-glactosidase in *M. bovis* BCG using an expression system isolated from *M. paratuberculosis* which induced humoral and cellular immune responses. Murray, A., *et al.* ...(A) 142

Induction of cellular immune reactions by A36, an antigen complex of *M. paratuberculosis*—comparison of A36 and Johin components. Gilot, P., *et al.* ...(A) 162

Molecular cloning and characterization of *M. paratuberculosis* promoters in *Escherichia coli*. Thomas, T. J., *et al.* ...(A) 179

Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ...(A) 169

Polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp *silvaticum* in long term cultures from Crohn's disease. Moss, M. T., *et al.* ...(A) 170

Mycobacterium simiae,

Isolation of *M. simiae* from the environment. Schroder, K. H., *et al.* ...(A) 376

Mycobacterium smegmatis,

Cloning and sequencing of the gene which encodes the highly inducible acetamidase of *M. smegmatis*. Mahenthiralingam, E., *et al.* ...(A) 496

Cloning of mycobacterial histidine synthesis genes by complementation of a *M. smegmatis* auxotroph. Hinshelwood, S. and Stoker, N. G. ...(A) 163

Expression of the *M. tuberculosis* 19-kilodalton antigen in *M. smegmatis*—immunological analysis and evidence of glycosylation. Garbe, T., *et al.* ...(A) 349

Inhibition of mycolic acid biosynthesis in a cell-wall preparation from *M. smegmatis* by methyl 4-(2 octadecylcyclopropen-1-Y1) butanoate, a structural analog of a key precursor. Wheeler, P. R., *et al.* ...(A) 670

Insertion into the *M. smegmatis* genome of the aph gene through lysogenization with the temperate mycobacteriophage Ms6. Anes, E., *et al.* ...(A) 140

Isolation and characterization of isoniazid-resistant mutants of *M. smegmatis* and *M. aurum*. Heym, B. and Cole, S. T. ...(A) 163

M. smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Levin, M. E. and Hatfull, G. F. ..... (A) 495
Regulation of phospholipid synthesis in *M. smegmatis* by cyclic adenosine monophosphate. Sareen, M., *et al.* ..... (A) 656
Stimulation of mycolic acid biosynthesis by incorporation of cis-tetracos-5-enoic acid in a cell-wall preparation of *M. smegmatis*. Wheeler, P. R., *et al.* ..... (A) 499

Mycobacterium tuberculosis,
A comparison of the T-cell delayed-type hypersensitivity epitopes of the 19-kD antigens from *M. tuberculosis* and *M. intracellulare* using overlapping synthetic peptides. Mackall, J. C., *et al.* ..... (A) 664
A family of cross-reacting proteins secreted by *M. tuberculosis*. Wiker, H. G., *et al.* ..... (A) 182
A novel protein antigen secreted by *M. leprae*: the homolog of *M. tuberculosis* MPT32. Wieles, B., *et al.* ..... (A) 84A
A rapid method for screening antimicrobial agents for activities against a strain of *M. tuberculosis* expressing firefly luciferase. Cooksey, R. C., *et al.* ..... (A) 494
A semiquantitative assessment of the cellular immune response to *M. tuberculosis* in HIV-infected patients. Lewin-Smith, M. R., *et al.* ..... (A) 123A
An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ..... (A) 90A
Antibodies against secreted and nonsecreted antigens in mice after infection with live *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 180
Characterization of B cell epitopes on the 16K antigen of *M. tuberculosis*. Verbon, A., *et al.* ..... (A) 179
Characterization of the katG gene encoding a catalase peroxidase required for the isoniazid susceptibility of *M. tuberculosis*. Heym, B., *et al.* ..... (A) 661
Cloning of the lsyA gene from *M. tuberculosis*. Andersen, A. B. and Hansen, E. B. ..... (A) 492
Comparative ability of human monocytes and macrophages to control the intracellular growth of *M. avium* and *M. tuberculosis*–effect of interferon-gamma and indomethacin. Desousa, J. P. C. and Rastogi, N. ..... (A) 504
Comparison of growth and susceptibility testing of pyrazinamide in different BACTEC media using strains of the *M. tuberculosis* complex. Fuursted, K. ..... (A) 504
Computer-assisted pattern recognition model for the identification of slowly growing mycobacteria including *M. tuberculosis*. Plikaytis, B. D., *et al.* ..... (A) 173
Cytokine secretion by CD4 T-lymphocytes acquired in response to *M. tuberculosis* infection. Orme, I. M., *et al.* ..... (A) 666
DNA fragment length polymorphism analysis of *M. tuberculosis* isolated by arbitrarily primed polymerase chain reaction. Palittapongarnpim, P., *et al.* ..... (A) 496
Detection and identification of *M. tuberculosis*, *M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Detection of *M. tuberculosis* DNA in clinical samples by using a simple lysis method and polymerase chain reaction. Folgueira, L., *et al.* ..... (A) 494
Detection of *M. tuberculosis* in clinical samples by 2-step polymerase chain reaction and nonistropic hybridization methods. Shawar, R. M., *et al.* ..... (A) 177
Detection of *M. tuberculosis* in clinical samples by using polymerase chain reaction and a nonradioactive detection system. Kolk, A. H. J., *et al.* ..... (A) 166
Detection of *M. tuberculosis* in sputum samples by polymerase chain reaction using a simplified procedure. Kocagoz, T., *et al.* ..... (A) 663
Detection of rifampicin-resistance mutations in *M. tuberculosis*. Telenti, A., *et al.* ..... (A) 497
Differential cytokine gene expression and secretion after phagocytosis by a human monocytic cell line of Toxoplasma gondii compared with *M. tuberculosis*. Friedland, J. S., *et al.* ..... (A) 370
Direct detection of *M. tuberculosis* in respiratory specimens in a clinical laboratory by polymerase chain reaction. Forbes, B. A. and Hicks, K. E. S. ..... (A) 660
Direct detection of *M. tuberculosis* in sputum by polymerase chain reaction and DNA hybridization. Nolte, F. S., *et al.* ..... (A) 666
Evaluation of polymerase chain reactions, tuberculostearic acid analysis, and direct microscopy for the detection of *M. tuberculosis* in sputum. Savic, B., *et al.* ..... (A) 176

Expression of the *M. tuberculosis* 19-kilodalton antigen in *M. smegmatis*—immunological analysis and evidence of glycosylation. Garbe, T., *et al.* ....(A) 349
Generation of cytolytic T-cells in individuals infected by *M. tuberculosis* and vaccinated with BCG. Pithie, A. D., *et al.* ....(A) 173
Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of *M. tuberculosis* by human and murine T cells. Harris, D. P., *et al.* ....(A) 661
Homologs of *M. leprae* 18-kilodalton and *M. tuberculosis* 19 kilodalton antigens in other mycobacteria. Booth, R. J., *et al.* ....(A) 493
Identification of 2-dimensional gel electrophoresis of a 58 kilodalton tumor necrosis factor-inducing protein of *M. tuberculosis*. Wallis, R. S., *et al.* ....(A) 355
Identification of IL-8 as a locomotor attractant for activated human lymphocytes in mononuclear cell cultures with anti-CD3 or purified protein derivative of *M. tuberculosis*. Wilkinson, P. C. and Newman, I. ....(A) 183
Identification of *M. tuberculosis* DNA in a case of lupus vulgaris. Serfling, U., *et al.* ....(A) 377
Identification of *M. tuberculosis* and *M. avium-intracellulare* directly from primary BACTEC cultures by using acridinium ester-labeled DNA probes. Evans, K. D., *et al.* ....(A) 160
Identification of immunodominant antigens during infection with *M. tuberculosis*. Andersen, P., *et al.* ....(A) 152
Immunization with extracellular proteins of *M. tuberculosis* includes cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Pal, P. G. and Horwitz, M. A. ....(A) 171
In vitro and *in vivo* activities of the nitroimidazole CGI 17431 against *M. tuberculosis*. Ashtekar, D. R., *et al.* ....(A) 365
M. tuberculosis DNA in tissue affected by sarcoidosis. Fidler, H. M., *et al.* ....(A) 503
Macrophage phagocytosis of virulent but not attenuated strains of *M. tuberculosis* is mediated by mannose receptors in addition to complement receptors. Schlesinger, L. S. ....(A) 490
Major histocompatibility complex class I-restricted T cells are required for resistance to *M. tuberculosis* infection. Flynn, J. L., *et al.* ....(A) 161
Mixed-linker polymerase chain reaction: a new method for rapid fingerprinting of isolates of the *M. tuberculosis* complex. Haas, W. H., *et al.* ....(A) 505
Molecular cloning and characterization of *M. paratuberculosis* promoters in *Escherichia coli*. Thomas, T. J., *et al.* ....(A) 179
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* ....(O) 227
Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from *M. tuberculosis* var. *bovis* bacillus Calmette Guerin. Mathur, M. and Kolattukudy, P. E. ....(A) 168
Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ....(A) 169
Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Carlucci, S., *et al.* ....(A) 368
Observations on the cultivation of *M. leprae* and *M. tuberculosis* in medium "V" and "V1.". Herbert, D. and Prabhakar, R. ....(A) 142
Pathogenesis of tuberculosis—interaction of *M. tuberculosis* with macrophages. McDonough, K. A., *et al.* ....(A) 665
Polymerase chain reaction to detect *M. tuberculosis* in a clinical microbiology laboratory. Veringa, E., *et al.* ....(A) 180
Powerful bactericidal activity of sparfloxacin (AT-4140) against *M. tuberculosis* in mice. Lalande, V., *et al.* ....(A) 374
Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ....(A) 155
Pulsed field gel electrophoresis of representatives of *M. tuberculosis* and *M. bovis* BCG strains. Varnerot, A., *et al.* ....(A) 179
Purification of polyphosphate and ATP glucose phosphotransferase from *M. tuberculosis* H37Ra: evidence that poly(P) and ATP glucokinase activities are catalyzed by the same enzyme. Hsieh, P.-C., *et al.* ....(A) 373
Rapid assessment of drug susceptibilities of *M. tuberculosis* by means of luciferase reporter phages. Jacobs, W. R., Jr., *et al.* ....(A) 507

Rapid, simple method of typing isolates of *M. tuberculosis* by using the polymerase chain reaction. Ross, B. C. and Dwyer, B. ..... (A) 376
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma-delta T cells activated by live *M. tuberculosis*. Boom, W. H., *et al.* ..... (A) 153
Similarities between alanine dehydrogenase and the N-terminal part of pyridine nucleotide transhydrogenase and their possible implication in the virulence mechanism of *M. tuberculosis*. Delforge, D., *et al.* ..... (A) 357
Specificity of a protective memory immune response against *M. tuberculosis*. Anderson, P. and Heron, I. ..... (A) 365
Strain identification of *M. tuberculosis* by DNA fingerprinting: recommendations for a standard methodology. van Embden, J. D., *et al.* ..... (A) 378
Structural eludication of a novel family of acyltrehaloses from *M. tuberculosis*. Besra, G. S., *et al.* ..... (A) 152
Susceptibility of strains of the *M. tuberculosis* complex to fusidic acid. Fuursted, K., *et al.* ..... (A) 161
T-cell response to *M. tuberculosis*. Orme, I. M., *et al.* ..... (A) 161
The 38-kDa protein of *M. tuberculosis*—a review. Harboe, M. and Wiker, H. G. ..... (A) 666
The 65-kDa protein of *M. habana* and its putative role in immunity against *M. tuberculosis*. Singh, N. B. ..... (A) 83A
The antigen-85 complex—a major secretion product of *M. tuberculosis*. Wiker, H. G. and Harboe, M. ..... (A) 182
The detection of *M. tuberculosis* in uncultured clinical specimens using the polymerase chain reaction and a non radioactive DNA probe. Thierry, D., *et al.* ..... (A) 178
The effect of *M. tuberculosis* on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Filley, E. A., *et al.* ..... (A) 132
The structure of an antigenic glycolipid (SL-IV) from *M. tuberculosis*. Baer, H. H. ..... (A) 492
Trifluoperazine inhibits the incorporation of labeled precursors into lipids, proteins and DNA of *M. tuberculosis* H37Rv. Ratnaker, P. and Murthy, P. A. ..... (A) 668
Whole-cell protein electrophoresis for typing *M. tuberculosis*. Millership, S. E. and Want, S. V. ..... (A) 170

Mycobacterium w,
An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ..... (A) 90A
Combined multidrug and *Mycobacterium w* vaccine therapy in patients with multibacillary leprosy. Zaheer, S. A., *et al.* ..... (A) 357
Field trials with an antileprosy vaccine *Mycobacterium w*. Walia, R., *et al.* ..... (A) 104A
Immunotherapy of MB leprosy patients with the antileprosy vaccine *Mycobacterium w*. Zaheer, S. A., *et al.* ..... (A) 18A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ..... (A) 345
Immunotherapy with *Mycobacterium w* vaccine in MB leprosy patients showing slow responses to MDT. Ramesh, V., *et al.* ..... (A) 18A
Induction of lepromin positivity by a candidate antileprosy vaccine *Mycobacterium w* and its immunoprophylactic effect in lepromin-negative healthy contacts or multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 95A
Induction of lepromin positivity by a candidate antileprosy vaccine, *Mycobacterium w*, in lepromin negative healthy contacts of multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 349
On histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w*. Reddy, B. N. and Porichha, D. ..... (C) 109
Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w*. Sharma, A. K., *et al.* ..... (A) 24A

Mycobacterium xenopi,
Secondary fatty alcohols of *M. xenopi*. Alugupalli, S. and Larsson, L. ..... (A) 152
Structure of a novel glycopeptidolipid antigen containing a O methylated serine isolated from *M. xenopi* complete H-1-NMR and C-13-NMR assignment. Riviere, M., *et al.* (A) 669

Mycobactin,
A simple and rapid method for the detection and identification of mycobacteria using mycobactin. Barclay, R., *et al.* ..... (A) 141
A simple and reliable EDDA method for mycobactin production in mycobacteria—optimal conditions and use in mycobacterial speciation. Bosne, S., *et al.* ..... (A) 502

Nepal,
Comparability of ball pen and nylon filaments in testing sensory function of patients with leprosy in Nepal and Ethiopia. Lienhardt, C., *et al.* ..... (A) 157A
Consultation in Kathmandu. ..... (N) 331
Drug resistance in Nepali leprosy patients. Butlin, C. R., *et al.* ..... (A) 46A
Experience gained in Nepal with cotrifazid. Pradhan, H. M. ..... (A) 14A
How to reduce leprosy prevalence in Nepal. Baral, J. P. and Louhenapessy, A. A. ..... (A) 40A
Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia and Nepal. Lienhardt, C., *et al.* ..... (A) 145A
Multi-drug therapy, leprosy and leprosy control in west Nepal. van Brakel, W. H. ..... (A) 124

Nerve(s),
A morphological study of nerve biopsies from cases of multibacillary leprosy given multidrug therapy. Jacobs, J. M., *et al.* ..... (A) 489
A preliminary study of correlation of immuno-histological and ultrastructural characteristics of neural granuloma in leprosy patients. Kumar, V., *et al.* ..... (A) 350
A study on factors influencing the recovery of motor nerve function with steroid therapy. Roberts, H., *et al.* ..... (A) 147A
Animal model to study the mechanism of nerve damage in leprosy-a preliminary report. Shetty, V. P. ..... (O) 70
Anti-peripheral nerve antibodies in leprosy patients recognize an epitope shared by the *M. leprae* 65 kDa heat shock protein. Launois, P., *et al.* ..... (A) 350
Antibodies to a nerve lipid extract (NLE) in sera of leprosy patients. Vartak, R., *et al.* (A) 97A
Assessment for quiet nerve paralysis in the field. Srinivasan, H., *et al.* ..... (A) 147A
Asymptomatic nerve hypertrophy in lepromatous leprosy—a clinical, electrophysiological and morphological study. Tzourio, C., *et al.* ..... (A) 127
Autoantibodies to neural antigens in leprosy. Vemuri, N., *et al.* ..... (A) 93A
Clinical, electrophysiological and bacteriological evaluation of nerve damage after regular MDT in leprosy. Antia, N., *et al.* ..... (A) 22A
Concurrent skin and nerve histology in leprosy and its role in the classification of leprosy. Kaur, S., *et al.* ..... (A) 652
Cytological needle aspiration of the nerve for the diagnosis of pure neural leprosy. Theuvenet, W. J., *et al.* ..... (O) 597
Denatured muscle autografts in peripheral nerve repair in a model of leprosy. de Blaquiere, G., *et al.* ..... (A) 79A
Denatured muscle autografts in peripheral nerve repair. 1. Surgical technique. Pereira, J. H., *et al.* ..... (A) 150A
Denatured muscle autografts in peripheral nerve repair. 2. Results on leprosy patients. Pereira, J. H., *et al.* ..... (A) 150A
Effect of *M. leprae* in peripheral nerve on the skin of patients with leprosy. Ridley, M. and Waters, M. F. R. ..... (A) 121A
Identification of peripheral nerve damage in Hansen's disease and its implications for control program management. Lehman, L., *et al.* ..... (A) 147A
In leprosy the presence of mycobacteria in the nerve is an essential factor in the cycle and spectrum of *M. leprae* infection. Negesse, Y., *et al.* ..... (A) 654
Infected trophic ulcers and tenderness of posterior tibial nerve in cured leprosy patients. Patki, A. H. ..... (C) 472
Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia and Nepal. Lienhardt, C., *et al.* ..... (A) 145A
Is nerve damage in leprosy an autoimmune phenomenon involving antiperipheral nerve antibodies? Desikan, P., *et al.* ..... (A) 96A
M. leprae viability in skin and nerve after MDT and their sensitivity to antileprosy drugs. Shetty, V., *et al.* ..... (A) 4A
Management of common peroneal nerve damage (foot drop) in Hansen's disease—Dhoolpet Leprosy Research Center approach. Solomon, V. K., *et al.* ..... (A) 154A

Monitoring of peripheral nerve involvement underlying disability of the hand in HD: a 7-year follow up in a U.S. population. Bell-Krotoski, J. ..... (A) 146A
Monitoring peripheral nerve involvement during reactions. Figarola, J. ..... (A) 146A
Nature and location of permanent damage to peripheral nerves in advanced treated leprosy. Miko, T. L., *et al.* ..... (A) 148A
Nerve condition study technique in the armadillo. Garbino, J., *et al.* ..... (A) 82A
Nerve function assessment in leprosy—comparison of various clinical methods. van Brakel, W. H., *et al.* ..... (A) 21A
Nerve lesions induced by macrophage activation. Said, G. and Hontebeyrie-Joskowicz, M. ..... (A) 352
Neuritis of the lateral femoral cutaneous nerve in leprosy. Theuvenet, W. J., *et al.* ..... (O) 592
Neurological examination of patients suffering from leprosy: is it worthwhile? Jennekens, F. G. E. and Jennekens-Schinkel, A. ..... (A) 126
Neurolyses *et* decompressions nerveuses. Bernardin, R. and Berman, T. ..... (A) 150A
Persistence of *M. leprae* in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Shetty, V. P., *et al.* ..... (A) 344
Pregnancy is a risk factor for relapse and new nerve damage even after MDT. Duncan, M. E., *et al.* ..... (A) 21A
Prevalence of antineural antibodies among leprosy patients. Cho, S.-N., *et al.* ..... (A) 97A
Quiet nerve paralysis assessment with respect to MDT and corticosteroid therapy. Gupte, M. D., *et al.* ..... (A) 147A
Recovery of sensation by nerve decompression using selective meshing of the epineurium. Hatano, K., *et al.* ..... (A) 151A
Relative significance of abd. dig. min. palm. inter, and 1st dor. inter, with regard to detection follow up; evaluation of ulnar nerve damage. Syed, M., *et al.* ..... (A) 145A
Reliability of manual muscle strength testing in the evaluation of peripheral nerve dysfunction in leprosy patients. Brandsma, J. W., *et al.* ..... (A) 145A
Replacement of the main sensory nerves of hands and feet in leprosy patients with freeze-thawed muscle as graft material. Kazen, R., *et al.* ..... (A) 150A
Results of ulnar nerve decompression in leprosy patients. Virmond, M., *et al.* ..... (A) 150A
Role of skin and cutaneous nerve biopsies in paucibacillary borderline tuberculoid Hansen's disease. Thomas, S., *et al.* ..... (A) 122A
Serologic responses to nerve antigens in sooty mangabey monkeys with experimental leprosy. Cho, S.-N., *et al.* ..... (O) 236
Solitary neurofibroma mimicking nerve abscess of leprosy. Reddy, B. S. N., *et al.* ..... (A) 651
Subcellular localization of DDS and rifampin in the skin and nerve of multidrug-treated cases of leprosy. Shetty, V., *et al.* ..... (A) 18A
Subplasmalemmal linear densities in mononuclear cells induced by an antigen in human sensory peripheral nerve. Crawford, C. L. and Hardwicke, P. M. D. ..... (A) 79A
The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. van Brakel, W. H., *et al.* ..... (A) 128
Ultrastructural alterations of dermal nerves in early cutaneous leprous macules. Antunes, S. L. G. and Sarno, E. N. ..... (A) 126A
Visible corneal nerves in leprosy. Daniel, E. and Rao, P. S. S. ..... (A) 119A

Netherlands, The,
Ivone Bergsma moves to new position. ..... (N) 481
[The Netherlands Foundation for Leprosy Control: medical work under adverse conditions.] Spanier, J. M. ..... (A) 120

Neuritis,
Neuritis of the lateral femoral cutaneous nerve in leprosy. Theuvenet, W. J., *et al.* ..... (O) 592
Risk of neuritis among multibacillary patients during multidrug therapy. Rajan Babu, G. ..... (A) 20A
The experience of using reflexotherapy in leprosy patients with chronic neuritis. Shats, E., *et al.* ..... (A) 35A

Neuropathy,
Clinical assessment of early leprous neuropathy with electrophysiologic correlation. Brown, T. R., *et al.* ..... (A) 148A

Elimination of leprosy and its complications: the case of hand neuropathy. Vergara-Vargas, M. G., *et al.* ..... (A) 152A
Frequency of leprosy neuropathy in hyperendemic areas of Mexico and its correlation with clinical, epidemiological and structural findings. Valdez-Valenzuela, F., *et al.* ..... (A) 141A
Gangliosides (cronassial) and leprosy neuropathy; a randomized, placebo-controlled trial. Salafia, A., *et al.* ..... (A) 14A

Neutrophil(s),
An *in vitro* comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase-A2 activity and superoxide generation. Krajewska, M. M. and Anderson, R. ..... (A) 486

New Caledonia,
Multidrug therapy for treatment of leprosy patients in New Caledonia and French Polynesia; results after 10 years. Crouzat, M., *et al.* ..... (A) 2A

New Zealand,
Acquisition of autoimmunity genes by New Zealand mice is associated with natural resistance to infection by mycobacteria. Esaguy, N., *et al.* ..... (A) 160
Leprosy elimination plan for South Pacific agreed. ..... (N) 331

Nicaragua,
[A focus of leprosy in San Francisco Libre, Nicaragua–1990.] Gomez, C. A., *et al.* ..... (A) 148

Nigeria,
Evaluation of MDT implementation for leprosy control in Bendel State of Nigeria (1985-1990). Majoroh, T. O. ..... (A) 42A
Integration of eye care in leprosy control in northern Nigeria. Verhage, R. ..... (A) 41A
Integration of leprosy control program into primary health care; 4-year preliminary study in Ogun State of Nigeria. Krishnan, S. A. R., *et al.* ..... (A) 51A
Leprosy among university and high school students in Benin City, Nigeria: an eight year review. Kubeyinje, E. P. and Onunu, A. N. ..... (A) 126
Results of MDT implementation in the Mile Four Leprosy Control Project, Abakaliki, Enugu State, Nigeria. MacRae, M. A. and Vennemann, M. ..... (A) 53A
Sixty years of leprosy control in southeastern Nigeria: the Uzuakoli experience. Chukwu, J. N. and Ededezie, U. M. ..... (A) 58A

Nose,
Application of a polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. Douglas, J. T., *et al.* ..... (A) 109A
Correction of mild and moderate saddle nose deformity in leprosy by a one-stage procedure. Malaviya, G. N. and Husain, S. ..... (A) 151A
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of leprosy patients and their contacts. Pattyn, S. R., *et al.* ..... (O) 389
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of patients and their contacts. Pattyn, S., *et al.* ..... (A) 107A
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Detection of *M. leprae* nasal carriage in a leprosy-endemic population. Klatser, P. R., *et al.* ..... (A) 75A
Enhanced chemiluminescent assay (ECL): a highly sensitive method for the detection of *M. leprae* infection in nasal secretions. Sciulli, R., *et al.* ..... (A) 109A
Leprosy bacilli in smears from nasal mucosa. MaCrery, R., *et al.* ..... (A) 32A
[Memories on the investigation of leprosy of the upper respiratory tract.] Yoshie, Y. ..... (A) 345
Polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. De Wit, M. Y. L., *et al.* ..... (A) 362

Nutrition,
Nutrition, growth and mental development of children of urban leprosy patients. Rao, K. N. ..... (A) 140A

Obituaries,
Edgar, William Robert. Hastings, R. C ..... (Ob) 112
Tarabini-Castellani, Prof. Giovanni. Terencio de las Aguas, J. ..... (Ob) 113

Ofloxacin,
Bactericidal activity of ofloxacin against *M. leprae*. Franco, R. J., *et al.* ..... (A) 14A
In vitro synergistic activity between ofloxacin and ansamycin against *M. leprae*. Dhople, A. M., *et al.* ..... (A) 485
LAMMA monitoring of ofloxacin-treated patients. Haas, M. ..... (A) 314
Ofloxacin in antileprosy combinations; preliminary experiences. Leguizamon, O. R. ... (A) 314
Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 8A
Ofloxacin-rifampin trials in multibacillary leprosy-preliminary observations on reactive episodes. Ganapati, R., *et al.* ..... (A) 8A
Possible role of ofloxacin in arresting reversal reaction. Kharkar, R. D., *et al.* ..... (A) 34A
Sparfloxacin is more bactericidal than ofloxacin against *M. leprae* in mice. Franzblau, S. G., *et al.* ..... (O) 66
Susceptibility of M. kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Witzig, R. S. and Franzblau, S. G. ..... (A) 671
The effect of ofloxacin to MDT resistance—a case report. Ishida, Y. and Mizushima, M. ..... (A) 169A
Therapeutic efficacy of some new quinolones and a combination of ofloxacin and rifampin against *M. leprae* infection induced in athymic nude mice. Tomioka, H. and Saito, H. ..... (O) 250

Onchocerciasis,
Integration of a leprosy-tuberculosis-onchocerciasis control program into a primary health care program in the forest region of Guinea. Wiher, H. and Sherif, A. ..... (A) 42A

Pakistan,
Leprosy in Karachi. Arain, G. M., *et al.* ..... (A) 656

Papua New Guinea,
National Leprosy Elimination Program of Papua New Guinea, first year of implementation. Malau, C. and Quimpo, R. J. ..... (A) 47A

Paraguay,
A 20-year review of amputations in the National Leprosy Control Program in Paraguay. Duerksen, F., *et al.* ..... (A) 162A
Leprosy in a HIV-positive and syphilitic young Paraguayan man. von Ballestrem, W., *et al.* ..... (A) 341

Pathology,
Effect of treatment on leprosy pathology. Cree, I., *et al.* ..... (A) 126A
Intraocular pressure in leprosy patients without apparent anterior segment pathology. Daniel, E., *et al.* ..... (A) 119A
Secondary amyloidosis in leprosy. Abalos, R. M., *et al.* ..... (A) 125A

Pefloxacin,
[Effects of short-term pefloxacin on MB leprosy patients and follow up for them.] Li, W.-H., *et al.* ..... (A) 338

Peroxidase,
Characterization of the katG gene encoding a catalase peroxidase required for the isoniazid susceptibility of *M. tuberculosis*. Heym, B., *et al.* ..... (A) 661
Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Bozeman, P. M., *et al.* ..... (A) 121
Phagocytic myeloperoxidase as a killing factor for *M. leprae*. Maslov, A. ..... (A) 113A
The catalase-peroxidase of *M. intracellulare*: nucleotide sequence analysis and expression in *Escherichia coli*. Morris, S. L., *et al.* ..... (A) 142

Persisters,
Bacillary persisters in murine leprosy. Chang, Y. T. ..... (A) 76A
Granuloma persistance after clinical inactivity. Porichha, D., *et al.* ..... (A) 124A
Neonatally thymectomized Lewis rat as a model for the elimination of "persisters" by chemotherapy. Siu, P., *et al.* ..... (A) 78A
Persistence of *M. leprae* in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Shetty, V. P., *et al.* ..... (A) 344

Peru,
Active search for leprosy patients by paramedical personnel in Alto Amazonas Province, Loreto Region, Perus, November 1987 December 1989. Falconi, E., *et al.* .....(A) 49A
Leprosy control program (LCP) in Alto Amazonas Province, Loreto Region, Peru, October 1987-September 1990. Legua, P., *et al.* .....(A) 49A
Leprosy control program in Loreto Region, Peru, October 1990 March 1992. Falconi, E., *et al.* .....(A) 63A
Psychological aspects of leprosy patients in Alto Amazonas Province, Loreto Region, Peru, October 1987-September 1990. Valencia, E., *et al.* .....(A) 131A

Phagocyte(s),
Inhibition of growth of *M. avium* in murine and human mononuclear phagocytes by migration inhibitory factor. Orme, I. M., *et al.* .....(A) 375
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma-delta T cells activated by live *M. tuberculosis*. Boom, W. H., *et al.* .....(A) 153

Pharmacokinetic(s),
Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteer. Edstein, M. D. and Rieckmann, K. H. .....(A) 647

Phenolic glycolipid(s),
A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemo-autotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* .....(A) 112A
A longitudinal study of the predictive value of the lepromin response and anti-PGL-I serology in children. Naik, S., *et al.* .....(A) 72A
A prospective immunoepidemiologic study using MLSA and ELISA for antibodies against PGL-I. Krishnamurthy, P., *et al.* .....(A) 73A
A seroepidemiological study of leprosy in household contacts and healthy population based on ELISA using ND-O-BSA and PGL I as antigens. Li, W., *et al.* .....(A) 67A
A 10-year follow-up study on leprosy contact population by PGL I serology for the early diagnosis of leprosy. Chanteau, S., *et al.* .....(A) 72A
A trial based on PGL-I serology for leprosy control; preliminary results. Gonzalez-Abreu, E. and Gonzalez, A. B. .....(A) 49A
Anti-PGL-I levels in leprosy patients and their contacts. Foss, N. T., *et al.* .....(A) 500
Characterization of the specific recognition sites of monoclonal antibodies to the PGL-I of *M. leprae*. Fujiwara, T., *et al.* .....(A) 78A
Clinical significance of anti-PGL-I antibody in multibacillary leprosy patients. Ma, J., *et al.* .....(A) 31A
Demonstration of PGL-I and LAM-B in paraffin sections of leprosy skin lesions. Wang, T., *et al.* .....(A) 120A
Detection of IgA anti-PGL-I in mangabey monkey inoculated with *M. leprae*. Saad, M. H. F., *et al.* .....(A) 80A
Detection of PGL-I in the chemoautotrophic nocardioform (CAN) bacteria. Sen, A., *et al.* .....(A) 112A
Detection of antibodies to phenolic glycolipid by ELISA in leprosy patients. Lal, H., *et al.* .....(A) 350
[Determination of antiphenolic glycolipid antibodies in a general population of an area endemic for leprosy.] Mor, N., *et al.* .....(A) 363
Does the difference of the properties of trisaccharide-BSA conjugate (NT-P-BSA) of *M. leprae* phenolic glycolipid influence its seroreactivity? Fujiwara, T., *et al.* .....(A) 348
Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Drowart, A., *et al.* .....(O) 29
Gelatin particle agglutination assay to detect anti-PGL-I antibodies in leprosy patients and in household contacts: a preliminary study. Mahajan, P., *et al.* .....(A) 351
Higher specificity in the serodiagnosis of leprosy by combined titration of antiphenolic glycolipid-I and antiphospholipid antibodies. Fiallo, P., *et al.* .....(C) 464
Human leprosy lesions *in situ* using suction-induced blisters: cell changes with IgM antibody to PGL-I and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum. Bhoopat, L., *et al.* .....(A) 99A
IgM serum antibodies to PGL-I by ELISA in healthy subjects and leprosy patients. Meng, M., *et al.* .....(A) 92A

Immunohistochemical demonstration of PGL-I antigen in the skin and nervous system of leprosy patients. Goto, M., *et al.* ..... (A) 120A
Investigation of patients with longstanding high levels of anti-PGL-I after release from treatment. Faber, W. R. and Klatser, P. R. ..... (A) 23A
Low predictive value of PGL-I serology for the early diagnosis of leprosy in family contacts: results of a 10 yeaer prospective field study in French Polynesia. Chanteau, S., *et al.* ..... (O) 533
M. leprae LAM and PGL-I antibodies crossreact with HIV-1 antibodies in sera from HIV-1-seronegative leprosy patients and their contacts. Kashala, O., *et al.* ..... (A) 97A
PGL-I-like antigen in renal carcinoma. Makino, M., *et al.* ..... (A) 91A
Palmitric acid oxidation and PGL-I synthesis. Franzblau, S. G., *et al.* ..... (A) 308
Production of monoclonal antibody to a phenolic glycolipid of *M. tuberculosis* and its use in detection of the antigen in clinical isolates. Cho, S.-N., *et al.* ..... (A) 155
Relationship between anti-PGL-I antibody (IgM) level and relapses in cured leprosy patients. Sun, C., *et al.* ..... (A) 32A
Role of anti-*M. leprae* PGL-I antibodies in assessing the contacts of leprosy patients in a low-endemic area. Soares, D. J., *et al.* ..... (A) 73A
Sensitization *in vitro* of human peripheral blood mononuclear cells to phenolic glycolipid I of *M. leprae* in liposomes. Schauf, V., *et al.* ..... (A) 138
Significance of antibodies to phenolic glycolipid-I in leprosy diagnosis. Prakash, K., *et al.* ..... (A) 654
Suppression of human monocyte cytokine release by PGL-I of *M. leprae.* Silva, C. L., *et al.* ..... (A) 92A
Suppression of human monocyte cytokine release by phenolic glycolipid-I of *M. leprae.* Silva, C. L., *et al.* ..... (C) 107
Use of PGL-immunoassays in seroepidemiological studies of *M. leprae* infection in Malaysia. Gan, S. C. and Fujiwara, T. ..... (A) 73A
Use of PGl-I in the follow up of multibacillary leprosy patients under surveillance after release from treatment (RFT). Avelleira, J. C., *et al.* ..... (A) 11A

Philippines, The,
A study of prevalence of child leprosy in Ilocos Norte, The Philippines (1986)1992). Cabanos, G. C. ..... (A) 71A
Cross-sectional assessment of ELISA reactivity in leprosy patient, contacts, and normal population using the semisynthetic antigen natural disaccharide octyl bovine serum albumin (ND-O-BSA) in Cebu, The Philippines. Cellona, R. V., *et al.* ..... (O) 192
Primary dapsone resistance in Cebu, The Philippines: recent findings. Cellona, R. V., *et al.* ..... (A) 6A
Seroepidemiological assessment of leprosy in Culion, The Philippines. Cunanan, A., Jr., *et al.* ..... (A) 73A
Study of 315 multibacillary cases of leprosy under MDT at JNRMH, Tala, Rizal, The Philippines. Samson, R. C. and Dayunghirang, J. ..... (A) 10A
The Philippines' Manual of Training; MDT for Leprosy available. ..... (N) 118

Phospholipid(s),
An *in vitro* comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase-A2 activity and superoxide generation. Krajewska, M. M. and Anderson, R. ..... (A) 486
Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Van Rensburg, C. E. J., *et al.* ..... (A) 124
Higher specificity in the serodiagnosis of leprosy by combined titration of antiphenolic glycolipid-I and antiphospholipid antibodies. Fiallo, P., *et al.* ..... (C) 464
Regulation of phospholipid synthesis in *M. smegmatis* by cyclic adenosine monophosphate. Sareen, M., *et al.* ..... (A) 656
The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines *in vitro* by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Van Rensburg, C. E. J., *et al.* ..... (A) 378

Polymerase chain reaction (PCR),
Application of a polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. Douglas, J. T., *et al.* ..... (A) 109A

Assessment of mycobacterial infection and multiplication in macrophages of polymerase chain reaction. Barrera, L. F., *et al.* ..... (A) 367
Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65-kDa antigen gene, in the diagnosis of tuberculosis. Walker, D. A., *et al.* ..... (A) 181
DNA fragment length polymorphism analysis of *M. tuberculosis* isolated by arbitrarily primed polymerase chain reaction. Palittapongarnpim, P., *et al.* ..... (A) 496
Detection and identification of *M. tuberculosis, M. bovis* BCG and *M. avium* by 2-step polymerase chain reaction—comparison with ELISA using A60 antigen. Bollet, C., *et al.* ..... (A) 153
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ..... (A) 145
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of leprosy patients and their contacts. Pattyn, S. R., *et al.* ..... (O) 389
Detection of *M. leprae* by the polymerase chain reaction in nasal swabs of patients and their contacts. Pattyn, S., *et al.* ..... (A) 107A
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Detection of *M. tuberculosis* DNA in clinical samples by using a simple lysis method and polymerase chain reaction. Folgueira, L., *et al.* ..... (A) 494
Detection of *M. tuberculosis* in clinical samples by 2-step polymerase chain reaction and nonistropic hybridization methods. Shawar, R. M., *et al.* ..... (A) 177
Detection of *M. tuberculosis* in clinical samples by using polymerase chain reaction and a nonradioactive detection system. Kolk, A. H. J., *et al.* ..... (A) 166
Detection of *M. tuberculosis* in sputum samples by polymerase chain reaction using a simplified procedure. Kocagoz, T., *et al.* ..... (A) 663
Detection of leprosy infection by serology and polymerase chain reaction; an epidemiological study in South Sulawesi, Indonesia. van Beers, S., *et al.* ..... (A) 67A
Detection of mycobacteria in tissue by polymerase chain reaction. Gerdes, J., *et al.* ..... (A) 309
Diagnosis of *M. avium* bacteremia by polymerase chain reaction. Iralu, J. V., *et al.* ..... (A) 662
Direct detection of *M. tuberculosis* in respiratory specimens in a clnical laboratory by polymerase chain reaction. Forbes, B. A. and Hicks, K. E. S. ..... (A) 660
Direct detection of *M. tuberculosis* in sputum by polymerase chain reaction and DNA hybridization. Nolte, F. S., *et al.* ..... (A) 666
Effects of fixation on polymerase chain reaction detection of *M. leprae.* Fiallo, P., *et al.* (A) 141
Electron microscopy, polymerase chain reaction and serodiagnosis as tools for assessing leprosy treatment. Nasr, E. M., *et al.* ..... (A) 17A
Evaluation of polymerase chain reaction amplification of *M. leprae*-specific repetitive sequence in biopsy specimens from leprosy patients. Yoon, K.-H., *et al.* ..... (A) 360
Evaluation of polymerase chain reactions, tuberculostearic acid analysis, and direct microscopy for the detection of *M. tuberculosis* in sputum. Savic, B., *et al.* ..... (A) 176
Genus-specific polymerase chain reaction for the mycobacterial dnaJ gene and species-specific oligonucleotide probes. Takewaki, S., *et al.* ..... (A) 377
M. smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Levin, M. E. and Hatfull, G. F. ..... (A) 495
Mixed-linker polymerase chain reaction: a new method for rapid fingerprinting of isolates of the *M. tuberculosis* complex. Haas, W. H., *et al.* ..... (A) 505
Molecular cloning and characterization of contiguously located repetitive and single copy DNA sequences of *M. tuberculosis*: development of PCR-based diagnostic assay. Reddi, P. P., *et al.* ..... (O) 227
Polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp. *silvaticum* in long term cultures from Crohn's disease. Moss, M. T., *et al.* ..... (A) 170
Polymerase chain reaction en la lepra. Terencio de las Aguas, J., *et al.* ..... (A) 33A
Polymerase chain reaction for detection of *M. leprae* in nasal swab specimens. De Wit, M. Y. L., *et al.* ..... (A) 362
Polymerase chain reaction for the detection of *M. leprae* in skin tissue. Kampirapap, K., *et al.* ..... (A) 108A
Polymerase chain reaction to detect *M. tuberculosis* in a clinical microbiology laboratory. Veringa, E., *et al.* ..... (A) 180

Progress toward a simplified polymerase chain reaction and it application to diagnosis of tuberculosis. Wilson, S. M., *et al.* ..... (A) 360
Rapid detection of tuberculous and non-tuberculous mycobacteria by polymerase chain reaction amplification of a 162 bp DNA fragment from antigen-85. Fauvilledufaux, M., *et al.* ..... (A) 161
Rapid identification of mycobacteria to the species level of polymerase chain reaction and restriction enzyme analysis. Telenti, A., *et al.* ..... (A) 377
Rapid, simple method of typing isolates of *M. tuberculosis* by using the polymerase chain reaction. Ross, B. C. and Dwyer, B. ..... (A) 376
The detection of *M. tuberculosis* in uncultured clinical specimens using the polymerase chain reaction and a non radioactive DNA probe. Thierry, D., *et al.* ..... (A) 178
Utilizacion de 3 sistemas de PCR para la deteccion de ADN de *M. leprae* en muestras quimicas. Maestre Mesa, J., *et al.* ..... (A) 109A

Polynesia,
Association of leprosy and tuberculosis between 1902 and 1991 in French Polynesia. Glaziou, P., *et al.* ..... (A) 64A
Leprosy in French Polynesia. Cartel, J.-L., *et al.* ..... (A) 147
Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Cartel, J.-L., *et al.* ..... (A) 147
Low predictive value of PGL-I sserology for the early diagnosis of leprosy in family contacts: results of a 10 yeaer prospective field study in French Polynesia. Chanteau, S., *et al.* ..... (O) 533
Multidrug therapy for treatment of leprosy patients in New Caledonia and French Polynesia; results after 10 years. Crouzat, M., *et al.* ..... (A) 2A
Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia. Glaziou, P., *et al.* ..... (O) 199

Pregnancy,
Pregnancy is a risk factor for relapse and new nerve damage even after MDT. Duncan, M. E., *et al.* ..... (A) 21A

Protein(s),
A 25-kDa portion of the 65-kDa protein of *M. leprae* has immunoprotective properties. Mahadevan, P. R. and Kulkarni, A. ..... (A) 83A
A family of cross-reacting proteins secreted by *M. tuberculosis.* Wiker, H. G., *et al.* ... (A) 182
A novel protein antigen secreted by *M. leprae*: the homolog of *M. tuberculosis* MPT32. Wieles, B., *et al.* ..... (A) 84A
Altered calcium-binding ability of plasma proteins as the cause of hypocalcemia in lepromatous leprosy. Vidal, M. C., *et al.* ..... (O) 586
Analysis of B-cell epitopes on the variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein. Peake, P. W., *et al.* ..... (A) 352
Anti-peripheral nerve antibodies in leprosy patients recognize an epitope shared by the *M. leprae* 65 kDa heat shock protein. Launois, P., *et al.* ..... (A) 350
Antibodies to *M. paratuberculosis*-specific protein antigens in Crohn's disease. Elsaghier, A., *et al.* ..... (A) 159
Application of S-100 protein stain in the diagnosis of leprosy. Shen, J., *et al.* ..... (A) 121A
Biochemical characterization of two new major proteins of *M. leprae.* Pessolani, C., *et al.* ..... (A) 115A
Cloning and expression of portions of the 34-kilodalton protein gene to *M. paratuberculosis*: its application to serological analysis of Johne's disease. De Kesel, M., *et al.* (A) 369
Composition and immunological properties of the protein fraction of A36, a major antigen complex of *M. paratuberculosis.* DeKesel, M., *et al.* ..... (A) 141
Correlation between TNK production, increase of plasma C reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Foss, N. T., *et al.* ..... (O) 218
Detection of 65-kDa heat-shock protein from sera of leprosy patients—mycobacterial or autoantigen origin. Elangeswaran, N., *et al.* ..... (A) 90A
Effect of multidrug therapy on plasma level of high density lipoprotein cholesterol (HDL-C) in patients of lepromatous leprosy. Kumar, N. and Sharma, B. L. ..... (A) 33A

Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Drowart, A., *et al.* ..... (O) 29
Genetic control of immune responses to the 18-kDa protein of *M. leprae*; different TH1 subsets may be involved in proliferative and delayed-type hypersensitivity. Backstrom, B. T., *et al.* ..... (A) 129
Heat-shock proteins in leprosy reversal reactions. Lockwood, D., *et al.* ..... (A) 84A
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kDa-region proteins and the secreted antigen-85 complex and demonstration of antigen-85B on the *M. leprae* cell wall surface. Rambukkana, A., *et al.* ..... (A) 136
Human T-cell clones recognize mycobacterial specific and shared epitopes on *M. leprae* 70-kDa protein. Adams, E., *et al.* ..... (A) 104A
IL-6 production in response to purified mycobacterial heat shock proteins and to antigen 85 in leprosy. Launois, P., *et al.* ..... (A) 653
Identification and characterization of epitopes shared between the mycobacterial 65-kilodalton heat shock protein and the actively secreted antigen-85 complex—their *in situ* expression on the cell wall surface of *M. leprae*. Rambukkana, A., *et al.* ..... (A) 143
Identification of 2-dimensional gel electrophoresis of a 58 kilodalton tumor necrosis factor-inducing protein of *M. tuberculosis*. Wallis, R. S., *et al.* ..... (A) 355
Identification of IL-8 as a locomotor attractant for activated human lymphocytes in mononuclear cell cultures with anti-CD3 or purified protein derivative of *M. tuberculosis*. Wilkinson, P. C. and Newman, I. ..... (A) 183
Identification of T-cell stimulatory epitopes from the 18-kDa protein of *M. leprae*. Doherty, T. M., *et al.* ..... (A) 652
IgG activity toward purified heat-shock proteins and antigen 86\5 in leprosy patients and their contacts. Launois, P., *et al.* ..... (A) 89A
Immunization with extracellular proteins of *M. tuberculosis* includes cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Pal, P. G. and Horwitz, M. A. ..... (A) 171
Immunochemical characterization of 32-kDa cytosolic protein of *M. habana*: a candidate vaccine. Sinha, S., *et al.* ..... (A) 91A
Isolation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunized with living mycobacteria. Romain, F., *et al.* (A) 490
Labeling of the 65-kDa heat-shock protein in *M. leprae* and other mycobacterial species. Esaguy, N. ..... (A) 110A
Localisation of linear epitopes at the carboxy-terminal end of the mycobacterial 71 kDa heat shock protein. Elsaghier, A., *et al.* ..... (A) 159
M. leprae 10-kDa heat-shock protein is a major T-cell antigen. Mehra, V., *et al.* ..... (A) 88A
Major histocompatibility complex non-restricted presentation to CD4+ lymphocytes-T of *M. leprae* heat-shock protein-65 antigen by macrophages transfected with the mycobacterial gene. Silva, C. L., *et al.* ..... (A) 354
Mycobacterial 65,000 MW heat-shock protein shares a carboxy terminal epitope with human epidermal cytokeratin-1/2. Rambukkana, A., *et al.* ..... (A) 174
Mycobacterial heat-shock proteins as carrier molecules. Lussow, A. R., *et al.* ..... (A) 135
Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Friedland, J. S., *et al.* ..... (A) 347
N-Terminal amino-acid sequencing of *M. leprae* proteins: definition of the L12 ribosomal protein. Pessolani, C., *et al.* ..... (A) 106A
Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen. Yokota, S., *et al.* (A) 491
Protection of mice by vaccination with purified and recombinant major *M. leprae* proteins and polypeptides. Gelber, R. H., *et al.* ..... (A) 103A
Serological response against crossreactive cell-wall antigens (65-kDa protein and LAM-B) in leprosy. Elangeswaran, N., *et al.* ..... (A) 89A
Stable integration and expression of *Plasmodium falciparum* circumsporozoite protein coding sequence in mycobacteria. Haeseleer, F., *et al.* ..... (A) 372
Structures of glycopeptidolipid antigens of serovar-25 and serovar-26 of the *M. avium* serocomplex, synthesis of allyl glycosides of the outer disaccharide units and serology of the derived neoglycoproteins. Aspinall, G. O., *et al.* ..... (A) 366
Subcellular fractionation of *M. leprae* and the search for new proteins. Chitale, S. and Brennan, P. J. ..... (A) 115A

Synthesis of species-specific *M. avium* trisaccharide (serovar 21) for the preparation of a neoglycoprotein for immunological studies. Ziegler, T. ..... (A) 183
T-cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. Pervin, K., *et al.* ..... (A) 667
TNF-alpha response to human monocyte-derived macrophages to *M. avium*, serovar 4, is a brief duration and protein kinase C dependent. Gan, H., *et al.* ..... (A) 494
The 38-kDa protein of *M. tuberculosis*—a review. Harboe, M. and Wiker, H. G. ..... (A) 162
The 65-kDa protein of *M. habana* and its putative role in immunity against *M. tuberculosis*. Singh, N. B. ..... (A) 83A
Trifluoperazine inhibits the incorporation of labeled precursors into lipids, proteins and DNA of *M. tuberculosis* H37Rv. Ratnaker, P. and Murthy, P. A. ..... (A) 668
Whole-cell protein electrophoresis for typing *M. tuberculosis*. Millership, S. E. and Want, S. V. ..... (A) 170

Prothionamide,
Treatment of paucibacillary leprosy with a regimen containing rifampicin, dapsone and prothionamide. Katoch, K., *et al.* ..... (A) 123
Treatment of paucibacillary patients with MDT containing rifampin, dapsone and prothionamide. Katoch, K., *et al.* ..... (A) 2A

Psychosocial,
A survey of job satisfaction among leprosy personnel. Premkumar, R., *et al.* ..... (A) 136A
Action kit: a means of promoting leprosy awareness. Gruner, M. ..... (A) 163A
Analysis of mental health state of leprosy patients. Yi, S. and Miao, Z. ..... (A) 131A
Coping style in leprosy. Henry, D. E., *et al.* ..... (A) 135A
Determinant about irregularity on ambulatorial treatment of leprosy in a university hospital. Rosa Santos, O. L., *et al.* ..... (A) 136A
Health education has changed the attitude of society toward leprosy. Roy, P. K., *et al.* (A) 12A
How the media affects leprosy patients. Malo, B. and Monson, V. ..... (A) 137A
Human relations research among leprosy personnel and strategies for behavior modification. Premkumar, R., *et al.* ..... (A) 138A
Informacion, conocimiento y estigma en la enfermedad de Hansen. Perez, M., *et al.* ..... (A) 133A
Leprosy: a sociological or medical problem? Ekekezie, U. M. ..... (A) 130A
Proyecto de educacion en salud para el combate al estigma de la lepra. Cypreste, D. M. (A) 133A
Proyecto para el atendimiento a los pacientes idiozos del Sanatorio Dr. Pedro Fontes. Cypreste, D. M. ..... (A) 133A
Psychosocial problems of cured leprosy patients; an intercontinental comparative study. Abraham, T., *et al.* ..... (A) 130A
Psychosocial treatment for leprosy patients: methodology for individualized approach in routine treatment. Raju, M. A., *et al.* ..... (A) 134A
Public preconceptions of leprosy; a linguistic approach. Bjune, G., *et al.* ..... (A) 137A
Restructuring the colony-asylum hospital; a shared activity of the government, patients and society at large. Rodrigues, A. L., *et al.* ..... (A) 139A
Social action for leprosy control. Mutatkar, R. K. ..... (A) 130A
Social advertising for leprosy. Salgado, S., *et al.* ..... (A) 134A
Social marketing: a new strategy to eliminate leprosy. Grewal, P., *et al.* ..... (A) 134A
Social marketing approach to leprosy. Dewapura, D., *et al.* ..... (A) 129A
Social problems of women leprosy patients- a study conducted at Delhi urban leprosy centers. Kaur, H. and Ramesh, V. ..... (A) 130A
Sociocultural dimensions of leprosy in Botswanna. Kumaresan, J. A. and Maganu, E. T. ..... (A) 128A
Socioeconomic and psychosocial dimensions of leprosy: a case study on treatment types and patient compliance. Shanmuganandan, S., *et al.* ..... (A) 137A
The future of leprosy stigma in view of its present metaphors: a comparative analysis. Navon, L. ..... (A) 128A
The social identity of the physical handicapped. Rodrigues, M. M. P., *et al.* ..... (A) 134A
Toward an understanding of the stigmatization of leprosy. Spink, M. J., *et al.* ..... (A) 132A

Purification,
Purification of a mycobacterial adhesin for fibronectin. Ratliff, T. L., *et al.* ..... (A) 497
Purification of polyphosphate and ATP glucose phosphotransferase from *M. tuberculosis* H37Ra: evidence that poly(P) and ATP glucokinase activities are catalyzed by the same enzyme. Hsieh, P.-C., *et al.* ..... (A) 373

Purified protein derivative (PPD),
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (O) 204
Identification of IL-8 as a locomotor attractant for activated human lymphocytes in mononuclear cell cultures with anti-CD3 or purified protein derivative of *M. tuberculosis*. Wilkinson, P. C. and Newman, I. ..... (A) 183

Rat(s),
Neonatally thymectomized Lewis rat as a model for the elimination of "persisters" by chemotherapy. Siu, P., *et al.* ..... (A) 78A
Reconstruction of antileprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and C(rat)EDTA (a source of C3-C9). Kashyap, A., *et al.* ..... (A) 123
The neonatally thymectomized Lewis rat as a tool for chemotherapy research. Gelber, R. H. ..... (A) 311

Reaction, leprosy,
A potential marker for the prediction of ENL reactions. Singh, S., *et al.* ..... (A) 99A
Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A
Antibody responses to various antigens of *M. leprae* in borderline leprosy with or in reaction. Sudha, R. and Stanley, J. N. A. ..... (A) 93A
Appearance of delta-gamma T cell receptor-positive cells following alpha-beta T cell receptor-positive cells in the lepromin reaction of human skin. Fujita, M., *et al.* ..... (A) 348
Association of NK (CD16+) cells and cytokines with *M. leprae* specific responses in type 1 reactions. Esquenazi, D. A., *et al.* ..... (A) 87A
Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Lockwood, D. N. J., *et al.* ..... (O) 9
Clinical study of lepra reactions in 123 cases treated by MDT. Mohareb, R. W. ..... (A) 24A
Colchicine in type 2 lepra reaction and its comparison with corticosteroids. Katkar, K. N. and Jagavkar, C. K. ..... (A) 8A
Consensual ophthalmotonic reaction in leprosy patients. Karacorlu, M. and Cakiner, T. ... (A) 117A
Correlation between TNF production, increase of CRP level, and suppression of T lymphocytes during ENL reaction. Foss, N. T. and Silva, C. L. ..... (A) 102A
Cyclosporin treatment in reversal reaction. Chin-A-Lien, R. A. M., *et al.* ..... (A) 25A
Cytokine mRNA expression in lepromatous leprosy and the reactional states in leprosy. Sampaio, E. P., *et al.* ..... (A) 102A
Cytokines in immunopathology of lepra reaction. Parida, S. K., *et al.* ..... (A) 87A
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (O) 204
Factors affecting risk of type 1 reaction among multibacillary patients. Muliyil, J. ..... (A) 24A
Heat-shock proteins in leprosy reversal reactions. Lockwood, D., *et al.* ..... (A) 84A
Histological analysis of the Mitsuda reaction in contacts of multibacillary leprosy patients. Trindade, M. A. B. and Fleury, R. N. ..... (C) 109
Histopathological analysis of skin biopsies performed in leprosy patients: reaction or relapse? Schettini, A. P., *et al.* ..... (A) 122A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ..... (A) 345
Late reversal reaction in paucibacillary patients after MDT—its incidence rate, time of onset, modes or presentation. Ananth Reddy, S., *et al.* ..... (A) 25A
Leprosy reversal reaction in HIV-positive patients. Blum, L., *et al.* ..... (O) 214
M. leprae-responsive T lymphocytes and blood monocytes in a rare reactional form of leprosy, the Lucio phenomenon. Pereira, G. M. B., *et al.* ..... (A) 95A
Monitoring peripheral nerve involvement during reactions. Figarola, J. ..... (A) 146A

Natural history and clinical features of reversal reaction in Hyderabad, India. Lockwood, D., *et al.* ..... (A) 23A
Neopterin as a marker for reactional leprosy. Hamerlinck, F. F. V., *et al.* ..... (A) 25A
Possible role of ofloxacin in arresting reversal reaction. Kharkar, R. D., *et al.* ..... (A) 34A
Reaction in borderline tuberculoid leprosy presenting with multiple subcutaneous nodules. Jayakumar, J., *et al.* ..... (A) 650
Reaction type 2 of HD (ENL) with visceral involvement: index for the severity of the disease, clinical, laboratorial and autopsy study of 34 patients. Margarido-Marchese, L. C., *et al.* ..... (A) 124A
[Reactional episodes in leprosy.] Sanchez, L. N. and Diaz, H. B. ..... (A) 487
Reactions immunologiques observees a l'Institut Cardinal Leger pendant une periode de 8 ans. Leveille, C. A., *et al.* ..... (A) 24A
Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w*. Sharma, A. K., *et al.* ..... (A) 24A
Shoreline nails following type II lepra reaction. Pavithran, K. ..... (A) 650
Significance and management of reactive patches in leprosy type 1 reaction. Kiran, U., *et al.* ..... (A) 24A
Study of late reversal reaction in paucibacillary patients after multidrug treatment—its incidence rate, time of onset, mode of presentation and management. Chopra, N. K., *et al.* ..... (A) 25A
Thalidomide—a clinical study of 33 cases of type 2 lepra reaction. Kishore, V. ..... (A) 23A
Tumor necrosis factor (TNF) in leprosy patient with type 2 reaction. Gomez, M., *et al.* ..... (A) 101A

Rehabilitation,
Comparison of sensory results of the thermal tester and the Semmes-Weinstein light touch/pressure in persons with Hansen's disease and without known disease. Lehman, L. and Berenhoff, J. ..... (A) 145A
Community-based rehabilitation program of The Leprosy Mission, India. Samson, P. D., *et al.* ..... (A) 140A
Elimination of leprosy and prospects for rehabilitation. Smith, W. C. S. and Jesudasan, K. ..... (A) 363
Evaluation of community-based rehabilitation for leprosy patients in the South India experience. Rajan Babu, G. ..... (A) 152A
External fixators and distractors in leprosy. Salafia, A. and Chauhan, G. ..... (A) 149A
First North American Regional Conference of Rehabilitation International to be held. (N) 334
Following the rehabilitation of Hansen's disease patients under social aspects. Oliveira, E. R., *et al.* ..... (A) 135A
Genesis and profile of leprosy beggars in Madras city and its lessons for rehabilitation programs. Lobo, D., *et al.* ..... (A) 129A
Importance of social rehabilitation of the patients in leprosy control. Soydan, M., *et al.* ..... (A) 135A
Integration of leprosy into general rehabilitation schemes—an experiment in Bombay. Kathe, V., *et al.* ..... (A) 140A
Leprosy and rehabilitation—a primary health care approach. Awofeso, N. ..... (A) 142A
Pre- and postoperative rehabilitation for tendon transfers. Hoard, A. and Mathews, R. ..... (A) 162A
Project for implanting integrated health attention centers for rehabilitation in the 65 health subregions of the State of Sao Paulo, Brazil, for the period 1993 to 1995. Nogueira, W., *et al.* ..... (A) 47A
Rehabilitation International Working Group on Leprosy. ..... (N) 331
Rehabilitation of leprosy handicap by Modulan grip aids; an evaluation. Shah, A., *et al.* ..... (A) 152A
Rehabilitation of people with leprosy. Akai, P. S. ..... (A) 155A
Rehabilitation organizations initiate coordination process. ..... (N) 480
Rehabilitation: restoring to usefulness. Malo, M. ..... (A) 132A
Semmes-Weinsein monofilament detection thresholds: a comparative study. Bell-Krotoski, J. and Coor, V. ..... (A) 146A
Social aspects of disability and rehabilitation in leprosy. Saxena, M. and Kochar, V. ..... (A) 130A
Socioeconomic rehabilitation of leprosy patients released from control; the Karigiri experience. Thomas, M. V., *et al.* ..... (A) 128A
Study of psychiatric morbidity in Hansen's disease at a rehabilitation center. Sagar Reddy, V. V., *et al.* ..... (A) 137A

Relapse(s),
An analysis of relapses among 21, 878 cured leprosy patients. Hong, B., *et al.* .....(A) 55A
Borderline tuberculoid relapse in lepromatous leprosy. Girdhar, B. K., *et al.* .....(A) 649
Clinical assessment, BI, MI, relapse rate. Waters, M. F. R. .....(A) 311
Clinically atypical relapses in multibacillary patients. Jamet, P. and Bobin, P. .....(A) 21A
Histopathological analysis of skin biopsies performed in leprosy patients: reaction or relapse? Schettini, A. P., *et al.* .....(A) 122A
Low risk of relapse after paucibacillary treatment among childhood leprosy patients. Jayaraj, V. P. and Samson, P. D. .....(A) 3A
Pregnancy is a risk factor for relapse and new nerve damage even after MDT. Duncan, M. E., *et al.* .....(A) 21A
Preliminary exploration of leprosy relapse surveillance with immunologic assays. Weng, X., *et al.* .....(A) 61A
Problems of leprosy relapse in China. Li, H.-Y. .....(O) 1
Profile of relapse cases in field trial of combined therapy in multibacillary leprosy. Rajendran, V., *et al.* .....(A) 4A
Relapses after dapsone monotherapy; an analysis of 769 cases in Jiangsu Province, China. Xie, Z., *et al.* .....(A) 13A
Relapses in 20,091 cured leprosy cases in Shandong Province of China. Pan, Y., *et al.* (A) 6A
Relapses of 1455 leprosy cases cured with DDS monotherapy. Liu, Z., *et al.* .....(A) 15A
Relationship between anti-PGL-I antibody (IgM) level and relapses in cured leprosy patients. Sun, C., *et al.* .....(A) 32A
Short-term rifampin-containing regimens for MB leprosy yield to high risk of relapse. Blanc, L., *et al.* .....(A) 7A
Single dose rifampin cannot prevent relapse in skin-smear negative multibacillary leprosy patients after dapsone monotherapy. Jamet, P., *et al.* .....(A) 6A
Study of relapse in paucibacillary leprosy patients in multidrug therapy project in Bharuch District, Gujarat, India. Chopra, N. K. .....(A) 6A

Rifabutin,
Combinations of rifampin or rifabutin plus fluoroquinolones against *M. leprae*. Dhople, A. M. and Ibanez, M. A. .....(A) 77A

Rifampin,
A bioassay to detect nonogram concentrations of rifampin. Guebre Xabier, M., *et al.* .(A) 16A
A simple and rapid technique for the detection of rifampin resistance in *M. leprae*. Honore, N., *et al.* .....(A) 108A
A simple and rapid technique for the detection of rifampin resistance in *M. leprae*. Honore, N., *et al.* .....(O) 600
Acute renal failure caused by two single doses of rifampicin with a year of interval. Pelaez, E., *et al.* .....(A) 486
Bioavailability of clyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Hebert, M. F., *et al.* .....(A) 122
Brodimoprim-DDS and brodimporim-DDS/rifampin; *in vitro* and in vivo results for a newly developed effective MDT against leprosy. Seydel, J. K., *et al.* .....(A) 7A
Brodimoprim-dapsone and brodimporim/dapsone/rifampin; *in vitro* and *in vivo* results. Seydel, J. K. .....(A) 315
Clarithromycin is bactericidal against strains of *M. leprae* resistant and susceptible to dapsone and rifampin. Walker, L. L., *et al.* .....(O) 59
Combinations of rifampin or rifabutin plus fluoroquinolones against *M. leprae*. Dhople, A. M. and Ibanez, M. A. .....(A) 77A
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* .....(A) 5A
Detection of rifampicin-resistance mutations in *M. tuberculosis*. Telenti, A., *et al.* .....(A) 497
Dr. Almeida replies. Almeida, J. G. .....(C) 630
Efectos indeseables provocados por la rifampicina. Gomez Echevarria, J. R., *et al.* .....(A) 17A
Effects of rifampin and ciprofloxacin on mycolic acid levels in human tissue-derived *M. leprae* and its correlation with viability. Patil, M., *et al.* .....(A) 116A
Experiences with Isoprodian-rifampin in Tanzania. Chum, J. H. .....(A) 306
Fatal poisoning by rifampicin—a case report. Poitineau, Y., *et al.* .....(A) 648
Field experience in leprosy/tuberculosis program with Isoprodian-rifampin. Alvarenga, A. E. .....(A) 305

Five-year evaluation of a program of chemoprophylaxis for leprosy using a single dose of 25 mg/kg rifampin. Cartel, J.-L., *et al.* ..... (A) 61A
"Flu" syndrome associated with other systemic manifestations with once a month rifampicin in the treatment of multibacillary leprosy. Thomas, A., *et al.* ..... (A) 649
How effective is monthly rifampin? Response to the Letter to the Editor by Dr. J. G. Almeida. Levy, L. ..... (C) 629
Hypersensitivity to dapsone, rifampin and clofazimine in a lepromatous leprosy patient. Kumar, J. S., *et al.* ..... (A) 28A
Identification of rifampin-inducible P450-IIIA4 (CYP3A4) in human small bowel enterocytes. Kolars, J. C., *et al.* ..... (A) 123
India—the use of the fixed drug combination Isoprodian rifampin under field conditions. Graf, P. ..... (A) 306
Introduction of single dose of rifampin for the treatment of leprosy patients in outreach area. Gyi, M. M. ..... (A) 13A
M. smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Levin, M. E. and Hatfull, G. F. ..... (A) 495
Minocycline and rifampin in leprosy. Romero, R. C. ..... (A) 8A
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. ..... (A) 359
Molecular characterization of rifampin resistance in pathogenic mycobacteria. Williams, D. L. and Gillis, T. P. ..... (A) 108A
Ofloxacin-rifampin trials in multibacillary leprosy-preliminary observations on reactive episodes. Ganapati, R., *et al.* ..... (A) 8A
Penetration of dapsone, rifampin and clofazimine into macrophages and mycobacteria. Mathur, A., *et al.* ..... (A) 81A
Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. Mindermann, T., *et al.* ..... (A) 486
Primary resistance to dapsone and rifampin. Damasco, M. H. S., *et al.* ..... (A) 12A
Results of Isoprodian-rifampin in tuberculosis treatment. Urbanczik, R. ..... (A) 304
Rifampicin induced flu-syndrome and toxic psychosis. Salafia, A. and Candida. ..... (A) 486
Rifampin derivatives. Jacobson, R. R. ..... (A) 315
Salivary levels of isoniazid and rifampicin in tuberculous patients. Gurumurthy, P., *et al.* ..... (A) 372
Short-term chemotherapy with rifampin + cotrimoxazol + isoniazid (cotrifazide). Freerksen, E. ..... (A) 315
Short-term rifampin-containing regimens for MB leprosy yeild to high risk of relapse. Blanc, L., *et al.* ..... (A) 7A
Single dose rifampin cannot prevent relapse in skin-smear negative multibacillary leprosy patients after dapsone monotherapy. Jamet, P., *et al.* ..... (A) 6A
Subcellular localization of DDS and rifampin in the skin and nerve of multidrug-treated cases of leprosy. Shetty, V., *et al.* ..... (A) 18A
Survey for secondary dapsone and rifampicin resistance in Cuba. Gonzalez, A. B., *et al.* ..... (A) 647
Survey for secondary dapsone and rifampin resistance in Cuba. Gonzalez, A. B. and Maestre, J. L. ..... (A) 13A
The combined effect of rifampin and pyrazinamide with the human macrophage. Sbarbaro, J. A., *et al.* ..... (A) 176
The risk of isoniazid in the Isoprodian-rifampin regimen. Grosset, J. ..... (A) 304
Therapeutic efficacy of some new quinolones and a combination of ofloxacin and rifampin against *M. leprae* infection induced in athymic nude mice. Tomioka, H. and Saito, H. ..... (O) 250
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Goble, M., *et al.* ..... (A) 371
Treatment of paucibacillary leprosy with a regimen containing rifampicin, dapsone and prothionamide. Katoch, K., *et al.* ..... (A) 123
Treatment of paucibacillary patients with MDT containing rifampin, dapsone and prothionamide. Katoch, K., *et al.* ..... (A) 2A

Rifamycin,
Bactericidal action at low doses of a new rifamycin derivative, 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on *M. leprae* inoculated into foot pads of nude mice. Gidoh, M., *et al.* ..... (A) 337

In vitro antimicrobial activity of benzoxazinorifamycin, KRM 1648, against *M. avium* complex, determined by the radiometric method. Tomioka, H., *et al.* ..... (A) 345
In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648. Tomioka, H. and Saito, H. ..... (O) 255
Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental *M. avium* infections induced in rabbits. Emori, M., *et al.* ..... (A) 503

Saliva,
Salivary levels of isoniazid and rifampicin in tuberculous patients. Gurumurthy, P., *et al.* ..... (A) 372

Sarcoidosis,
Characterization of gamma/delta lymphocytes-T in the peripheral blood of patients with active tuberculosis—a comparison with normal subjects and patients in sarcoidosis. Tazi, A., *et al.* ..... (A) 178
Cutaneous sarcoidosis masquerading as relapsed borderline tuberculoid leprosy? Kaur, S., *et al.* ..... (E) 455

Screening,
A rapid method for screening antimicrobial agents for activities against a strain of *M. tuberculosis* expressing firefly luciferase. Cooksey, R. C., *et al.* ..... (A) 494
ATP measurement and thymidine uptake in patient monitoring and in *in vitro* drug screening. Dhople, A. ..... (A) 307
Application of laser microprobe mass analysis to *in vitro* drug screening. Lindner, B., *et al.* ..... (A) 110A
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H. ..... (A) 310
Mycobacterial model strains in drug screening. Visser, K. and Seydel, J. K. ..... (A) 306

Senegal,
Structures of the glycopeptidolipid antigens of two animal pathogens—*M. senegalense* and *M. procinum*. Marin, L. M. L., *et al.* ..... (A) 664
Training and education strategy in leprosy control program in Senegal. Naudin, J.-C., *et al.* ..... (A) 165A
4eme Cours International 1994. ..... (N) 480

Sensation(s),
Dangers of underestimating permanent loss of sensation. Currie, H., *et al.* ..... (A) 144A
Footsole sensation in normal subjects in Ethiopia. Currie, H. and Byass, P. ..... (A) 158A
Pan-sensory loss in leprosy- case reports. Pandya, S. and Bhatki, W. ..... (A) 159A
Prednisolone treatment in longer standing sensation loss. Moet, F. J. and Rongong, N. T. ..... (A) 19A
Recovery of sensation by nerve decompression using selective meshing of the epineurium. Hatano, K., *et al.* ..... (A) 151A
Semmes-Weinstein light touch/pressure in persons with Hansen's disease and without known disease. Lehman, L. and Berenhoff, J. ..... (A) 145A
Semmes-Weinstein monofilament detection thresholds: a comparative study. Bell-Krotoski, J. and Coor, V. ..... (A) 146A
Somatosensory-evoked potentionals in leprosy. Gupta, B. K., *et al.* ..... (A) 158A

Sensitivity, drug,
A rapid *in vitro* microassay for the viability and drug sensitivity of *M. leprae*. Butcher, P. D., *et al.* ..... (A) 111A

Serodiagnosis,
Comparative assessment of the leprosy antibody absorption test, *M. leprae* extract enzyme-linked immunosorbent assay, and gelatin particle agglutination test for serodiagnosis of lepromatous leprosy. Escobar-Gutierrez, A., *et al.* ..... (A) 488
Electron microscopy, polymerase chain reaction and serodiagnosis as tools for assessing leprosy treatment. Nasr, E. M., *et al.* ..... (A) 17A
Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology. Verbon, A., *et al.* ..... (A) 670
Higher specificity in the serodiagnosis of leprosy by combined titration of antiphenolic glycolipid-I and antiphospholipid antibodies. Fiallo, P., *et al.* ..... (C) 464

Lipoarabinomannan (LAM)-based enzyme-linked immunosorbent assay in serodiagnosis of leprosy. Gandhi, S., *et al.* ..... (A) 93A
Studies on potential uses of MLPA in leprosy. Wu, Z., *et al.* ..... (A) 88A
Utility of gelatin particle agglutination test (MLPA) for rapid serodiagnosis of leprosy in a hyperendemic area. Reddy, B. S. N., *et al.* ..... (A) 352

Serology,
[Serology of leprosy: current status and perspectives.] Chanteau, S., *et al.* ..... (A) 347
Therapeutical monitoring by serological tools. Patarroyo, M. E. ..... (A) 309

Serum,
Antibodies to a nerve lipid extract (NLE) in sera of leprosy patients. Vartak, R., *et al.* (A) 97A
Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes. Yamashita, J. T., *et al.* ..... (O) 44
Comparative evaluation of antibodies in the serum and urine of leprosy patients through diversified mycobacterial antigens. Gupta, H. P., *et al.* ..... (A) 92A
[Comparison between Ml- and Ms-ELISA in the determination of serum antibodies in leprosy.] Li, M.-H., *et al.* ..... (A) 134
Cross-sectional assessment of ELISA reactivity in leprosy patient, contacts, and normal population using the semisynthetic antigen natural disaccharide octyl bovine serum albumin (ND-O-BSA) in Cebu, The Philippines. Cellona, R. V., *et al.* ..... (O) 192
Detection of 65-kDa heat-shock protein from sera of leprosy patients—mycobacterial or autoantigen origin. Elangeswaran, N., *et al.* ..... (A) 90A
Detection of *M. leprae*-specific antigen with M-dot-ELISA in sera from household contacts of leprosy patients. Cao, Y., *et al.* ..... (A) 73A
Evaluation of four semi-synthetic *M. leprae* antigens with sera from healthy populations in endemic and non-endemic areas. Douglas, J. T., *et al.* ..... (A) 131
Hepatitis C and hepatitis B virus serum markers in Greek leprosy patients. Kontochristopoulos, G., *et al.* ..... (A) 35A
IgM serum antibodies to PGL-I by ELISA in healthy subjects and leprosy patients. Meng, M., *et al.* ..... (A) 92A
Immunoreactivity of mammalian liver component with leprosy sera. Despande, R. G., *et al.* ..... (A) 347
M. leprae infection triggers synthesis of stress-inducible HSP70 in Schwann cells and anti-HSP antibodies in sera. Mistry, Y., *et al.* ..... (A) 104A
Major antigens of *M. habana* recognized by sera of patients with lepromatous leprosy. Vilchis, M., *et al.* ..... (A) 90A
[Observations on inhibitory activity of alpha1 antipepsin in leprosy sera.] Chan, H., *et al.* ..... (A) 341
Reactivity of leprosy and control sera to crude and recombinant *M. leprae* antigens. Vega-Lopez, F., *et al.* ..... (A) 88A
Recognition of *M. leprae* antigens with antibodies present in sera from patients with lepromatous leprosy. Islas Rodriguez, A. E., *et al.* ..... (O) 245
Reconstruction of antileprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and C(rat)EDTA (a source of C3-C9). Kashyap, A., *et al.* ..... (A) 123
Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Klein, R., *et al.* ..... (A) 507
Serum lactoferrin in lepromatous leprosy patients. Parkash, O., *et al.* ..... (A) 33A
Serum transferrin (Tf) concentration and Tf receptors (R) on the surface of T lymphocytes in lepromatous leprosy (LL). Fafutis, M., *et al.* ..... (A) 101A
Studies on serum-antitrypsin inhibitory capacity of leprosy patients. Chen, J. and Gao, Y. ..... (A) 31A
The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guerin (BCG) vaccination in either South India or London. Das, S., *et al.* ..... (A) 158

Shoe(s),
Development and application of protective shoes for leprosy patients. Xu, S. and Watson, J. M. ..... (A) 153A

Effectiveness of protective orthopedic shoes in neuropathic and deformed feet in leprosy. Yuksel, A. and Erkilic, N. ..... (A) 154A

Singapore,
Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore. Lim, J. T.-E. and Tan, T. ..... (A) 648

Skin,
Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A
Appearance of delta-gamma T cell receptor-positive cells following alpha-beta T cell receptor-positive cells in the lepromin reaction of human skin. Fujita, M., *et al.* ..... (A) 348
Circulatory adaptation to the increased metabolism in the skin at the site of the tuberculin reaction. Abbot, N. C., *et al.* ..... (A) 129
Concurrent skin and nerve histology in leprosy and its role in the classification of leprosy. Kaur, S., *et al.* ..... (A) 652
Demonstration of PGL-I and LAM-B in paraffin sections of leprosy skin lesions. Wang, T., *et al.* ..... (A) 120A
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ..... (A) 145
Detection of *M. leprae* DNA by PCR in skin scrapings and nasal secretions from multibacillary and paucibacillary leprosy patients. Gillis, T. P., *et al.* ..... (A) 106A
Effect of *M. leprae* in peripheral nerve on the skin of patients with leprosy. Ridley, M. and Waters, M. F. R. ..... (A) 121A
Evolution of sensory loss in skin patches of Hansen's diseaes at the time of diagnosis and during treatment using the Semmes-Weinstein monofilaments. Lyon, S., *et al.* ..... (A) 158
FACS analysis of CD4+ T-cell subsets in reacting and nonreacting leprosy skin lesions. Utaipat, U., *et al.* ..... (A) 104A
Histological and immunohistochemical changes of eccrine sweat glands in leprosy. Wang, T., *et al.* ..... (A) 120A
Histopathological analysis of skin biopsies performed in leprosy patients: reaction or relapse? Schettini, A. P., *et al.* ..... (A) 122A
Immunobiology of melanocytes in relation to hypopigmentation in leprosy. Le Poole, C., *et al.* ..... (A) 105A
Immunohistochemical demonstration of PGL-I antigen in the skin and nervous system of leprosy patients. Goto, M., *et al.* ..... (A) 120A
Immunohistochemical identification of ferritin, lactoferrin and transferrin in leprosy lesions of human skin biopsies. Momotani, E., *et al.* ..... (A) 135
M. leprae viability in skin and nerve after MDT and their sensitivity to antileprosy drugs. Shetty, V., *et al.* ..... (A) 4A
Nucleic acid sequence-based amplification (NASBA) for identification and viability assessment of *M. leprae* in skin biopsy specimens. van der Vliet, G. M. E., *et al.* ..... (A) 107A
Observation on subcutaneous immune cells *in situ* in leprous nonreactive skin lesions. Zhu, S., *et al.* ..... (A) 98A
[Patients with calcinosis cutis in National Leprosarium Matsuoka Hoyo-En.] Ohtaka, K. ..... (A) 343
Persistence of *M. leprae* in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Shetty, V. P., *et al.* ..... (A) 344
Polymerase chain reaction for the detection of *M. leprae* in skin tissue. Kampirapap, K., *et al.* ..... (A) 108A
Relation of skin lesions with deformitites in nonlepromatous leprosy. Subuddhi, K. B. (A) 36A
Role of skin and cutaneous nerve biopsies in paucibacillary borderline tuberculoid Hansen's disease. Thomas, S., *et al.* ..... (A) 122A
Selective expansion of Vdelta1 + T-cells from leprosy skin lesions. Uyemura, K., *et al.* ..... (A) 355
Skin disease diagnostic, treatment and education (SDDTE) camps: a tool for community education in the tribal district Bharuch (Guajrat), India. Chopra, N. K., *et al.* ..... (A) 50A
Subcellular localization of DDS and rifampin in the skin and nerve of multidrug-treated cases of leprosy. Shetty, V., *et al.* ..... (A) 18A

T-cell receptor usage in blood and skin lesions in leprosy. Cross, C., *et al.* ..... (A) 104A
The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. van Brakel, W. H., *et al.* ..... (A) 128
Topically applied verapamil hydrochloride inhibits tuberculin induced delayed-type hypersensitivity reactions in human skin. McFadden, J., *et al.* ..... (A) 375
Treated indeterminate leprosy: a search for predictive histopathological and immunohistochemical parameters in skin biopsies taken from patients at admission and at clinical discharge. Takahashi, D., *et al.* ..... (A) 354
Treatment of neuropathic ulcers with full-thickness skin. Faber, W. R., *et al.* ..... (A) 161A

Skin smear(s),
Demonstration of mycobacterial antigens in the skin smears of tuberculoid patients of leprosy. Sengupta, U., *et al.* ..... (A) 85A
Method for quality control and its application in leprosy skin smear examination. Zhang, M., *et al.* ..... (A) 32A
Results of skin smears from 84 multibacillary patients on MDT MB regimen recommended by WHO. Cheng, Z. Q., *et al.* ..... (A) 10A
Sensibility of skin smears in 100 cases of multibacillary leprosy. Gutierrez, M., *et al.* ..(A) 23A
The slit-skin smear in leprosy—an impediment to MDT? de Soldenhoff, R. ..... (A) 12A

Skin test(s),
A longitudinal study of the predictive value of the lepromin response and anti-PGL-I serology in children. Naik, S., *et al.* ..... (A) 72A
Anergy and Mitsuda responses toward chemoautotrophic nocardiofirm antigens run parallel to lepromin across the leprosy spectrum. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 117A
Appearance of delta-gamma T cell receptor-positive cells following alpha-beta T cell receptor-positive cells in the lepromin reaction of human skin. Fujita, M., *et al.* ....(A) 348
Circulatory adaptation to the increased metabolism in the skin at the site of the tuberculin reaction. Abbot, N. C., *et al.* ..... (A) 129
Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Chu, C. Q., *et al.* ..... (A) 156
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (O) 204
Dynamic thermographic imaging for estimation of regional perfusion in the tuberculin reaction in healthy adults. Abbot, N. C., *et al.* ..... (A) 657
Histological analysis of the Mitsuda reaction in contacts of multibacillary leprosy patients. Trindade, M. A. B. and Fleury, R. N. ..... (C) 109
Histopathological analyses of lepromin tests performed at BCG ized and nonBCG-ized regions of multibacillary leprosy patients under multidrug therapy. Marques, A. B., *et al.* ..... (A) 121A
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* .... (A) 74A
Induction of lepromin positivity by a candidate antileprosy vaccine *Mycobacterium w* and its immunoprophylactic effect in lepromin-negative healthy contacts or multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 95A
Induction of lepromin positivity by a candidate antileprosy vaccine, *Mycobacterium w*, in lepromin negative healthy contacts of multibacillary leprosy patients. Kar, H. K., *et al.* ..... (A) 349
Influence of BCG vaccination and close contact with leprosy patients on the results of skin test with four new tuberculins. Bottasso, O., *et al.* ..... (A) 94A
Lepromin skin testing in the classification of Hansen's disease in the United States. Krotoski, W. A., *et al.* ..... (A) 342
M. leprae soluble antigen (Rees) skin test responses in an endemic population in India. Krishnamurthy, P., *et al.* ..... (A) 349

Pilot study to determine acceptability and ability of heat killed *M. leprae* plus BCG (HKML + BCG) vaccine to induce skin test conversion. Chen, Z.-L., *et al.* ..... (A) 651
Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: skin tests. Mous, H. V. H., *et al.* ..... (A) 100A
Significance of cellular morphology of Mitsuda lepromin response. Desikan, V. K. and Girdhar, B. K. ..... (A) 125A
Soluble *M. leprae* antigen skin testing and lepromin positivity in children of mothers with leprosy and healthy controls studied prospectively from birth to puberty. Duncan, M. E., *et al.* ..... (A) 105A
Ten-twelve years follow up of healthy contacts of leprosy cases using FLA-ABS and lepromin tests. Bharadwaj, V. P., *et al.* ..... (A) 67A
Topically applied verapamil hydrochloride inhibits tuberculin induced delayed-type hypersensitivity reactions in human skin. McFadden, J., *et al.* ..... (A) 375

South Africa,
Histoid leprosy at Westfort Hospital, South Africa. Wentzel, L. ..... (A) 31A
Primary neuritic leprosy in a black South African. Mafoyane, N. A., *et al.* ..... (A) 650
Primary neuritic leprosy in a black South African. Namafoyane, N. A., *et al.* ..... (A) 127

Spain,
Fontilles to take nonleprosy patients. ..... (N) 642
Incorporacion de la multiterapia en los enfermos de Cataluna; resultados e incoonvenientes. Perez, M., *et al.* ..... (A) 12A
[Leprosy in the district of Marina (Spain).] Terencio de las Aguas, J. ..... (A) 364

Spleen,
A role for gamma interferon, tumor necrosis factor, and soluble T-cell receptors in the depressed blastogenic response of spleen cells of *M. lepra*emurium-infected mice. Richard, L., *et al.* ..... (A) 137
Study of intracellular deposition of the anti-leprosy drug clofazimine in mouse spleen using laser microprobe mass analysis. Vandeputte, D., *et al.* ..... (A) 487

Sri Lanka,
Field-based deformity care services in Sri Lanka. Settinayake, S. and Shah, A. ..... (A) 157A
The impact of social marketing on the perception of leprosy in Sri Lanka. Gunawardena, P., *et al.* ..... (A) 129A

Stain(s),
A comparison of DNA/RNA, mycolates, PGL-I, antigenicity, enzymes, morphology and staining characteristics of the leprosy bacillus with the leprosy-derived chemoautotrophic nocardioform bacteria *in vitro*. Chakrabarty, A. N., *et al.* ..... (A) 112A
Application of S-100 protein stain in the diagnosis of leprosy. Shen, J., *et al.* ..... (A) 121A
Application of fluorescent staining to assessment of the chemotherapy responses/drug susceptibility testing in leprosy. Katoch, V. M. ..... (A) 307
Assessing the viability of *M. leprae* on 28 cases on MDT by the FDA/EB staining technique. Liu, G. and Shong, B. ..... (A) 111A
The use of improved silver impregnating staining method in the differential diagnosis of tuberculoid leprosy. Wang, T., *et al.* ..... (A) 356

Steroid(s),
A study on factors influencing the recovery of motor nerve function with steroid therapy. Roberts, H., *et al.* ..... (A) 147A
Colchicine in type 2 lepra reaction and its comparison with corticosteroids. Katkar, K. N. and Jagavkar, C. K. ..... (A) 8A
Quiet nerve paralysis assessment with respect to MDT and corticosteroid therapy. Gupte, M. D., *et al.* ..... (A) 147A

Streptomycin,
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against *M. avium-M. intracellulare* complex infections in human peripheral blood monocyte/macrophages. Majumdar, S., *et al.* ..... (A) 168
In-vitro activity of streptomycin and clofazimine against established infections of *M. avium* complex in beige mice. Gangadharam, P. R. J. and Parikh, K. ..... (A) 371

Subclinical,
Immunoepidemiological studies on subclinical infection in leprosy. II. Geographical distribution of seropositive responders with special reference to their possible source of infection. Abe, M., *et al.* ..... (A) 346
Immunoepidemiological studies on subclinical infection in leprosy. III. Yearly observations and follow-up studies of school children by using FLA-ABS and lepromin tests. Abe, M., *et al.* ..... (A) 346

Superoxide,
Activity of the protective enzyme superoxide dismutase and the levels of lipid peroxide in the skin sites of lepromatous leprosy with type 2 reactions. Chandrashekhar, R., *et al.* ..... (A) 125A
An *in vitro* comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase-A2 activity and superoxide generation. Krajewska, M. M. and Anderson, R. ..... (A) 486

Suppression,
Correlation between TNF production, increase of CRP level, and suppression of T lymphocytes during ENL reaction. Foss, N. T. and Silva, C. L. ..... (A) 102A
Correlation between TNK production, increase of plasma C reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Foss, N. T., *et al.* ..... (O) 218
Suppression of ADCC by immune complexes formed *in vitro* in *M. leprae*-infected mice. Vaishnavi, C., *et al.* ..... (A) 361
Suppression of human monocyte cytokine release by PGL-I of *M. leprae*. Silva, C. L., *et al.* ..... (A) 92A
Suppression of human monocyte cytokine release by phenolic glycolipid-I of *M. leprae*. Silva, C. L., *et al.* ..... (C) 107

Surgery,
Cataract surgery in a leprosy population in Liberia. Frucht-Pery, J. and Feldman, S. T. ..... (O) 20
Claw-toes correction: persnal technique. Salafia, A., *et al.* ..... (A) 160A
Observation on the effect of eyebrow transplantation by single autologous hair—a report of 274 cases. Wang, X., *et al.* ..... (A) 162A
Renal transplantation in leprosy patients. Roselino, A. M. F., *et al.* ..... (E) 102
Surgical rehabilitatie needs of leprosy patients released from control; the Karigiri experience. Solomon, s., *et al.* ..... (A) 151A
The vascular component in posterior tibial compartment surgery for plantar ulcers. Arolkar, S. and Antia, N. ..... (A) 162A

Suriname,
The epidemiology of Hansen's disease in the English-speaking Caribbean and Suriname: current status and trends. Tollefson, J. E., *et al.* ..... (A) 65A

Switzerland,
July 1992 meeting of WHO Working Group on Leprosy Control. ..... (N) 332
Report of a Meeting on HIV Infection in Leprosy ..... (N) 642
TDR Research Training Grants, 1993. ..... (N) 117
TDR's new targets and management structure. ..... (N) 643
Teaching and learning materials for leprosy. McDougall, A. C. ..... (N) 332

Tanzania,
Experiences with Isoprodian-rifampin in Tanzania. Chum, J. H. ..... (A) 306
HIV-1 infection as a risk factor for leprosy; a case-control study in Tanzania. Borgdorff, M. W., *et al.* ..... (O) 556
Leprosy and HIV in Tanzania. Chum, H. J., *et al.* ..... (A) 65A
Pros and cons of combining tuberculosis and leprosy control activities (based on 15 years' experience of the National TB Leprosy Program in Tanzania). Chum, H., *et al.* ..... (A) 41A
Training for national TB/leprosy program in Tanzania since July 1977. Chum, H., *et al.* ..... (A) 167A

Teeth,
Histoid leprosy in early macular lepromatous leprosy: incidental finding or sign of augmented local immunity? Fiallo, P., *et al.* ..... (C) 471

Testes,
Testicular insufficiency in multibacillary Hansen's diseaae–a five-year follow-up study. Frankel, R. I., *et al.* ..... (A) 20A

Testing,
Application of fluorescent staining to assessment of the chemotherapy responses/drug susceptibility testing in leprosy. Katoch, V. M. ..... (A) 307
Combination drug testing of *M. chelonae*. Matoba, A. Y., *et al.* ..... (A) 665
Comparison of growth and susceptibility testing of pyrazinamide in different BACTEC media using strains of the *M. tuberculosis* complex. Fuursted, K. ..... (A) 504
Comparison of techniques for antimicrobial susceptibility testing of mycobacteria. Limb, D. I., *et al.* ..... (A) 663
Effect of hand soaking on sensory testing. McAuley, D. M., *et al.* ..... (O) 16
Field testing of the community health education leaflet developed at the National Leprosy Training Center, Ujungpadang, Indonesia. Kurnia, D. and Aspar, N. ..... (A) 167A
In vitro antimicrobial susceptibility testing of rapid growing mycobacteria using the tablet diffusion method—resistance pattern of Norwegian *M. fortuitum* and *M. chelonae* isolates. Hoel, T., *et al.* ..... (A) 506
Reliability of manual muscle strength testing in the evaluation of peripheral nerve dysfunction in leprosy patients. Brandsma, J. W., *et al.* ..... (A) 145A
Semmes-Weinstein monofilament testing to determine normal sensory thresholds in the foot and hand: a comparative study in India. Jerskey, R. ..... (A) 159A
Specifications for the Semmes-Weinstein monofilaments for sensibility testing, and considerations for field filaments. Bell-Krotoski, J. ..... (A) 159A
Studies on potential uses of MLPA in leprosy. Wu, Z., *et al.* ..... (A) 88A
The test track: a useful tool in testing sensitivity of feet? Kazen, R., *et al.* ..... (A) 158A
The wrinkling test in leprosy patients. Virmond, M., *et al.* ..... (A) 159A
Translating theory into practice: the choice of sensory testing methods in different field conditions. Petter, I. ..... (A) 159A

Thailand,
Community-based leprosy control program; a case study in Nakhonratchasima Province, Thailand. Prasongthrap, P. ..... (A) 45A
Leprosy control program in Thailand. Chantraprachoom, C. and Kittampol, K. ..... (A) 656
Nylon filament measurements in leprosy patients and normal subjects in Thailand. Birke, J., *et al.* ..... (A) 146A
Social and cultural aspects of the stigma of leprosy in northeast rural Thailand. Predasat, P. ..... (A) 133A

Thalidomide,
Effects of clucocorticoids, dapsone and thalidomide on interleukin-1 production. Lew, W., *et al.* ..... (A) 92A
Influence of thalidomide on the histological manifestations of ENL. Miranda, A., *et al.* ..... (A) 99A
Thalidomide—a clinical study of 33 cases of type 2 lepra reaction. Kishore, V. ..... (A) 23A
Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Neubert, R., *et al.* ..... (A) 136
Thalidomide does not affect selected immunomodulating surface receptor molecules on cells with immune potential. Shannon, E. J., *et al.* ..... (A) 105A
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. Moreira, A. L., *et al.* ..... (A) 489

The Leprosy Mission (TLM),
Community-based rehabilitation program of The Leprosy Mission, India. Samson, P. D., *et al.* ..... (A) 140A

Therapy (see also **Chemotherapy**),
A study on factors influencing the recovery of motor nerve function with steroid therapy. Roberts, H., *et al.* ..... (A) 147A

Annual immunotherapy in treated lepromatous leprosy with three different BCG-based vaccines—a 6-year assessment. Waters, M. F. R., *et al.* ..... (A) 103A
Combined multidrug and *Mycobacterium w* vaccine therapy in patients with multibacillary leprosy. Zaheer, S. A., *et al.* ..... (A) 357
Detection of *M. leprae* and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams, D. L., *et al.* ..... (A) 145
Failure of therapy for tuberculosis in human immunodeficiency virus infection. Nolan, C. M. ..... (A) 170
Fixed duration therapy (FDT) in MB leprosy. Vijayakumaran, P., *et al.* ..... (A) 3A
Immunotherapy of MB leprosy patients with the antileprosy vaccine *Mycobacterium w*. Zaheer, S. A., *et al.* ..... (A) 18A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ..... (A) 345
Immunotherapy with *Mycobacterium w* vaccine in MB leprosy patients showing slow responses to MDT. Ramesh, V., *et al.* ..... (A) 18A
Initial intensive therapy for multibacillary leprosy patients-in retrospect. Rao, P. S., *et al.* ..... (A) 339
Investigation of lymphoedema as an adverse effect of clofazimine therapy in leprosy. Oommen, T., *et al.* ..... (A) 19A
Patients' compliance and drug trials: an analysis of efficiency of monotherapy and multidrug therapy (MDT) treatment. Saravanabavan, V. and Shanmuganandan, S. ..... (A) 54A
Pedal edema following clofazimine therapy; a case report. Tyagi, P. K. and Oommen, T. ..... (C) 636
Physiotherapy and health education—a Dhoolpet approach. Muzaffarullah, *et al.* ..... (A) 157A
Profile of relapse cases in field trial of combined therapy in multibacillary leprosy. Rajendran, V., *et al.* ..... (A) 4A
Quantitative morphological methods for assessment of the effectiveness of antileprosy therapy. Vasilyev, A., *et al.* ..... (A) 123A
Recent advances in cytokine therapy in leprosy. Kaplan, G. ..... (A) 349
Relapses after dapsone monotherapy; an analysis of 769 cases in Jiangsu Province, China. Xie, Z., *et al.* ..... (A) 13A
Relapses of 1455 leprosy cases cured with DDS monotherapy. Liu, Z., *et al.* ..... (A) 15A
Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w*. Sharma, A. K., *et al.* ..... (A) 24A
Selection of resistant mutants of *M. avium* in beige mice by clarithromycin monotherapy. Ji, B.-H., *et al.* ..... (A) 164
Single dose rifampin cannot prevent relapse in skin-smear negative multibacillary leprosy patients after dapsone monotherapy. Jamet, P., *et al.* ..... (A) 6A
The experience of using reflexotherapy in leprosy patients with chronic neuritis. Shats, E., *et al.* ..... (A) 35A

Thymidine,
ATP measurement and thymidine uptake in patient monitoring and in *in vitro* drug screening. Dhople, A. ..... (A) 307

Tissue(s),
Adaptation hormones and autosensibilization to connective tissue in leprosy. Balybin, E., *et al.* ..... (A) 34A
Attempts to cultivate *M. leprae* in fat tissue. Godard, C. M. ..... (A) 656
Detection of mycobacteria in tissue by polymerase chain reaction. Gerdes, J., *et al.* ..... (A) 309
Effects of rifampin and ciprofloxacin on mycolic acid levels in human tissue-derived *M. leprae* and its correlation with viability. Patil, M., *et al.* ..... (A) 116A
M. tuberculosis DNA in tissue affected by sarcoidosis. Fidler, H. M., *et al.* ..... (A) 503
Mycobacteria in Crohn's disease—DNA probes identify the wood pigeon strain of *M. avium* and *M. paratuberculosis* from human tissue. McFadden, J., *et al.* ..... (A) 169
Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. Mindermann, T., *et al.* ..... (A) 486
Polymerase chain reaction for the detection of *M. leprae* in skin tissue. Kampirapap, K., *et al.* ..... (A) 108A

Problems in detection of secretory antigens of intracellular mycobacteria in macrophage and Schwann cell tissue culture. Mistry, N., *et al.* ....(A) 87A
TNF-alpha-mediated tissue damage in mouse footpads primed with mycobacterial preparations. Al-Attouaj. R., *et al.* ....(A) 129
The mycobacterial secreted antigen-85 complex possesses epitopes that are differentially expressed in human leprosy lesions and *M. leprae*-infected armadillo tissues. Rambukkana, A., *et al.* ....(A) 496
Viability of acid-fast bacilli from gamma-irradiated and UV irradiated lepromatous armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ....(A) 158

Tongue,
Leprosy of the tongue. Soni, N. K. ....(A) 127

Training,
Action learning: its value for leprosy projects. Sommerfeld, P. and Watson, J. M. ....(A) 165A
ALERT in the 1990s: evolving to meet new needs in leprosy training. Bulto, T. and Alldred, N. ....(A) 163A
An evaluation instrument for leprosy training centers. Spencer, L., *et al.* ....(A) 165A
Artistic innovations in leprosy education. Freitas, P. and Johnson, I. ....(A) 163A
Demystifying video—training health workers in elementary video production. Joseph, M. ....(A) 163A
Differential effectiveness of individual communication methods in social education. Reddy, A., *et al.* ....(A) 164A
Disability in new cases of Hansen's disease in the State of Minas Gerais, Brazil, from 1988 to 1992 by regions of epidemiological priority and training. Lehman, L., *et al.* (A) 158A
Field testing of the community health education leaflet developed at the National Leprosy Training Center, Ujungpadang, Indonesia. Kurnia, D. and Aspar, N. ....(A) 167A
Hanseniasis en las escuelas. Cypreste, D. M. ....(A) 167A
Health education has changed the attitude of society toward leprosy. Roy, P. K., *et al.* (A) 132A
Impact of personnel training on the epidemiological and operational indicators—Brazil, 1986 to 1991. Rodrigues, A. L., *et al.* ....(A) 166A
Impact of personnel training on the indicators of the Hansen's disease control program in the Federal District of Brazil, 1990-1992. Sampaio, A. A. and Moreira, M. B. R. (A) 166A
Integrated approach in health education of leprosy to create mass awareness. Kishore, V. ....(A) 132A
Leprosy for Medical Practitioners and Paramedical Workers by S. J. Yawalker. Yoder, L., J. ....(B) 326
Leprosy literature access and retrieval by microcomputer using CD ROM. Foster, R., *et al.* ....(A) 168A
Leprosy teaching at medical schools through community-based leprosy control in a slum area. Oliveira, M. L. W., *et al.* ....(A) 166A
Measures and effects of leprosy propaganda in Sichuan Province. Wang R. ....(A) 164A
Participants' evaluation of a training program. Arunthathi, S. and Daniel, E. ....(A) 164A
Public education. Shah, P. B. ....(A) 169A
Research in leprosy health education- emerging trends and challenges. Cheriyan, C. S. and Abraham, T. ....(A) 165A
TDR Research Training Grants, 1993. ....(N) 117
Task-oriented training of primary health care personnel in leprosy case detection—an assessment. Revankar, C. R., *et al.* ....(A) 166A
Teaching and learning materials for leprosy, TAMILEP. ....(N) 118
Teaching and learning materials for leprosy. McDougall, A. C. ....(N) 332
Teaching of leprosy in medical colleges of Orissa, India. Sahu, J. ....(A) 168A
The Philippines' Manual of Training; MDT for Leprosy available. ....(N) 118
Training and education strategy in leprosy control program in Senegal. Naudin, J.-C., *et al.* ....(A) 165A
Training for national TB/leprosy program in Tanzania since July 1977. Chum, H., *et al.* ....(A) 167A
Use of matched questions in pre- and post-tests to evaluate trainees and faculty in a leprosy medical officer's training program. Satish Kumar, A., *et al.* ....(A) 166A

Transmission,
A natural ecosystem for leprosy-related chemoautotrophic nocardioform bacteria; transmission of leprosy bacillus to humans from fossil-fuel-rish soil. Dastidar, S. G. and Chakrabarty, A. N. ..... (A) 74A
Erradicar la transmision de la lepra para 1994; politica para la accion en Mexico. Rodriguez-Dominguez, J., *et al.* ..... (A) 38A
Intrafamilial transmission of leprosy in Vellore town, India. George, R., *et al.* ..... (O) 550
Intrafamiliar transmission of leprosy in Vellore town, India. George, R., *et al.* ..... (A) 75A
La planeaction estrategica de mercadotecnia utilizada para erradicar la transmision de la lepra en Mexico. Barocio, A. and Castellanos, F. ..... (A) 48A
Leprosy; another possible source of transmission. Devasundaram, J. K. ..... (C) 296
Possible transmission of *M. leprae* in a group of U.K. leprosy contacts. Dockrell, H. M., *et al.* ..... (A) 362
The dwelling as the site of leprosy transmission. Araujo, A. J. G., *et al.* ..... (A) 71A
Transmission of leprosy through thorn pricks in nude mice. Job, C. K., *et al.* ..... (A) 78A

Transplantation,
Observation on the effect of eyebrow transplantation by single autologous hair—a report of 274 cases. Wang, X., *et al.* ..... (A) 162A
Renal transplantation in leprosy patients. Roselino, A. M. F., *et al.* ..... (E) 102

Trial(s),
A trial based on PGL-I serology for leprosy control; preliminary results. Gonzalez-Abreu, E. and Gonzalez, A. B. ..... (A) 49A
Assessing effectiveness of leprosy education in rural India; a randomized-controlled community-based intervention trial. Dhariwal, A. C. ..... (A) 167A
Clinical trials of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 7A
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients; a 10-year report. Thomas, A., *et al.* ..... (A) 5A
Field trials with an antileprosy vaccine *Mycobacterium w.* Walia, R., *et al.* ..... (A) 104A
Gangliosides (cronassial) and leprosy neuropathy; a randomized, placebo-controlled trial. Salafia, A., *et al.* ..... (A) 14A
Leprosy clinical trial of clarithromycin. Chan, G., *et al.* ..... (A) 17A
Leprosy clinical trial of fusidic acid. Franzblau, S. G., *et al.* ..... (A) 17A
Leprosy clinical trial of sparfloxacin. Chan, G., *et al.* ..... (A) 18A
Mouse foot pad system in drug screening and in monitoring the therapeutic effects of clinical trials. Ji, B.-H. ..... (A) 310
Ofloxacin-rifampin trials in multibacillary leprosy-preliminary observations on reactive episodes. Ganapati, R., *et al.* ..... (A) 8A
On histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w.* Reddy, B. N. and Porichha, D. ..... (C) 109
Patients' compliance and drug trials: an analysis of efficiency of monotherapy and multidrug therapy (MDT) treatment. Saravanabavan, V. and Shanmuganandan, S. ..... (A) 54A
Profile of relapse cases in field trial of combined therapy in multibacillary leprosy. Rajendran, V., *et al.* ..... (A) 4A
Study of field trials of combined chemotherapy and fixed duration combined chemotherapy in multibacillary leprosy in MDT project, Bharuch District, Gujarat, India. Chopra, N. K. ..... (A) 49A

Tuberculin,
Circulatory adaptation to the increased metabolism in the skin at the site of the tuberculin reaction. Abbot, N. C., *et al.* ..... (A) 129
Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Chu, C. Q., *et al.* ..... (A) 156
Dynamic thermographic imaging for estimation of regional perfusion in the tuberculin reaction in healthy adults. Abbot, N. C., *et al.* ..... (A) 657
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* ..... (A) 74A
Influence of BCG vaccination and close contact with leprosy patients on the results of skin test with four new tuberculins. Bottasso, O., *et al.* ..... (A) 94A

Topically applied verapamil hydrochloride inhibits tuberculin induced delayed-type hypersensitivity reactions in human skin. McFadden, J., *et al.* ..... (A) 375

Tuberculoid leprosy,

Antibody response of patient with borderline lepromatous and borderline tuberculoid leprosy to mycobacterial 29/33-kDa doublet and 65-kDa singlet antigens. Burggraaf, J. D., *et al.* ..... (A) 86A

Borderline tuberculoid leprosy in an HIV+ patient; clinical, histologic and immunohistologic evaluation. Goodless, D. R., *et al.* ..... (A) 35A

Cutaneous sarcoidosis masquerading as relapsed borderline tuberculoid leprosy? Kaur, S., *et al.* ..... (E) 455

Electro-neuro-physiological studies in early tuberculoid leprosy. Rao, S. P. and Bharambe, M. S. ..... (A) 651

Histo-bacteriological investigation of borderline tuberculoid leprosy. Wang, T., *et al.* ..... (A) 355

Keratosic presentation on tuberculoid leprosy. Yamashita, J. T., *et al.* ..... (A) 29A

Late responses in tuberculoid leprosy. Gupta, B. K., *et al.* ..... (A) 146A

Reaction in borderline tuberculoid leprosy presenting with multiple subcutaneous nodules. Jayakumar, J., *et al.* ..... (A) 650

T-cell receptor beta-chain gene usage in the T-cell recognition of *M. leprae* antigens in one tuberculoid leprosy patient. van Schooten, W. C. A., *et al.* ..... (A) 139

The use of improved silver impregnating staining method in the differential diagnosis of tuberculoid leprosy. Wang, T., *et al.* ..... (A) 356

Tuberculoid leprosy associated with pulmonary tuberculosis. de Almeida, A. M., *et al.* ..... (A) 30A

Tuberculosis,

A comparison of clinical features in tuberculosis associated with infection with human immunodeficiency virus-1 and virus 2. Doorly, R., *et al.* ..... (A) 505

A rapid latex agglutination test for detection of antibodies in tuberculosis and Hansen's disease. Ganju, L., *et al.* ..... (A) 133

Alternative treatment for drug-resistant leprosy and tuberculosis. Prabhakaran, K., *et al.* ..... (A) 15A

Applications of molecular methods to epidemiology of tuberculosis. Crawford, J. T. ..... (A) 494

Aspects of tuberculosis in Africa. 3. Genetic "fingerprinting" for clues to the pathogenesis of tuberculosis. Godfrey-Faussett, P. and Stoker, N. G. ..... (A) 661

Association of leprosy and tuberculosis between 1902 and 1991 in French Polynesia. Glaziou, P., *et al.* ..... (A) 64A

BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ..... (A) 175

Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Orege, P., *et al.* ..... (O) 542

Characterization of gamma/delta lymphocytes-T in the peripheral blood of patients with active tuberculosis—a comparison with normal subjects and patients in sarcoidosis. Tazi, A., *et al.* ..... (A) 178

Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya—analysis of early (6-month) mortality. Nunn, P., *et al.* ..... (A) 171

Combined tuberculosis/leprosy detection program in an urban metropolitan city—a pilot study. Pandiaraj, L., *et al.* ..... (A) 51A

Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65-kDa antigen gene, in the diagnosis of tuberculosis. Walker, D. A., *et al.* ..... (A) 181

DNA restriction fragment analysis to define an extended cluster of tuberculosis in homeless men and their associates. Dwyer, B., *et al.* ..... (A) 369

Detection of lipoarabinomannan as a diagnostic test for tuberculosis. Sada, E., *et al.* ..... (A) 176

Diagnostic significance of circulating immune complexes in patients with pulmonary tuberculosis. Radhakrishnan, V. V., *et al.* ..... (A) 668

Dietary vitamin-D affects cell-mediated hypersensitivity but not resistance to experimental pulmonary tuberculosis in guinea pigs. Hernandez Frontera, E. and McMurray, D. N. ..... (A) 505

Does antibody to mycobacterial antigens including lipoarabinomannan, limit dissemination in childhood tuberculosis. Costello, A. M. D., *et al.* ..... (A) 368

Drug-resistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection. Chawla, P. K., *et al.* ..... (A) 155
Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology. Verbon, A., *et al.* ..... (A) 670
Failure of therapy for tuberculosis in human immunodeficiency virus infection. Nolan, C. M. ..... (A) 170
Field experience in leprosy/tuberculosis program with Isoprodian-rifampin. Alvarenga, A. E. ..... (A) 305
Heiser Program for Research in Leprosy and Tuberculosis. ..... (N) 482
Immunoscintigraphy in the detection of tuberculosis with radiolabelled antibody fragment against *M. bovis* bacillus Calmette-Guerin—a preliminary study in a rabbit model. Lee, J. D., *et al.* ..... (A) 167
Integration of a leprosy-tuberculosis-onchocerciasis control program into a primary health care program in the forest region of Guinea. Wiher, H. and Sherif, A. ..... (A) 42A
Leprosy, tuberculosis, and the new genetics. Young, D. B. and Cole, S. T. ..... (A) 361
Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Carlucci, S., *et al.* ..... (A) 368
Pathogenesis of tuberculosis—interaction of *M. tuberculosis* with macrophages. McDonough, K. A., *et al.* ..... (A) 665
Progress toward a simplified polymerase chain reaction and it application to diagnosis of tuberculosis. Wilson, S. M., *et al.* ..... (A) 360
Pros and cons of combining tuberculosis and leprosy control activities (based on 15 years' experience of the National TB Leprosy Program in Tanzania). Chum, H., *et al.* ..... (A) 41A
Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Brindle, R. J., *et al.* ..... (A) 502
Reduced natural killer cell activity in multi-drug resistant pulmonary tuberculosis. Ratcliffe, L. T., *et al.* ..... (A) 175
Results of Isoprodian-rifampin in tuberculosis treatment. Urbanczik, R. ..... (A) 304
Results of the 3rd Immunology of Leprosy/Immunology of Tuberculosis Antimycobacterial Monoclonal Antibody Workshop. Khanolkar-Young, S., *et al.* ..... (A) 134
Secular trends of tuberculosis in Western Europe. Raviglione, M. C., *et al.* ..... (A) 668
Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Klein, R., *et al.* ..... (A) 507
Serological response in leprosy and tuberculosis patients to the 18-kDa antigen of *M. leprae* and antigen 85B of *M. bovis* BCG. Vikerfors, T., *et al.* ..... (O) 571
T-cell repertoire in tuberculosis—selective anergy to an immunodominant epitope of the 38-kDa antigen in patients with active disease. Vordermeier, H. M., *et al.* ..... (A) 180
[Tarivid in the combined treatment of pulmonary tuberculosis patients.] Koryakin, V. A., *et al.* ..... (A) 167
The emergence of drug-resistant tuberculosis in New York City. Frieden, T. R., *et al.* ..... (A) 370
The impact of HIV infection on the global epidemiology of tuberculosis. Styblo, K. ..... (A) 177
Training for national TB/leprosy program in Tanzania since July 1977. Chum, H., *et al.* ..... (A) 167A
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Goble, M., *et al.* ..... (A) 371
Tuberculoid leprosy associated with pulmonary tuberculosis. de Almeida, A. M., *et al.* ..... (A) 30A
Tuberculosis and HIV infection in sub-saharan Africa. Decock, K. M., *et al.* ..... (A) 158
Tuberculosis and leprosy—attempts to identify T-cell antigens of potential value for vaccine design. Kaufmann, S. H. E., *et al.* ..... (A) 133
Tuberculosis control and research strategies for the 1990s: memorandum from a WHO meeting. ..... (A) 378
Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia. Glaziou, P., *et al.* ..... (O) 199
[Use of highly dispersed ferroparticles for raising sensitivity of the luminescence microscopic method to determine tuberculosis mycobacteria.] Polozov, A. I., *et al.* ..... (A) 173

Turkey,
Extent of leprosy-related disabilities in Turkey. Cakiner, T., *et al.* ..... (A) 26A
Follow-up study of 81 leprosy cases treated by short-term MDT in Turkey. Sutlas, M., *et al.* ..... (A) 5A
Women and leprosy in Turkey. Cakiner, T., *et al.* ..... (A) 364

U.K.,
BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ..... (A) 175
D. B. Young new Professor of Medical Microbiology. Rees, R. J. W. ..... (N) 333
Dr. Ian Cochrane retires. ..... (N) 481
Durston appointed new TLMI General Director. ..... (N) 481
Global estimates of new cases of leprosy. ..... (N) 334
ILEP Medical Bulletins available. ..... (N) 334
ILEP new appointments. ..... (N) 481
ILEP sponsorship of medical research. ..... (N) 334
M. bovis in England and Wales—past, present and future. Hardie, R. M. and Watson, J. M. ..... (A) 163
Possible transmission of *M. leprae* in a group of U.K. leprosy contacts. Dockrell, H. M., *et al.* ..... (A) 362
Teaching and learning materials for leprosy, TAMILEP. ..... (N) 118
The Philippines' Manual of Training; MDT for Leprosy available. ..... (N) 118

Ulcer(s),
Can self care prevent ulcers in anesthetic limbs? Philip, R., *et al.* ..... (A) 153A
Chronic plantar ulcer of a leprosy patient treated by fasciocutaneous instep flap transfer—preliminary result. Majoroh, T. O. ..... (A) 501
Chronic plantar ulcers of leprosy patients treated by musculo cutaneous instep flap transfer. Majoroh, T. O. ..... (A) 161A
Comprehensive protection effects on leprosy sole ulcer and simple sole sensory loss. Xu, S. and Watson, J. M. ..... (A) 153A
Healing rates of plantar ulcers in leprosy and diabetes. Birke, J. A., *et al.* ..... (A) 364
Impact of health education in the prevention of plantar ulcers in a leprosy control project—preliminary findings. Basskaran, E., *et al.* ..... (A) 153A
Infected trophic ulcers and tenderness of posterior tibial nerve in cured leprosy patients. Patki, A. H. ..... (C) 472
Long-term observation on the effect of surgical treatment of leprous plantar ulcers. Wang, Z., *et al.* ..... (A) 161A
Malignant transformation of chronic plantar ulcers in leprosy patients. Grauwin, M.-Y., *et al.* ..... (A) 37A
Neoplastic transformation of chronic ulcers in leprosy. Awofeso, N. ..... (A) 35A
Newer techniques for resurfacing the plantar ulcers. Shah, A. ..... (A) 151A
Nursing care for leprous plantar ulcers cured with dorso-pedis vessel pedicle flap. Ling, X. and Yu, B. ..... (A) 161A
Squamous cell carcinoma in chronic ulcers of leprosy patients. Richardus, J. H. and Smith, T. C. ..... (A) 37A
The vascular component in posterior tibial compartment surgery for plantar ulcers. Arolkar, S. and Antia, N. ..... (A) 162A
Treatment of neuropathic ulcers with full-thickness skin. Faber, W. R., *et al.* ..... (A) 161A

Ultrastructure (see also **Electron Microscopy**),
Comparative effects of *M. avium* glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells. Pourshafie, M., *et al.* ..... (A) 667
Mycobacterial growth and ultrastructure in mouse L-929 fibroblasts and bone marrow-derived macrophages—evidence that infected fibroblasts secrete mediators capable of modulating bacterial growth in macrophages. Rastogi, N., *et al.* ..... (A) 137

Urine,
Comparative evaluation of antibodies in the serum and urine of leprosy patients through diversified mycobacterial antigens. Gupta, H. P., *et al.* ..... (A) 92A

U.S.A.,
First North American Regional Conference of Rehabilitation International to be held. ..... (N) 334
Heiser Program for Research in Leprosy and Tuberculosis. ..... (N) 482
Lechat inaugurates John H. Hanks Lectureship Program. ..... (N) 118
Lepromin skin testing in the classification of Hansen's disease in the United States. Krotoski, W. A., *et al.* ..... (A) 342

PATH offers major equipment for peripheral laboratories. ....(N) 119
Total HD cases in 1991. ....(N) 119

U.S.S.R. (see **Commonwealth of Independent States**),

Vaccine(s), vaccination,
An immunodominant 30-kDa antigen(s) of a candidate antileprosy vaccine, *Mycobacterium w*, shares T and B cell determinants with *M. leprae* and *M. tuberculosis*. Yadava, A. and Mukherjee, R. ....(A) 90A
Annual immunotherapy in treated lepromatous leprosy with three different BCG-based vaccines—a 6-year assessment. Waters, M. F. R., *et al.* ....(A) 103A
Armadillos (*Dasypus novemcinctus*) as a model to test antileprosy vaccines; a preliminary report. Job, C. K., *et al.* ....(O) 394
BCG vaccination as protection against leprosy. Alvim, M. F. S., *et al.* ....(A) 94A
BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. Rodrigues, L. C., *et al.* ....(A) 175
BCG vaccination protects against leprosy in Venezuela. Convit, J., *et al.* ....(A) 103A
BCG vaccination protects against leprosy in Venezuela: a case control study. Convit, J., *et al.* ....(O) 185
BCG vaccine and leprosy. Baker, D. M. and Nguyen, V. T. J. S. ....(A) 147
Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Orege, P., *et al.* ....(O) 542
Combined multidrug and *Mycobacterium w* vaccine therapy in patients with multibacillary leprosy. Zaheer, S. A., *et al.* ....(A) 357
[Correlation between vaccination with BCG and the clinical forms of leprosy.] Castro Chavez, R., *et al.* ....(A) 148
Field trials with an antileprosy vaccine *Mycobacterium w*. Walia, R., *et al.* ....(A) 104A
Generation of cytolytic T-cells in individuals infected by *M. tuberculosis* and vaccinated with BCG. Pithie, A. D., *et al.* ....(A) 173
Immunochemical characterization of 32-kDa cytosolic protein of *M. habana*: a candidate vaccine. Sinha, S., *et al.* ....(A) 91A
Immunogenicity and protection studies with recombinant vaccinia and BCG each expressing the 18-kDa antigen of *M. leprae*. Baumgart, K. W., *et al.* ....(A) 86A
Immunotherapeutic potential of ICRC vaccine: a case control study. Bhatki, W. S. and Ghulawala, R. G. ....(A) 340
Immunotherapy of MB leprosy patients with the antileprosy vaccine *Mycobacterium w*. Zaheer, S. A., *et al.* ....(A) 18A
Immunotherapy with *Mycobacterium w* vaccine decreases the incidence and severity of type 2 (ENL) reactions. Zaheer, S. A., *et al.* ....(A) 345
Immunotherapy with *Mycobacterium w* vaccine in MB leprosy patients showing slow responses to MDT. Ramesh, V., *et al.* ....(A) 18A
Implications of delayed-type hypersensitivity to *M. leprae* soluble antigens and to tuberculin for natural and vaccine derived immunity to leprosy. Fine, P. E. M., *et al.* ....(A) 74A
Induction of lepromin positivity by a candidate antileprosy vaccine *Mycobacterium w* and its immunoprophylactic effect in lepromin-negative healthy contacts or multibacillary leprosy patients. Kar, H. K., *et al.* ....(A) 95A
Induction of lepromin positivity by a candidate antileprosy vaccine, *Mycobacterium w*, in lepromin negative healthy contacts of multibacillary leprosy patients. Kar, H. K., *et al.* ....(A) 349
Influence of BCG vaccination and close contact with leprosy patients on the results of skin test with four new tuberculins. Bottasso, O., *et al.* ....(A) 94A
Leprosy immunopathogenesis and vaccine development. Chatterjee, B. R. ....(A) 131
Mouse vaccination against leprosy with *M. leprae* subunit vaccines are more effective than with whole sonicated *M. leprae*. Gelber, R. H., *et al.* ....(A) 76A
Pilot study to determine acceptability and ability of heat killed *M. leprae* plus BCG (HKML + BCG) vaccine to induce skin test conversion. Chen, Z.-L., *et al.* ....(A) 651
Postvaccination sensitization with ICRC vaccine. Gupte, M. D., *et al.* ....(A) 103A
Protection of mice by vaccination with purified and recombinant major *M. leprae* proteins and polypeptides. Gelber, R. H., *et al.* ....(A) 103A

Reversal reaction in multibacillary leprosy patients following MDT with/without immunotherapy with a candidate antileprosy vaccine *Mycobacterium w*. Sharma, A. K., *et al.* ..... (A) 24A

The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guerin (BCG) vaccination in either South India or London. Das, S., *et al.* ..... (A) 158

Tuberculosis and leprosy—attempts to identify T-cell antigens of potential value for vaccine design. Kaufmann, S. H. E., *et al.* ..... (A) 133

Venezuela,

BCG vaccination protects against leprosy in Venezuela. Convit, J., *et al.* ..... (A) 103A

BCG vaccination protects against leprosy in Venezuela: a case control study. Convit, J., *et al.* ..... (O) 185

Vitamin(s),

Dietary vitamin-D affects cell-mediated hypersensitivity but not resistance to experimental pulmonary tuberculosis in guinea pigs. Hernandez Frontera, E. and McMurray, D. N. ..... (A) 505

Yemen,

Formulation of a new leprosy control program in the Republic of Yemen as cooperation between GLRA and MOPH. Al Qubati, Y. and Al Nabhani, M. G. ..... (A) 45A

Zaire,

Lutte contre la lepra au Zaire, 1987-1991. Boyau, M. L. ..... (A) 58A

Seroprofile of HBV, HIV, and HTLV infections in Zairian leprosy patients and their contacts. Ilunga, N., *et al.* ..... (A) 97A

Zimbabwe,

Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: ELISA. De Lange, W. E., *et al.* ..... (A) 100A

Sensitization to mycobacteria in two areas in Zimbabwe with different distribution of leprosy type and incidence: skin tests. Mous, H. V. H., *et al.* ..... (A) 100A

Ten years of multidrug therapy in Zimbabwe. Mudarikwa, L. C. and ten Ham, P. B. G. (A) 44A